WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, September 13, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L13	L12 AND ALK	6
☐	L12	pleiotrophin AND human AND receptor	210
☐	L11	L10 AND human	210
☐	L10	L9 AND receptor	222
☐	L9	L8 AND pleiotrophin	274
☐	L8	(pleiotrophin OR PTN OR ALK)	47607
☐	L7	L4 AND ALK	127
☐	L6	L4 AND PTN	24
☐	L5	L4 AND pleiotrophin	32
☐	L4	530/300,350.CCLS.	16901
☐	L3	Wellstein.IN.	45
☐	L2	Wellstein-A.IN.	12
☐	L1	(Wellstein-Anton.IN.)	13

END OF SEARCH HISTORY

h e b b cg b chh e f c e c ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 32 of 32 returned.

☐ 1. Document ID: US 20040076955 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 32 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076955
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076955 A1

TITLE: Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mack, David H.	Menlo Park	CA	US	
Aziz, Natasha	Palo Alto	CA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20040072295 A1

L5: Entry 2 of 32 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072295
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072295 A1

TITLE: Human RGR oncogene and truncated transcripts thereof detected in T cell malignancies, antibodies to the encoded polypeptides and methods of use

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pellicer, Angel	New York	NY	US	
Leonardi, Peter	East Haven	CT	US	
Inghirami, Giorgio	Mt. Vernon	NY	US	

US-CL-CURRENT: 435/69.1; 424/143.1, 435/320.1, 435/325, 530/350, 530/388.22, 536/23.5

ABSTRACT:

h e b b g e e e f e ef b e

Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention further provides methods for diagnosing and treating T cell malignancies associated with abnormally truncated transcripts of human rgr oncogene and/or abnormal truncation of human Rgr protein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 3. Document ID: US 20040044182 A1

L5: Entry 3 of 32 File: PGPB Mar 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040044182
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040044182 A1

TITLE: Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g

PUBLICATION-DATE: March 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hunt, Joan S	Shawnee Mission	KS	US	
Morales, Pedro J.	Kansas City	MO	US	
Pertroff, Margaret G.	Merriam	KS	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

Methods of producing and using recombinant soluble HLA-G are provided. This recombinant soluble HLA-G alters immune responses to tissues, organs, fetuses, and embryos which are genetically distinct from the organism receiving or possessing such antigenic material. Preferable forms of this protein include sequences having at least 70% sequence homology with naturally occurring forms of HLA-G. Specifically, each recombinant form of HLA-G produced and used by the present methods must include a sequence having at least 70% sequence homology to introm 4 expressed by the HLA-G gene and at least one sequence having at least 70% sequence homology to one of the .alpha. domains expressed by the HLA-G gene. Preferable forms of the present invention include one isoform which includes the .alpha.1 domain, the .alpha.2 domain, the .alpha.3 domain, and intron 4, and a second isoform which includes the .alpha.1 domain, the .alpha.3 domain and intron 4. Still more preferably, the sequences include a purification-assisting peptide sequence and a signal peptide.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 4. Document ID: US 20040001846 A1

L5: Entry 4 of 32 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040001846
PGPUB-FILING-TYPE: new

h e b b g e e e f e ef b e

DOCUMENT-IDENTIFIER: US 20040001846 A1

TITLE: Prostate-specific membrane antigen and uses thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Israeli, Ron S.	Staten Island	NY	US	
Heston, Warren D.W.	New York	NY	US	
Fair, William R.	New York	NY	US	
Ouerfelli, Ouathek	New York	NY	US	
Pinto, John	East Norwalk	CT	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen.

This invention provides a method of detecting a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen and a method of detecting a prostate tumor cell in a subject.

Lastly, this invention provides a pharmaceutical composition comprising a compound in a therapeutically effective amount and a pharmaceutically acceptable carrier and a method of making prostate cells susceptible to a cytotoxic chemotherapeutic agent.

☐ 5. Document ID: US 20030219745 A1

L5: Entry 5 of 32 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219745
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219745 A1

TITLE: Novel nucleic acids and polypeptides

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Y. Tom	San Jose	CA	US	
Goodrich, Ryle	San Jose	CA	US	
Liu, Chenghua	San Jose	CA	US	
Ren, Feiyan	Cupertino	CA	US	
Wang, Dunrui	Poway	CA	US	

h e b b g e e e f e ef b e

Drmanac, Radoje T. Palo Alto CA US

US-CL-CURRENT: 435/6; 424/146.1, 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 514/12, 530/350, 530/388.1, 536/23.2

ABSTRACT:

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 6. Document ID: US 20030211078 A1

L5: Entry 6 of 32 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211078
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211078 A1

TITLE: Pseudo-antibody constructs

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Heavner, George A.	Malvern	PA	US	

US-CL-CURRENT: 424/85.1; 424/130.1, 514/12, 514/54, 525/54.1, 530/350, 530/351, 530/387.1, 536/123

ABSTRACT:

This invention relates to novel pharmaceutically useful compositions that bind to a biological molecule, having improved circulatory half-life, increased avidity, increased affinity, or multifunctionality, and methods of use thereof. The present invention provides a pseudo-antibody comprising an organic moiety covalenty coupled to at least two target-binding moieties, wherein the target-binding moieties are selected from the group consisting of a protein, a peptide, a peptidomimetic, and a non-peptide molecule that binds to a specific targeted biological molecule. The pseudo-antibody of the present invention may affect a specific ligand in vitro, in situ and/or in vivo. The pseudo-antibodies of the present invention can be used to measure or effect in an cell, tissue, organ or animal (including humans), to diagnose, monitor, modulate, treat, alleviate, help prevent the incidence of, or reduce the symptoms of, at least one condition.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 7. Document ID: US 20030148410 A1

L5: Entry 7 of 32 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148410
PGPUB-FILING-TYPE: new

h e b b g e e e f e ef b e

DOCUMENT-IDENTIFIER: US 20030148410 A1

TITLE: Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Berger, Allison	Watertown	MA	US	
Guillemette, Tracy L.	Plaistow	NH	US	
Schlegel, Robert	Auburndale	MA	US	
Monahan, John E.	Walpole	MA	US	
Kamatkar, Shubhangi	Newton	MA	US	
Thibodeau, Stephen N.	Rochester	MN	US	
Burgart, Lawrence J.	Rochester	MN	US	

US-CL-CURRENT: 435/7.23; 435/183, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.2

ABSTRACT:

The invention relates to newly discovered nucleic acid molecules and proteins associated with colon cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided.

8. Document ID: US 20030099974 A1

L5: Entry 8 of 32 File: PGPB May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030099974
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030099974 A1

TITLE: Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lillie, James	Natick	MA	US	
Xu, Yongyao	Belmont	MA	US	
Wang, Youzhen	Newton	MA	US	
Steinmann, Kathleen	Winchester	MA	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.3, 435/7.23, 530/350, 530/388.8, 536/23.2

ABSTRACT:

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly

h e b b g e e e f e ef b e

identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.

☐ 9. Document ID: US 20030087255 A1

L5: Entry 9 of 32 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087255
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087255 A1

TITLE: Peptides which stimulate the immune response and tissue regeneration

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Barritault, Denis	Paris		FR	
Achour, Ammar	Creteil		FR	
Courty, Jose	Villecresnes		FR	

US-CL-CURRENT: 435/6; 435/5, 435/7.1, 514/12, 514/13, 514/14, 514/15, 530/324, 530/325, 530/326, 530/327, 530/350

ABSTRACT:

A pharmaceutical composition for stimulating production of cytokines of inflammation including a peptide corresponding to formula (I) below:

(A).sub.n-A1-A1-A2-A1-A3-A4-A1-(A).sub.m

in which A is any amino acid, n and m are each whole numbers from 0 to 20 whose sum n+m is between 0 and 20, A1 is a basic amino acid and more particularly lysine (Lys) or arginine (Arg), A2 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly) and aspartic acid (Asp), A3 is an amino acid selected from the group consisting of basic amino acids, proline (Pro), glutamic acid (Glu) and glutamine (Gln), A4 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly), serine (Ser) and valine (Val), and a pharmaceutically acceptable carrier.

☐ 10. Document ID: US 20030065140 A1

L5: Entry 10 of 32 File: PGPB Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030065140
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030065140 A1

TITLE: Novel proteins and nucleic acids encoding same

h e b b g e e e f e ef b e

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vernet, Corine A.M.	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Fernandes, Elma R.	Branford	CT	US	
Taupier, Raymond J. JR.	East Haven	CT	US	
Quinn, Kerry E.	Hamden	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Rastelli, Luca	Guilford	CT	US	
Herrmann, John L.	Guilford	CT	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

☐ 11. Document ID: US 20030027751 A1

L5: Entry 11 of 32 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027751
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027751 A1

TITLE: VEGF fusion proteins

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kovesdi, Imre	Rockville	MD	US	
Kessler, Paul D.	Frederick	MD	US	

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing

h e b b g e e e f e ef b e

using such proteins, polynucleotides, and vectors.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 12. Document ID: US 20020169125 A1

L5: Entry 12 of 32 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169125
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169125 A1

TITLE: Recombinant production of polyanionic polymers and uses thereof

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leung, David W.	Mercer Island	WA	US	
Bergman, Philip A.	Mountlake Terrace	WA	US	
Lofquist, Alan	Kirkland	WA	US	
Pietz, Gregory E.	Seattle	WA	US	
Tompkins, Christopher K.	Bothell	WA	US	
Waggoner, David W. JR.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 424/85.1, 424/85.2, 424/85.4, 435/69.5, 435/69.7, 530/350, 530/351, 530/399

ABSTRACT:

A polyanionic polymer can improve the bioactivity and water-solubility properties of a drug to which it is joined. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemically or recombinantly joined to a polyanionic polymer to increase its biological half-life and/or solubility. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 13. Document ID: US 20020151681 A1

L5: Entry 13 of 32 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

h e b b g e e e f e ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5

ABSTRACT:

This invention relates to newly identified prostate or prostate cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "prostate cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, and to antibodies that immunospecifically bind these polypeptides, as well as the use of such prostate cancer polynucleotides, antigens, and antibodies for detection, prevention, prognosis, and treatment of disorders of the reproductive system, particularly disorders of the prostate, including, but not limited to, the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer nucleic acid molecules are provided encoding novel prostate cancer polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

14. Document ID: US 20020115607 A1

L5: Entry 14 of 32 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115607
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115607 A1

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 424/146.1, 435/194, 435/226, 530/350

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that

h e b b g e e e f e ef b e

are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 15. Document ID: US 20020034768 A1

L5: Entry 15 of 32 File: PGPB Mar 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020034768
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020034768 A1

TITLE: Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders

PUBLICATION-DATE: March 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wellstein, Anton	Washington	DC	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 16. Document ID: US 6572851 B2

L5: Entry 16 of 32 File: USPT Jun 3, 2003

US-PAT-NO: 6572851
DOCUMENT-IDENTIFIER: US 6572851 B2

TITLE: Method for suppressing or treating drug-induced nephropathy

DATE-ISSUED: June 3, 2003

INVENTOR-INFORMATION:

h e b b g ee e f e ef b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Muramatsu; Takashi	Aichi			JP
Kadomatsu; Kenji	Aichi			JP
Oda; Munehiro	Kanagawa			JP
Ikematsu; Shinya	Kanagawa			JP
Sakuma; Sadatoshi	Kanagawa			JP

US-CL-CURRENT: 424/85.1; 424/198.1, 514/12, 514/2, 530/350, 530/399

ABSTRACT:

The present invention provides a novel drug for relieving drug-induced nephropathy and acute hepatopahy containing a midkine (MK) family protein such as pleiotrophin (PTN). The MK family proteins can inhibit nephropathy induced by an antitumor agent or acute hepatopathy caused by carbon tetrachloride and thus effectively relieve drug-induced nephropathy or hepatopathy.

4 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

17. Document ID: US 6569432 B1

L5: Entry 17 of 32 File: USPT May 27, 2003

US-PAT-NO: 6569432
DOCUMENT-IDENTIFIER: US 6569432 B1

TITLE: Prostate-specific membrane antigen and uses thereof

DATE-ISSUED: May 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Israeli; Ron S.	Staten Island	NY		
Heston; Warren D. W.	New York	NY		
Fair; William R.	New York	NY		
Ouerfelli; Ouathek	New York	NY		
Pinto; John	East Norwalk	CT		

US-CL-CURRENT: 424/185.1; 424/277.1, 530/350

ABSTRACT:

This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen. This invention provides a method of detecting a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen and a method of detecting a prostate tumor cell in a subject. Lastly, this invention provides a pharmaceutical composition comprising a

h e b b g e e e f e ef b e

compound in a therapeutically effective amount and a pharmaceutically acceptable carrier and a method of making prostate cells susceptible to a cytotoxic chemotherapeutic agent.

1 Claims, 106 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 102

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 18. Document ID: US 6383480 B1

L5: Entry 18 of 32 File: USPT May 7, 2002

US-PAT-NO: 6383480
DOCUMENT-IDENTIFIER: US 6383480 B1

TITLE: Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kikuchi; Makoto	Fukuoka			JP
Ikematsu; Shinya	Kanagawa			JP
Oda; Munehiro	Kanagawa			JP
Sakuma; Sadatoshi	Kanagawa			JP
Muramatsu; Takashi	Aichi			JP

US-CL-CURRENT: 424/85.1; 424/85.2, 514/2, 514/885, 530/300, 530/350, 530/399

ABSTRACT:

The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an agent for remarkably enhancing the above-described effect for promoting the proliferation of hematopoietic stem cells and hematopoietic precursor cells, comprising the MK family in combination with known hematopoietic factors such as IL-3, IL-6, G-CSF, GM-CSF, M-CSF, SCF, and EPO.

22 Claims, 17 Drawing figures
Exemplary Claim Number: 11
Number of Drawing Sheets: 17

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 19. Document ID: US 6277974 B1

L5: Entry 19 of 32 File: USPT Aug 21, 2001

US-PAT-NO: 6277974
DOCUMENT-IDENTIFIER: US 6277974 B1

h e b b g e e e f e ef b e

TITLE: Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

DATE-ISSUED: August 21, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lo; Donald C.	Chapel Hill	NC		
Barney; Shawn	Apex	NC		
Thomas; Mary Beth	Chapel Hill	NC		
Portbury; Stuart D.	Durham	NC		
Puranam; Kasturi	Durham	NC		
Katz; Lawrence C.	Durham	NC		

US-CL-CURRENT: 536/23.1; 424/93.1, 424/93.2, 424/93.21, 435/320.1, 435/325, 435/352, 435/69.1, 530/300, 530/350, 536/23.5

ABSTRACT:

The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced. The invention encompasses nucleic acids of the protective sequence, host cell expression systems of the protective sequence, and hosts that have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel protective sequence products, including proteins, polypeptides and peptides containing amino acid sequences of the proteins, fusion proteins of proteins, polypeptides and peptides, and antibodies directed against such gene products. The invention further relates to target sequences, including upstream and downstream regulatory sequences or complete gene sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, and/or their regulatory elements involved in cell death. The present invention also relates to methods and compositions for the diagnosis and treatment of conditions, disorders, or diseases, involving cell death, including, but not limited to, treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system, including neurological and psychiatric conditions, disorders, or diseases, and those of the peripheral nervous system. Further, the invention relates to methods of using the protective sequence, protective sequence products, and/or their regulatory elements for the identification of compounds that modulate the expression of the protective sequence and/or the activity of the protective sequence product. Such compounds can be useful as therapeutic agents in the treatment of various conditions, disorders, or diseases involving cell death.

12 Claims, 262 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 92

☐ 20. Document ID: US 6258550 B1

L5: Entry 20 of 32 File: USPT Jul 10, 2001

h e b b g e e e f e ef b e

US-PAT-NO: 6258550
DOCUMENT-IDENTIFIER: US 6258550 B1

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 435/7.1; 435/183, 530/300

ABSTRACT:

Among other things, methods of obtaining putative protein-protein interaction sites of biologically-active polypeptides are provided. The methods include searching the polypeptides for a regions that are flanked on each termini by at least one proline residue; and isolating or producing the flanked regions.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 21. Document ID: US 6251403 B1

L5: Entry 21 of 32 File: USPT Jun 26, 2001

US-PAT-NO: 6251403
DOCUMENT-IDENTIFIER: US 6251403 B1

TITLE: Recombinant swinepox virus

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cochran; Mark D.	Carlsbad	CA		
Junker; David E.	San Diego	CA		

US-CL-CURRENT: 424/199.1; 424/204.1, 424/232.1, 435/235.1, 435/320.1, 530/350, 536/23.72

ABSTRACT:

This invention provides a recombinant swinepox virus comprising a foreign DNA sequence inserted into the swinepox virus genomic DNA, wherein the foreign DNA sequence is inserted within a HindIII M fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.

21 Claims, 114 Drawing figures
Exemplary Claim Number: 1,4

h e b b g e e e f e ef b e

Number of Drawing Sheets: 114

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

22. Document ID: US 6207812 B1

L5: Entry 22 of 32 File: USPT Mar 27, 2001

US-PAT-NO: 6207812
DOCUMENT-IDENTIFIER: US 6207812 B1

TITLE: Chondrosarcoma associated genes

DATE-ISSUED: March 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Terek; Richard M.	Providence	RI		

US-CL-CURRENT: 536/23.1; 530/350, 530/358, 536/23.2, 536/23.4, 536/23.5, 536/23.51, 536/23.52, 536/23.53, 536/24.3, 536/24.31, 536/24.32, 536/24.33

ABSTRACT:

The invention features a nucleic acid molecule encoding a chondrosarcoma associated polypeptide and methods for diagnosing patients with chondrosarcoma. the gene.

7 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

23. Document ID: US 6200956 B1

L5: Entry 23 of 32 File: USPT Mar 13, 2001

US-PAT-NO: 6200956
DOCUMENT-IDENTIFIER: US 6200956 B1

TITLE: Nucleic acid-containing composition, preparation and use thereof

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Scherman; Daniel	Paris			FR
Byk; Gerardo	Creteil			FR
Schwartz; Bertrand	Maisons Alford			FR

US-CL-CURRENT: 514/13; 514/12, 514/14, 514/15, 530/300, 530/326, 530/327, 530/328

ABSTRACT:

h e b b g e e e f e ef b e

Pharmaceutical composition useful for transfecting a nucleic acid and characterised in that it contains, in addition to the nucleic acid, at least one transfecting agent and a compound causing the condensation of the nucleic acid, wherein the compound is totally or partly derived from a histone, a nucleoline, a protamine and/or a derivative thereof. The use of the composition for transferring nucleic acids in vitro, ex vivo and/or in vivo is also described.

36 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

---

☐ 24. Document ID: US 6153597 A

L5: Entry 24 of 32 File: USPT Nov 28, 2000

US-PAT-NO: 6153597
DOCUMENT-IDENTIFIER: US 6153597 A

TITLE: Pharmaceutical composition useful for nucleic acid transfection, and use thereof

DATE-ISSUED: November 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blanche; Francis	Paris			FR
Cameron; Beatrice	Paris			FR
Crouzet; Joel	Sceaux			FR
Thuillier; Vincent	Paris			FR

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/366, 435/455, 435/458, 530/350, 530/358, 530/387.1, 530/387.3, 536/23.1, 536/23.5, 536/24.5

ABSTRACT:

A pharmaceutical composition useful for nucleic acid transfection is disclosed. The composition contains, in addition to a nucleic acid and at least one transfection agent, at least one compound that combines DNA binding properties with a nuclear DNA vectorisation capability, and preferably belongs to the HMG ("High mobility group") protein family. The use of said composition for in vitro, ex vivo and/or in vivo nucleic acid transfer is also disclosed.

27 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

---

☐ 25. Document ID: US 6103880 A

L5: Entry 25 of 32 File: USPT Aug 15, 2000

US-PAT-NO: 6103880

h e b b g e e e f e ef b e

DOCUMENT-IDENTIFIER: US 6103880 A

TITLE: HARP family growth factors

DATE-ISSUED: August 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barritault; Denis	Paris			FR
Courty; Jose	Villecresnes			FR
Laaroubi; Khalid	Sidi Kacem			MA

US-CL-CURRENT: 530/399; 530/350

ABSTRACT:

Novel peptides having a SEQ ID No. 2 and SEQ ID No. 4 which peptides possess mitogenic properties.

1 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

---

☐ 26. Document ID: US 6063758 A

L5: Entry 26 of 32 File: USPT May 16, 2000

US-PAT-NO: 6063758
DOCUMENT-IDENTIFIER: US 6063758 A
**** See image for Certificate of Correction ****

TITLE: Substance P-Saporin (SP-SAP) conjugates and methods of use thereof

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lappi; Douglas A.	Del Mar	CA		
Wiley; Ronald G.	Brentwood	TN		

US-CL-CURRENT: 514/2; 514/13, 530/320, 530/350

ABSTRACT:

This invention provides a conjugate comprising Substance P, and analogs thereof, and Saporin. This invention provides a method of reducing the perception of pain by a subject comprising administering to the subject an effective dose of the pharmaceutical composition of the conjugate comprising Substance P, and analogs thereof, and Saporin, so as to reduce the perception of pain by the subject. This invention provides a method of selectively destroying NK-1 receptor expressing cells in a subject comprising administering to the subject an effective dose of the conjugate comprising Substance P, and analogs thereof, and Saporin so as to selectively destroy NK-1 receptor expressing cells. Lastly, this invention provides a method for treating a NK-1 receptor associated disorder in a subject, which comprises

h e b b g e e e f e ef b e

administering to the subject an amount of the pharmaceutical composition comprising Substance P, and analogs thereof, and Saporin thereby treating the disorder associated with the NK-1 receptor.

9 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 27. Document ID: US 6033904 A

L5: Entry 27 of 32 File: USPT Mar 7, 2000

US-PAT-NO: 6033904
DOCUMENT-IDENTIFIER: US 6033904 A

TITLE: Recombinant swinepox virus

DATE-ISSUED: March 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cochran; Mark D.	Carlsbad	CA		
Junker; David E.	San Diego	CA		

US-CL-CURRENT: 435/320.1; 424/204.1, 424/232.1, 435/235.1, 435/69.1, 530/350

ABSTRACT:

This invention provides a recombinant swinepox virus comprising a foreign DNA sequence inserted into the swinepox virus genomic DNA, wherein the foreign DNA sequence is inserted within a HindIII N fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.

32 Claims, 114 Drawing figures
Exemplary Claim Number: 1,7
Number of Drawing Sheets: 114

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 28. Document ID: US 5965698 A

L5: Entry 28 of 32 File: USPT Oct 12, 1999

US-PAT-NO: 5965698
DOCUMENT-IDENTIFIER: US 5965698 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site

DATE-ISSUED: October 12, 1999

h e b b g e e e f e ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 530/326; 530/300, 530/324, 530/333, 530/380, 548/533

ABSTRACT:

Homologs and analogs of naturally-occurring polypeptides contain one or more interaction sites of the natural counterpart. The interaction sites are flanked by conformation-constraining moieties, such as proline or cysteine.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 29. Document ID: US 5945400 A

L5: Entry 29 of 32 File: USPT Aug 31, 1999

US-PAT-NO: 5945400
DOCUMENT-IDENTIFIER: US 5945400 A

TITLE: Nucleic acid-containing composition, preparation and use thereof

DATE-ISSUED: August 31, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Scherman; Daniel	Paris			FR
Byk; Gerardo	Creteil			FR
Schwartz; Bertrand	Maisons Alfort			FR

US-CL-CURRENT: 514/13; 514/12, 514/14, 514/15, 530/300, 530/326, 530/327, 530/328

ABSTRACT:

Pharmaceutical composition useful for transfecting a nucleic acid and characterised in that it contains, in addition to the nucleic acid, at least one transfecting agent and a compound causing the condensation of the nucleic acid, wherein the compound is totally or partly derived from a histone, a nucleoline, a protamine and/or a derivative thereof. The use of the composition for transferring nucleic acids in vitro, ex vivo and/or in vivo is also described.

34 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 30. Document ID: US 5928896 A

h e b b g e e e f e ef b e

L5: Entry 30 of 32 File: USPT Jul 27, 1999

US-PAT-NO: 5928896
DOCUMENT-IDENTIFIER: US 5928896 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 435/69.1; 435/91.2, 530/300, 530/324

ABSTRACT:

Homologs and analogs of naturally-occurring polypeptides contain one or more interaction sites of the natural counterpart. The interaction sites are flanked by conformation-constraining moieties, such as proline or cysteine.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 31. Document ID: US 5908831 A

L5: Entry 31 of 32 File: USPT Jun 1, 1999

US-PAT-NO: 5908831
DOCUMENT-IDENTIFIER: US 5908831 A

TITLE: Histone-like protein

DATE-ISSUED: June 1, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA		
Goli; Surya K.	Sunnyvale	CA		
Zhang; Hong	Fremont	CA		

US-CL-CURRENT: 514/12; 435/252.3, 435/320.1, 435/69.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

The present invention provides a human histone-like protein (HLP) and polynucleotides which identify and encode HLP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for producing HTP and for treating disorders associated with the expression of HLP.

h e b b g e e e f e ef b e

3 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 32. Document ID: US 5851799 A

L5: Entry 32 of 32 File: USPT Dec 22, 1998

US-PAT-NO: 5851799
DOCUMENT-IDENTIFIER: US 5851799 A

TITLE: Histone-like protein

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA		
Goli; Surya K.	Sunnyvale	CA		
Zhang; Hong	Fremont	CA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 530/350, 536/23.1, 536/23.4, 536/23.5

ABSTRACT:

The present invention provides a human histone-like protein (HLP) and polynucleotides which identify and encode HLP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for producing HTP and for treating disorders associated with the expression of HLP.

7 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L4 AND pleiotrophin	32

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 24 of 24 returned.

☐ 1. Document ID: US 20030219745 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 24 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219745
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219745 A1

TITLE: Novel nucleic acids and polypeptides

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Y. Tom	San Jose	CA	US	
Goodrich, Ryle	San Jose	CA	US	
Liu, Chenghua	San Jose	CA	US	
Ren, Feiyan	Cupertino	CA	US	
Wang, Dunrui	Poway	CA	US	
Drmanac, Radoje T.	Palo Alto	CA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 514/12, 530/350, 530/388.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20030211078 A1

L6: Entry 2 of 24 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211078
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211078 A1

TITLE: Pseudo-antibody constructs

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Heavner, George A.	Malvern	PA	US	

US-CL-CURRENT: 424/85.1; 424/130.1, 514/12, 514/54, 525/54.1, 530/350, 530/351, 530/387.1, 536/123

h e b b g e e e f e ef b e

ABSTRACT:

This invention relates to novel pharmaceutically useful compositions that bind to a biological molecule, having improved circulatory half-life, increased avidity, increased affinity, or multifunctionality, and methods of use thereof. The present invention provides a pseudo-antibody comprising an organic moiety covalenty coupled to at least two target-binding moieties, wherein the target-binding moieties are selected from the group consisting of a protein, a peptide, a peptidomimetic, and a non-peptide molecule that binds to a specific targeted biological molecule. The pseudo-antibody of the present invention may affect a specific ligand in vitro, in situ and/or in vivo. The pseudo-antibodies of the present invention can be used to measure or effect in an cell, tissue, organ or animal (including humans), to diagnose, monitor, modulate, treat, alleviate, help prevent the incidence of, or reduce the symptoms of, at least one condition.

☐ 3. Document ID: US 20030166167 A1

L6: Entry 3 of 24 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166167
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166167 A1

TITLE: Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
van Es, Helmuth	Hoofddorp		NL	
Bernards, Rene	Leiderdorp		NL	
Michiels, Godefridus A.M.	Leiderdorp		NL	
Brys, Reginald C.X.	Kessel-Lo		BE	
Tomme, Peter H. M.	Gent		BE	

US-CL-CURRENT: 435/91.1; 435/5, 435/69.1, 435/91.2, 435/91.33, 530/350

ABSTRACT:

Abstract The invention relates to the field of molecular genetics and medicine. In particular the present invention relates to the field of functional genomics. The present invention provides the methods and means for the identification of nucleic acids and the polypeptides encoded by these nucleic acids that have a function related to the E2F pathway, which were isolated in a high-throughput screening assay using the E2F transcription factor activity as a read-out. The identified compounds are suitable drug-targets to treat human diseases.

☐ 4. Document ID: US 20030087255 A1

h e b b g e e e f e ef b e

L6: Entry 4 of 24 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087255
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087255 A1

TITLE: Peptides which stimulate the immune response and tissue regeneration

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Barritault, Denis	Paris		FR	
Achour, Ammar	Creteil		FR	
Courty, Jose	Villecresnes		FR	

US-CL-CURRENT: 435/6; 435/5, 435/7.1, 514/12, 514/13, 514/14, 514/15, 530/324, 530/325, 530/326, 530/327, 530/350

ABSTRACT:

A pharmaceutical composition for stimulating production of cytokines of inflammation including a peptide corresponding to formula (I) below:

(A).sub.n-A1-A1-A2-A1-A3-A4-A1-(A).sub.m

in which A is any amino acid, n and m are each whole numbers from 0 to 20 whose sum n+m is between 0 and 20, A1 is a basic amino acid and more particularly lysine (Lys) or arginine (Arg), A2 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly) and aspartic acid (Asp), A3 is an amino acid selected from the group consisting of basic amino acids, proline (Pro), glutamic acid (Glu) and glutamine (Gln), A4 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly), serine (Ser) and valine (Val), and a pharmaceutically acceptable carrier.

☐ 5. Document ID: US 20030065140 A1

L6: Entry 5 of 24 File: PGPB Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030065140
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030065140 A1

TITLE: Novel proteins and nucleic acids encoding same

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vernet, Corine A.M.	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Fernandes, Elma R.	Branford	CT	US	

h e b b g e e e f e ef b e

Taupier, Raymond J. JR.	East Haven	CT	US
Quinn, Kerry E.	Hamden	CT	US
Spytek, Kimberly A.	New Haven	CT	US
Rastelli, Luca	Guilford	CT	US
Herrmann, John L.	Guilford	CT	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 6. Document ID: US 20030027751 A1

L6: Entry 6 of 24 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027751
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027751 A1

TITLE: VEGF fusion proteins

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kovesdi, Imre	Rockville	MD	US	
Kessler, Paul D.	Frederick	MD	US	

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

h e b b g e e e f e ef b e

☐ 7. Document ID: US 20020151681 A1

L6: Entry 7 of 24 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5

ABSTRACT:

This invention relates to newly identified prostate or prostate cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "prostate cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, and to antibodies that immunospecifically bind these polypeptides, as well as the use of such prostate cancer polynucleotides, antigens, and antibodies for detection, prevention, prognosis, and treatment of disorders of the reproductive system, particularly disorders of the prostate, including, but not limited to, the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer nucleic acid molecules are provided encoding novel prostate cancer polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 8. Document ID: US 20020034768 A1

L6: Entry 8 of 24 File: PGPB Mar 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020034768
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020034768 A1

TITLE: Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders

PUBLICATION-DATE: March 21, 2002

h e b b g e e e f e ef b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wellstein, Anton	Washington	DC	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 530/388.22, 536/23.5

ABSTRACT:

This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

---

☐ 9. Document ID: US 6572851 B2

L6: Entry 9 of 24 File: USPT Jun 3, 2003

US-PAT-NO: 6572851
DOCUMENT-IDENTIFIER: US 6572851 B2

TITLE: Method for suppressing or treating drug-induced nephropathy

DATE-ISSUED: June 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Muramatsu; Takashi	Aichi			JP
Kadomatsu; Kenji	Aichi			JP
Oda; Munehiro	Kanagawa			JP
Ikematsu; Shinya	Kanagawa			JP
Sakuma; Sadatoshi	Kanagawa			JP

US-CL-CURRENT: 424/85.1; 424/198.1, 514/12, 514/2, 530/350, 530/399

ABSTRACT:

The present invention provides a novel drug for relieving drug-induced nephropathy and acute hepatopahy containing a midkine (MK) family protein such as pleiotrophin (PTN). The MK family proteins can inhibit nephropathy induced by an antitumor agent or acute hepatopathy caused by carbon tetrachloride and thus effectively relieve drug-induced nephropathy or hepatopathy.

4 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

h e b b g e e e f e ef b e

☐ 10. Document ID: US 6383480 B1

L6: Entry 10 of 24 File: USPT May 7, 2002

US-PAT-NO: 6383480
DOCUMENT-IDENTIFIER: US 6383480 B1

TITLE: Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kikuchi; Makoto	Fukuoka			JP
Ikematsu; Shinya	Kanagawa			JP
Oda; Munehiro	Kanagawa			JP
Sakuma; Sadatoshi	Kanagawa			JP
Muramatsu; Takashi	Aichi			JP

US-CL-CURRENT: 424/85.1; 424/85.2, 514/2, 514/885, 530/300, 530/350, 530/399

ABSTRACT:

The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an agent for remarkably enhancing the above-described effect for promoting the proliferation of hematopoietic stem cells and hematopoietic precursor cells, comprising the MK family in combination with known hematopoietic factors such as IL-3, IL-6, G-CSF, GM-CSF, M-CSF, SCF, and EPO.

22 Claims, 17 Drawing figures
Exemplary Claim Number: 11
Number of Drawing Sheets: 17

☐ 11. Document ID: US 6271017 B1

L6: Entry 11 of 24 File: USPT Aug 7, 2001

US-PAT-NO: 6271017
DOCUMENT-IDENTIFIER: US 6271017 B1

TITLE: Genes of Heliciobacter pylori necessary for the regulation and maturation of urease and their use

DATE-ISSUED: August 7, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Labigne; Agnes	Bures sur Yvette			FR
Cussac; Valerie	Paris			FR
Ferrero; Richard	Paris			FR

h e b b g e e e f e ef b e

US-CL-CURRENT: 435/252.3; 435/320.1, 435/69.1, 435/91.2, 530/300, 530/328, 530/350, 530/387.1, 530/388.1, 530/389.5

ABSTRACT:

Oligonucletodie sequences are disclosed specific to H. pylori urease and useful as DNA probes and primers in the detection of H. pylori infection in humans.

18 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 12. Document ID: US 6201110 B1

L6: Entry 12 of 24 File: USPT Mar 13, 2001

US-PAT-NO: 6201110
DOCUMENT-IDENTIFIER: US 6201110 B1

TITLE: Polypeptide with reduced respiratory allergenicity

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Arne Agerlin	Virum			DK
Hansen; Lars Bo	Herlev			DK
Beck; Thomas Christian	Birker.o slashed.d			DK

US-CL-CURRENT: 530/402; 435/189, 435/190, 530/350, 530/403

ABSTRACT:

The invention relates to modified polypeptides with reduced respiratory allergenicity comprising a parent polypeptide with a molecular weight from between 10 kDa and 100 kDa conjugated to a polymer with a molecular weight (M.sub.r) in the range of 1 kDa and 60 kDa. The modified polypeptide are produced using a process including the step of conjugating from 1 to 30 polymer molecules with the parent polypeptide. Further the invention relates to compositions comprising said polypeptides and further ingredients normally used in e.g. detergents, including dishwashing detergents and soap bars, household article, agrochemicals, personal care products, cosmetics, toiletries, oral and dermal pharmaceuticals, composition for treating textiles, and compositions used for manufacturing food and feed. Finally the invention is directed to uses of polypeptides with reduced allergenicity or compositions thereof for reducing the allergenicity of products for a vast number of industrial applications.

14 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

h e b b g e e e f e ef b e

☐ 13. Document ID: US 6114509 A

L6: Entry 13 of 24 File: USPT Sep 5, 2000

US-PAT-NO: 6114509
DOCUMENT-IDENTIFIER: US 6114509 A

TITLE: Polypeptide with reduced allergenicity

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Arne Agerlin	Virum			DK
Hansen; Lars Bo	Herlev			DK
Beck; Thomas Christian	Birker.o slashed.d			DK

US-CL-CURRENT: 530/402; 435/189, 435/190, 530/350, 530/403

ABSTRACT:

The invention relates to modified polypeptides with reduced allergenicity comprising a parent polypeptide with a molecular weight from between 10 kDa and 100 kDa conjugated to a polymer with a molecular weight (M.sub.r) in the range of 1 kDa and 60 kDa. The modified polypeptide are produced using a process including the step of conjugating from 1 to 30 polymer molecules with the parent polypeptide. Further the invention relates to compositions comprising said polypeptides and further ingredients normally used in e.g. detergents, including dishwashing detergents and soap bars, household article, agrochemicals, personal care products, cosmetics, toiletries, oral and dermal pharmaceuticals, composition for treating textiles, and compositions used for manufacturing food and feed. Finally the invention is directed to uses of polypeptides with reduced allergenicity or compositions thereof for reducing the allergenicity of products for a vast number of industrial applications.

21 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 14. Document ID: US 6103880 A

L6: Entry 14 of 24 File: USPT Aug 15, 2000

US-PAT-NO: 6103880
DOCUMENT-IDENTIFIER: US 6103880 A

TITLE: HARP family growth factors

DATE-ISSUED: August 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barritault; Denis	Paris			FR
Courty; Jose	Villecresnes			FR
Laaroubi; Khalid	Sidi Kacem			MA

h e b b g e e e f e ef b e

US-CL-CURRENT: 530/399; 530/350

ABSTRACT:

Novel peptides having a SEQ ID No. 2 and SEQ ID No. 4 which peptides possess mitogenic properties.

1 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 15. Document ID: US 5986051 A

L6: Entry 15 of 24 File: USPT Nov 16, 1999

US-PAT-NO: 5986051
DOCUMENT-IDENTIFIER: US 5986051 A

TITLE: Genes of Helicobacter pylori necessary for the regulation and maturation of urease and their use

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Labigne; Agnes	Bures Sur Yvette			FR
Cussac; Valerie	Paris			FR
Ferrero; Richard	Paris			FR

US-CL-CURRENT: 530/350; 530/300, 530/328, 530/387.1, 530/388.1, 530/389.5

ABSTRACT:

This invention relates to Helicobacter polypeptides, particularly UreE, UreF, UreG, UreH, and UreI, immunogenic fragments of those polypeptides, and compositions containing those polypeptides or fragments. This invention also relates to purified antibodies that bind to the polypeptides of this invention and to compositions comprising those antibodies.

16 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 16. Document ID: US 5981718 A

L6: Entry 16 of 24 File: USPT Nov 9, 1999

US-PAT-NO: 5981718
DOCUMENT-IDENTIFIER: US 5981718 A

h e b b g e e e f e ef b e

TITLE: Polypeptide with reduced allergenicity

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Arne Agerlin	Virum			DK
Hansen; Lars Bo	Herlev			DK
Beck; Thomas Christian	Birker.o slashed.d			DK

US-CL-CURRENT: 530/402; 435/189, 435/193, 530/350, 530/403

ABSTRACT:

The invention relates to modified polypeptides with reduced allergenicity comprising a parent polypeptide with a molecular weight from between 10 kDa and 100 kDa conjugated to a polymer with a molecular weight (M.sub.r) in the range of 1 kDa and 60 kDa. The modified polypeptide are produced using a process including the step of conjugating from 1 to 30 polymer molecules with the parent polypeptide. Further the invention relates to compositions comprising said polypeptides and fruther ingredients normally used in e.g. detergents, including dishwashing detergents and soap bars, household article, agrochemicals, personal care products, cosmetics, toiletries, oral and dermal pharmaceuticals, composition for treating textiles, and compositions used for manufacturing food and feed. Finally the invention is directed to uses of polypeptides with reduced allergenicity or compositions thereof for reducing the allergenicity of products for a vast number of industrial applications.

12 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 17. Document ID: US 5886151 A

L6: Entry 17 of 24 File: USPT Mar 23, 1999

US-PAT-NO: 5886151
DOCUMENT-IDENTIFIER: US 5886151 A
**** See image for Certificate of Correction ****

TITLE: Candida albicans integrin-like protein

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hostetter; Margaret K.	Minneapolis	MN		
Gale; Cheryl A.	Minneapolis	MN		
Bendel; Catherine M.	Hopkins	MN		
Tao; Nian-jun	Malden	MA		
Kendrick; Kathleen	Columbus	OH		

US-CL-CURRENT: 530/371; 424/274.1, 530/300, 530/326

h e b b g e e e f e ef b e

ABSTRACT:

An isolated and purified DNA molecule encoding Candida albicans protein with integrin-like motifs, the protein itself, antibodies thereto, and methods of use, are provided.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 18. Document ID: US 5876730 A

L6: Entry 18 of 24 File: USPT Mar 2, 1999

US-PAT-NO: 5876730
DOCUMENT-IDENTIFIER: US 5876730 A

TITLE: Heparin-binding growth factor (HBGF) polypeptides

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brigstock; David R.	Dublin	OH		
Harding; Paul A.	Cincinnati	OH		

US-CL-CURRENT: 424/198.1; 435/69.4, 530/300, 530/350, 530/399, 530/850, 930/120

ABSTRACT:

Substantially pure heparin-binding growth factor polypeptides (HBGFs), nucleic acids encoding the HBGFs and antibodies which bind to the HBGFs of the invention are provided. The HBGF polypeptides are useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing. HBGF is related to Connective Tissue Growth Factor (CTGF).

9 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 19. Document ID: US 5856451 A

L6: Entry 19 of 24 File: USPT Jan 5, 1999

US-PAT-NO: 5856451
DOCUMENT-IDENTIFIER: US 5856451 A

TITLE: Method for reducing respiratory allergenicity

h e b b g e e e f e ef b e

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Arne Agerlin	Virum			DK
Hansen; Lars Bo	Herlev			DK
Beck; Thomas Christian	Birker.o slashed.d			DK

US-CL-CURRENT: 530/402; 435/189, 435/193, 530/350, 530/403

ABSTRACT:

The invention relates to modified polypeptides with reduced allergenicity comprising a parent polypeptide with a molecular weight from between 10 kDa and 100 kDa conjugated to a polymer with a molecular weight (M.sub.r) in the range of 1 kDa and 60 kDa. The modified polypeptide are produced using a process including the step of conjugating from 1 to 30 polymer molecules with the parent polypeptide. Further the invention relates to compositions comprising said polypeptides and further ingredients normally used in e.g. detergents, including dishwashing detergents and soap bars, household article, agrochemicals, personal care products, cosmetics, toiletries, oral and dermal pharmaceuticals, composition for treating textiles, and compositions used for manufacturing food and feed. Finally the invention is directed to uses of polypeptides with reduced allergenicity or compositions thereof for reducing the allergenicity of productsfor a vast number of industrial applications.

37 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 20. Document ID: US 5656436 A

L6: Entry 20 of 24 File: USPT Aug 12, 1997

US-PAT-NO: 5656436
DOCUMENT-IDENTIFIER: US 5656436 A

TITLE: Analog of Haemophilus Hin47 with reduced protease activity

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Loosmore; Sheena M.	Aurora			CA
Yang; Yan-Ping	Willowdale			CA
Chong; Pele	Richmond Hill			CA
Oomen; Raymond P.	Schomberg			CA
Klein; Michel H.	Willowdale			CA

US-CL-CURRENT: 435/7.1; 424/256.1, 435/252.3, 435/6, 435/7.32, 530/350, 536/23.1, 536/23.7

ABSTRACT:

h e b b g e e e f e ef b e

An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.

3 Claims, 23 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 23

21. Document ID: US 5187080 A

L6: Entry 21 of 24 File: USPT Feb 16, 1993

US-PAT-NO: 5187080
DOCUMENT-IDENTIFIER: US 5187080 A

TITLE: DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella

DATE-ISSUED: February 16, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andrews; William H.	San Mateo	CA		
Brothers; Virginia M.	Albany	CA		
Files; James G.	Belmont	CA		
Kuhn; Irene	San Francisco	CA		
McCaman; Michael T.	San Bruno	CA		
Sias; Stacey R.	San Anselmo	CA		
Paul; Leland S.	Island Lake	IL		
Gore; Thomas C.	Charles City	IA		
Newman, Jr.; Karel Z.	Eden Prairie	MN		
Tedesco; John L.	St. Peters	MO		

US-CL-CURRENT: 435/69.3; 424/191.1, 424/267.1, 435/235.1, 435/252.3, 435/252.33, 435/320.1, 435/69.1, 435/91.41, 530/300 , 530/350, 530/388.6, 536/23.4, 536/23.7

ABSTRACT:

Nucleic acid molecules are provided which encode antigenic proteins capable of inducing in a chicken an immune response conferring protection against Eimeria tenella. Expression vectors containing the nucleic acid molecules are also provided. Methods for producing the proteins or antigenic polypeptides having amino acid sequences included within these proteins are also provided.

20 Claims, 25 Drawing figures

h e b b g e e e f e ef b é

Exemplary Claim Number: 1,3,10,18,19
Number of Drawing Sheets: 33

☐ 22. Document ID: US 5185431 A

L6: Entry 22 of 24 File: USPT Feb 9, 1993

US-PAT-NO: 5185431
DOCUMENT-IDENTIFIER: US 5185431 A

TITLE: Recombinant natural killer cell activator

DATE-ISSUED: February 9, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yoshimatsu; Kentaro	Ibaraki			JP
Ohya; Yukio	Ibaraki			JP
Shikata; Yasushi	Ibaraki			JP
Tanaka; Isao	Ibaraki			JP
Hasegawa; Yoshikazu	Ibaraki			JP
Seto; Toshio	Ibaraki			JP
Osawa; Toshio	Tokyo			JP

US-CL-CURRENT: 530/351; 424/85.1, 435/69.5, 530/350, 530/395, 530/820, 930/120

ABSTRACT:

A recombinant natural killer cell activating factor is disclosed, preferably having a peptide of the following amino acid sequence in its molecule. The invention provides a cDNA coding for a recombinant natural killer cell activating factor, a expression plasmid involving the cDNA, a host transformed with the plasmid, an antitumor agent containing the recombinant natural killer cell activating factor and a pharmaceutical composition which comprises a pharmacologically effective amount of the antitumor agent and a pharmacologically acceptable carrier.

6 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 23. Document ID: US 5028694 A

L6: Entry 23 of 24 File: USPT Jul 2, 1991

US-PAT-NO: 5028694
DOCUMENT-IDENTIFIER: US 5028694 A

TITLE: Antigenic proteins and vaccines containing them for prevention of coccidiosis caused by eimeria Eimeria necatrix and Eimeria tenella

h e b b g e e e f e ef b e

DATE-ISSUED: July 2, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mewman, Jr.; Karel Z.	Charles City	IA		
Tedesco; John L.	Charles City	IA		
Gore; Thomas C.	Charles City	IA		
Petersen; Gary R.	Charles City	IA		
Brothers; Virginia M.	Albany	CA		
Files; James G.	Belmont	CA		
Paul; Leland S.	Woodside	CA		

US-CL-CURRENT: 530/350; 424/267.1, 530/388.6, 530/806, 530/825, 536/23.7

ABSTRACT:

A purified antigenic protein has been obtained which is capable of inducing in a chicken an immune response conferring protection against infection by Eimeria necatrix or Eimeria tenella. The protein has a molecular weight of about 26,000 and is composed of two polypeptides joined by a disulfide bond. The two polypeptide subunits have molecular weights of about 18,000 and about 8,000, respectively. The gene encoding the protein has been sequenced and the amino acid sequence of the protein deduced therefrom.

The protein and antigenic polypeptides having an amino acid sequence included within the protein may be incorporated into a vaccine for conferring upon a chicken active immunity against infection by E. necatrix or E. tenella.

1 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

24. Document ID: US 4874705 A

L6: Entry 24 of 24 File: USPT Oct 17, 1989

US-PAT-NO: 4874705
DOCUMENT-IDENTIFIER: US 4874705 A

TITLE: DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella

DATE-ISSUED: October 17, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andrews; William H.	Belmont	CA		
Brothers; Virginia M.	Albany	CA		
Files; James G.	Belmont	CA		
Kuhn; Irene	San Francisco	CA		
McCaman; Michael T.	San Bruno	CA		
Paul; Leland S.	Woodside	CA		

h e b b g e e e f e ef b e

Sias; Stacey R.	San Anselmo	CA
Gore; Thomas C.	Charles City	IA
Newman, Jr.; Karel Z.	Clear Lake	IA
Tedesco; John L.	St. Peters	MO

US-CL-CURRENT: 435/252.33; 424/191.1, 424/267.1, 435/320.1, 435/69.3, 530/350, 530/806, 536/23.5, 536/23.53

ABSTRACT:

A genomic DNA molecule having the nucleic acid sequence set forth in FIG. 1 and encoding an antigenic protein derived from Eimeria tenella has been isolated. The protein has a molecular weight of about 25,000 daltons and is composed of two polypeptides joined by a disulfide bond. One of the polypeptides is characterized by a molecular weight of about 17,000 daltons and by a blocked N-terminal amino acid and having the amino acid sequence set forth in FIG. 1. The other polypeptide is characterized by a molecular weight of about 8,000 daltons and has the amino acid sequence set forth in FIG. 1.

A cDNA molecule encoding the 25,000 dalton polypeptide with a continuous amino acid sequence has been inserted into expression vectors capable of expressing the 25,000 dalton polypeptide directly or as a fused polypeptide. The polypeptides produced are used in vaccines to immunize chickens against infection by Eimeria tenella.

26 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Terms	Documents
L4 AND PTN	24

h e b b g e e e f e ef b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for pleiotrophin Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-267 of 267 One page.

1: Furuta M, Shiraishi T, Okamoto H, Mineta T, Tabuchi K, Shiwa M. Related Articles, Links

Identification of pleiotrophin in conditioned medium secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry.
Brain Res Dev Brain Res. 2004 Sep 17;152(2):189-97.
PMID: 15351507 [PubMed - in process]

2: Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-Vozari R, Murer MG, Ruberg M, Gershanik O. Related Articles, Links

Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system.
J Neurochem. 2004 Sep;90(6):1348-58.
PMID: 15341519 [PubMed - in process]

3: Chen HW, Yu SL, Chen WJ, Yang PC, Chien CT, Chou HY, Li HN, Peck K, Huang CH, Lin FY, Chen JJ, Lee YT. Related Articles, Links

Dynamic changes of gene expression profiles during postnatal development of the heart in mice.
Heart. 2004 Aug;90(8):927-34.
PMID: 15253972 [PubMed - in process]

4: Deepa SS, Yamada S, Zako M, Goldberger O, Sugahara K. Related Articles, Links

Chondroitin Sulfate Chains on Syndecan-1 and Syndecan-4 from Normal Murine Mammary Gland Epithelial Cells Are Structurally and Functionally Distinct and Cooperate with Heparan Sulfate Chains to Bind Growth Factors: A NOVEL FUNCTION TO CONTROL BINDING OF MIDKINE, PLEIOTROPHIN, AND BASIC FIBROBLAST GROWTH FACTOR.
J Biol Chem. 2004 Sep 3;279(36):37368-76. Epub 2004 Jun 28.
PMID: 15226297 [PubMed - in process]

5: Liedert A, Augat P, Ignatius A, Hausser HJ, Claes L. Related Articles, Links

Mechanical regulation of HB-GAM expression in bone cells.
Biochem Biophys Res Commun. 2004 Jul 2;319(3):951-8.
PMID: 15184074 [PubMed - indexed for MEDLINE]

6: Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H. Related Articles, Links

Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells.
FASEB J. 2004 Aug;18(11):1237-9. Epub 2004 Jun 04.
PMID: 15180956 [PubMed - in process]

7: Oreffo RO. Related Articles, Links

Growth factors for skeletal reconstruction and fracture repair.
Curr Opin Investig Drugs. 2004 Apr;5(4):419-23. Review.
PMID: 15134283 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

8: Wang YT, Han S, Zhang KH, Jin Y, Xu XM, Lu PH. Related Articles, Links

Upregulation of heparin-binding growth-associated molecule after spinal cord injury in adult rats.
Acta Pharmacol Sin. 2004 May;25(5):611-6.
PMID: 15132827 [PubMed - indexed for MEDLINE]

9: Hienola A, Pekkanen M, Raulo E, Vanttola P, Rauvala H. Related Articles, Links

HB-GAM inhibits proliferation and enhances differentiation of neural stem cells.
Mol Cell Neurosci. 2004 May;26(1):75-88.
PMID: 15121180 [PubMed - indexed for MEDLINE]

10: Bonson S, Jeansonne BG, Lallier TE. Related Articles, Links

Root-end filling materials alter fibroblast differentiation.
J Dent Res. 2004 May;83(5):408-13.
PMID: 15111634 [PubMed - indexed for MEDLINE]

11: Rose FR, Hou Q, Oreffo RO. Related Articles, Links

Delivery systems for bone growth factors - the new players in skeletal regeneration.
J Pharm Pharmacol. 2004 Apr;56(4):415-27. Review.
PMID: 15099436 [PubMed - indexed for MEDLINE]

12: Ohyama K, Tan-Takeuchi K, Kutsche M, Schachner M, Uyemura K, Kawamura K. Related Articles, Links

Neural cell adhesion molecule L1 is required for fasciculation and routing of thalamocortical fibres and corticothalamic fibres.
Neurosci Res. 2004 Apr;48(4):471-5.
PMID: 15041201 [PubMed - indexed for MEDLINE]

13: Tsujimura A, Hashimoto-Gotoh T. Related Articles, Links

[Future perspectives on the osteoporosis gene therapy]
Nippon Rinsho. 2004 Feb;62 Suppl 2:794-8. Review. Japanese. No abstract available.
PMID: 15035229 [PubMed - indexed for MEDLINE]

14: Kadomatsu K, Muramatsu T. Related Articles, Links

Midkine and pleiotrophin in neural development and cancer.
Cancer Lett. 2004 Feb 20;204(2):127-43. Review.
PMID: 15013213 [PubMed - indexed for MEDLINE]

15: Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, Courty J. Related Articles, Links

Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.
Oncogene. 2004 Mar 4;23(9):1745-53.
PMID: 15001987 [PubMed - indexed for MEDLINE]

16: Tsai WC, Tsai ST, Ko JY, Jin YT, Li C, Huang W, Young KC, Lai MD, Liu HS, Wu LW. Related Articles, Links

The mRNA profile of genes in betel quid chewing oral cancer patients.
Oral Oncol. 2004 Apr;40(4):418-26.
PMID: 14969821 [PubMed - indexed for MEDLINE]

17: Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, Kiss E, Cohen CD, Madden S, Porubsky S, Grone EF, Schlondorff D, Nelson PJ, Grone HJ. Related Articles, Links

Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression.
Kidney Int. 2004 Mar;65(3):904-17.

h cb h g e e e fcg e ch b e

PMID: 14871410 [PubMed - in process]

18: Umehara Y, Yamada S, Nishimura S, Shioi J, Robakis NK, Sugahara K. Related Articles, Links

Chondroitin sulfate of appican, the proteoglycan form of amyloid precursor protein, produced by C6 glioma cells interacts with heparin-binding neuroregulatory factors.
FEBS Lett. 2004 Jan 16;557(1-3):233-8.
PMID: 14741373 [PubMed - indexed for MEDLINE]

19: Bernard-Pierrot I, Delbe J, Heroult M, Rosty C, Soulie P, Barritault D, Milhiet PE, Courty J. Related Articles, Links

Heparin affin regulatory peptide in milk: its involvement in mammary gland homeostasis.
Biochem Biophys Res Commun. 2004 Jan 30;314(1):277-82.
PMID: 14715276 [PubMed - indexed for MEDLINE]

20: Brunet-de Carvalho N, Raulais D, Rauvala H, Souttou B, Vigny M. Related Articles, Links

HB-GAM/Pleiotrophin and Midkine are differently expressed and distributed during retinoic acid-induced neural differentiation of P19 cells.
Growth Factors. 2003 Sep-Dec;21(3-4):139-49.
PMID: 14708942 [PubMed - indexed for MEDLINE]

21: Matsuoka A, Tsuchiya T. Related Articles, Links

Gene expression changes in BALB/3T3 transformants induced by poly(L-lactic acid) or polyurethane films.
J Biomed Mater Res. 2004 Feb 1;68A(2):376-82.
PMID: 14704980 [PubMed - indexed for MEDLINE]

22: Bao X, Nishimura S, Mikami T, Yamada S, Itoh N, Sugahara K. Related Articles, Links

Chondroitin sulfate/dermatan sulfate hybrid chains from embryonic pig brain, which contain a higher proportion of L-iduronic acid than those from adult pig brain, exhibit neuritogenic and growth factor binding activities.
J Biol Chem. 2004 Mar 12;279(11):9765-76. Epub 2003 Dec 29.
PMID: 14699094 [PubMed - indexed for MEDLINE]

23: Ulbricht U, Brockmann MA, Aigner A, Eckerich C, Muller S, Fillbrandt R, Westphal M, Lamszus K. Related Articles, Links

Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.
J Neuropathol Exp Neurol. 2003 Dec;62(12):1265-75.
PMID: 14692702 [PubMed - indexed for MEDLINE]

24: Pacicca DM, Patel N, Lee C, Salisbury K, Lehmann W, Carvalho R, Gerstenfeld LC, Einhorn TA. Related Articles, Links

Expression of angiogenic factors during distraction osteogenesis.
Bone. 2003 Dec;33(6):889-98.
PMID: 14678848 [PubMed - indexed for MEDLINE]

25: Sakurai H. Related Articles, Links

Molecular mechanism of ureteric bud development.
Semin Cell Dev Biol. 2003 Aug;14(4):217-24. Review.
PMID: 14627120 [PubMed - indexed for MEDLINE]

26: Paddock HN, Schultz GS, Baker HV, Varela JC, Beierle EA, Moldawer LL, Mozingo DW. Related Articles, Links

Analysis of gene expression patterns in human postburn hypertrophic scars.
J Burn Care Rehabil. 2003 Nov-Dec;24(6):371-7.
PMID: 14610421 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

27: Petersen W, Wildemann B, Pufe T, Raschke M, Schmidmaier G. Related Articles, Links

The angiogenic peptide pleiotrophin (PTN/HB-GAM) is expressed in fracture healing: an immunohistochemical study in rats.
Arch Orthop Trauma Surg. 2003 Oct 30 [Epub ahead of print]
PMID: 14586627 [PubMed - as supplied by publisher]

28: Murasugi A, Kido I, Kumai H, Asami Y. Related Articles, Links

Efficient production of recombinant human pleiotrophin in yeast, Pichia pastoris.
Biosci Biotechnol Biochem. 2003 Oct;67(10):2288-90.
PMID: 14586125 [PubMed - indexed for MEDLINE]

29: Muller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, von Schack D, Chin DJ, Lohr SC, Westphal M, Melcher T. Related Articles, Links

A role for receptor tyrosine phosphatase zeta in glioma cell migration.
Oncogene. 2003 Oct 2;22(43):6661-8.
PMID: 14555979 [PubMed - indexed for MEDLINE]

30: Barthlen W, Flaadt D, Girgert R, Conzelmann J, Schweizer P, Zugmaier G, Buck M, Knabbe C. Related Articles, Links

Significance of heparin-binding growth factor expression on cells of solid pediatric tumors.
J Pediatr Surg. 2003 Sep;38(9):1296-304.
PMID: 14523809 [PubMed - indexed for MEDLINE]

31: Mentlein R, Held-Feindt J. Related Articles, Links

Angiogenesis factors in gliomas: a new key to tumour therapy?
Naturwissenschaften. 2003 Sep;90(9):385-94. Epub 2003 Jul 29. Review.
PMID: 14504780 [PubMed - indexed for MEDLINE]

32: Aigner A, Brachmann P, Beyer J, Jager R, Raulais D, Vigny M, Neubauer A, Heidenreich A, Weinknecht S, Czubayko F, Zugmaier G. Related Articles, Links

Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients.
Ann Oncol. 2003 Oct;14(10):1525-9.
PMID: 14504053 [PubMed - indexed for MEDLINE]

33: Yang XB, Green DW, Roach HI, Clarke NM, Anderson HC, Howdle SM, Shakesheff KM, Oreffo RO. Related Articles, Links

Novel osteoinductive biomimetic scaffolds stimulate human osteoprogenitor activity--implications for skeletal repair.
Connect Tissue Res. 2003;44 Suppl 1:312-7.
PMID: 12952215 [PubMed - indexed for MEDLINE]

34: Maeda N, He J, Yajima Y, Mikami T, Sugahara K, Yabe T. Related Articles, Links

Heterogeneity of the chondroitin sulfate portion of phosphacan/6B4 proteoglycan regulates its binding affinity for pleiotrophin/heparin binding growth-associated molecule.
J Biol Chem. 2003 Sep 12;278(37):35805-11. Epub 2003 Jul 02.
PMID: 12840014 [PubMed - indexed for MEDLINE]

35: Hida H, Jung CG, Wu CZ, Kim HJ, Kodama Y, Masuda T, Nishino H. Related Articles, Links

Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro.
Eur J Neurosci. 2003 May;17(10):2127-34.
PMID: 12786979 [PubMed - indexed for MEDLINE]

Ikematsu S, Nakagawara A, Nakamura Y, Sakuma S, Wakai K,

36: Muramatsu T, Kadomatsu K. Related Articles, Links

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas.
Br J Cancer. 2003 May 19;88(10):1522-6.
PMID: 12771916 [PubMed - indexed for MEDLINE]

37: Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. Related Articles, Links

Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors.
Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399.
PMID: 12762884 [PubMed - indexed for MEDLINE]

38: Wang D, Oparil S, Feng JA, Li P, Perry G, Chen LB, Dai M, John SW, Chen YF. Related Articles, Links

Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse.
Hypertension. 2003 Jul;42(1):88-95. Epub 2003 May 19.
PMID: 12756220 [PubMed - indexed for MEDLINE]

39: Winkler C, Schafer M, Duschl J, Schartl M, Volff JN. Related Articles, Links

Functional divergence of two zebrafish midkine growth factors following fish-specific gene duplication.
Genome Res. 2003 Jun;13(6A):1067-81. Epub 2003 May 12.
PMID: 12743018 [PubMed - indexed for MEDLINE]

40: Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R. Related Articles, Links

Pleiotrophin, an embryonic differentiation and growth factor, is expressed in osteoarthritis.
Osteoarthritis Cartilage. 2003 Apr;11(4):260-4.
PMID: 12681952 [PubMed - indexed for MEDLINE]

41: Tanaka M, Maeda N, Noda M, Marunouchi T. Related Articles, Links

A chondroitin sulfate proteoglycan PTPzeta /RPTPbeta regulates the morphogenesis of Purkinje cell dendrites in the developing cerebellum.
J Neurosci. 2003 Apr 1;23(7):2804-14.
PMID: 12684467 [PubMed - indexed for MEDLINE]

42: Okopien B, Cwalina L, Haberka M, Kowalski J, Zielinski M, Szwed Z, Kalina Z, Herman ZS. Related Articles, Links

[Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia]
Pol Merkuriusz Lek. 2002 Dec;13(78):465-9. Polish.
PMID: 12666442 [PubMed - indexed for MEDLINE]

43: Moon HS, Park WI, Sung SH, Choi EA, Chung HW, Woo BH. Related Articles, Links

Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer.
Gynecol Oncol. 2003 Mar;88(3):289-97.
PMID: 12648577 [PubMed - indexed for MEDLINE]

44: Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R. Related Articles, Links

Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis.
Arthritis Rheum. 2003 Mar;48(3):660-7.
PMID: 12632418 [PubMed - indexed for MEDLINE]

45: Fujikawa A, Shirasaka D, Yamamoto S, Ota H, Yahiro K, Fukada M, Shintani T, Wada A, Aoyama N, Hirayama T, Fukamachi H, Related Articles, Links

Noda M.

Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.
Nat Genet. 2003 Mar;33(3):375-81. Epub 2003 Feb 24. Erratum in: Nat Genet. 2003 Apr;33(4):533.
PMID: 12598897 [PubMed - indexed for MEDLINE]

46: Seykora JT, Jih D, Elenitsas R, Horng WH, Elder DE. Related Articles, Links

Gene expression profiling of melanocytic lesions.
Am J Dermatopathol. 2003 Feb;25(1):6-11.
PMID: 12544092 [PubMed - indexed for MEDLINE]

47: Yang X, Tare RS, Partridge KA, Roach HI, Clarke NM, Howdle SM, Shakesheff KM, Oreffo RO. Related Articles, Links

Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering.
J Bone Miner Res. 2003 Jan;18(1):47-57.
PMID: 12510805 [PubMed - indexed for MEDLINE]

48: Dong Y, He C, Lu CL. Related Articles, Links

[Recent advances in the studies of Midkine family]
Sheng Li Ke Xue Jin Zhan. 1998 Jan;29(1):52-4. Review. Chinese. No abstract available.
PMID: 12501706 [PubMed - indexed for MEDLINE]

49: Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F. Related Articles, Links

Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression.
Gene Ther. 2002 Dec;9(24):1700-7.
PMID: 12457284 [PubMed - indexed for MEDLINE]

50: Beltran PJ, Bixby JL. Related Articles, Links

Receptor protein tyrosine phosphatases as mediators of cellular adhesion.
Front Biosci. 2003 Jan 01;8:d87-99. Review.
PMID: 12456340 [PubMed - indexed for MEDLINE]

51: Mentlein R, Held-Feindt J. Related Articles, Links

Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas.
J Neurochem. 2002 Nov;83(4):747-53.
PMID: 12421346 [PubMed - indexed for MEDLINE]

52: Tare RS, Oreffo RO, Sato K, Rauvala H, Clarke NM, Roach HI. Related Articles, Links

Effects of targeted overexpression of pleiotrophin on postnatal bone development.
Biochem Biophys Res Commun. 2002 Nov 1;298(3):324-32.
PMID: 12413943 [PubMed - indexed for MEDLINE]

53: Tare RS, Oreffo RO, Clarke NM, Roach HI. Related Articles, Links

Pleiotrophin/Osteoblast-stimulating factor 1: dissecting its diverse functions in bone formation.
J Bone Miner Res. 2002 Nov;17(11):2009-20.
PMID: 12412809 [PubMed - indexed for MEDLINE]

54: Wang Y, Chen Z, Chen Z, Guan X, Song H, Wu X, Liu Y. Related Articles, Links

Recombinant human heparin-binding neurite-promoting factor expressed with yeast stimulates neurites outgrowth.

h cb h g e e e fcg e ch b e

Chin Med J (Engl). 2002 Sep;115(9):1352-7.
PMID: 12411111 [PubMed - indexed for MEDLINE]

55: Kabasawa Y. Related Articles, Links

[The expression pattern of the chick pleiotrophin and its possible role in early embryogenesis]
Kokubyo Gakkai Zasshi. 2002 Sep;69(3):215-23. Japanese.
PMID: 12400177 [PubMed - indexed for MEDLINE]

56: Kaksonen M, Pavlov I, Voikar V, Lauri SE, Hienola A, Riekki R, Lakso M, Taira T, Rauvala H. Related Articles, Links

Syndecan-3-deficient mice exhibit enhanced LTP and impaired hippocampus-dependent memory.
Mol Cell Neurosci. 2002 Sep;21(1):158-72.
PMID: 12359158 [PubMed - indexed for MEDLINE]

57: Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K. Related Articles, Links

Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues.
J Biol Chem. 2002 Nov 15;277(46):43707-16. Epub 2002 Sep 06.
PMID: 12221095 [PubMed - indexed for MEDLINE]

58: Muramatsu T. Related Articles, Links

Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis.
J Biochem (Tokyo). 2002 Sep;132(3):359-71. Review.
PMID: 12204104 [PubMed - indexed for MEDLINE]

59: D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA, Chodosh LA. Related Articles, Links

Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland.
Mol Endocrinol. 2002 Sep;16(9):2034-51.
PMID: 12198241 [PubMed - indexed for MEDLINE]

60: Piscione TD, Rosenblum ND. Related Articles, Links

The molecular control of renal branching morphogenesis: current knowledge and emerging insights.
Differentiation. 2002 Aug;70(6):227-46. Review.
PMID: 12190985 [PubMed - indexed for MEDLINE]

61: Bastias J, Wei MX, Huynh R, Chaubet F, Jozefonvicz J, Crepin M. Related Articles, Links

Anti-proliferative and antitumoral activities of a functionalized dextran (CMDBJ) on the 1205 L-U human tumor melanoma cells.
Anticancer Res. 2002 May-Jun;22(3):1603-13.
PMID: 12168844 [PubMed - indexed for MEDLINE]

62: Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Related Articles, Links

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
J Biol Chem. 2002 Sep 27;277(39):35990-8. Epub 2002 Jul 16.
PMID: 12122009 [PubMed - indexed for MEDLINE]

63: Iseki K, Hagino S, Mori T, Zhang Y, Yokoya S, Takaki H, Tase C, Murakawa M, Wanaka A. Related Articles, Links

Increased syndecan expression by pleiotrophin and FGF receptor-

h cb hg e e e fcg e ch b e

expressing astrocytes in injured brain tissue.
Glia. 2002 Jul;39(1):1-9.
PMID: 12112370 [PubMed - indexed for MEDLINE]

64: Bowden ET, Stoica GE, Wellstein A. Related Articles, Links

Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase.
J Biol Chem. 2002 Sep 27;277(39):35862-8. Epub 2002 Jul 09.
PMID: 12107166 [PubMed - indexed for MEDLINE]

65: Pavlov I, Voikar V, Kaksonen M, Lauri SE, Hienola A, Taira T, Rauvala H. Related Articles, Links

Role of heparin-binding growth-associated molecule (HB-GAM) in hippocampal LTP and spatial learning revealed by studies on overexpressing and knockout mice.
Mol Cell Neurosci. 2002 Jun;20(2):330-42.
PMID: 12093164 [PubMed - indexed for MEDLINE]

66: Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D, Raulais D, Barritault D, Courty J, Milhiet PE. Related Articles, Links

Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.
J Biol Chem. 2002 Aug 30;277(35):32071-7. Epub 2002 Jun 17.
PMID: 12070152 [PubMed - indexed for MEDLINE]

67: Asahina K, Sato H, Yamasaki C, Kataoka M, Shiokawa M, Katayama S, Tateno C, Yoshizato K. Related Articles, Links

Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver.
Am J Pathol. 2002 Jun;160(6):2191-205.
PMID: 12057922 [PubMed - indexed for MEDLINE]

68: Sugino T, Kusakabe T, Hoshi N, Yamaguchi T, Kawaguchi T, Goodison S, Sekimata M, Homma Y, Suzuki T. Related Articles, Links

An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model.
Am J Pathol. 2002 Jun;160(6):1973-80.
PMID: 12057902 [PubMed - indexed for MEDLINE]

69: Qin LX, Tang ZY. Related Articles, Links

The prognostic molecular markers in hepatocellular carcinoma.
World J Gastroenterol. 2002 Jun;8(3):385-92. Review.
PMID: 12046056 [PubMed - indexed for MEDLINE]

70: Sato Y, Takita H, Ohata N, Tamura M, Kuboki Y. Related Articles, Links

Pleiotrophin regulates bone morphogenetic protein (BMP)-induced ectopic osteogenesis.
J Biochem (Tokyo). 2002 Jun;131(6):877-86.
PMID: 12038985 [PubMed - indexed for MEDLINE]

71: Kohashi T, Tateaki Y, Tateno C, Asahara T, Obara M, Yoshizato K. Related Articles, Links

Expression of pleiotrophin in hepatic nonparenchymal cells and preneoplastic nodules in carbon tetrachloride-induced fibrotic rat liver.
Growth Factors. 2002 Mar;20(1):53-60.
PMID: 11999218 [PubMed - indexed for MEDLINE]

72: Jager R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A, Zugmaier G. Related Articles, Links

Serum levels of the angiogenic factor pleiotrophin in relation to disease

stage in lung cancer patients.
Br J Cancer. 2002 Mar 18;86(6):858-63.
PMID: 11953815 [PubMed - indexed for MEDLINE]

73: Achour A, Laaroubi D, Caruelle D, Barritault D, Courty J. Related Articles, Links

The angiogenic factor heparin affin regulatory peptide (HARP) induces proliferation of human peripheral blood mononuclear cells.
Cell Mol Biol (Noisy-le-grand). 2001;47 Online Pub:OL73-7.
PMID: 11936877 [PubMed - indexed for MEDLINE]

74: Chung HW, Wen Y, Choi EA, Hao-Li, Moon HS, Yu HK, Polan ML. Related Articles, Links

Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis.
Mol Hum Reprod. 2002 Apr;8(4):350-5.
PMID: 11912283 [PubMed - indexed for MEDLINE]

75: Klomp HJ, Zernial O, Flachmann S, Wellstein A, Juhl H. Related Articles, Links

Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients.
Clin Cancer Res. 2002 Mar;8(3):823-7.
PMID: 11895915 [PubMed - indexed for MEDLINE]

76: Magee TR, Qian A, Rajfer J, Sander FC, Levine LA, Gonzalez-Cadavid NF. Related Articles, Links

Gene expression profiles in the Peyronie's disease plaque.
Urology. 2002 Mar;59(3):451-7.
PMID: 11880101 [PubMed - indexed for MEDLINE]

77: Soulie P, Heroult M, Bernard J, Kerros ME, Milhiet PE, Delbe J, Barritault D, Caruelle D, Courty J. Related Articles, Links

Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids.
J Immunoassay Immunochem. 2002;23(1):33-48.
PMID: 11848100 [PubMed - indexed for MEDLINE]

78: Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Related Articles, Links

Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway.
Arch Biochem Biophys. 2002 Jan 15;397(2):162-71. Review.
PMID: 11795867 [PubMed - indexed for MEDLINE]

79: Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Related Articles, Links

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
J Biol Chem. 2002 Apr 19;277(16):14153-8. Epub 2002 Jan 23.
PMID: 11809760 [PubMed - indexed for MEDLINE]

80: Sakurai H, Bush KT, Nigam SK. Related Articles, Links

Identification of pleiotrophin as a mesenchymal factor involved in ureteric bud branching morphogenesis.
Development. 2001 Sep;128(17):3283-93.
PMID: 11546745 [PubMed - indexed for MEDLINE]

81: Haynes L, Rumsby M. Related Articles, Links

The pleiotropin/midkine family of cytokines: role in glial-neuronal signalling.
Prog Brain Res. 2001;132:313-24. Review. No abstract available.
PMID: 11545000 [PubMed - indexed for MEDLINE]

82: Satoh J, Kuroda Y. Related Articles, Links

Differing effects of IFN beta vs IFN gamma in MS: gene expression in cultured astrocytes.
Neurology. 2001 Aug 28;57(4):681-5.
PMID: 11524479 [PubMed - indexed for MEDLINE]

83: Sanchez-Ramos JR, Song S, Kamath SG, Zigova T, Willing A, Cardozo-Pelaez F, Stedeford T, Chopp M, Sanberg PR. Related Articles, Links

Expression of neural markers in human umbilical cord blood.
Exp Neurol. 2001 Sep;171(1):109-15.
PMID: 11520125 [PubMed - indexed for MEDLINE]

84: Petersen W, Rafii M. Related Articles, Links

Immunolocalization of the angiogenetic factor pleiotrophin (PTN) in the growth plate of mice.
Arch Orthop Trauma Surg. 2001 Jul;121(7):414-6.
PMID: 11510908 [PubMed - indexed for MEDLINE]

85: Amet LE, Lauri SE, Hienola A, Croll SD, Lu Y, Levorse JM, Prabhakaran B, Taira T, Rauvala H, Vogt TF. Related Articles, Links

Enhanced hippocampal long-term potentiation in mice lacking heparin-binding growth-associated molecule.
Mol Cell Neurosci. 2001 Jun;17(6):1014-24.
PMID: 11414790 [PubMed - indexed for MEDLINE]

86: Hendrickx S, Thomas P, Preston BN, Stanton PG, Van Damme MP. Related Articles, Links

Partial characterization of matrix components interacting with cartilage proteoglycans.
Arch Biochem Biophys. 2001 Jun 15;390(2):186-94.
PMID: 11396921 [PubMed - indexed for MEDLINE]

87: Kawachi H, Fujikawa A, Maeda N, Noda M. Related Articles, Links

Identification of GIT1/Cat-1 as a substrate molecule of protein tyrosine phosphatase zeta /beta by the yeast substrate-trapping system.
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6593-8. Epub 2001 May 29.
PMID: 11381105 [PubMed - indexed for MEDLINE]

88: Benko I, Kovacs P, Szegedi I, Megyeri A, Kiss A, Balogh E, Olah E, Kappelmayer J, Kiss C. Related Articles, Links

Effect of myelopoietic and pleiotropic cytokines on colony formation by blast cells of children with acute lymphoblastic leukemia.
Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):499-508.
PMID: 11383710 [PubMed - indexed for MEDLINE]

89: Chen J, Zhong Q, Wang J, Cameron RS, Borke JL, Isales CM, Bollag RJ. Related Articles, Links

Microarray analysis of Tbx2-directed gene expression: a possible role in osteogenesis.
Mol Cell Endocrinol. 2001 May 25;177(1-2):43-54.
PMID: 11377819 [PubMed - indexed for MEDLINE]

90: Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, Muramatsu T, Kadomatsu K. Related Articles, Links

Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase.
J Biol Chem. 2001 May 11;276(19):15868-75.
PMID: 11340082 [PubMed - indexed for MEDLINE]

91: Stuart RO, Bush KT, Nigam SK. Related Articles, Links

Changes in global gene expression patterns during development and maturation of the rat kidney.
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5649-54. Epub 2001 May 01.
PMID: 11331749 [PubMed - indexed for MEDLINE]

92: Kuroi K, Toi M. Related Articles, Links

Circulating angiogenesis regulators in cancer patients.
Int J Biol Markers. 2001 Jan-Mar;16(1):5-26. Review.
PMID: 11288955 [PubMed - indexed for MEDLINE]

93: Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Related Articles, Links

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin.
J Biol Chem. 2001 May 18;276(20):16772-9. Epub 2001 Feb 08.
PMID: 11278720 [PubMed - indexed for MEDLINE]

94: Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P. Related Articles, Links

HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides.
Biochem Biophys Res Commun. 2001 Mar 23;282(1):306-13.
PMID: 11264008 [PubMed - indexed for MEDLINE]

95: Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. Related Articles, Links

The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Oncogene. 2001 Jan 4;20(1):97-105.
PMID: 11244508 [PubMed - indexed for MEDLINE]

96: Souttou B, Raulais D, Vigny M. Related Articles, Links

Pleiotrophin induces angiogenesis: involvement of the phosphoinositide-3 kinase but not the nitric oxide synthase pathways.
J Cell Physiol. 2001 Apr;187(1):59-64.
PMID: 11241349 [PubMed - indexed for MEDLINE]

97: Xue L, Tassiopoulos AK, Woloson SK, Stanton DL Jr, Ms CS, Hampton B, Burgess WH, Greisler HP. Related Articles, Links

Construction and biological characterization of an HB-GAM/FGF-1 chimera for vascular tissue engineering.
J Vasc Surg. 2001 Mar;33(3):554-60.
PMID: 11241127 [PubMed - indexed for MEDLINE]

98: Bany BM, Schultz GA. Related Articles, Links

Pleiotrophin messenger ribonucleic acid levels increase in mouse endometrial stromal cells during decidualization.
Endocrinology. 2001 Feb;142(2):955-8.
PMID: 11159869 [PubMed - indexed for MEDLINE]

99: Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE. Related Articles, Links

The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities.
J Biol Chem. 2001 Apr 13;276(15):12228-34. Epub 2001 Jan 09.
PMID: 11150308 [PubMed - indexed for MEDLINE]

100: Poulsen FR, Lagord C, Courty J, Pedersen EB, Barritault D, Finsen B. Related Articles, Links

h cb h g e e e fcg e ch b e

Increased synthesis of heparin affin regulatory peptide in the perforant path lesioned mouse hippocampal formation.
Exp Brain Res. 2000 Dec;135(3):319-30.
PMID: 11146810 [PubMed - indexed for MEDLINE]

101: Dewing P, Ching ST, Zhang YH, Huang BL, Peirce RM, McCabe ER, Vilain E. Related Articles, Links

Midkine is expressed early in rat fetal adrenal development.
Mol Genet Metab. 2000 Dec;71(4):616-22.
PMID: 11136554 [PubMed - indexed for MEDLINE]

102: Azizan A, Gaw JU, Govindraj P, Tapp H, Neame PJ. Related Articles, Links

Chondromodulin I and pleiotrophin gene expression in bovine cartilage and epiphysis.
Matrix Biol. 2000 Nov;19(6):521-31.
PMID: 11068206 [PubMed - indexed for MEDLINE]

103: Satyamoorthy K, Oka M, Herlyn M. Related Articles, Links

An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin.
Pigment Cell Res. 2000;13 Suppl 8:87-93.
PMID: 11041363 [PubMed - indexed for MEDLINE]

104: Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H. Related Articles, Links

Pleiotrophin can be rate-limiting for pancreatic cancer cell growth.
Cancer Res. 2000 Sep 15;60(18):5284-8.
PMID: 11016659 [PubMed - indexed for MEDLINE]

105: Ikeda S, Ichihara-Tanaka K, Azuma T, Muramatsu T, Yamada M. Related Articles, Links

Effects of midkine during in vitro maturation of bovine oocytes on subsequent developmental competence.
Biol Reprod. 2000 Oct;63(4):1067-74.
PMID: 10993828 [PubMed - indexed for MEDLINE]

106: Virkola R, Brummer M, Rauvala H, van Alphen L, Korhonen TK. Related Articles, Links

Interaction of fimbriae of Haemophilus influenzae type B with heparin-binding extracellular matrix proteins.
Infect Immun. 2000 Oct;68(10):5696-701.
PMID: 10992473 [PubMed - indexed for MEDLINE]

107: Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, Kilpelainen I. Related Articles, Links

Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility.
Matrix Biol. 2000 Sep;19(5):377-87. Review.
PMID: 10980414 [PubMed - indexed for MEDLINE]

108: Schulte AM, Malerczyk C, Cabal-Manzano R, Gajarsa JJ, List HJ, Riegel AT, Wellstein A. Related Articles, Links

Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of growth factor pleiotrophin: a critical role of a retroviral Sp1-binding site.
Oncogene. 2000 Aug 17;19(35):3988-98.
PMID: 10962555 [PubMed - indexed for MEDLINE]

109: Papadimitriou E, Heroult M, Courty J, Polykratis A, Stergiou C, Katsoris P. Related Articles, Links

Endothelial cell proliferation induced by HARP: implication of N or C

terminal peptides.
Biochem Biophys Res Commun. 2000 Jul 21;274(1):242-8.
PMID: 10903925 [PubMed - indexed for MEDLINE]

☐ **110:** Kadomatsu K. Related Articles, Links

[Recent progress of midkine research on cancer]
Nippon Rinsho. 2000 Jun;58(6):1337-47. Review. Japanese.
PMID: 10879061 [PubMed - indexed for MEDLINE]

☐ **111:** Zou K, Muramatsu H, Ikematsu S, Sakuma S, Salama RH, Shinomura T, Kimata K, Muramatsu T. Related Articles, Links

A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican.
Eur J Biochem. 2000 Jul;267(13):4046-53.
PMID: 10866805 [PubMed - indexed for MEDLINE]

☐ **112:** Inui T, Nakao M, Nishio H, Nishiuchi Y, Kojima S, Muramatsu T, Kimura T. Related Articles, Links

Solution synthesis and biological activity of human pleiotrophin, a novel heparin-binding neurotrophic factor consisting of 136 amino acid residues with five disulfide bonds.
J Pept Res. 2000 May;55(5):384-97.
PMID: 10863935 [PubMed - indexed for MEDLINE]

☐ **113:** Fan QW, Muramatsu T, Kadomatsu K. Related Articles, Links

Distinct expression of midkine and pleiotrophin in the spinal cord and placental tissues during early mouse development.
Dev Growth Differ. 2000 Apr;42(2):113-9.
PMID: 10830434 [PubMed - indexed for MEDLINE]

☐ **114:** Cherrington JM, Strawn LM, Shawver LK. Related Articles, Links

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
Adv Cancer Res. 2000;79:1-38. Review.
PMID: 10818676 [PubMed - indexed for MEDLINE]

☐ **115:** Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. Related Articles, Links

Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta.
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8.
PMID: 10706604 [PubMed - indexed for MEDLINE]

☐ **116:** Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Related Articles, Links

Regulation of cell migration by amphoterin.
J Cell Sci. 2000 Feb;113 (Pt 4):611-20.
PMID: 10652254 [PubMed - indexed for MEDLINE]

☐ **117:** Yoshioka N, Inoue H, Nakanishi K, Oka K, Yutsudo M, Yamashita A, Hakura A, Nojima H. Related Articles, Links

Isolation of transformation suppressor genes by cDNA subtraction: lumican suppresses transformation induced by v-src and v-K-ras.
J Virol. 2000 Jan;74(2):1008-13.
PMID: 10623765 [PubMed - indexed for MEDLINE]

☐ **118:** Sakakibara S. Related Articles, Links

Chemical synthesis of proteins in solution.
Biopolymers. 1999;51(4):279-96. Review.

PMID: 10618596 [PubMed - indexed for MEDLINE]

119: Tapp H, Hernandez DJ, Neame PJ, Koob TJ. Related Articles, Links

Pleiotrophin inhibits chondrocyte proliferation and stimulates proteoglycan synthesis in mature bovine cartilage.
Matrix Biol. 1999 Dec;18(6):543-56.
PMID: 10607916 [PubMed - indexed for MEDLINE]

120: Bernard-Pierrot I, Heroult M, Lemaitre G, Barritault D, Courty J, Milhiet PE. Related Articles, Links

Glycosaminoglycans promote HARP/PTN dimerization.
Biochem Biophys Res Commun. 1999 Dec 20;266(2):437-42.
PMID: 10600521 [PubMed - indexed for MEDLINE]

121: Neame PJ, Tapp H, Azizan A. Related Articles, Links

Noncollagenous, nonproteoglycan macromolecules of cartilage.
Cell Mol Life Sci. 1999 Aug 15;55(10):1327-40. Review.
PMID: 10487209 [PubMed - indexed for MEDLINE]

122: Godden JL, Edward M, MacKie RM. Related Articles, Links

Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor.
Eur J Cancer. 1999 Mar;35(3):473-80.
PMID: 10448302 [PubMed - indexed for MEDLINE]

123: Permi P, Heikkinen S, Kilpelainen I, Annila A. Related Articles, Links

Measurement of homonuclear (2)J-couplings from spin-state selective double-/zero-quantum two-dimensional NMR spectra.
J Magn Reson. 1999 Aug;139(2):273-80.
PMID: 10423364 [PubMed - indexed for MEDLINE]

124: Fath M, VanderNoot V, Kilpelainen I, Kinnunen T, Rauvala H, Linhardt RJ. Related Articles, Links

Interaction of soluble and surface-bound heparin binding growth-associated molecule with heparin.
FEBS Lett. 1999 Jul 2;454(1-2):105-8.
PMID: 10413105 [PubMed - indexed for MEDLINE]

125: Rumsby M, Suggitt F, Haynes L, Hughson E, Kidd D, McNulty S. Related Articles, Links

Substratum of pleiotrophin (HB-GAM) stimulates rat CG-4 line oligodendrocytes to adopt a bipolar morphology and disperse: primary O-2A progenitor glial cells disperse similarly on pleiotrophin.
Glia. 1999 Jun;26(4):361-7.
PMID: 10383055 [PubMed - indexed for MEDLINE]

126: Delbe J, Katsoris P, Milhiet PE, Barritault D, Caruelle D, Courty J. Related Articles, Links

[Implication of HARP in angiogenesis and possible therapeutic role]
Pathol Biol (Paris). 1999 Apr;47(4):352-7. Review. French.
PMID: 10372404 [PubMed - indexed for MEDLINE]

127: Zhang N, Yeh HJ, Zhong R, Li YS, Deuel TF. Related Articles, Links

A dominant-negative pleiotrophin mutant introduced by homologous recombination leads to germ-cell apoptosis in male mice.
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6734-8.
PMID: 10359781 [PubMed - indexed for MEDLINE]

128: Zhang N, Zhong R, Deuel TF. Related Articles, Links

Domain structure of pleiotrophin required for transformation.
J Biol Chem. 1999 May 7;274(19):12959-62.
PMID: 10224041 [PubMed - indexed for MEDLINE]

129: Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. Related Articles, Links

A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta.
J Biol Chem. 1999 Apr 30;274(18):12474-9.
PMID: 10212223 [PubMed - indexed for MEDLINE]

130: Yamakawa T, Kurosawa N, Kadomatsu K, Matsui T, Itoh K, Maeda N, Noda M, Muramatsu T. Related Articles, Links

Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers.
Cancer Lett. 1999 Jan 8;135(1):91-6.
PMID: 10077226 [PubMed - indexed for MEDLINE]

131: Vacherot F, Delbe J, Heroult M, Barritault D, Fernig DG, Courty J. Related Articles, Links

Glycosaminoglycans differentially bind HARP and modulate its biological activity.
J Biol Chem. 1999 Mar 19;274(12):7741-7.
PMID: 10075664 [PubMed - indexed for MEDLINE]

132: Kinnunen A, Niemi M, Kinnunen T, Kaksonen M, Nolo R, Rauvala H. Related Articles, Links

Heparan sulphate and HB-GAM (heparin-binding growth-associated molecule) in the development of the thalamocortical pathway of rat brain.
Eur J Neurosci. 1999 Feb;11(2):491-502.
PMID: 10051750 [PubMed - indexed for MEDLINE]

133: Wakisaka S, Tabata MJ, Maeda T, Matsumoto K, Wanaka A, Muramatsu H, Muramatsu T, Kurisu K. Related Articles, Links

Immunohistochemical localization of pleiotrophin and midkine in the lingual epithelium of the adult rat.
Arch Histol Cytol. 1998 Dec;61(5):475-80.
PMID: 9990431 [PubMed - indexed for MEDLINE]

134: Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP, Courty J. Related Articles, Links

Involvement of heparin affin regulatory peptide in human prostate cancer.
Prostate. 1999 Feb 1;38(2):126-36.
PMID: 9973098 [PubMed - indexed for MEDLINE]

135: Juhl H, Czubayko F, Henne-Bruns D. Related Articles, Links

[Ribozyme targeting as gene therapy method for treatment of malignant tumors]
Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1474-7. German.
PMID: 9931916 [PubMed - indexed for MEDLINE]

136: Zhang N, Deuel TF. Related Articles, Links

Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors.
Curr Opin Hematol. 1999 Jan;6(1):44-50. Review.
PMID: 9915553 [PubMed - indexed for MEDLINE]

137: Sato H, Funahashi M, Kristensen DB, Tateno C, Yoshizato K. Related Articles, Links

Pleiotrophin as a Swiss 3T3 cell-derived potent mitogen for adult rat

hepatocytes.
Exp Cell Res. 1999 Jan 10;246(1):152-64.
PMID: 9882525 [PubMed - indexed for MEDLINE]

138: Milhiet PE, Vacherot F, Caruelle JP, Barritault D, Caruelle D, Courty J. Related Articles, Links

Upregulation of the angiogenic factor heparin affin regulatory peptide by progesterone in rat uterus.
J Endocrinol. 1998 Sep;158(3):389-99.
PMID: 9846168 [PubMed - indexed for MEDLINE]

139: Imai S, Kaksonen M, Raulo E, Kinnunen T, Fages C, Meng X, Lakso M, Rauvala H. Related Articles, Links

Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM).
J Cell Biol. 1998 Nov 16;143(4):1113-28.
PMID: 9817766 [PubMed - indexed for MEDLINE]

140: Liu X, Mashour GA, Webster HF, Kurtz A. Related Articles, Links

Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin.
Glia. 1998 Dec;24(4):390-7.
PMID: 9814819 [PubMed - indexed for MEDLINE]

141: Nishiuchi Y, Inui T, Nishio H, Bodi J, Kimura T, Tsuji FI, Sakakibara S. Related Articles, Links

Chemical synthesis of the precursor molecule of the Aequorea green fluorescent protein, subsequent folding, and development of fluorescence.
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13549-54.
PMID: 9811837 [PubMed - indexed for MEDLINE]

142: Peng HB, Ali AA, Daggett DF, Rauvala H, Hassell JR, Smalheiser NR. Related Articles, Links

The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction.
Cell Adhes Commun. 1998 Sep;5(6):475-89.
PMID: 9791728 [PubMed - indexed for MEDLINE]

143: Soutiou B, Juhl H, Hackenbruck J, Rockseisen M, Klomp HJ, Raulais D, Vigny M, Wellstein A. Related Articles, Links

Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors.
J Natl Cancer Inst. 1998 Oct 7;90(19):1468-73.
PMID: 9776412 [PubMed - indexed for MEDLINE]

144: Lauri SE, Rauvala H, Kaila K, Taira T. Related Articles, Links

Effect of heparin-binding growth-associated molecule (HB-GAM) on synaptic transmission and early LTP in rat hippocampal slices.
Eur J Neurosci. 1998 Jan;10(1):188-94.
PMID: 9753126 [PubMed - indexed for MEDLINE]

145: Kinnunen A, Kinnunen T, Kaksonen M, Nolo R, Panula P, Rauvala H. Related Articles, Links

N-syndecan and HB-GAM (heparin-binding growth-associated molecule) associate with early axonal tracts in the rat brain.
Eur J Neurosci. 1998 Feb;10(2):635-48.
PMID: 9749725 [PubMed - indexed for MEDLINE]

146: Fages C, Kaksonen M, Kinnunen T, Punnonen EL, Rauvala H. Related Articles, Links

Regulation of mRNA localization by transmembrane signalling: local interaction of HB-GAM (heparin-binding growth-associated molecule) with the cell surface localizes beta-actin mRNA.
J Cell Sci. 1998 Oct;111 (Pt 20):3073-80.
PMID: 9739080 [PubMed - indexed for MEDLINE]

147: Maeda N, Noda M. Related Articles, Links

Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration.
J Cell Biol. 1998 Jul 13;142(1):203-16.
PMID: 9660874 [PubMed - indexed for MEDLINE]

148: Dreyfus J, Brunet-de Carvalho N, Duprez D, Raulais D, Vigny M. Related Articles, Links

HB-GAM/pleiotrophin but not RIHB/midkine enhances chondrogenesis in micromass culture.
Exp Cell Res. 1998 May 25;241(1):171-80.
PMID: 9633525 [PubMed - indexed for MEDLINE]

149: Schulte AM, Wellstein A. Related Articles, Links

Structure and phylogenetic analysis of an endogenous retrovirus inserted into the human growth factor gene pleiotrophin.
J Virol. 1998 Jul;72(7):6065-72.
PMID: 9621070 [PubMed - indexed for MEDLINE]

150: Yeh HJ, He YY, Xu J, Hsu CY, Deuel TF. Related Articles, Links

Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury.
J Neurosci. 1998 May 15;18(10):3699-707.
PMID: 9570800 [PubMed - indexed for MEDLINE]

151: Dreyfus J, Brunet-de Carvalho N, Duprez D, Raulais D, Vigny M. Related Articles, Links

HB-GAM/pleiotrophin: localization of mRNA and protein in the chicken developing leg.
Int J Dev Biol. 1998 Mar;42(2):189-98.
PMID: 9551864 [PubMed - indexed for MEDLINE]

152: Milev P, Chiba A, Haring M, Rauvala H, Schachner M, Ranscht B, Margolis RK, Margolis RU. Related Articles, Links

High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule.
J Biol Chem. 1998 Mar 20;273(12):6998-7005.
PMID: 9507007 [PubMed - indexed for MEDLINE]

153: Kurtz A, Spitzer E, Zschiesche W, Wellstein A, Grosse R. Related Articles, Links

Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophin.
Biochem Soc Symp. 1998;63:51-69. Review.
PMID: 9513711 [PubMed - indexed for MEDLINE]

154: Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ, Burrow CR. Related Articles, Links

Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases.
J Biol Chem. 1998 Feb 6;273(6):3654-60.

PMID: 9452495 [PubMed - indexed for MEDLINE]

☐ **155:** Czubayko F, Downing SG, Hsieh SS, Goldstein DJ, Lu PY, Trapnell BC, Wellstein A. Related Articles, Links

Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation.
Gene Ther. 1997 Sep;4(9):943-9.
PMID: 9349431 [PubMed - indexed for MEDLINE]

☐ **156:** Iwasaki W, Nagata K, Hatanaka H, Inui T, Kimura T, Muramatsu T, Yoshida K, Tasumi M, Inagaki F. Related Articles, Links

Solution structure of midkine, a new heparin-binding growth factor.
EMBO J. 1997 Dec 1;16(23):6936-46.
PMID: 9384573 [PubMed - indexed for MEDLINE]

☐ **157:** Haltia A, Solin ML, Muramatsu T, Jalanko H, Holmberg C, Miettinen A, Holthofer H. Related Articles, Links

Expression of nine developmental stage-specific genes in human kidney and cultured renal cells.
Exp Nephrol. 1997 Nov-Dec;5(6):457-64.
PMID: 9438174 [PubMed - indexed for MEDLINE]

☐ **158:** Jager R, Noll K, Havemann K, Pfluger KH, Knabbe C, Rauvala H, Zugmaier G. Related Articles, Links

Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines.
Int J Cancer. 1997 Nov 14;73(4):537-43.
PMID: 9389569 [PubMed - indexed for MEDLINE]

☐ **159:** Sato M, Miyado K, Okazaki M, Kimura M. Related Articles, Links

Regulation of osteoblast-specific factor-1 (OSF-1) mRNA expression by dual promoters as revealed by RT-PCR.
Biochem Biophys Res Commun. 1997 Sep 29;238(3):831-7.
PMID: 9325176 [PubMed - indexed for MEDLINE]

☐ **160:** Corbley MJ. Related Articles, Links

Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin.
J Biol Chem. 1997 Sep 26;272(39):24696-702.
PMID: 9305941 [PubMed - indexed for MEDLINE]

☐ **161:** Masuda H, Tsujimura A, Yoshioka M, Arai Y, Kuboki Y, Mukai T, Nakamura T, Tsuji H, Nakagawa M, Hashimoto-Gotoh T. Related Articles, Links

Bone mass loss due to estrogen deficiency is compensated in transgenic mice overexpressing human osteoblast stimulating factor-1.
Biochem Biophys Res Commun. 1997 Sep 18;238(2):528-33.
PMID: 9299545 [PubMed - indexed for MEDLINE]

☐ **162:** Ledoux D, Caruelle D, Sabourin JC, Liu J, Crepin M, Barritault D, Courty J. Related Articles, Links

Cellular distribution of the angiogenic factor heparin affin regulatory peptide (HARP) mRNA and protein in the human mammary gland.
J Histochem Cytochem. 1997 Sep;45(9):1239-45.
PMID: 9283611 [PubMed - indexed for MEDLINE]

☐ **163:** Nakanishi T, Kadomatsu K, Okamoto T, Tomoda Y, Muramatsu T. Related Articles, Links

Expression of midkine and pleiotropin in ovarian tumors.
Obstet Gynecol. 1997 Aug;90(2):285-90.
PMID: 9241309 [PubMed - indexed for MEDLINE]

☐ **164:** Souttou B, Ahmad S, Riegel AT, Wellstein A. Related Articles, Links

Signal transduction pathways involved in the mitogenic activity of pleiotrophin. Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways.
J Biol Chem. 1997 Aug 1;272(31):19588-93.
PMID: 9235965 [PubMed - indexed for MEDLINE]

☐ **165:** Zhang N, Zhong R, Wang ZY, Deuel TF. Related Articles, Links

Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant.
J Biol Chem. 1997 Jul 4;272(27):16733-6.
PMID: 9201975 [PubMed - indexed for MEDLINE]

☐ **166:** Rauvala H, Peng HB. Related Articles, Links

HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts.
Prog Neurobiol. 1997 Jun;52(2):127-44. Review.
PMID: 9185236 [PubMed - indexed for MEDLINE]

☐ **167:** Ratovitski EA, Burrow CR. Related Articles, Links

Midkine stimulates Wilms' tumor cell proliferation via its signaling receptor.
Cell Mol Biol (Noisy-le-grand). 1997 May;43(3):425-31.
PMID: 9193798 [PubMed - indexed for MEDLINE]

☐ **168:** Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. Related Articles, Links

An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis.
Cancer Res. 1997 May 1;57(9):1814-9.
PMID: 9135027 [PubMed - indexed for MEDLINE]

☐ **169:** Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Related Articles, Links

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Cancer Res. 1997 Mar 1;57(5):963-9.
PMID: 9041202 [PubMed - indexed for MEDLINE]

☐ **170:** Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP, Evans AE. Related Articles, Links

Expression of TrkA, TrkB and TrkC in human neuroblastomas.
J Neurooncol. 1997 Jan;31(1-2):49-55.
PMID: 9049830 [PubMed - indexed for MEDLINE]

☐ **171:** Jonakait GM. Related Articles, Links

Cytokines in neuronal development.
Adv Pharmacol. 1997;37:35-67. Review. No abstract available.
PMID: 8891099 [PubMed - indexed for MEDLINE]

☐ **172:** Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, Wellstein A. Related Articles, Links

Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus.
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14759-64.

PMID: 8962128 [PubMed - indexed for MEDLINE]

173: Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Related Articles, Links

Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin.
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14753-8.
PMID: 8962127 [PubMed - indexed for MEDLINE]

174: Hornum L, Markholst H. Related Articles, Links

Mapping of the rat Ptn gene to chromosome 4.
Mamm Genome. 1996 Dec;7(12):923-4. No abstract available.
PMID: 8995771 [PubMed - indexed for MEDLINE]

175: Chen Y, McKenzie KE, Aldaz CM, Sukumar S. Related Articles, Links

Midkine in the progression of rat N-nitroso-N-methylurea-induced mammary tumors.
Mol Carcinog. 1996 Nov;17(3):112-6.
PMID: 8944070 [PubMed - indexed for MEDLINE]

176: Silos-Santiago I, Yeh HJ, Gurrieri MA, Guillerman RP, Li YS, Wolf J, Snider W, Deuel TF. Related Articles, Links

Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neural-glial interactions during development and in maturity.
J Neurobiol. 1996 Nov;31(3):283-96.
PMID: 8910787 [PubMed - indexed for MEDLINE]

177: Husmann I, Soulet L, Gautron J, Martelly I, Barritault D. Related Articles, Links

Growth factors in skeletal muscle regeneration.
Cytokine Growth Factor Rev. 1996 Oct;7(3):249-58. Review.
PMID: 8971480 [PubMed - indexed for MEDLINE]

178: Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. Related Articles, Links

6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM).
J Biol Chem. 1996 Aug 30;271(35):21446-52.
PMID: 8702927 [PubMed - indexed for MEDLINE]

179: Szabat E, Rauvala H. Related Articles, Links

Role of HB-GAM (heparin-binding growth-associated molecule) in proliferation arrest in cells of the developing rat limb and its expression in the differentiating neuromuscular system.
Dev Biol. 1996 Aug 25;178(1):77-89.
PMID: 8812110 [PubMed - indexed for MEDLINE]

180: Nolo R, Kaksonen M, Rauvala H. Related Articles, Links

Developmentally regulated neurite outgrowth response from dorsal root ganglion neurons to heparin-binding growth-associated molecule (HB-GAM) and the expression of HB-GAM in the targets of the developing dorsal root ganglion neurites.
Eur J Neurosci. 1996 Aug;8(8):1658-65.
PMID: 8921256 [PubMed - indexed for MEDLINE]

181: Lauri SE, Taira T, Kaila K, Rauvala H. Related Articles, Links

Activity-induced enhancement of HB-GAM expression in rat hippocampal slices.

h cb h g e e e fcg e ch b e

Neuroreport. 1996 Jul 8;7(10):1670-4.
PMID: 8904779 [PubMed - indexed for MEDLINE]

182: Muramatsu H, Song XJ, Koide N, Hada H, Tsuji T, Kadomatsu K, Inui T, Kimura T, Sakakibara S, Muramatsu T Related Articles, Links

Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas.
J Biochem (Tokyo). 1996 Jun;119(6):1171-5.
PMID: 8827454 [PubMed - indexed for MEDLINE]

183: Wisniewski T, Lalowski M, Baumann M, Rauvala H, Raulo E, Nolo R, Frangione B. Related Articles, Links

HB-GAM is a cytokine present in Alzheimer's and Down's syndrome lesions.
Neuroreport. 1996 Jan 31;7(2):667-71.
PMID: 8730853 [PubMed - indexed for MEDLINE]

184: Kinnunen T, Raulo E, Nolo R, Maccarana M, Lindahl U, Rauvala H. Related Articles, Links

Neurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface.
J Biol Chem. 1996 Jan 26;271(4):2243-8.
PMID: 8567685 [PubMed - indexed for MEDLINE]

185: Daggett DF, Cohen MW, Stone D, Nikolics K, Rauvala H, Peng HB. Related Articles, Links

The role of an agrin-growth factor interaction in ACh receptor clustering.
Mol Cell Neurosci. 1996;8(4):272-85.
PMID: 9026315 [PubMed - indexed for MEDLINE]

186: Harris AL, Zhang H, Moghaddam A, Fox S, Scott P, Pattison A, Gatter K, Stratford I, Bicknell R. Related Articles, Links

Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Breast Cancer Res Treat. 1996;38(1):97-108. Review.
PMID: 8825127 [PubMed - indexed for MEDLINE]

187: Brigstock DR, Kim GY, Steffen CL. Related Articles, Links

Pig uterine luminal fluid contains the developmentally regulated neurotrophic factor, pleiotrophin.
J Endocrinol. 1996 Jan;148(1):103-11.
PMID: 8568456 [PubMed - indexed for MEDLINE]

188: Wanaka A. Related Articles, Links

Expression of heparin-binding growth factors and their receptors in neural development.
Kaibogaku Zasshi. 1995 Dec;70(6):512-20. Review. No abstract available.
PMID: 8721807 [PubMed - indexed for MEDLINE]

189: Kojima S, Inui T, Muramatsu H, Kimura T, Sakakibara S, Muramatsu T. Related Articles, Links

Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension.
Biochem Biophys Res Commun. 1995 Nov 13;216(2):574-81.
PMID: 7488150 [PubMed - indexed for MEDLINE]

190: Vacherot F, Laaroubi K, Caruelle D, Delbe J, Barritault D, Caruelle JP, Courty J. Related Articles, Links

Upregulation of heparin-affin regulatory peptide by androgen.
In Vitro Cell Dev Biol Anim. 1995 Oct;31(9):647-8. No abstract available.
PMID: 8564072 [PubMed - indexed for MEDLINE]

191: Wewetzer K, Rauvala H, Unsicker K. Related Articles, Links

Immunocytochemical localization of the heparin-binding growth-associated molecule (HB-GAM) in the developing and adult rat cerebellar cortex.
Brain Res. 1995 Sep 25;693(1-2):31-8.
PMID: 8653419 [PubMed - indexed for MEDLINE]

192: Tsujimura A, Yasojima K, Kuboki Y, Suzuki A, Ueno N, Shiokawa K, Hashimoto-Gotoh T. Related Articles, Links

Developmental and differential regulations in gene expression of Xenopus pleiotrophic factors-alpha and -beta.
Biochem Biophys Res Commun. 1995 Sep 14;214(2):432-9.
PMID: 7677748 [PubMed - indexed for MEDLINE]

193: Takeda A, Onodera H, Sugimoto A, Itoyama Y, Kogure K, Rauvala H, Shibahara S. Related Articles, Links

Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury.
Neuroscience. 1995 Sep;68(1):57-64.
PMID: 7477935 [PubMed - indexed for MEDLINE]

194: Nakamura H, Kimura S, Kenmotsu S, Sakai H, Saku T, Ozawa H. Related Articles, Links

Immunolocalization of CD44 and heparan sulfate chains on the stratum intermedium and papillary layer in the rat enamel organ.
Arch Histol Cytol. 1995 Aug;58(3):323-34.
PMID: 8527239 [PubMed - indexed for MEDLINE]

195: Sekiguchi K, Yokota C, Asashima M, Kaname T, Fan QW, Muramatsu T, Kadomatsu K. Related Articles, Links

Restricted expression of Xenopus midkine gene during early development.
J Biochem (Tokyo). 1995 Jul;118(1):94-100.
PMID: 8537332 [PubMed - indexed for MEDLINE]

196: Obama H, Tsutsui J, Ozawa M, Yoshida H, Yoshida Y, Osame M, Muramatsu T. Related Articles, Links

Midkine (MK) expression in extraembryonic tissues, amniotic fluid, and cerebrospinal fluid during mouse embryogenesis.
J Biochem (Tokyo). 1995 Jul;118(1):88-93.
PMID: 8537330 [PubMed - indexed for MEDLINE]

197: Delbe J, Vacherot F, Laaroubi K, Barritault D, Courty J. Related Articles, Links

Effect of heparin on bovine epithelial lens cell proliferation induced by heparin affin regulatory peptide.
J Cell Physiol. 1995 Jul;164(1):47-54.
PMID: 7790396 [PubMed - indexed for MEDLINE]

198: Muramatsu T. Related Articles, Links

[Midkine in relation to development and pathological status of the nervous system]
Nihon Shinkei Seishin Yakurigaku Zasshi. 1995 Jun;15(3):275-9. Review. Japanese.
PMID: 7584721 [PubMed - indexed for MEDLINE]

199: Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM. Related Articles, Links

Differential expression of pleiotrophin and midkine in advanced neuroblastomas.
Cancer Res. 1995 Apr 15;55(8):1792-7.
PMID: 7712489 [PubMed - indexed for MEDLINE]

200: Peng HB, Ali AA, Dai Z, Daggett DF, Raulo E, Rauvala H. Related Articles, Links

The role of heparin-binding growth-associated molecule (HB-GAM) in the postsynaptic induction in cultured muscle cells.
J Neurosci. 1995 Apr;15(4):3027-38.
PMID: 7722643 [PubMed - indexed for MEDLINE]

201: Lai S, Schulte AM, Wellstein A, Riegel AT. Related Articles, Links

An additional 5'-upstream exon exists in the human pleiotrophin-encoding gene.
Gene. 1995 Feb 14;153(2):301-2.
PMID: 7875612 [PubMed - indexed for MEDLINE]

202: Kojima S, Inui T, Kimura T, Sakakibara S, Muramatsu H, Amanuma H, Maruta H, Muramatsu T. Related Articles, Links

Synthetic peptides derived from midkine enhance plasminogen activator activity in bovine aortic endothelial cells.
Biochem Biophys Res Commun. 1995 Jan 17;206(2):468-73.
PMID: 7826363 [PubMed - indexed for MEDLINE]

203: Kurtz A, Schulte AM, Wellstein A. Related Articles, Links

Pleiotrophin and midkine in normal development and tumor biology.
Crit Rev Oncog. 1995;6(2):151-77. Review.
PMID: 8792088 [PubMed - indexed for MEDLINE]

204: Laaroubi K, Vacherot F, Delbe J, Caruelle D, Barritault D, Courty J. Related Articles, Links

Biochemical and mitogenic properties of the heparin-binding growth factor HARP.
Prog Growth Factor Res. 1995;6(1):25-34. Review.
PMID: 8714367 [PubMed - indexed for MEDLINE]

205: Czubayko F, Schulte AM, Missner SC, Hsieh SS, Colley KJ, Wellstein A. Related Articles, Links

Molecular and pharmacologic targeting of angiogenesis factors--the example of pleiotrophin.
Breast Cancer Res Treat. 1995;36(2):157-68. Review.
PMID: 8534864 [PubMed - indexed for MEDLINE]

206: Mitsiadis TA, Salmivirta M, Muramatsu T, Muramatsu H, Rauvala H, Lehtonen E, Jalkanen M, Thesleff I. Related Articles, Links

Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis.
Development. 1995 Jan;121(1):37-51.
PMID: 7867507 [PubMed - indexed for MEDLINE]

207: O'Hara B, Jenkins NA, Gilbert DJ, Copeland NG, Shows TB, Eddy RL, Bohlen P, Kovesdi I. Related Articles, Links

Chromosomal assignment of the heparin-binding cytokine genes MDK and PTN in mouse and man.
Cytogenet Cell Genet. 1995;69(1-2):40-3.
PMID: 7835084 [PubMed - indexed for MEDLINE]

208: Zhang L, Rees MC, Bicknell R. Related Articles, Links

The isolation and long-term culture of normal human endometrial epithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges.
J Cell Sci. 1995 Jan;108 (Pt 1):323-31.
PMID: 7537745 [PubMed - indexed for MEDLINE]

209: Take M, Tsutsui J, Obama H, Ozawa M, Nakayama T, Maruyama I, Arima T, Muramatsu T. Related Articles, Links

Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM).
J Biochem (Tokyo). 1994 Nov;116(5):1063-8.
PMID: 7896734 [PubMed - indexed for MEDLINE]

210: Ohyama Y, Miyamoto K, Minamino N, Matsuo H. Related Articles, Links

Isolation and identification of midkine and pleiotrophin in bovine follicular fluid.
Mol Cell Endocrinol. 1994 Nov;105(2):203-8.
PMID: 7859927 [PubMed - indexed for MEDLINE]

211: Matsumoto K, Wanaka A, Mori T, Taguchi A, Ishii N, Muramatsu H, Muramatsu T, Tohyama M. Related Articles, Links

Localization of pleiotrophin and midkine in the postnatal developing cerebellum.
Neurosci Lett. 1994 Sep 12;178(2):216-20.
PMID: 7824199 [PubMed - indexed for MEDLINE]

212: Fu C, Maminta-Smith LD, Guo C, Deuel TF. Related Articles, Links

Cloning and sequence of the Xenopus laevis homologue of the midkine cDNA.
Gene. 1994 Sep 2;146(2):311-2.
PMID: 8076838 [PubMed - indexed for MEDLINE]

213: Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Related Articles, Links

Midkine and pleiotrophin expression in normal and malignant breast tissue.
Cancer. 1994 Sep 1;74(5):1584-90.
PMID: 7520350 [PubMed - indexed for MEDLINE]

214: Czubayko F, Riegel AT, Wellstein A. Related Articles, Links

Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth.
J Biol Chem. 1994 Aug 19;269(33):21358-63.
PMID: 8063762 [PubMed - indexed for MEDLINE]

215: Sapi E, Flick MB, Kacinski BM. Related Articles, Links

The first intron of human c-fms proto-oncogene contains a processed pseudogene (RPL7P) for ribosomal protein L7.
Genomics. 1994 Aug;22(3):641-5.
PMID: 8001978 [PubMed - indexed for MEDLINE]

216: Mailleux P, Preud'homme X, Albala N, Vanderwinden JM, Vanderhaeghen JJ. Related Articles, Links

delta-9-Tetrahydrocannabinol regulates gene expression of the growth factor pleiotrophin in the forebrain.
Neurosci Lett. 1994 Jul 4;175(1-2):25-7.
PMID: 7970205 [PubMed - indexed for MEDLINE]

217: Matsumoto K, Wanaka A, Takatsuji K, Muramatsu H, Muramatsu T, Tohyama M. Related Articles, Links

A novel family of heparin-binding growth factors, pleiotrophin and midkine, is expressed in the developing rat cerebral cortex.
Brain Res Dev Brain Res. 1994 Jun 17;79(2):229-41.
PMID: 7955321 [PubMed - indexed for MEDLINE]

218: Rauvala H, Vanhala A, Castren E, Nolo R, Raulo E, Merenmies J, Panula P. Related Articles, Links

Expression of HB-GAM (heparin-binding growth-associated molecules) in the pathways of developing axonal processes in vivo and neurite outgrowth in vitro induced by HB-GAM.
Brain Res Dev Brain Res. 1994 Jun 17;79(2):157-76.
PMID: 7955315 [PubMed - indexed for MEDLINE]

219: Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H. Related Articles, Links

Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3).
J Biol Chem. 1994 Apr 29;269(17):12999-3004.
PMID: 8175719 [PubMed - indexed for MEDLINE]

220: Obama H, Matsubara S, Guenet JL, Muramatsu T. Related Articles, Links

The midkine (MK) family of growth/differentiation factors: structure of an MK-related sequence in a pseudogene and evolutionary relationships among members of the MK family.
J Biochem (Tokyo). 1994 Mar;115(3):516-22.
PMID: 8056766 [PubMed - indexed for MEDLINE]

221: Seddon AP, Hulmes JD, Decker MM, Kovesdi I, Fairhurst JL, Backer J, Dougher-Vermazen M, Bohlen P. Related Articles, Links

Refolding and characterization of human recombinant heparin-binding neurite-promoting factor.
Protein Expr Purif. 1994 Feb;5(1):14-21.
PMID: 8167469 [PubMed - indexed for MEDLINE]

222: Riegel AT, Wellstein A. Related Articles, Links

The potential role of the heparin-binding growth factor pleiotrophin in breast cancer.
Breast Cancer Res Treat. 1994;31(2-3):309-14. Review.
PMID: 7533562 [PubMed - indexed for MEDLINE]

223: Wellstein A. Related Articles, Links

Growth factor targeted and conventional therapy of breast cancer.
Breast Cancer Res Treat. 1994;31(2-3):141-51. Review.
PMID: 7533560 [PubMed - indexed for MEDLINE]

224: Laaroubi K, Delbe J, Vacherot F, Desgranges P, Tardieu M, Jaye M, Barritault D, Courty J. Related Articles, Links

Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide.
Growth Factors. 1994;10(2):89-98.
PMID: 7520717 [PubMed - indexed for MEDLINE]

225: Novotny WF, Maffi T, Mehta RL, Milner PG. Related Articles, Links

Identification of novel heparin-releasable proteins, as well as the cytokines midkine and pleiotrophin, in human postheparin plasma.
Arterioscler Thromb. 1993 Dec;13(12):1798-805.
PMID: 8241100 [PubMed - indexed for MEDLINE]

226: Gieffers C, Engelhardt W, Brenzel G, Matsuishi T, Frey J. Related Articles, Links

Receptor binding of osteoblast-specific factor 1 (OSF-1/HB-GAM) to human osteosarcoma cells promotes cell attachment.
Eur J Cell Biol. 1993 Dec;62(2):352-61.
PMID: 7925491 [PubMed - indexed for MEDLINE]

227: Peichel CL, Scherer SW, Tsui LC, Beier DR, Vogt TF. Related Articles, Links

Mapping the midkine family of developmentally regulated signaling molecules.
Mamm Genome. 1993 Nov;4(11):632-8.
PMID: 8281012 [PubMed - indexed for MEDLINE]

228: Garver RI Jr, Chan CS, Milner PG. Related Articles, Links

Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues.
Am J Respir Cell Mol Biol. 1993 Nov;9(5):463-6.
PMID: 8217186 [PubMed - indexed for MEDLINE]

229: Wewetzer K, Janet T, Heymann D, Unsicker K. Related Articles, Links

Cell blotting and isoelectric focusing of neuroblastoma-derived heparin-binding neurotrophic activities: detection of basic fibroblast growth factor protein and mRNA.
J Neurosci Res. 1993 Oct 1;36(2):209-15.
PMID: 8263972 [PubMed - indexed for MEDLINE]

230: Li YS, Deuel TF. Related Articles, Links

Pleiotrophin stimulates tyrosine phosphorylation in NIH 3T3 and NB41A3 cells.
Biochem Biophys Res Commun. 1993 Sep 15;195(2):1089-95.
PMID: 7690551 [PubMed - indexed for MEDLINE]

231: Fabri L, Maruta H, Muramatsu H, Muramatsu T, Simpson RJ, Burgess AW, Nice EC. Related Articles, Links

Structural characterisation of native and recombinant forms of the neurotrophic cytokine MK.
J Chromatogr. 1993 Aug 27;646(1):213-25.
PMID: 8408430 [PubMed - indexed for MEDLINE]

232: Neame PJ, Young CN, Brock CW, Treep JT, Ganey TM, Sasse J, Rosenberg LC. Related Articles, Links

Pleiotrophin is an abundant protein in dissociative extracts of bovine fetal epiphyseal cartilage and nasal cartilage from newborns.
J Orthop Res. 1993 Jul;11(4):479-91.
PMID: 8340821 [PubMed - indexed for MEDLINE]

233: Hulmes JD, Seddon AP, Decker MM, Bohlen P. Related Articles, Links

Comparison of the disulfide bond arrangements of human recombinant and bovine brain heparin binding neurite-promoting factors.
Biochem Biophys Res Commun. 1993 Apr 30;192(2):738-46.
PMID: 8484780 [PubMed - indexed for MEDLINE]

234: Kretschmer PJ, Fairhurst JL, Hulmes JD, Popjes ML, Bohlen P, Kovesdi I Related Articles, Links

Genomic organization of the human HBNF gene and characterization of an HBNF variant protein as a splice mutant.
Biochem Biophys Res Commun. 1993 Apr 30;192(2):420-9.
PMID: 8484754 [PubMed - indexed for MEDLINE]

235: Wanaka A, Carroll SL, Milbrandt J. Related Articles, Links

Developmentally regulated expression of pleiotrophin, a novel heparin binding growth factor, in the nervous system of the rat.
Brain Res Dev Brain Res. 1993 Mar 19;72(1):133-44.
PMID: 8453763 [PubMed - indexed for MEDLINE]

236: Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T. Related Articles, Links

A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas.
Cancer Res. 1993 Mar 15;53(6):1281-5.
PMID: 8383007 [PubMed - indexed for MEDLINE]

237: Muramatsu T. Related Articles, Links

Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation.
Int J Dev Biol. 1993 Mar;37(1):183-8. Review.
PMID: 8507561 [PubMed - indexed for MEDLINE]

238: Chauhan AK, Li YS, Deuel TF. Related Articles, Links

Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice.
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):679-82.
PMID: 8421705 [PubMed - indexed for MEDLINE]

239: Li YS, Hoffman RM, Le Beau MM, Espinosa R 3rd, Jenkins NA, Gilbert DJ, Copeland NG, Deuel TF. Related Articles, Links

Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization.
J Biol Chem. 1992 Dec 25;267(36):26011-6.
PMID: 1464612 [PubMed - indexed for MEDLINE]

240: Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Related Articles, Links

Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer.
J Biol Chem. 1992 Dec 25;267(36):25889-97.
PMID: 1464602 [PubMed - indexed for MEDLINE]

241: Bloch B, Normand E, Kovesdi I, Bohlen P. Related Articles, Links

Expression of the HBNF (heparin-binding neurite-promoting factor) gene in the brain of fetal, neonatal and adult rat: an in situ hybridization study.
Brain Res Dev Brain Res. 1992 Dec 18;70(2):267-78.
PMID: 1477961 [PubMed - indexed for MEDLINE]

242: Ostrander M, Fingar H, Seddon A, Bohlen P, Backer J. Related Articles, Links

Anti-viral activity of human recombinant heparin-binding proteins HBNF and MK.
Biochem Biophys Res Commun. 1992 Dec 15;189(2):1189-95.
PMID: 1335242 [PubMed - indexed for MEDLINE]

243: Milner PG, Shah D, Veile R, Donis-Keller H, Kumar BV. Related Articles, Links

Cloning, nucleotide sequence, and chromosome localization of the human pleiotrophin gene.
Biochemistry. 1992 Dec 8;31(48):12023-8.
PMID: 1457401 [PubMed - indexed for MEDLINE]

244: Katoh K, Takeshita S, Sato M, Ito T, Amann E. Related Articles, Links

Genomic organization of the mouse OSF-1 gene.
DNA Cell Biol. 1992 Dec;11(10):735-43.

PMID: 1457042 [PubMed - indexed for MEDLINE]

245: Nurcombe V, Fraser N, Herlaar E, Heath JK. Related Articles, Links

MK: a pluripotential embryonic stem-cell-derived neuroregulatory factor.
Development. 1992 Dec;116(4):1175-83.
PMID: 1295735 [PubMed - indexed for MEDLINE]

246: Fabri L, Nice EC, Ward LD, Maruta H, Burgess AW, Simpson RJ. Related Articles, Links

Characterization of bovine heparin-binding neurotrophic factor (HBNF): assignment of disulfide bonds.
Biochem Int. 1992 Oct;28(1):1-9.
PMID: 1445382 [PubMed - indexed for MEDLINE]

247: Lai S, Czubayko F, Riegel AT, Wellstein A. Related Articles, Links

Structure of the human heparin-binding growth factor gene pleiotrophin.
Biochem Biophys Res Commun. 1992 Sep 16;187(2):1113-22.
PMID: 1530608 [PubMed - indexed for MEDLINE]

248: Vanderwinden JM, Mailleux P, Schiffmann SN, Vanderhaeghen JJ. Related Articles, Links

Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues.
Anat Embryol (Berl). 1992 Sep;186(4):387-406.
PMID: 1416088 [PubMed - indexed for MEDLINE]

249: Nakamoto M, Matsubara S, Miyauchi T, Obama H, Ozawa M, Muramatsu T. Related Articles, Links

A new family of heparin binding growth/differentiation factors: differential expression of the midkine (MK) and HB-GAM genes during mouse development.
J Biochem (Tokyo). 1992 Sep;112(3):346-9.
PMID: 1343086 [PubMed - indexed for MEDLINE]

250: Mailleux P, Vanderwinden JM, Vanderhaeghen JJ. Related Articles, Links

The new growth factor pleiotrophin (HB-GAM) mRNA is selectively present in the meningothelial cells of human meningiomas.
Neurosci Lett. 1992 Aug 3;142(1):31-5.
PMID: 1407714 [PubMed - indexed for MEDLINE]

251: Merenmies J. Related Articles, Links

Cell density-dependent expression of heparin-binding growth-associated molecule (HB-GAM, p18) and its down-regulation by fibroblast growth factors.
FEBS Lett. 1992 Aug 3;307(3):297-300.
PMID: 1379543 [PubMed - indexed for MEDLINE]

252: Raulo E, Julkunen I, Merenmies J, Pihlaskari R, Rauvala H. Related Articles, Links

Secretion and biological activities of heparin-binding growth-associated molecule. Neurite outgrowth-promoting and mitogenic actions of the recombinant and tissue-derived protein.
J Biol Chem. 1992 Jun 5;267(16):11408-16.
PMID: 1597470 [PubMed - indexed for MEDLINE]

253: Takamatsu H, Itoh M, Kimura M, Gospodarowicz D, Amann E. Related Articles, Links

Expression and purification of biologically active human OSF-1 in Escherichia coli.
Biochem Biophys Res Commun. 1992 May 29;185(1):224-30. Erratum in: Biochem Biophys Res Commun 1992 Aug 31;187(1):561.

h cb h g e e e fcg e ch b e

PMID: 1599459 [PubMed - indexed for MEDLINE]

254: Li YS, Gurrieri M, Deuel TF. Related Articles, Links

Pleiotrophin gene expression is highly restricted and is regulated by platelet-derived growth factor.
Biochem Biophys Res Commun. 1992 Apr 15;184(1):427-32.
PMID: 1373617 [PubMed - indexed for MEDLINE]

255: Naito A, Yoshikura H, Iwamoto A. Related Articles, Links

Similarity of the genomic structure between the two members in a new family of heparin-binding factors.
Biochem Biophys Res Commun. 1992 Mar 16;183(2):701-7.
PMID: 1550576 [PubMed - indexed for MEDLINE]

256: Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, Sasse J, Riegel AT, Lippman ME. Related Articles, Links

A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine.
J Biol Chem. 1992 Feb 5;267(4):2582-7.
PMID: 1733956 [PubMed - indexed for MEDLINE]

257: Kuo MD, Huang SS, Huang JS. Related Articles, Links

Characterization of heparin-binding growth-associated factor receptor on NIH 3T3 cells.
Biochem Biophys Res Commun. 1992 Jan 15;182(1):188-94.
PMID: 1731778 [PubMed - indexed for MEDLINE]

258: Hampton BS, Marshak DR, Burgess WH. Related Articles, Links

Structural and functional characterization of full-length heparin-binding growth associated molecule.
Mol Biol Cell. 1992 Jan;3(1):85-93.
PMID: 1550956 [PubMed - indexed for MEDLINE]

259: Courty J, Dauchel MC, Caruelle D, Perderiset M, Barritault D. Related Articles, Links

Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin.
Biochem Biophys Res Commun. 1991 Oct 15;180(1):145-51.
PMID: 1819274 [PubMed - indexed for MEDLINE]

260: Tsutsui J, Uehara K, Kadomatsu K, Matsubara S, Muramatsu T. Related Articles, Links

A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse.
Biochem Biophys Res Commun. 1991 Apr 30;176(2):792-7.
PMID: 2025291 [PubMed - indexed for MEDLINE]

261: Bohlen P, Muller T, Gautschi-Sova P, Albrecht U, Rasool CG, Decker M, Seddon A, Fafeur V, Kovesdi I, Kretschmer P. Related Articles, Links

Isolation from bovine brain and structural characterization of HBNF, a heparin-binding neurotrophic factor.
Growth Factors. 1991;4(2):97-107.
PMID: 2049182 [PubMed - indexed for MEDLINE]

262: Bohlen P, Kovesdi I. Related Articles, Links

HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function.
Prog Growth Factor Res. 1991;3(2):143-57. Review.
PMID: 1773041 [PubMed - indexed for MEDLINE]

Kretschmer PJ, Fairhurst JL, Decker MM, Chan CP, Gluzman Y. Related Articles, Links

263: Bohlen P, Kovesdi I.

Cloning, characterization and developmental regulation of two members of a novel human gene family of neurite outgrowth-promoting proteins.
Growth Factors. 1991;5(2):99-114.
PMID: 1768439 [PubMed - indexed for MEDLINE]

264: Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, Milbrandt J, Deuel TF. Related Articles, Links

Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity.
Science. 1990 Dec 21;250(4988):1690-4.
PMID: 2270483 [PubMed - indexed for MEDLINE]

265: Tezuka K, Takeshita S, Hakeda Y, Kumegawa M, Kikuno R, Hashimoto-Gotoh T. Related Articles, Links

Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblasts and brain tissues.
Biochem Biophys Res Commun. 1990 Nov 30;173(1):246-51.
PMID: 1701634 [PubMed - indexed for MEDLINE]

266: Kovesdi I, Fairhurst JL, Kretschmer PJ, Bohlen P. Related Articles, Links

Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins.
Biochem Biophys Res Commun. 1990 Oct 30;172(2):850-4.
PMID: 1700712 [PubMed - indexed for MEDLINE]

267: Merenmies J, Rauvala H. Related Articles, Links

Molecular cloning of the 18-kDa growth-associated protein of developing brain.
J Biol Chem. 1990 Oct 5;265(28):16721-4.
PMID: 2170351 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Aug 30 2004 06:52:01

h cb hg e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: Eur J Biochem. 1999 Sep;264(3):702-6.

Related Articles, Links

Full text
blackwell-synergy.com

A new member of the alpha4-related molecule (alpha4-b) that binds to the protein phosphatase 2A is expressed selectively in the brain and testis.

Maeda K, Inui S, Tanaka H, Sakaguchi N.

Department of Immunology, Kumamoto University School of Medicine, Kumamoto, Japan.

A murine alpha4, identified in lymphocytes, binds to protein phosphatase 2A (PP2A). We found another murine alpha4-related gene (named alpha4-b) expressed selectively in the brain and testis. The alpha4-b transcript is expressed in the brain and testis, but is not detected in the spleen, thymus, bone marrow, liver, kidney, lung, heart or muscle. In-situ RNA hybridization analysis suggested that alpha4-b is expressed in most neuronal cells in the brain, but it is not expressed in the glial cells. The alpha4-b cDNA encodes a putative protein that is highly homologous (66% identity in amino-acid sequence) to the alpha4 molecule. The alpha4-b protein associates with the catalytic subunit of PP2A (PP2Ac), suggesting that the alpha4-b protein is involved in the regulation of phosphatase activity in neuronal cells.

PMID: 10491115 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Aug 30 2004 06:52:01

h cb hg e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Biol Chem. 2001 May 18;276(20):16772-9. Epub 2001 Feb 08.

Related Articles, Links

FREE full text article at www.jbc.org

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin.

Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A.

Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA.

Pleiotrophin (PTN) is a secreted growth factor that induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. During tumor growth PTN can serve as an angiogenic factor and drive tumor invasion and metastasis. To identify a receptor for PTN, we panned a phage display human cDNA library against immobilized PTN protein as a bait. From this we isolated a phage insert that was homologous to an amino acid sequence stretch in the extracellular domain (ECD) of the orphan receptor tyrosine kinase anaplastic lymphoma kinase (ALK). In parallel with PTN, ALK is highly expressed during perinatal development of the nervous system and down-modulated in the adult. Here we show in cell-free assays as well as in radioligand receptor binding studies in intact cells that PTN binds to the ALK ECD with an apparent Kd of 32 +/- 9 pm. This receptor binding is inhibited by an excess of PTN, by the ALK ECD, and by anti-PTN and anti-ECD antibodies. PTN added to ALK-expressing cells induces phosphorylation of both ALK and of the downstream effector molecules IRS-1, Shc, phospholipase C-gamma, and phosphatidylinositol 3-kinase. Furthermore, the growth stimulatory effect of PTN on different cell lines in culture coincides with the endogenous expression of ALK mRNA, and the effect of PTN is enhanced by ALK overexpression. From this we conclude that ALK is a receptor that transduces PTN-mediated signals and propose that the PTN-ALK axis can play a significant role during development and during disease processes.

PMID: 11278720 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

h cb hg e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Biol Chem. 1999 May 7;274(19):12959-62.

Related Articles, Links

FREE full text article at www.jbc.org

Domain structure of pleiotrophin required for transformation.

Zhang N, Zhong R, Deuel TF.

Division of Growth Regulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. emaldona@machi.med.uchile.cl

The pleiotrophin (PTN) gene (Ptn) is a potent proto-oncogene that is highly expressed in many primary human tumors and constitutively expressed in cell lines derived from these tumors. The product of the Ptn gene is a secreted 136-amino acid heparin binding cytokine with distinct lysine-rich clusters within both the N- and C-terminal domains. To seek domains of PTN functionally important in neoplastic transformation, we constructed a series of mutants and tested their transforming potential by four independent criteria. Our data establish that a domain within PTN residues 41 to 64 and either but not both the N- or C-terminal domains are required for transformation; deletion of both the N and C termini abolishes the transformation potential of PTN. Furthermore, deletion of two internal 5-amino acid residue repeats enhances the transformation potency of PTN 2-fold. Our data indicate that PTN residues 41-64 contain an essential domain for transformation and suggest the hypothesis that this domain requires an additional interaction of the highly basic clusters of the N or C terminus of PTN with a negatively charged "docking" site to enable the transforming domain itself to engage and initiate PTN signaling through its cognate receptor.

PMID: 10224041 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Aug 30 2004 06:52:01

h cb hg e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Biol Chem. 1994 Apr 29;269(17):12999-3004.

Related Articles, Links

Free full text article at www.jbc.org

Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3).

Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H.

Laboratory of Molecular Neurobiology, University of Helsinki, Finland.

HB-GAM (heparin binding growth-associated molecule; pleiotrophin) is a secretory, extracellular matrix-associated protein that is strongly expressed in developing nervous tissues and belongs to a novel family of differentiation/growth factors. It promotes axonal growth from perinatal rat brain neurons and is suggested to be mitogenic for some cell types and to display cell-transforming activity. Since the receptors of HB-GAM in cells are unknown, we have started isolation of putative cell surface receptors from brain neurons and from perinatal rat brain. For this purpose, recombinant HB-GAM was produced with the aid of a baculovirus vector and used as an affinity matrix in receptor isolation. A detergent-solubilized component from cultured brain neurons and from brain was identified that binds specifically to HB-GAM and migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a broad smear with an apparent molecular mass of about 200 kDa. This cell surface component was found to contain heparan sulfate chains, which are bound to a core protein with an apparent molecular mass of 120 kDa. Gel electrophoretic characteristics, immunochemical analysis, and partial peptide sequencing revealed that the cell surface component isolated as an HB-GAM receptor is N-syndecan (syndecan-3). In a solid phase binding assay, N-syndecan was found to bind to HB-GAM in a similar manner as to basic fibroblast growth factor (KD = 0.6 nM). Immunofluorescence microscopy indicated that in brain neurons, N-syndecan occurs at the surface of the cell soma and of the neurites that grow along HB-GAM-coated substrates. Anti-N-syndecan antibodies added to culture media had an inhibitory effect on HB-GAM-induced neurite outgrowth. We suggest that N-syndecan mediates the neurite outgrowth-promoting signal from HB-GAM to the cytoskeleton of growing neurites.

PMID: 8175719 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

h cb h g e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
Search PubMed for Go Clear
Limits Preview/Index History Clipboard Details

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Biol Chem. 1996 Aug 30;271(35):21446-52.

Related Articles, Links

Free full text article at www.jbc.org

6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM).

Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M.

Division of Molecular Neurobiology, National Institute for Basic Biology, and the Department of Molecular Biomechanics, The Graduate University for Advanced Studies, Okazaki 444, Japan.

A major chondroitin sulfate proteoglycan in the brain, 6B4 proteoglycan/phosphacan, corresponds to the extracellular region of a receptor-like protein-tyrosine phosphatase, PTPzeta/RPTPbeta. Here, we purified and characterized 6B4 proteoglycan-binding proteins from rat brain. From the CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid) extract of brain microsomal fractions, 18-, 28-, and 40-kDa proteins were specifically isolated using 6B4 proteoglycan-Sepharose. N-terminal amino acid sequencing identified the 18-kDa protein as pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). Scatchard analysis of 6B4 proteoglycan-pleiotrophin binding revealed low (Kd = 3 nM) and high (Kd = 0.25 nM) affinity binding sites. Chondroitinase ABC digestion of the proteoglycan decreased the binding affinities to a single value (Kd = 13 nM) without changing the number of binding sites. This suggested the presence of two subpopulations of the proteoglycan with different chondroitin sulfate structures. Heparin potently inhibited binding of 6B4 proteoglycan to pleiotrophin (IC50 = 3.5 ng/ml). Heparan sulfate and chondroitin sulfate C inhibited moderately (IC50 = 150 and 400 ng/ml, respectively), but, in contrast, chondroitin sulfate A and keratan sulfate were poor inhibitors (IC50 > 100 microg/ml). Immunofluorescence and immunoblotting analyses indicated that both 6B4 proteoglycan and PTPzeta are located on cortical neurons. Anti-6B4 proteoglycan antibody added to the culture medium suppressed pleiotrophin-induced neurite outgrowth of cortical neurons. These results suggested that interaction between 6B4 proteoglycan and pleiotrophin is required for the action of pleiotrophin, and chondroitin sulfate chains on 6B4 proteoglycan play regulatory roles in its binding.

PMID: 8702927 [PubMed - indexed for MEDLINE]

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Biol Chem. 1999 Apr 30;274(18):12474-9. Related Articles, Links

FREE full text article at www.jbc.org

A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta.

Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M.

Division of Molecular Neurobiology, National Institute for Basic Biology, Graduate University for Advanced Studies, Okazaki 444-8585, Japan.

Midkine is a 13-kDa heparin-binding growth factor with 45% sequence identity to pleiotrophin. Pleiotrophin has been demonstrated to bind to protein-tyrosine phosphatase zeta (PTPzeta) with high affinity. In this study, we examined the binding of midkine to PTPzeta by solid-phase binding assay. Midkine and pleiotrophin binding to PTPzeta were equally inhibited by soluble pleiotrophin and also by some specific glycosaminoglycans. For both bindings, Scatchard analysis revealed low (3.0 nM) and high (0.58 nM) affinity binding sites. These results suggested that PTPzeta is a common receptor for midkine and pleiotrophin. Midkine is structurally divided into the N- and C-terminal halves, and the latter exhibited full activity for PTPzeta binding and neuronal migration induction. The C-terminal half contains two heparin-binding sites consisting of clusters of basic amino acids, Clusters I and II. A mutation at Arg78 in Cluster I resulted in loss of the high affinity binding and reduced neuronal migration-inducing activity, while mutations at Lys83 and Lys84 in Cluster II showed almost no effect on either activity. Chondroitinase ABC-treated PTPzeta exhibited similar low affinity binding both to the native midkine and midkine mutants at Arg78. These results suggested that Arg78 in midkine plays an essential role in high affinity binding to PTPzeta by interacting with the chondroitin sulfate portion of this receptor.

PMID: 10212223 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services

h cb hg e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo
Search PubMed for Go Clear
Limits Preview/Index History Clipboard Details

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Biol Chem. 1999 Apr 30;274(18):12474-9. Related Articles, Links

FREE full text article at www.jbc.org

A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta.

Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M.

Division of Molecular Neurobiology, National Institute for Basic Biology, Graduate University for Advanced Studies, Okazaki 444-8585, Japan.

Midkine is a 13-kDa heparin-binding growth factor with 45% sequence identity to pleiotrophin. Pleiotrophin has been demonstrated to bind to protein-tyrosine phosphatase zeta (PTPzeta) with high affinity. In this study, we examined the binding of midkine to PTPzeta by solid-phase binding assay. Midkine and pleiotrophin binding to PTPzeta were equally inhibited by soluble pleiotrophin and also by some specific glycosaminoglycans. For both bindings, Scatchard analysis revealed low (3.0 nM) and high (0.58 nM) affinity binding sites. These results suggested that PTPzeta is a common receptor for midkine and pleiotrophin. Midkine is structurally divided into the N- and C-terminal halves, and the latter exhibited full activity for PTPzeta binding and neuronal migration induction. The C-terminal half contains two heparin-binding sites consisting of clusters of basic amino acids, Clusters I and II. A mutation at Arg78 in Cluster I resulted in loss of the high affinity binding and reduced neuronal migration-inducing activity, while mutations at Lys83 and Lys84 in Cluster II showed almost no effect on either activity. Chondroitinase ABC-treated PTPzeta exhibited similar low affinity binding both to the native midkine and midkine mutants at Arg78. These results suggested that Arg78 in midkine plays an essential role in high affinity binding to PTPzeta by interacting with the chondroitin sulfate portion of this receptor.

PMID: 10212223 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo
Search PubMed for Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: J Cell Biol. 1998 Jul 13;142(1):203-16. Related Articles, Links

FREE full text or Info at www.jcb.org

Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration.

Maeda N, Noda M.

Division of Molecular Neurobiology, National Institute for Basic Biology, and Department of Molecular Biomechanics, The Graduate University for Advanced Studies, Okazaki 444-8585, Japan.

Pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) is a specific ligand of protein tyrosine phosphatase zeta (PTPzeta)/receptor-like protein tyrosine phosphatase beta (RPTPbeta) expressed in the brain as a chondroitin sulfate proteoglycan. Pleiotrophin and PTPzeta isoforms are localized along the radial glial fibers, a scaffold for neuronal migration, suggesting that these molecules are involved in migratory processes of neurons during brain development. In this study, we examined the roles of pleiotrophin-PTPzeta interaction in the neuronal migration using cell migration assay systems with glass fibers and Boyden chambers. Pleiotrophin and poly-L-lysine coated on the substratums stimulated cell migration of cortical neurons, while laminin, fibronectin, and tenascin exerted almost no effect. Pleiotrophin-induced and poly-L-lysine-induced neuronal migrations showed significant differences in sensitivity to various molecules and reagents. Polyclonal antibodies against the extracellular domain of PTPzeta, PTPzeta-S, an extracellular secreted form of PTPzeta, and sodium vanadate, a protein tyrosine phosphatase inhibitor, added into the culture medium strongly suppressed specifically the pleiotrophin-induced neuronal migration. Furthermore, chondroitin sulfate C but not chondroitin sulfate A inhibited pleiotrophin-induced neuronal migration, in good accordance with our previous findings that chondroitin sulfate constitutes a part of the pleiotrophin-binding site of PTPzeta, and PTPzeta-pleiotrophin binding is inhibited by chondroitin sulfate C but not by chondroitin sulfate A. Immunocytochemical analysis indicated that the transmembrane forms of PTPzeta are expressed on the migrating neurons especially at the lamellipodia along the leading processes. These results suggest that PTPzeta is involved in the neuronal migration as a neuronal receptor of pleiotrophin distributed along radial glial fibers.

PMID: 9660874 [PubMed - indexed for MEDLINE]

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo
Search PubMed for Go Clear
Limits Preview/Index History Clipboard Details

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8. Related Articles, Links

FREE full text article at www.pnas.org
Free full text article in PubMed Central

Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta.

Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF.

Division of Growth Regulation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Pleiotrophin (PTN) is a platelet-derived growth factor-inducible, 18-kDa heparin-binding cytokine that signals diverse phenotypes in normal and deregulated cellular growth and differentiation. To seek the mechanisms of PTN signaling, we studied the interactions of PTN with the receptor protein tyrosine phosphatase (RPTP) beta/zeta in U373-MG cells. Our results suggest that PTN is a natural ligand for RPTP beta/zeta. PTN signals through "ligand-dependent receptor inactivation" of RPTP beta/zeta and disrupts its normal roles in the regulation of steady-state tyrosine phosphorylation of downstream signaling molecules. We have found that PTN binds to and functionally inactivates the catalytic activity of RPTP beta/zeta. We also have found that an active site-containing domain of RPTP beta/zeta both binds beta-catenin and functionally reduces its levels of tyrosine phosphorylation when added to lysates of pervanidate-treated cells. In contrast, an (inactivating) active-site mutant of RPTP beta/zeta also binds beta-catenin but fails to reduce tyrosine phosphorylation of beta-catenin. Finally, in parallel to its ability to inactivate endogenous RPTP beta/zeta, PTN sharply increases tyrosine phosphorylation of beta-catenin in PTN-treated cells. The results suggest that in unstimulated cells, RPTP beta/zeta is intrinsically active and functions as an important regulator in the reciprocal control of the steady-state tyrosine phosphorylation levels of beta-catenin by tyrosine kinases and phosphatases. The results also suggest that RPTP beta/zeta is a functional receptor for PTN; PTN signals through ligand-dependent receptor inactivation of RPTP beta/zeta to increase levels of tyrosine phosphorylation of beta-catenin to initiate downstream signaling. PTN is the first natural ligand identified for any of the RPTP family; its identification provides a unique tool to pursue the novel signaling pathway activated by PTN and the relationship of PTN signaling with other pathways regulating beta-catenin.

NCBI PubMed National Library of Medicine

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for pleiotrophin AND receptor Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-68 of 68 One page.

1: Furuta M, Shiraishi T, Okamoto H, Mineta T, Tabuchi K, Shiwa M. Related Articles, Links

Identification of pleiotrophin in conditioned medium secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry.
Brain Res Dev Brain Res. 2004 Sep 17;152(2):189-97.
PMID: 15351507 [PubMed - in process]

2: Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H. Related Articles, Links

Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells.
FASEB J. 2004 Aug;18(11):1237-9. Epub 2004 Jun 04.
PMID: 15180956 [PubMed - in process]

3: Hienola A, Pekkanen M, Raulo E, Vanttola P, Rauvala H. Related Articles, Links

HB-GAM inhibits proliferation and enhances differentiation of neural stem cells.
Mol Cell Neurosci. 2004 May;26(1):75-88.
PMID: 15121180 [PubMed - indexed for MEDLINE]

4: Kadomatsu K, Muramatsu T. Related Articles, Links

Midkine and pleiotrophin in neural development and cancer.
Cancer Lett. 2004 Feb 20;204(2):127-43. Review.
PMID: 15013213 [PubMed - indexed for MEDLINE]

5: Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, Courty J. Related Articles, Links

Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.
Oncogene. 2004 Mar 4;23(9):1745-53.
PMID: 15001987 [PubMed - indexed for MEDLINE]

6: Bernard-Pierrot I, Delbe J, Heroult M, Rosty C, Soulie P, Barritault D, Milhiet PE, Courty J. Related Articles, Links

Heparin affin regulatory peptide in milk: its involvement in mammary gland homeostasis.
Biochem Biophys Res Commun. 2004 Jan 30;314(1):277-82.
PMID: 14715276 [PubMed - indexed for MEDLINE]

7: Ulbricht U, Brockmann MA, Aigner A, Eckerich C, Muller S, Fillbrandt R, Westphal M, Lamszus K. Related Articles, Links

Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.
J Neuropathol Exp Neurol. 2003 Dec;62(12):1265-75.
PMID: 14692702 [PubMed - indexed for MEDLINE]

8: Pacicca DM, Patel N, Lee C, Salisbury K, Lehmann W, Carvalho R, Gerstenfeld LC, Einhorn TA. Related Articles, Links

h cb h g e e e fcg e ch b e

Expression of angiogenic factors during distraction osteogenesis.
Bone. 2003 Dec;33(6):889-98.
PMID: 14678848 [PubMed - indexed for MEDLINE]

9: Muller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, von Schack D, Chin DJ, Lohr SC, Westphal M, Melcher T. Related Articles, Links

A role for receptor tyrosine phosphatase zeta in glioma cell migration.
Oncogene. 2003 Oct 2;22(43):6661-8.
PMID: 14555979 [PubMed - indexed for MEDLINE]

10: Maeda N, He J, Yajima Y, Mikami T, Sugahara K, Yabe T. Related Articles, Links

Heterogeneity of the chondroitin sulfate portion of phosphacan/6B4 proteoglycan regulates its binding affinity for pleiotrophin/heparin binding growth-associated molecule.
J Biol Chem. 2003 Sep 12;278(37):35805-11. Epub 2003 Jul 02.
PMID: 12840014 [PubMed - indexed for MEDLINE]

11: Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. Related Articles, Links

Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors.
Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399.
PMID: 12762884 [PubMed - indexed for MEDLINE]

12: Tanaka M, Maeda N, Noda M, Marunouchi T. Related Articles, Links

A chondroitin sulfate proteoglycan PTPzeta /RPTPbeta regulates the morphogenesis of Purkinje cell dendrites in the developing cerebellum.
J Neurosci. 2003 Apr 1;23(7):2804-14.
PMID: 12684467 [PubMed - indexed for MEDLINE]

13: Fujikawa A, Shirasaka D, Yamamoto S, Ota H, Yahiro K, Fukada M, Shintani T, Wada A, Aoyama N, Hirayama T, Fukamachi H, Noda M. Related Articles, Links

Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.
Nat Genet. 2003 Mar;33(3):375-81. Epub 2003 Feb 24. Erratum in: Nat Genet. 2003 Apr;33(4):533.
PMID: 12598897 [PubMed - indexed for MEDLINE]

14: Beltran PJ, Bixby JL. Related Articles, Links

Receptor protein tyrosine phosphatases as mediators of cellular adhesion.
Front Biosci. 2003 Jan 01;8:d87-99. Review.
PMID: 12456340 [PubMed - indexed for MEDLINE]

15: Tare RS, Oreffo RO, Sato K, Rauvala H, Clarke NM, Roach HI. Related Articles, Links

Effects of targeted overexpression of pleiotrophin on postnatal bone development.
Biochem Biophys Res Commun. 2002 Nov 1;298(3):324-32.
PMID: 12413943 [PubMed - indexed for MEDLINE]

16: Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K. Related Articles, Links

Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues.
J Biol Chem. 2002 Nov 15;277(46):43707-16. Epub 2002 Sep 06.
PMID: 12221095 [PubMed - indexed for MEDLINE]

17: Muramatsu T. Related Articles, Links

Midkine and pleiotrophin: two related proteins involved in development,

survival, inflammation and tumorigenesis.
J Biochem (Tokyo). 2002 Sep;132(3):359-71. Review.
PMID: 12204104 [PubMed - indexed for MEDLINE]

18: Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Related Articles, Links

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
J Biol Chem. 2002 Sep 27;277(39):35990-8. Epub 2002 Jul 16.
PMID: 12122009 [PubMed - indexed for MEDLINE]

19: Iseki K, Hagino S, Mori T, Zhang Y, Yokoya S, Takaki H, Tase C, Murakawa M, Wanaka A. Related Articles, Links

Increased syndecan expression by pleiotrophin and FGF receptor-expressing astrocytes in injured brain tissue.
Glia. 2002 Jul;39(1):1-9.
PMID: 12112370 [PubMed - indexed for MEDLINE]

20: Bowden ET, Stoica GE, Wellstein A. Related Articles, Links

Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase.
J Biol Chem. 2002 Sep 27;277(39):35862-8. Epub 2002 Jul 09.
PMID: 12107166 [PubMed - indexed for MEDLINE]

21: Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D, Raulais D, Barritault D, Courty J, Milhiet PE. Related Articles, Links

Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.
J Biol Chem. 2002 Aug 30;277(35):32071-7. Epub 2002 Jun 17.
PMID: 12070152 [PubMed - indexed for MEDLINE]

22: Asabina K, Sato H, Yamasaki C, Kataoka M, Shiokawa M, Katayama S, Tateno C, Yoshizato K. Related Articles, Links

Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver.
Am J Pathol. 2002 Jun;160(6):2191-205.
PMID: 12057922 [PubMed - indexed for MEDLINE]

23: Qin LX, Tang ZY. Related Articles, Links

The prognostic molecular markers in hepatocellular carcinoma.
World J Gastroenterol. 2002 Jun;8(3):385-92. Review.
PMID: 12046056 [PubMed - indexed for MEDLINE]

24: Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Related Articles, Links

Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway.
Arch Biochem Biophys. 2002 Jan 15;397(2):162-71. Review.
PMID: 11795867 [PubMed - indexed for MEDLINE]

25: Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Related Articles, Links

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
J Biol Chem. 2002 Apr 19;277(16):14153-8. Epub 2002 Jan 23.
PMID: 11809760 [PubMed - indexed for MEDLINE]

26: Sakurai H, Bush KT, Nigam SK. Related Articles, Links

Identification of pleiotrophin as a mesenchymal factor involved in ureteric bud branching morphogenesis.
Development. 2001 Sep;128(17):3283-93.

PMID: 11546745 [PubMed - indexed for MEDLINE]

27: Kawachi H, Fujikawa A, Maeda N, Noda M. Related Articles, Links

Identification of GIT1/Cat-1 as a substrate molecule of protein tyrosine phosphatase zeta /beta by the yeast substrate-trapping system.
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6593-8. Epub 2001 May 29.
PMID: 11381105 [PubMed - indexed for MEDLINE]

28: Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, Muramatsu T, Kadomatsu K. Related Articles, Links

Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase.
J Biol Chem. 2001 May 11;276(19):15868-75.
PMID: 11340082 [PubMed - indexed for MEDLINE]

29: Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Related Articles, Links

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin.
J Biol Chem. 2001 May 18;276(20):16772-9. Epub 2001 Feb 08.
PMID: 11278720 [PubMed - indexed for MEDLINE]

30: Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE. Related Articles, Links

The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities.
J Biol Chem. 2001 Apr 13;276(15):12228-34. Epub 2001 Jan 09.
PMID: 11150308 [PubMed - indexed for MEDLINE]

31: Dewing P, Ching ST, Zhang YH, Huang BL, Peirce RM, McCabe ER, Vilain E. Related Articles, Links

Midkine is expressed early in rat fetal adrenal development.
Mol Genet Metab. 2000 Dec;71(4):616-22.
PMID: 11136554 [PubMed - indexed for MEDLINE]

32: Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, Kilpelainen I. Related Articles, Links

Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility.
Matrix Biol. 2000 Sep;19(5):377-87. Review.
PMID: 10980414 [PubMed - indexed for MEDLINE]

33: Zou K, Muramatsu H, Ikematsu S, Sakuma S, Salama RH, Shinomura T, Kimata K, Muramatsu T. Related Articles, Links

A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican.
Eur J Biochem. 2000 Jul;267(13):4046-53.
PMID: 10866805 [PubMed - indexed for MEDLINE]

34: Cherrington JM, Strawn LM, Shawver LK. Related Articles, Links

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
Adv Cancer Res. 2000;79:1-38. Review.
PMID: 10818676 [PubMed - indexed for MEDLINE]

35: Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. Related Articles, Links

Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type

protein tyrosine phosphatase beta/zeta.
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8.
PMID: 10706604 [PubMed - indexed for MEDLINE]

36: Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Related Articles, Links

Regulation of cell migration by amphoterin.
J Cell Sci. 2000 Feb;113 (Pt 4):611-20.
PMID: 10652254 [PubMed - indexed for MEDLINE]

37: Godden JL, Edward M, MacKie RM. Related Articles, Links

Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor.
Eur J Cancer. 1999 Mar;35(3):473-80.
PMID: 10448302 [PubMed - indexed for MEDLINE]

38: Zhang N, Zhong R, Deuel TF. Related Articles, Links

Domain structure of pleiotrophin required for transformation.
J Biol Chem. 1999 May 7;274(19):12959-62.
PMID: 10224041 [PubMed - indexed for MEDLINE]

39: Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. Related Articles, Links

A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta.
J Biol Chem. 1999 Apr 30;274(18):12474-9.
PMID: 10212223 [PubMed - indexed for MEDLINE]

40: Yamakawa T, Kurosawa N, Kadomatsu K, Matsui T, Itoh K, Maeda N, Noda M, Muramatsu T. Related Articles, Links

Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers.
Cancer Lett. 1999 Jan 8;135(1):91-6.
PMID: 10077226 [PubMed - indexed for MEDLINE]

41: Kinnunen A, Niemi M, Kinnunen T, Kaksonen M, Nolo R, Rauvala H. Related Articles, Links

Heparan sulphate and HB-GAM (heparin-binding growth-associated molecule) in the development of the thalamocortical pathway of rat brain.
Eur J Neurosci. 1999 Feb;11(2):491-502.
PMID: 10051750 [PubMed - indexed for MEDLINE]

42: Juhl H, Czubayko F, Henne-Bruns D. Related Articles, Links

[Ribozyme targeting as gene therapy method for treatment of malignant tumors]
Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1474-7. German.
PMID: 9931916 [PubMed - indexed for MEDLINE]

43: Imai S, Kaksonen M, Raulo E, Kinnunen T, Fages C, Meng X, Lakso M, Rauvala H. Related Articles, Links

Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM).
J Cell Biol. 1998 Nov 16;143(4):1113-28.
PMID: 9817766 [PubMed - indexed for MEDLINE]

44: Liu X, Mashour GA, Webster HF, Kurtz A. Related Articles, Links

Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin.

Glia. 1998 Dec;24(4):390-7.
PMID: 9814819 [PubMed - indexed for MEDLINE]

☐ **45:** Peng HB, Ali AA, Daggett DF, Rauvala H, Hassell JR, Smalheiser NR Related Articles, Links

The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction.
Cell Adhes Commun. 1998 Sep;5(6):475-89.
PMID: 9791728 [PubMed - indexed for MEDLINE]

☐ **46:** Lauri SE, Rauvala H, Kaila K, Taira T. Related Articles, Links

Effect of heparin-binding growth-associated molecule (HB-GAM) on synaptic transmission and early LTP in rat hippocampal slices.
Eur J Neurosci. 1998 Jan;10(1):188-94.
PMID: 9753126 [PubMed - indexed for MEDLINE]

☐ **47:** Kinnunen A, Kinnunen T, Kaksonen M, Nolo R, Panula P, Rauvala H. Related Articles, Links

N-syndecan and HB-GAM (heparin-binding growth-associated molecule) associate with early axonal tracts in the rat brain.
Eur J Neurosci. 1998 Feb;10(2):635-48.
PMID: 9749725 [PubMed - indexed for MEDLINE]

☐ **48:** Fages C, Kaksonen M, Kinnunen T, Punnonen EL, Rauvala H. Related Articles, Links

Regulation of mRNA localization by transmembrane signalling: local interaction of HB-GAM (heparin-binding growth-associated molecule) with the cell surface localizes beta-actin mRNA.
J Cell Sci. 1998 Oct;111 (Pt 20):3073-80.
PMID: 9739080 [PubMed - indexed for MEDLINE]

☐ **49:** Maeda N, Noda M. Related Articles, Links

Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration.
J Cell Biol. 1998 Jul 13;142(1):203-16.
PMID: 9660874 [PubMed - indexed for MEDLINE]

☐ **50:** Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ, Burrow CR. Related Articles, Links

Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases.
J Biol Chem. 1998 Feb 6;273(6):3654-60.
PMID: 9452495 [PubMed - indexed for MEDLINE]

☐ **51:** Czubayko F, Downing SG, Hsieh SS, Goldstein DJ, Lu PY, Trapnell BC, Wellstein A. Related Articles, Links

Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation.
Gene Ther. 1997 Sep;4(9):943-9.
PMID: 9349431 [PubMed - indexed for MEDLINE]

☐ **52:** Haltia A, Solin ML, Muramatsu T, Jalanko H, Holmberg C, Miettinen A, Holthofer H. Related Articles, Links

Expression of nine developmental stage-specific genes in human kidney and cultured renal cells.
Exp Nephrol. 1997 Nov-Dec;5(6):457-64.
PMID: 9438174 [PubMed - indexed for MEDLINE]

☐ **53:** Rauvala H, Peng HB. Related Articles, Links

h cb h g e e e fcg e ch b e

HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts.
Prog Neurobiol. 1997 Jun;52(2):127-44. Review.
PMID: 9185236 [PubMed - indexed for MEDLINE]

54: Ratovitski EA, Burrow CR. Related Articles, Links

Midkine stimulates Wilms' tumor cell proliferation via its signaling receptor.
Cell Mol Biol (Noisy-le-grand). 1997 May;43(3):425-31.
PMID: 9193798 [PubMed - indexed for MEDLINE]

55: Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Related Articles, Links

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Cancer Res. 1997 Mar 1;57(5):963-9.
PMID: 9041202 [PubMed - indexed for MEDLINE]

56: Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP, Evans AE. Related Articles, Links

Expression of TrkA, TrkB and TrkC in human neuroblastomas.
J Neurooncol. 1997 Jan;31(1-2):49-55.
PMID: 9049830 [PubMed - indexed for MEDLINE]

57: Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. Related Articles, Links

6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM).
J Biol Chem. 1996 Aug 30;271(35):21446-52.
PMID: 8702927 [PubMed - indexed for MEDLINE]

58: Szabat E, Rauvala H. Related Articles, Links

Role of HB-GAM (heparin-binding growth-associated molecule) in proliferation arrest in cells of the developing rat limb and its expression in the differentiating neuromuscular system.
Dev Biol. 1996 Aug 25;178(1):77-89.
PMID: 8812110 [PubMed - indexed for MEDLINE]

59: Lauri SE, Taira T, Kaila K, Rauvala H. Related Articles, Links

Activity-induced enhancement of HB-GAM expression in rat hippocampal slices.
Neuroreport. 1996 Jul 8;7(10):1670-4.
PMID: 8904779 [PubMed - indexed for MEDLINE]

60: Kinnunen T, Raulo E, Nolo R, Maccarana M, Lindahl U, Rauvala H. Related Articles, Links

Neurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface.
J Biol Chem. 1996 Jan 26;271(4):2243-8.
PMID: 8567685 [PubMed - indexed for MEDLINE]

61: Daggett DF, Cohen MW, Stone D, Nikolics K, Rauvala H, Peng HB. Related Articles, Links

The role of an agrin-growth factor interaction in ACh receptor clustering.
Mol Cell Neurosci. 1996;8(4):272-85.

PMID: 9026315 [PubMed - indexed for MEDLINE]

62: Tsujimura A, Yasojima K, Kuboki Y, Suzuki A, Ueno N, Shiokawa K, Hashimoto-Gotoh T. Related Articles, Links

Developmental and differential regulations in gene expression of Xenopus pleiotrophic factors-alpha and -beta.
Biochem Biophys Res Commun. 1995 Sep 14;214(2):432-9.
PMID: 7677748 [PubMed - indexed for MEDLINE]

63: Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM. Related Articles, Links

Differential expression of pleiotrophin and midkine in advanced neuroblastomas.
Cancer Res. 1995 Apr 15;55(8):1792-7.
PMID: 7712489 [PubMed - indexed for MEDLINE]

64: Peng HB, Ali AA, Dai Z, Daggett DF, Raulo E, Rauvala H. Related Articles, Links

The role of heparin-binding growth-associated molecule (HB-GAM) in the postsynaptic induction in cultured muscle cells.
J Neurosci. 1995 Apr;15(4):3027-38.
PMID: 7722643 [PubMed - indexed for MEDLINE]

65: Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Related Articles, Links

Midkine and pleiotrophin expression in normal and malignant breast tissue.
Cancer. 1994 Sep 1;74(5):1584-90.
PMID: 7520350 [PubMed - indexed for MEDLINE]

66: Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H. Related Articles, Links

Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3).
J Biol Chem. 1994 Apr 29;269(17):12999-3004.
PMID: 8175719 [PubMed - indexed for MEDLINE]

67: Gieffers C, Engelhardt W, Brenzel G, Matsuishi T, Frey J. Related Articles, Links

Receptor binding of osteoblast-specific factor 1 (OSF-1/HB-GAM) to human osteosarcoma cells promotes cell attachment.
Eur J Cell Biol. 1993 Dec;62(2):352-61.
PMID: 7925491 [PubMed - indexed for MEDLINE]

68: Kuo MD, Huang SS, Huang JS. Related Articles, Links

Characterization of heparin-binding growth-associated factor receptor on NIH 3T3 cells.
Biochem Biophys Res Commun. 1992 Jan 15;182(1):188-94.
PMID: 1731778 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb hg e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo
Search PubMed for Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: Cancer Lett. 1999 Jan 8;135(1):91-6.

Related Articles, Links

FULL-TEXT ARTICLE

Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers.

Yamakawa T, Kurosawa N, Kadomatsu K, Matsui T, Itoh K, Maeda N, Noda M, Muramatsu T.

Department of Biochemistry, Nagoya University School of Medicine, Japan.

Pleiotrophin (PTN) and midkine (MK) form a distinct family of heparin binding growth factors. In a variety of human cancers, MK mRNA levels have been found to be increased as compared to adjacent non-cancerous tissues. We examined the expression of PTN, its putative receptor, namely protein tyrosine phosphatase zeta (PTPzeta, also known as RPTPbeta), and a related protein, receptor-type protein tyrosine phosphatase gamma (RPTPgamma), in human colorectal cancers and the adjacent normal mucosae. PTN and PTPzeta mRNA levels were generally decreased in colorectal cancers as compared to those in adjacent normal mucosae, while the RPTPzeta level was not significantly different between them.

PMID: 10077226 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Aug 30 2004 06:52:01

h cb hg e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for ALK AND receptor AND human Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-155 of 155 One page.

1: Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. Related Articles, Links

ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.
J Cell Sci. 2004 Jul 1;117(Pt 15):3319-29.
PMID: 15226403 [PubMed - in process]

2: Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G. Related Articles, Links

Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):33S-39S. Review.
PMID: 15194176 [PubMed - indexed for MEDLINE]

3: Takeda M, Otsuka F, Nakamura K, Inagaki K, Suzuki J, Miura D, Fujio H, Matsubara H, Date H, Ohe T, Makino H. Related Articles, Links

Characterization of the bone morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells isolated from a sporadic case of primary pulmonary hypertension: roles of BMP type IB receptor (activin receptor-like kinase-6) in the mitotic action.
Endocrinology. 2004 Sep;145(9):4344-54. Epub 2004 Jun 10.
PMID: 15192043 [PubMed - in process]

4: Li XQ, Hisaoka M, Shi DR, Zhu XZ, Hashimoto H. Related Articles, Links

Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases.
Hum Pathol. 2004 Jun;35(6):711-21.
PMID: 15188137 [PubMed - indexed for MEDLINE]

5: Kim BC, van Gelder H, Kim TA, Lee HJ, Baik KG, Chun HH, Lee DA, Choi KS, Kim SJ. Related Articles, Links

Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells.
J Biol Chem. 2004 Jul 2;279(27):28458-65. Epub 2004 Apr 23.
PMID: 15107418 [PubMed - indexed for MEDLINE]

6: Pulford K, Morris SW, Turturro F. Related Articles, Links

Anaplastic lymphoma kinase proteins in growth control and cancer.
J Cell Physiol. 2004 Jun;199(3):330-58. Review.
PMID: 15095281 [PubMed - indexed for MEDLINE]

7: Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T. Related Articles, Links

The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
Cancer Cell. 2004 Apr;5(4):353-64.
PMID: 15093542 [PubMed - indexed for MEDLINE]

8: Related Articles, Links

Abdalla SA, Gallione CJ, Barst RJ, Horn EM, Knowles JA, Marchuk

DA, Letarte M, Morse JH.

Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Eur Respir J. 2004 Mar;23(3):373-7.
PMID: 15065824 [PubMed - indexed for MEDLINE]

9: DaCosta Byfield S, Major C, Laping NJ, Roberts AB. Related Articles, Links

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
Mol Pharmacol. 2004 Mar;65(3):744-52.
PMID: 14978253 [PubMed - indexed for MEDLINE]

10: Xu B, Wu YQ, Huey M, Arthur HM, Marchuk DA, Hashimoto T, Young WL, Yang GY. Related Articles, Links

Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
J Cereb Blood Flow Metab. 2004 Feb;24(2):237-44.
PMID: 14747750 [PubMed - indexed for MEDLINE]

11: Osyczka AM, Diefenderfer DL, Bhargave G, Leboy PS. Related Articles, Links

Different effects of BMP-2 on marrow stromal cells from human and rat bone.
Cells Tissues Organs. 2004;176(1-3):109-19.
PMID: 14745240 [PubMed - in process]

12: Bernard-Pierrot I, Delbe J, Heroult M, Rosty C, Soulie P, Barritault D, Milhiet PE, Courty J. Related Articles, Links

Heparin affin regulatory peptide in milk: its involvement in mammary gland homeostasis.
Biochem Biophys Res Commun. 2004 Jan 30;314(1):277-82.
PMID: 14715276 [PubMed - indexed for MEDLINE]

13: Mei-Zahav M. Related Articles, Links

[Osler-Weber-Rendu--a life-threatening disease in adults and children]
Harefuah. 2003 Dec;142(12):852-6, 876. Review. Hebrew.
PMID: 14702755 [PubMed - indexed for MEDLINE]

14: Passoni L, Gambacorti-Passerini C. Related Articles, Links

ALK a novel lymphoma-associated tumor antigen for vaccination strategies.
Leuk Lymphoma. 2003 Oct;44(10):1675-81. Review.
PMID: 14692518 [PubMed - indexed for MEDLINE]

15: Baade Ro T, Utne Holt R, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A, Borset M. Related Articles, Links

Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.
Oncogene. 2004 Apr 15;23(17):3024-32.
PMID: 14691444 [PubMed - indexed for MEDLINE]

16: Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Laitinen T, Morrell NW, Trembath RC, Halme M, Raisanen-Sokolowski A. Related Articles, Links

Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
J Med Genet. 2003 Dec;40(12):865-71.
PMID: 14684682 [PubMed - indexed for MEDLINE]

☐ **17:** Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Misbima HK, Imamura T, Miyazono K, Miyazawa K. Related Articles, Links

SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
Cancer Res. 2003 Nov 15;63(22):7791-8.
PMID: 14633705 [PubMed - indexed for MEDLINE]

☐ **18:** Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, Wechselberger C, Arra C, Strizzi L, Sanicola M, Salomon DS. Related Articles, Links

Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells.
J Cell Physiol. 2004 Jan;198(1):31-9.
PMID: 14584041 [PubMed - indexed for MEDLINE]

☐ **19:** Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. Related Articles, Links

Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling.
Mol Cell. 2003 Oct;12(4):817-28.
PMID: 14580334 [PubMed - indexed for MEDLINE]

☐ **20:** Harms PW, Chang C. Related Articles, Links

Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto.
Genes Dev. 2003 Nov 1;17(21):2624-9. Epub 2003 Oct 16.
PMID: 14563676 [PubMed - indexed for MEDLINE]

☐ **21:** Lee HH, Norris A, Weiss JB, Frasch M. Related Articles, Links

Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers.
Nature. 2003 Oct 2;425(6957):507-12.
PMID: 14523446 [PubMed - indexed for MEDLINE]

☐ **22:** Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozawa H, Yamashita Y, Mori N. Related Articles, Links

ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
Mod Pathol. 2003 Aug;16(8):828-32.
PMID: 12920229 [PubMed - indexed for MEDLINE]

☐ **23:** Jinquan T, Jacobi HH, Jing C, Millner A, Sten E, Hviid L, Anting L, Ryder LP, Glue C, Skov PS, Jarman E, Lamberth K, Malling HJ, Poulsen LK Related Articles, Links

CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells.
J Immunol. 2003 Aug 15;171(4):1722-31.
PMID: 12902471 [PubMed - indexed for MEDLINE]

☐ **24:** Nagata K, Hirai H. Related Articles, Links

The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes.
Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):169-77. Review.
PMID: 12895600 [PubMed - indexed for MEDLINE]

☐ **25:** Kang NS, Yim HE, Bae IS, Choi JH, Choi BM, Yoo KH, Hong YS, Lee JW, Kim SK. Related Articles, Links

ACE inhibition modulates transforming growth factor-beta receptors in the young rat.

Pediatr Nephrol. 2003 Sep;18(9):865-71. Epub 2003 Jul 23.
PMID: 12883979 [PubMed - indexed for MEDLINE]

26: Hirai H, Abe H, Tanaka K, Takatsu K, Sugamura K, Nakamura M, Nagata K. Related Articles, Links

Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor.
Biochem Biophys Res Commun. 2003 Aug 8;307(4):797-802.
PMID: 12878180 [PubMed - indexed for MEDLINE]

27: Yurtsever H, Kempf W, Laeng RH. Related Articles, Links

Posttransplant CD30+ anaplastic large cell lymphoma with skin and lymph node involvement.
Dermatology. 2003;207(1):107-10.
PMID: 12835569 [PubMed - indexed for MEDLINE]

28: Lamant L, Gascoyne RD, Duplantier MM, Armstrong F, Raghab A, Chhanabhai M, Rajcan-Separovic E, Raghab J, Delsol G, Espinos E. Related Articles, Links

Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
Genes Chromosomes Cancer. 2003 Aug;37(4):427-32.
PMID: 12800156 [PubMed - indexed for MEDLINE]

29: De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P, Vandenberghe P, Speleman F, Praet M, De Wolf-Peeters C, Marynen P, Wlodarska I. Related Articles, Links

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.
Blood. 2003 Oct 1;102(7):2638-41. Epub 2003 May 15.
PMID: 12750159 [PubMed - indexed for MEDLINE]

30: Morse JH. Related Articles, Links

Genetic studies of pulmonary arterial hypertension.
Lupus. 2003;12(3):209-12. Review.
PMID: 12708784 [PubMed - indexed for MEDLINE]

31: Althini S, Bengtsson H, Usoskin D, Soderstrom S, Kylberg A, Lindqvist E, Chuva de Sousa Lopes S, Olson L, Lindeberg J, Ebendal T. Related Articles, Links

Normal nigrostriatal innervation but dopamine dysfunction in mice carrying hypomorphic tyrosine hydroxylase alleles.
J Neurosci Res. 2003 May 15;72(4):444-53.
PMID: 12704806 [PubMed - indexed for MEDLINE]

32: Abdalla SA, Cymerman U, Johnson RM, Deber CM, Letarte M. Related Articles, Links

Disease-associated mutations in conserved residues of ALK-1 kinase domain.
Eur J Hum Genet. 2003 Apr;11(4):279-87.
PMID: 12700602 [PubMed - indexed for MEDLINE]

33: Lee HK, Kim HJ, Lee EH, Kim SY, Park TI, Kang CS, Yang WI. Related Articles, Links

Epstein-Barr virus-associated peripheral T-Cell lymphoma involving spleen in a renal transplant patient.
J Korean Med Sci. 2003 Apr;18(2):272-6.
PMID: 12692428 [PubMed - indexed for MEDLINE]

34: van den Driesche S, Mummery CL, Westermann CJ. Related Articles, Links

Hereditary hemorrhagic telangiectasia: an update on transforming growth

factor beta signaling in vasculogenesis and angiogenesis.
Cardiovasc Res. 2003 Apr 1;58(1):20-31. Review.
PMID: 12667943 [PubMed - indexed for MEDLINE]

35: Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM. Related Articles, Links

Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L209-21. Epub 2003 Mar 28.
PMID: 12665463 [PubMed - indexed for MEDLINE]

36: Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, Zuppan C, Bridge JA. Related Articles, Links

Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
Genes Chromosomes Cancer. 2003 May;37(1):98-105.
PMID: 12661011 [PubMed - indexed for MEDLINE]

37: Nishihara A, Fujii M, Sampath TK, Miyazono K, Reddi AH. Related Articles, Links

Bone morphogenetic protein signaling in articular chondrocyte differentiation.
Biochem Biophys Res Commun. 2003 Feb 7;301(2):617-22.
PMID: 12565908 [PubMed - indexed for MEDLINE]

38: Evens AM, Gartenhaus RB. Related Articles, Links

Molecular etiology of mature T-cell non-Hodgkin's lymphomas.
Front Biosci. 2003 Jan 01;8:d156-75. Review.
PMID: 12456315 [PubMed - indexed for MEDLINE]

39: Totonchi KF, Engel G, Weisenberg E, Rhone DP, Macon WR. Related Articles, Links

Testicular natural killer/t-cell lymphoma, nasal type, of true natural killer-cell origin.
Arch Pathol Lab Med. 2002 Dec;126(12):1527-9.
PMID: 12456216 [PubMed - indexed for MEDLINE]

40: Lamouille S, Mallet C, Feige JJ, Bailly S. Related Articles, Links

Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis.
Blood. 2002 Dec 15;100(13):4495-501.
PMID: 12453878 [PubMed - indexed for MEDLINE]

41: Costes-Martineau V, Delfour C, Obled S, Lamant L, Pageaux GP, Baldet P, Blanc P, Delsol G. Related Articles, Links

Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review.
J Clin Pathol. 2002 Nov;55(11):868-71. Review.
PMID: 12401829 [PubMed - indexed for MEDLINE]

42: Mo J, Fang SJ, Chen W, Blobe GC. Related Articles, Links

Regulation of ALK-1 signaling by the nuclear receptor LXRbeta.
J Biol Chem. 2002 Dec 27;277(52):50788-94. Epub 2002 Oct 18.
PMID: 12393874 [PubMed - indexed for MEDLINE]

43: Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K. Related Articles, Links

Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
J Cell Physiol. 2002 Dec;193(3):299-318.
PMID: 12384983 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

44: Muehleman C, Kuettner KE, Rueger DC, Ten Dijke P, Chubinskaya S. Related Articles, Links

Immunohistochemical localization of osteogenetic protein (OP-1) and its receptors in rabbit articular cartilage.
J Histochem Cytochem. 2002 Oct;50(10):1341-50.
PMID: 12364567 [PubMed - indexed for MEDLINE]

45: Miyazono K, Miyazawa K. Related Articles, Links

Id: a target of BMP signaling.
Sci STKE. 2002 Sep 24;2002(151):PE40. Review.
PMID: 12297674 [PubMed - indexed for MEDLINE]

46: Kutok JL, Aster JC. Related Articles, Links

Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
J Clin Oncol. 2002 Sep 1;20(17):3691-702. Review.
PMID: 12202671 [PubMed - indexed for MEDLINE]

47: Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R. Related Articles, Links

Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.
Oncogene. 2002 Aug 29;21(38):5823-34.
PMID: 12185581 [PubMed - indexed for MEDLINE]

48: Vermeer MH, Dukers DF, ten Berge RL, Bloemena E, Wu L, Vos W, de Vries E, Tensen CP, Meijer CJ, Willemze R. Related Articles, Links

Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Mod Pathol. 2002 Aug;15(8):838-44.
PMID: 12181269 [PubMed - indexed for MEDLINE]

49: Villalva C, Trempat P, Greenland C, Thomas C, Girard JP, Moebius F, Delsol G, Brousset P. Related Articles, Links

Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma.
Br J Haematol. 2002 Sep;118(3):791-8.
PMID: 12181047 [PubMed - indexed for MEDLINE]

50: Rosendahl A, Pardali E, Speletas M, Ten Dijke P, Heldin CH, Sideras P. Related Articles, Links

Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation.
Am J Respir Cell Mol Biol. 2002 Aug;27(2):160-9.
PMID: 12151307 [PubMed - indexed for MEDLINE]

51: Humbert M. Related Articles, Links

[Mutations of genes coding for TGF-beta receptors (BMPR2 and ALK-1) in primary pulmonary arterial hypertension]
J Soc Biol. 2002;196(1):53-8. Review. French.
PMID: 12134634 [PubMed - indexed for MEDLINE]

52: Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Related Articles, Links

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
J Biol Chem. 2002 Sep 27;277(39):35990-8. Epub 2002 Jul 16.
PMID: 12122009 [PubMed - indexed for MEDLINE]

☐ **53:** Dirks WG, Fahrnich S, Lis Y, Becker E, MacLeod RA, Drexler HG. Related Articles, Links

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines.
Int J Cancer. 2002 Jul 1;100(1):49-56.
PMID: 12115586 [PubMed - indexed for MEDLINE]

☐ **54:** Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P. Related Articles, Links

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Genes Chromosomes Cancer. 2002 Aug;34(4):354-62.
PMID: 12112524 [PubMed - indexed for MEDLINE]

☐ **55:** Wilkins MR, Moller GM, Ren X, Wharton J. Related Articles, Links

Developments in therapeutics for pulmonary arterial hypertension.
Minerva Cardioangiol. 2002 Jun;50(3):175-87. Review.
PMID: 12107399 [PubMed - indexed for MEDLINE]

☐ **56:** Bowden ET, Stoica GE, Wellstein A. Related Articles, Links

Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase.
J Biol Chem. 2002 Sep 27;277(39):35862-8. Epub 2002 Jul 09.
PMID: 12107166 [PubMed - indexed for MEDLINE]

☐ **57:** Valcourt U, Gouttenoire J, Moustakas A, Herbage D, Mallein-Gerin F. Related Articles, Links

Functions of transforming growth factor-beta family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes.
J Biol Chem. 2002 Sep 13;277(37):33545-58. Epub 2002 Jun 24.
PMID: 12082094 [PubMed - indexed for MEDLINE]

☐ **58:** Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D, Raulais D, Barritault D, Courty J, Milhiet PE. Related Articles, Links

Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.
J Biol Chem. 2002 Aug 30;277(35):32071-7. Epub 2002 Jun 17.
PMID: 12070152 [PubMed - indexed for MEDLINE]

☐ **59:** Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. Related Articles, Links

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Mol Pharmacol. 2002 Jul;62(1):65-74.
PMID: 12065756 [PubMed - indexed for MEDLINE]

☐ **60:** Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA. Related Articles, Links

Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Mol Pharmacol. 2002 Jul;62(1):58-64.
PMID: 12065755 [PubMed - indexed for MEDLINE]

☐ **61:** Liu X, Nagarajan RP, Vale W, Chen Y. Related Articles, Links

Phosphorylation regulation of the interaction between Smad7 and activin type I receptor.
FEBS Lett. 2002 May 22;519(1-3):93-8.
PMID: 12023024 [PubMed - indexed for MEDLINE]

62: Hernandez L, Bea S, Bellosillo B, Pinyol M, Falini B, Carbone A, Ott G, Rosenwald A, Fernandez A, Pulford K, Mason D, Morris SW, Santos E, Campo E. Related Articles, Links

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.
Am J Pathol. 2002 Apr;160(4):1487-94.
PMID: 11943732 [PubMed - indexed for MEDLINE]

63: Bonvini P, Gastaldi T, Falini B, Rosolen A. Related Articles, Links

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Cancer Res. 2002 Mar 1;62(5):1559-66.
PMID: 11888936 [PubMed - indexed for MEDLINE]

64: Strange JW, Wharton J, Phillips PG, Wilkins MR. Related Articles, Links

Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.
Clin Sci (Lond). 2002 Mar;102(3):253-68. Review.
PMID: 11869166 [PubMed - indexed for MEDLINE]

65: Hillmann G, Steinkamp-Zucht A, Geurtsen W, Gross G, Hoffmann A. Related Articles, Links

Culture of primary human gingival fibroblasts on biodegradable membranes.
Biomaterials. 2002 Mar;23(6):1461-9.
PMID: 11829442 [PubMed - indexed for MEDLINE]

66: Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Related Articles, Links

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
J Biol Chem. 2002 Apr 19;277(16):14153-8. Epub 2002 Jan 23.
PMID: 11809760 [PubMed - indexed for MEDLINE]

67: Lin WD, Wu JY, Hsu HB, Tsai FJ, Lee CC, Tsai CH. Related Articles, Links

Mutation analysis of a family with hereditary hemorrhagic telangiectasia associated with hepatic arteriovenous malformation.
J Formos Med Assoc. 2001 Dec;100(12):817-9.
PMID: 11802521 [PubMed - indexed for MEDLINE]

68: Falini B, Mason DY. Related Articles, Links

Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.
Blood. 2002 Jan 15;99(2):409-26. Review.
PMID: 11781220 [PubMed - indexed for MEDLINE]

69: Greenland C, Touriol C, Chevillard G, Morris SW, Bai R, Duyster J, Delsol G, Allouche M. Related Articles, Links

Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.

Oncogene. 2001 Nov 1;20(50):7386-97.
PMID: 11704868 [PubMed - indexed for MEDLINE]

70: Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T. Related Articles, Links

Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Cancer Res. 2001 Sep 1;61(17):6517-23.
PMID: 11522649 [PubMed - indexed for MEDLINE]

71: Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Related Articles, Links

Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.
Circulation. 2001 Aug 14;104(7):790-5.
PMID: 11502704 [PubMed - indexed for MEDLINE]

72: Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GW, Antonescu CR, Ladanyi M, Morris SW. Related Articles, Links

Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.
Am J Pathol. 2001 Aug;159(2):411-5.
PMID: 11485898 [PubMed - indexed for MEDLINE]

73: Kulikov VI, Muzya GI. Related Articles, Links

Inhibition of human platelet aggregation by amides and ester of salicylic acid with platelet-activating factor analogs.
Biochemistry (Mosc). 2001 Jun;66(6):658-61.
PMID: 11421815 [PubMed - indexed for MEDLINE]

74: Clark AT, Young RJ, Bertram JF. Related Articles, Links

In vitro studies on the roles of transforming growth factor-beta 1 in rat metanephric development.
Kidney Int. 2001 May;59(5):1641-53.
PMID: 11318934 [PubMed - indexed for MEDLINE]

75: Mould TL, Roberts-Thomson PJ. Related Articles, Links

Pathogenesis of telangiectasia in scleroderma.
Asian Pac J Allergy Immunol. 2000 Dec;18(4):195-200.
PMID: 11316039 [PubMed - indexed for MEDLINE]

76: Souza CJ, MacDougall C, MacDougall C, Campbell BK, McNeilly AS, Baird DT. Related Articles, Links

The Booroola (FecB) phenotype is associated with a mutation in the bone morphogenetic receptor type 1 B (BMPR1B) gene.
J Endocrinol. 2001 May;169(2):R1-6.
PMID: 11312159 [PubMed - indexed for MEDLINE]

77: Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T. Related Articles, Links

Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Cancer Res. 2001 Mar 1;61(5):2194-9.
PMID: 11280786 [PubMed - indexed for MEDLINE]

78: Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A. Related Articles, Links

Identification of anaplastic lymphoma kinase as a receptor for the growth

factor pleiotrophin.
J Biol Chem. 2001 May 18;276(20):16772-9. Epub 2001 Feb 08.
PMID: 11278720 [PubMed - indexed for MEDLINE]

79: Wilson T, Wu XY, Juengel JL, Ross IK, Lumsden JM, Lord EA, Dodds KG, Walling GA, McEwan JC, O'Connell AR, McNatty KP, Montgomery GW. Related Articles, Links

Highly prolific Booroola sheep have a mutation in the intracellular kinase domain of bone morphogenetic protein IB receptor (ALK-6) that is expressed in both oocytes and granulosa cells.
Biol Reprod. 2001 Apr;64(4):1225-35.
PMID: 11259271 [PubMed - indexed for MEDLINE]

80: Souttou B, Carvalho NB, Raulais D, Vigny M. Related Articles, Links

Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway.
J Biol Chem. 2001 Mar 23;276(12):9526-31. Epub 2000 Dec 19.
PMID: 11121404 [PubMed - indexed for MEDLINE]

81: Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. Related Articles, Links

CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Blood. 2000 Dec 1;96(12):3681-95. Review.
PMID: 11090048 [PubMed - indexed for MEDLINE]

82: Gaal K, Sun NC, Hernandez AM, Arber DA. Related Articles, Links

Sinonasal NK/T-cell lymphomas in the United States.
Am J Surg Pathol. 2000 Nov;24(11):1511-7.
PMID: 11075852 [PubMed - indexed for MEDLINE]

83: Gruber R, Mayer C, Schulz W, Graninger W, Peterlik M, Watzek G, Luyten FP, Erlacher L. Related Articles, Links

Stimulatory effects of cartilage-derived morphogenetic proteins 1 and 2 on osteogenic differentiation of bone marrow stromal cells.
Cytokine. 2000 Nov;12(11):1630-8.
PMID: 11052813 [PubMed - indexed for MEDLINE]

84: Azuma H. Related Articles, Links

Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia.
J Med Invest. 2000 Aug;47(3-4):81-90. Review.
PMID: 11019486 [PubMed - indexed for MEDLINE]

85: Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Related Articles, Links

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Leukemia. 2000 Sep;14(9):1533-59. Review.
PMID: 10994999 [PubMed - indexed for MEDLINE]

86: Akiyama H, Shukunami C, Nakamura T, Hiraki Y. Related Articles, Links

Differential expressions of BMP family genes during chondrogenic differentiation of mouse ATDC5 cells.
Cell Struct Funct. 2000 Jun;25(3):195-204.
PMID: 10984103 [PubMed - indexed for MEDLINE]

87: Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA. Related Articles, Links

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
Am J Pathol. 2000 Aug;157(2):377-84.
PMID: 10934142 [PubMed - indexed for MEDLINE]

88: Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, Dorfman DM. Related Articles, Links

Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma.
Blood. 2000 Jul 15;96(2):685-90.
PMID: 10887135 [PubMed - indexed for MEDLINE]

89: Foss HD, Marafioti T, Stein H. Related Articles, Links

[The many faces of anaplastic large cell lymphoma]
Pathologe. 2000 Mar;21(2):124-36. Review. German.
PMID: 10840818 [PubMed - indexed for MEDLINE]

90: Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariame B. Related Articles, Links

Expression of the ALK tyrosine kinase gene in neuroblastoma.
Am J Pathol. 2000 May;156(5):1711-21.
PMID: 10793082 [PubMed - indexed for MEDLINE]

91: Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M. Related Articles, Links

Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.
Hum Mol Genet. 2000 May 1;9(8):1227-37.
PMID: 10767348 [PubMed - indexed for MEDLINE]

92: Lux A, Gallione CJ, Marchuk DA. Related Articles, Links

Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms.
Hum Mol Genet. 2000 Mar 22;9(5):745-55.
PMID: 10749981 [PubMed - indexed for MEDLINE]

93: Olsson N, Piek E, ten Dijke P, Nilsson G. Related Articles, Links

Human mast cell migration in response to members of the transforming growth factor-beta family.
J Leukoc Biol. 2000 Mar;67(3):350-6.
PMID: 10733095 [PubMed - indexed for MEDLINE]

94: Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW. Related Articles, Links

Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Blood. 2000 Mar 15;95(6):2144-9.
PMID: 10706887 [PubMed - indexed for MEDLINE]

95: Klaus DJ, Gallione CJ, Anthony K, Yeh EY, Yu J, Lux A, Johnson DW, Marchuk DA. Related Articles, Links

Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164. Online.
Hum Mutat. 1998;12(2):137.
PMID: 10694922 [PubMed - indexed for MEDLINE]

☐ **96:** Tigyi G, Fisher DJ, Lilion K, Guo Z, Virag T, Sun G, Miller DD, Murakami-Murofushi K, Kobayashi S, Erickson JR. Related Articles, Links

Determinants of receptor subtype specificity in the LPA-like lipid mediator family.
Adv Exp Med Biol. 1999;469:245-51. No abstract available.
PMID: 10667337 [PubMed - indexed for MEDLINE]

☐ **97:** Spangfort MD, Mirza O, Svensson LA, Larsen JN, Gajhede M, Ipsen H. Related Articles, Links

Crystallization and preliminary X-ray analysis of birch-pollen allergen Bet v 1 in complex with a murine monoclonal IgG Fab' fragment.
Acta Crystallogr D Biol Crystallogr. 1999 Dec;55 (Pt 12):2035-6.
PMID: 10666582 [PubMed - indexed for MEDLINE]

☐ **98:** Agrotis A, Condron M, Bobik A. Related Articles, Links

Alternative splicing within the TGF-beta type I receptor gene (ALK-5) generates two major functional isoforms in vascular smooth muscle cells.
FEBS Lett. 2000 Feb 4;467(1):128-32.
PMID: 10664470 [PubMed - indexed for MEDLINE]

☐ **99:** Pardali E, Xie XQ, Tsapogas P, Itoh S, Arvanitidis K, Heldin CH, ten Dijke P, Grundstrom T, Sideras P. Related Articles, Links

Smad and AML proteins synergistically confer transforming growth factor beta1 responsiveness to human germ-line IgA genes.
J Biol Chem. 2000 Feb 4;275(5):3552-60.
PMID: 10652350 [PubMed - indexed for MEDLINE]

☐ **100:** Hubinger G, Scheffrahn I, Muller E, Bai R, Duyster J, Morris SW, Schrezenmeier H, Bergmann L. Related Articles, Links

The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Exp Hematol. 1999 Dec;27(12):1796-805.
PMID: 10641597 [PubMed - indexed for MEDLINE]

☐ **101:** Wurtzen PA, Bufe A, Wissenbach M, Madsen HO, Ipsen H, Amved J, Van Neerven RJ. Related Articles, Links

Identification of isoform-specific T-cell epitopes in the major timothy grass pollen allergen, Phl p 5.
Clin Exp Allergy. 1999 Dec;29(12):1614-25.
PMID: 10594537 [PubMed - indexed for MEDLINE]

☐ **102:** Carey MJ, Medeiros LJ, Roepke JE, Kjeldsberg CR, Elenitoba-Johnson KS. Related Articles, Links

Primary anaplastic large cell lymphoma of the small intestine.
Am J Clin Pathol. 1999 Nov;112(5):696-701.
PMID: 10549257 [PubMed - indexed for MEDLINE]

☐ **103:** Kitten AM, Kreisberg JI, Olson MS. Related Articles, Links

Expression of osteogenic protein-1 mRNA in cultured kidney cells.
J Cell Physiol. 1999 Dec;181(3):410-5.
PMID: 10528226 [PubMed - indexed for MEDLINE]

☐ **104:** Kagami Y, Suzuki R, Taji H, Yatabe Y, Takeuchi T, Maeda S, Kondo E, Kojima M, Motoori T, Mizoguchi Y, Okamoto M, Ohnishi K, Yamabe H, Seto M, Ogura M, Koshikawa T, Takahashi T, Kurita S, Morishima Y, Suchi T, Nakamura S. Related Articles, Links

Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.
Am J Surg Pathol. 1999 Oct;23(10):1184-200.

h cb h g e e e fcg e ch b e

PMID: 10524519 [PubMed - indexed for MEDLINE]

☐ **105:** Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, Nakamura M, Takano S. Related Articles, Links

CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s).
FEBS Lett. 1999 Oct 8;459(2):195-9.
PMID: 10518017 [PubMed - indexed for MEDLINE]

☐ **106:** Hattori H, Nagano M, Iwata F, Homma Y, Egashira T, Okada T. Related Articles, Links

Identification of recurrent and novel mutations in the LDL receptor gene in Japanese familial hypercholesterolemia. Mutation in brief no. 248. Online.
Hum Mutat. 1999;14(1):87.
PMID: 10447263 [PubMed - indexed for MEDLINE]

☐ **107:** Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, Tararak E, Condron M, Kostolias G. Related Articles, Links

Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development.
Circulation. 1999 Jun 8;99(22):2883-91.
PMID: 10359732 [PubMed - indexed for MEDLINE]

☐ **108:** Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. Related Articles, Links

A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
Blood. 1999 May 1;93(9):3088-95.
PMID: 10216106 [PubMed - indexed for MEDLINE]

☐ **109:** Lux A, Attisano L, Marchuk DA. Related Articles, Links

Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
J Biol Chem. 1999 Apr 9;274(15):9984-92.
PMID: 10187774 [PubMed - indexed for MEDLINE]

☐ **110:** Wuytens G, Verschueren K, de Winter JP, Gajendran N, Beek L, Devos K, Bosman F, de Waele P, Andries M, van den Eijnden-van Raaij AJ, Smith JC, Huylebroeck D. Related Articles, Links

Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors.
J Biol Chem. 1999 Apr 2;274(14):9821-7.
PMID: 10092672 [PubMed - indexed for MEDLINE]

☐ **111:** Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K, Takano S. Related Articles, Links

Selective expression of a novel surface molecule by human Th2 cells in vivo.
J Immunol. 1999 Feb 1;162(3):1278-86.
PMID: 9973380 [PubMed - indexed for MEDLINE]

☐ **112:** Trumper L, Pfreundschuh M, Bonin FV, Daus H. Related Articles, Links

Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals.
Br J Haematol. 1998 Dec;103(4):1138-44.
PMID: 9886332 [PubMed - indexed for MEDLINE]

☐ **113:** Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Related Articles, Links

h cb hg e e e fcg e ch b e

Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Cancer Res. 1998 Dec 1;58(23):5329-32.
PMID: 9850059 [PubMed - indexed for MEDLINE]

114: Marchuk DA. Related Articles, Links

Genetic abnormalities in hereditary hemorrhagic telangiectasia.
Curr Opin Hematol. 1998 Sep;5(5):332-8. Review.
PMID: 9776212 [PubMed - indexed for MEDLINE]

115: Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L. Related Articles, Links

ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
Am J Pathol. 1998 Sep;153(3):875-86.
PMID: 9736036 [PubMed - indexed for MEDLINE]

116: Kadin ME, Morris SW. Related Articles, Links

The t(2;5) in human lymphomas.
Leuk Lymphoma. 1998 Apr;29(3-4):249-56. Review.
PMID: 9684923 [PubMed - indexed for MEDLINE]

117: Kim IY, Zelner DJ, Lee C. Related Articles, Links

The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
Exp Cell Res. 1998 May 25;241(1):151-60.
PMID: 9633523 [PubMed - indexed for MEDLINE]

118: Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Related Articles, Links

Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries.
Atherosclerosis. 1998 Apr;137(2):267-75.
PMID: 9622270 [PubMed - indexed for MEDLINE]

119: Gogusev J, Nezelof C. Related Articles, Links

Malignant histiocytosis. Histologic, cytochemical, chromosomal, and molecular data with a nosologic discussion.
Hematol Oncol Clin North Am. 1998 Apr;12(2):445-63. Review.
PMID: 9561912 [PubMed - indexed for MEDLINE]

120: Cheifetz S. Related Articles, Links

RNAse protection assay for BMP type I receptors.
Eur J Oral Sci. 1998 Jan;106 Suppl 1:174-8.
PMID: 9541222 [PubMed - indexed for MEDLINE]

121: Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris SW. Related Articles, Links

Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.
Cancer Res. 1998 Mar 1;58(5):1057-62.
PMID: 9500471 [PubMed - indexed for MEDLINE]

122: Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, Zhou H, Bridges AJ. Related Articles, Links

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]

pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.
Biochem Pharmacol. 1997 Oct 15;54(8):877-87.
PMID: 9354588 [PubMed - indexed for MEDLINE]

☐ **123:** Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW. Related Articles, Links

Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.
Blood. 1997 Oct 15;90(8):2901-10.
PMID: 9376569 [PubMed - indexed for MEDLINE]

☐ **124:** Choi ME, Liu A, Ballermann BJ. Related Articles, Links

Differential expression of transforming growth factor-beta receptors in rat kidney development.
Am J Physiol. 1997 Sep;273(3 Pt 2):F386-95.
PMID: 9321911 [PubMed - indexed for MEDLINE]

☐ **125:** Toyono T, Nakashima M, Kuhara S, Akamine A. Related Articles, Links

Temporal changes in expression of transforming growth factor-beta superfamily members and their receptors during bovine preodontoblast differentiation in vitro.
Arch Oral Biol. 1997 Jul;42(7):481-8.
PMID: 9296267 [PubMed - indexed for MEDLINE]

☐ **126:** Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, Jackson CE, Porteous ME, Marchuk DA. Related Articles, Links

The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
Am J Hum Genet. 1997 Jul;61(1):60-7.
PMID: 9245985 [PubMed - indexed for MEDLINE]

☐ **127:** Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP. Related Articles, Links

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
Oncogene. 1997 May 8;14(18):2175-88. Erratum in: Oncogene 1997 Dec 4;15(23):2883.

PMID: 9174053 [PubMed - indexed for MEDLINE]

☐ **128:** Ramp U, Jaquet K, Reinecke P, Nitsch T, Gabbert HE, Gerharz CD. Related Articles, Links

Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma.
Lab Invest. 1997 May;76(5):739-49.
PMID: 9166292 [PubMed - indexed for MEDLINE]

☐ **129:** Bischof D, Pulford K, Mason DY, Morris SW. Related Articles, Links

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
Mol Cell Biol. 1997 Apr;17(4):2312-25.
PMID: 9121481 [PubMed - indexed for MEDLINE]

☐ **130:** Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY. Related Articles, Links

A new subtype of large B-cell lymphoma expressing the ALK kinase and

lacking the 2; 5 translocation.
Blood. 1997 Mar 1;89(5):1483-90.
PMID: 9057627 [PubMed - indexed for MEDLINE]

☐ **131:** Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T. Related Articles, Links

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Oncogene. 1997 Jan 30;14(4):439-49.
PMID: 9053841 [PubMed - indexed for MEDLINE]

☐ **132:** Trumper L, Daus H, Merz H, von Bonin F, Loftin U, Cochlovius C, Moller P, Feller AC, Pfreundschuh M. Related Articles, Links

NPM/ALK fusion mRNA expression in Hodgkin and Reed-Sternberg cells is rare but does occur: results from single-cell cDNA analysis.
Ann Oncol. 1997;8 Suppl 2:83-7.
PMID: 9209648 [PubMed - indexed for MEDLINE]

☐ **133:** Johnson PW, Leek J, Swinbank K, Angus B, Roberts P, Markham AF, Selby PJ, MacLennan KA. Related Articles, Links

The use of fluorescent in situ hybridization for detection of the t(2;5) (p23;q35) translocation in anaplastic large-cell lymphoma.
Ann Oncol. 1997;8 Suppl 2:65-9.
PMID: 9209644 [PubMed - indexed for MEDLINE]

☐ **134:** Morita N, Takumi T, Kiyama H. Related Articles, Links

Distinct localization of two serine-threonine kinase receptors for activin and TGF-beta in the rat brain and down-regulation of type I activin receptor during peripheral nerve regeneration.
Brain Res Mol Brain Res. 1996 Dec;42(2):263-71.
PMID: 9013782 [PubMed - indexed for MEDLINE]

☐ **135:** Beylot-Barry M, Lamant L, Vergier B, de Muret A, Fraitag S, Delord B, Dubus P, Vaillant L, Delaunay M, MacGrogan G, Beylot C, de Mascarel A, Delsol G, Merlio JP. Related Articles, Links

Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
Am J Pathol. 1996 Aug;149(2):483-92.
PMID: 8701987 [PubMed - indexed for MEDLINE]

☐ **136:** Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T. Related Articles, Links

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6.
PMID: 8633037 [PubMed - indexed for MEDLINE]

☐ **137:** Panchenko MP, Williams MC, Brody JS, Yu Q. Related Articles, Links

Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels.
Am J Physiol. 1996 Apr;270(4 Pt 1):L547-58.
PMID: 8928814 [PubMed - indexed for MEDLINE]

☐ **138:** Simonitsch I, Panzer-Gruemayer ER, Ghali DW, Zoubek A, Radaszkiewicz T, Gadner H, Kovar H. Related Articles, Links

NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1 positive anaplastic large cell lymphomas.
Br J Haematol. 1996 Mar;92(4):866-71.

PMID: 8616079 [PubMed - indexed for MEDLINE]

139: Alexander JM, Bikkal HA, Zervas NT, Laws ER Jr, Klibanski A. Related Articles, Links

Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
J Clin Endocrinol Metab. 1996 Feb;81(2):783-90.
PMID: 8636304 [PubMed - indexed for MEDLINE]

140: Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. Related Articles, Links

The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.
Blood. 1996 Feb 1;87(3):882-6.
PMID: 8562957 [PubMed - indexed for MEDLINE]

141: Wu X, Robinson CE, Fong HW, Crabtree JS, Rodriguez BR, Roe BA, Gimble JM. Related Articles, Links

Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog.
Biochem Biophys Res Commun. 1995 Nov 2;216(1):78-83.
PMID: 7488127 [PubMed - indexed for MEDLINE]

142: Schluns KS, Grutkoski PS, Cook JE, Engelmann GL, Le PT. Related Articles, Links

Human thymic epithelial cells produce TGF-beta 3 and express TGF-beta receptors.
Int Immunol. 1995 Oct;7(10):1681-90.
PMID: 8562514 [PubMed - indexed for MEDLINE]

143: Zoubek A, Simonitsch I, Panzer-Grumayer ER, Ghali D, Pfleiderer C, Haas OA, Mann G, Lang S, Radaszkiewicz T, Gadner H, et al. Related Articles, Links

Ewing tumor after treatment of Ki-1+ anaplastic large cell lymphoma. Therapy-associated secondary neoplasm or unrelated coincidence?
Cancer Genet Cytogenet. 1995 Aug;83(1):5-11.
PMID: 7656205 [PubMed - indexed for MEDLINE]

144: Dewulf N, Verschueren K, Lonnoy O, Moren A, Grimsby S, Vande Spiegle K, Miyazono K, Huylebroeck D, Ten Dijke P. Related Articles, Links

Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis.
Endocrinology. 1995 Jun;136(6):2652-63.
PMID: 7750489 [PubMed - indexed for MEDLINE]

145: Mathew P, Morris SW, Kane JR, Shurtleff SA, Pasquini M, Jenkins NA, Gilbert DJ, Copeland NG. Related Articles, Links

Localization of the murine homolog of the anaplastic lymphoma kinase (AIK) gene on mouse chromosome 17.
Cytogenet Cell Genet. 1995;70(1-2):143-4.
PMID: 7736780 [PubMed - indexed for MEDLINE]

146: ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin CH, Miyazono K. Related Articles, Links

Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4.
J Biol Chem. 1994 Jun 24;269(25):16985-8.
PMID: 8006002 [PubMed - indexed for MEDLINE]

147: Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Related Articles, Links

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-

Hodgkin's lymphoma.
Science. 1994 Mar 4;263(5151):1281-4. Erratum in: Science. 1995 Jan 20;267 (5196):316-7.
PMID: 8122112 [PubMed - indexed for MEDLINE]

148: O'Flaherty JT, Tessner T, Greene D, Redman JR, Wykle RL. Related Articles, Links

Comparison of 1-O-alkyl-, 1-O-alk-1'-enyl-, and 1-O-acyl-2-acetyl-sn-glycero-3-phosphoethanolamines and -3-phosphocholines as agonists of the platelet-activating factor family.
Biochim Biophys Acta. 1994 Jan 3;1210(2):209-16.
PMID: 8280772 [PubMed - indexed for MEDLINE]

149: ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H, Heldin CH, Miyazono K. Related Articles, Links

Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity.
Oncogene. 1993 Oct;8(10):2879-87.
PMID: 8397373 [PubMed - indexed for MEDLINE]

150: Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. Related Articles, Links

Immunotherapy and allergic inflammation.
Clin Exp Allergy. 1991 Jan;21 Suppl 1:206-10.
PMID: 2032147 [PubMed - indexed for MEDLINE]

151: Hellstrand K, Hermodsson S. Related Articles, Links

Monocyte-mediated suppression of IL-2-induced NK-cell activation. Regulation by 5-HT1A-type serotonin receptors.
Scand J Immunol. 1990 Aug;32(2):183-92.
PMID: 2117776 [PubMed - indexed for MEDLINE]

152: Hellstrand K, Hermodsson S. Related Articles, Links

Enhancement of human natural killer cell cytotoxicity by serotonin: role of non-T/CD16+ NK cells, accessory monocytes, and 5-HT1A receptors.
Cell Immunol. 1990 Apr 15;127(1):199-214.
PMID: 2138518 [PubMed - indexed for MEDLINE]

153: Sugatani J, Lee DY, Hughes KT, Saito K. Related Articles, Links

Development of a novel scintillation proximity radioimmunoassay for platelet-activating factor measurement: comparison with bioassay and GC/MS techniques.
Life Sci. 1990;46(20):1443-50.
PMID: 2111868 [PubMed - indexed for MEDLINE]

154: Frank TS, Trojanowski JQ, Roberts SA, Brooks JJ. Related Articles, Links

A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor.
Mod Pathol. 1989 Nov;2(6):638-51.
PMID: 2479946 [PubMed - indexed for MEDLINE]

155: Olsson RA, Kusachi S, Thompson RD, Ukena D, Padgett W, Daly JW. Related Articles, Links

N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.
J Med Chem. 1986 Sep;29(9):1683-9.
PMID: 3018244 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb h g e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Abstract Show: 20 Sort Send to Text

1: Oncogene. 1997 Jan 30;14(4):439-49.

Related Articles, Links

nature publishing group

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.

Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T.

Department of Oncology, Institute of Medical Science, University of Tokyo, Japan.

The 2;5 chromosomal translocation is frequently associated with anaplastic large cell lymphomas (ALCLs). The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5. A recent study shows that the product of the npm-alk fusion gene is oncogenic. To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biological function of the alk gene product, ALK. Here, we show molecular cloning of cDNAs for both the human and mouse ALK proteins. The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain. These sequences are absent in the product of the transforming npm-alk gene. ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biological function is presently unknown. RNA blot hybridization analysis of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord. Immunoblotting with anti-ALK antibody shows that ALK is highly expressed in the neonatal brain. Furthermore, RNA in situ hybridization analysis shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice. These data suggest that ALK plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.

PMID: 9053841 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

h cb h g e e e fcg c e e e b b e b c

Welcome to STN International! Enter x:x
* * * * * * * * * * Welcome to STN International * * * * * * * * * *
* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:25:09 ON 13 SEP 2004

=> file BIOSCIENCE
FILE 'ADISCTI' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 09:25:17 ON 13 SEP 2004

FILE 'AQUALINE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 09:25:17 ON 13 SEP 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 09:25:17 ON 13 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 09:25:17 ON 13 SEP 2004

FILE 'CAPLUS' ENTERED AT 09:25:17 ON 13 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 09:25:17 ON 13 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 09:25:17 ON 13 SEP 2004

FILE 'CROPU' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 09:25:17 ON 13 SEP 2004

FILE 'FOMAD' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 09:25:17 ON 13 SEP 2004

FILE 'HEALSAFE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi

FILE 'LIFESCI' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'NIOSHTIC' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 09:25:17 ON 13 SEP 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 09:25:17 ON 13 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 09:25:17 ON 13 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 09:25:17 ON 13 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 09:25:17 ON 13 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 09:25:17 ON 13 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:25:17 ON 13 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 09:25:17 ON 13 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

```
=> s pleiotrophin
  49 FILES SEARCHED...
L1         3116 PLEIOTROPHIN

=> S L1 AND receptor
  29 FILES SEARCHED...
  61 FILES SEARCHED...
L2          965 L1 AND RECEPTOR

=> S L2 AND human
  14 FILES SEARCHED...
  25 FILES SEARCHED...
  47 FILES SEARCHED...
  63 FILES SEARCHED...
L3          586 L2 AND HUMAN

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4           365 DUP REM L3 (221 DUPLICATES REMOVED)

=> D L4 1-365

L4   ANSWER 1 OF 365  PHIN COPYRIGHT 2004 PJB on STN

AN   2004:2057  PHIN
DN   S00828224
DED  6 Jan 2004
TI   PHARMAPROJECTS - New drug development strategies for January 2004
SO   Scrip-Online-plus (2004)
DT   Newsletter
FS   FULL

L4   ANSWER 2 OF 365  CAPLUS  COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN   2004:80223  CAPLUS
DN   140:151910
TI   Trans-splicing ribozyme mediated preparation of biopharmaceutical and
     protein for therapeutic and diagnostic applications
IN   Thompson, James
PA   USA
SO   U.S. Pat. Appl. Publ., 28 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   US 2004018520        A1    20040129    US 2003-421015          20030422
PRAI US 2002-374427P      P     20020422

L4   ANSWER 3 OF 365  IFIPAT  COPYRIGHT 2004 IFI on STN DUPLICATE 2
AN    10531131  IFIPAT;IFIUDB;IFICDB
TI    SYNTHETIC HEPARIN-BINDING GROWTH FACTOR ANALOGS
IN    Glass John D; Lin Xinhua; Pena Louis A; Zamora Paul
PA    Unassigned Or Assigned To Individual (68000)
PI    US 2004038348   A1  20040226
AI    US 2002-224268      20020820
FI    US 2004038348       20040226
DT    Utility; Patent Application - First Publication
FS    CHEMICAL
      APPLICATION
CLMN  82
GI     10 Figure(s).
      FIG. 1: Sequence of synthetic peptide analog F2A3.
      FIG. 2: Sequence of synthetic peptide analog F2A4.
      FIG. 3: Elution of F2A3 from a heparin affinity column.
      FIG. 4: Specific binding of F2A3 to FGFRs on HUVECs.
      FIG. 5: Equivalence of bFGF analogs F2A3 and F2A4 to native, recombinant
       bFGF in MAP kinase phosphorylation and activation.
      FIG. 6: Stimulation of cell proliferation in fibroblast cultures.
       Mitogenic dose response of F2A3 and F2A4 versus bFGF.
```

Attachment after two hours of CH310T1/2 murine fibroblasts to polystyrene coated with silyl-heparin alone or with silyl-heparin plus bFGF or F2A3. (*) indicates p less than 0.05. Panel B: Micrographs of bovine aortic endothelial cells (BAEC) grown on polycaprolactone with (left panel) or without (right panel) a coating of F2A3.

FIG. 8: Photomicrographs of coated polylactide sutures in rat muscle at 2 weeks. Panel A: No coating. B: Silyl heparin coated. C: F2A3 coated. D: Coated with silyl heparin plus F2A3.

FIG. 9: Radiation protection in endothelial cell cultures. Apoptosis induced by 8 Gy x-ray irradiation is reduced by 50 ng/ ml bFGF or F2A3.

FIG. 10: Radioprotection from G.I. syndrome in vivo.

L4 ANSWER 4 OF 365 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3
AN 10506959 IFIPAT;IFIUDB;IFICDB
TI MODULATION OF ***PLEIOTROPHIN*** SIGNALING BY ***RECEPTOR*** -TYPE PROTEIN TYROSINE PHOSPHATASE BETA/C
IN Deuel Thomas
PA Unassigned Or Assigned To Individual (68000)
PI US 2004014162 A1 20040122
AI US 2003-220459 20030123
WO 2001-US6476 20010228
20030123 PCT 371 date
20030123 PCT 102(e) date
FI US 2004014162 20040122
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 33
GI 3 Figure(s).

FIGS. 1A, 1B and 1C are a set of three western blots showing the association of RPTP beta / zeta with PTN. FIG. 1A shows lysates of U373-MG glioblastoma cells immunoprecipitated with anti-RPTP beta / zeta monoclonal antibodies. The immunoprecipitates were separated on 6% acrylamide gel, transferred to a poly(vinylidene difluoride) membrane, and probed with anti-RPTP beta / zeta antibodies. The arrowheads indicate the RPTP beta / zeta-spliced products of approximate 230, 130 and 85 kDa. FIG. 1B shows Western analysis of RPTP beta / zeta captured by PTNFc. Lysates of U373-MG cells were incubated with PTN-Fc and proteins interactive with PTN-Fc (right lane) were captured with Protein A Sepharose-4B beads for 2 hours. The beads were washed in cold lysis buffer, boiled in SDS/PAGE sample buffer, and the eluted proteins were separated on an 8% acrylamide gel and analyzed by Western blots probed with anti-RPTP beta / zeta monoclonal antibodies. As a control, PTN-Fc was replaced with an equal amount of ***human*** IgG (left lane). The arrowheads indicate the approximate 130 and approximate 85 kDa-spliced products of RPTP beta / zeta . FIG. 1C shows western analysis of RPTP beta / zeta captured by endogenous PTN. Lysates of U373MG cells were incubated with anti-PTN monoclonal antibodies (right lane) and the complexes were captured with Protein A Sepharose-4B beads for 2 hours. The beads were washed in cold lysis buffers, boiled in SDS-PAGE sample buffer, and the eluted proteins were separated on an 8% acrylamide gel and analyzed by Wester blots probes with anti-RPTP beta / zeta monoclonal antibodies. As a control, mouse IgG replaced the anti-PTN antibody (left lane). The arrowheads indicate the 130 and =85 kda-spliced products of RPTP beta / zeta .

FIGS. 2A, 2B and 2C are a set of three bar charts showing PTNdependent inhibition of the intrinsic tyrosine phosphatase activity of RPTP beta / zeta . FIG. 2A shows inhibition of the endogenous RPTP beta / zeta tyrosine phosphatase activity in PTN-treated U373-MG cells. The left bar represents tyrosine phosphatase activity in immunoprecipitates from lysates of untreated cells with mouse IgG (control) to replace the antiRPTP beta / zeta antibodies. The center bar represents tyrosine phosphatase activity in immunoprecipitates with anti-RPTP beta / zeta antibodies from lysates of untreated cells, and the right bar represents tyrosine phosphatase activity of immunoprecipitates with anti-RPTP beta / zeta antibodies from lysates of cells treated with recombinant PTN (50 ng/ml). FIG. 2B shows inhibition of recombinant RPTP beta / zeta phasphatase activity in Sf9 cell membranes. The right two bars show membrane fractions of Sf9 cells that were infected by a baculovirus containing a cDNA-encoding RPTP beta / zeta, or were uninfected (left two bars) that were untreated (-PTN) or treated (+PTN) with 50 ng/ml PTN. FIG. 2C shows a time course of PTN-dependent inactivation of RPTP beta / zeta in PTNtreated (50 ng/ml) Sf9 cell membranes expressing RPTP beta / zeta (solid bars) and SF9 cell membranes without RPTP beta / zeta (open bar, t=0 only).

blots, respectively, showing physical and functional association of beta-catenin with PTN/RPTP beta / zeta . FIG. 3A shows that PTN-Fc is in complex with RPTP beta / zeta and beta-catenin. PTN-Fc treated confluent U373-MG cells from 60mm dish were chemically cross-linked with 3,3'dithiobis sulfosuccinmidyl propionate. Lysates from PTN-Fc-treated, chemically cross-linked cells (lanes 1) or Fc-(alone) treated (control) U373-MG cells (lane 2) were incubated with Protein A Sepharose, washed, eluted with SDS sample buffer with 5% 2mercaptoethanol, and analyzed in 6% SDS gels and Western blots. Lysates from untreated U373-MG cells alone (lane 3) were also analyzed as a control. Western blots were analyzed with antibeta-catenin (right) or anti-RPTP beta / zeta antibodies (left) . Arrowheads identify RPTP beta / zeta-spliced products of =250, 230, 180 and 85 kDa (left) and beta-catenin (94 kDa) (right). FIG. 2B shows that beta-catenin interacts with proximal (catalytic) domain of RPTP beta / zeta . The GST-D1RPTP beta / zeta wild-type, GST-D1-Cys-1925-Ser (inactivating) mutant fusion protein or GST alone were expressed and immobilized with glutathione-Sepharose-48 beads, incubated with U373-MG cell lysates, washed, and analyzed in Western analysis with the a-phosphotyrosine antibodies and visualized with the enhanced chemiluminescence ECLPLUS system (lower). The same blot was reprobed with alpha-beta-catenin antibodies and detected as above (upper).

L4 ANSWER 5 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:430923 CAPLUS
DN 141:1221
TI Surrogate marker gene expression-based methods for identifying antineoplastic agents
IN Fanton, Christie; Mackichan, Mary Lee
PA Chiron Corporation, USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004044154	A2	20040527	WO 2003-US35688	20031107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-426074P	P	20021107		
	US 2003-487228P	P	20030716		
	US 2003-516738P	P	20031104		

L4 ANSWER 6 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:308529 CAPLUS
DN 140:333599
TI Gene expression profile of ***human*** and mouse genes in atopic dermatitis and psoriasis patients and its use for diagnosis, therapy, and drug screening
IN Itoh, Mikito; Ogawa, Kaoru; Shinagawa, Akira; Sudo, Hajime; Ogawa, Hideoki; Ra, Chisei; Mitsuishi, Kouichi
PA Genox Research, Inc., Japan; Juntendo University
SO PCT Int. Appl., 611 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031386	A1	20040415	WO 2003-JP9808	20030801
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG,				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2002-229318 A 20020806
JP 2003-136543 A 20030514
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:308510 CAPLUS
DN 140:316242
TI Method for regulating expression of genes by modulating the expression of H19 gene and use for finding out angiogenesis-controlling genes
IN Hochberg, Abraham; Ayesh, Suhail; Poradosu, Enrique
PA Yissum Research and Development, Israel; McInnis, Patricia
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031359	A2	20040415	WO 2003-US31306	20031003

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-415528P P 20021003

L4 ANSWER 8 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:203961 CAPLUS
DN 140:216187
TI Generation and therapeutic application of dendritic cells
IN Rice, Alison Mary; Hart, Derek; Vukovic, Slavica
PA The Corporation of the Trustees of the Order of the Sisters of Mercy in Queensland, Australia
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020613	A1	20040311	WO 2003-AU1113	20030829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI AU 2002-951082 A 20020830
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 365 USPATFULL on STN
AN 2004:221363 USPATFULL
TI RECOMBINANT INFECTIOUS LARYNGOTRACHEITIS VIRUS AND USES THEREOF
IN Wild, Martha A., San Diego, CA, UNITED STATES
Cochran, Mark D., Carlsbad, CA, UNITED STATES
PI US 2004171132 A1 20040902
AI US 2001-993777 A1 20011106 (9)
RLI Continuation of Ser. No. US 1995-468190, filed on 6 Jun 1995, ABANDONED

Continuation-in-part of Ser. No. US 1993-126597, filed on 24 Sep 1993, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 5956
INCL INCLM: 435/235.100
INCLS: 424/199.100
NCL NCLM: 435/235.100
NCLS: 424/199.100
IC [7]
ICM: A61K039-12
ICS: C12N007-00

L4 ANSWER 10 OF 365 USPATFULL on STN
AN 2004:215978 USPATFULL
TI Complexation of rna, especially ribozymes, with polyrthylenimines for the stabilization and cellular introduction thereof
IN Aigner, Achim, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Czubayko, Frank, Kirchhain, GERMANY, FEDERAL REPUBLIC OF
Kissel, Thomas, Satufen, GERMANY, FEDERAL REPUBLIC OF
Fischer, Dagmar, Meeder, GERMANY, FEDERAL REPUBLIC OF
PI US 2004167087 A1 20040826
AI US 2003-168125 A1 20030221 (10)
WO 2000-EP12413 20001208
PRAI DE 1999-19960206 19991214
DT Utility
FS APPLICATION
LN.CNT 878
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00

L4 ANSWER 11 OF 365 USPATFULL on STN
AN 2004:214995 USPATFULL
TI Treatment for arthritis
IN Elia, James P., Scottsdale, AZ, UNITED STATES
PI US 2004166100 A1 20040826
AI US 2004-791648 A1 20040302 (10)
RLI Continuation of Ser. No. US 2002-179589, filed on 25 Jun 2002, PENDING
Continuation-in-part of Ser. No. US 1998-64000, filed on 21 Apr 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 2441
INCL INCLM: 424/093.210
NCL NCLM: 424/093.210
IC [7]
ICM: A61K048-00

L4 ANSWER 12 OF 365 USPATFULL on STN
AN 2004:204688 USPATFULL
TI Method for determination of co-occurences of attributes
IN Kotlyar, Max, Kingston, CANADA
Somogyi, Roland, Sydenham, CANADA
Green, James, Kingston, CANADA
Steeg, Evan, Kingston, CANADA
Ableson, Alan D., Kingston, CANADA
PI US 2004158581 A1 20040812
AI US 2003-478418 A1 20031121 (10)
WO 2002-CA731 20020517
DT Utility
FS APPLICATION
LN.CNT 5505
INCL INCLM: 707/104.100
NCL NCLM: 707/104.100
IC [7]
ICM: G06F017-00

L4 ANSWER 13 OF 365 USPATFULL on STN
AN 2004:196865 USPATFULL
TI Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
IN Lee, Chichang, Norristown, PA, UNITED STATES
Moore, Gordon, Wayne, PA, UNITED STATES

Shi, Xiaomei, Collegeville, PA, UNITED STATES
PI US 2004152170 A1 20040805
AI US 2003-727432 A1 20031204 (10)
RLI Continuation-in-part of Ser. No. US 2002-316308, filed on 11 Dec 2002, PENDING
PRAI US 2001-339428P 20011214 (60)
DT Utility
FS APPLICATION
LN.CNT 2600
INCL INCLM: 435/070.210
INCLS: 435/328.000; 435/366.000
NCL NCLM: 435/070.210
NCLS: 435/328.000; 435/366.000
IC [7]
ICM: C12P021-04
ICS: C12N005-06; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 365 USPATFULL on STN
AN 2004:196424 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004151728 A1 20040805
AI US 2003-666834 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39129
INCL INCLM: 424/184.100
INCLS: 424/199.100; 424/200.100; 530/395.000
NCL NCLM: 424/184.100
NCLS: 424/199.100; 424/200.100; 530/395.000
IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 365 USPATFULL on STN
AN 2004:178988 USPATFULL
TI Cea-expression inhibiting ribozymes and methods for the treatment of cancer based thereon
IN Juhl, Hartmut, Hamburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2004138158 A1 20040715
AI US 2004-469091 A1 20040218 (10)
WO 2002-US5257 20020225
DT Utility
FS APPLICATION
LN.CNT 1140
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 365 USPATFULL on STN
AN 2004:178985 USPATFULL
TI Devices containing DNA encoding neurotrophic agents and related compositions and methods
IN Baird, Andrew, London, UNITED KINGDOM
Gonzalez, Ana Maria, San Diego, CA, UNITED STATES
Logan, Ann, Stourport on Severn, UNITED KINGDOM
Berry, Martin, Edgbaston, UNITED KINGDOM
PA Selective Genetics, Inc., San Diego, CA (non-U.S. corporation)
University of Birmingham, Edgbaston, UNITED KINGDOM (non-U.S. corporation)
King's College, London, UNITED KINGDOM (non-U.S. corporation)
PI US 2004138155 A1 20040715
AI US 2003-348051 A1 20030117 (10)
RLI Continuation of Ser. No. US 1998-178286, filed on 23 Oct 1998, GRANTED, Pat. No. US 6551618 Continuation-in-part of Ser. No. US 1998-88419,

1997-805381, filed on 24 Feb 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-805382, filed on 24 Feb 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-805383, filed on 24 Feb 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-718904, filed on 24 Sep 1996, GRANTED, Pat. No. US 6037329 Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-213447, filed on 15 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-297961, filed on 29 Aug 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-305771, filed on 13 Sep 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3891
INCL INCLM: 514/044.000
INCLS: 424/426.000
NCL NCLM: 514/044.000
NCLS: 424/426.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 365 USPATFULL on STN
AN 2004:165307 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126793 A1 20040701
AI US 2003-666885 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 28979
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 365 USPATFULL on STN
AN 2004:164872 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126357 A1 20040701
AI US 2003-666886 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39007
INCL INCLM: 424/085.100
INCLS: 424/093.200; 424/185.100
NCL NCLM: 424/085.100
NCLS: 424/093.200; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-00; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 365 USPATFULL on STN
AN 2004:159255 USPATFULL
TI PPAR-gamma ligands in the treatment of asthma and allergies

August, Avery, State College, PA, UNITED STATES
Vanden Heuvel, John P., Port Matilda, PA, UNITED STATES
PA The Penn State Research Foundation (U.S. corporation)
PI US 2004122059 A1 20040624
AI US 2003-674395 A1 20031001 (10)
PRAI US 2002-415452P 20021001 (60)
US 2002-418818P 20021011 (60)
DT Utility
FS APPLICATION
LN.CNT 1687
INCL INCLM: 514/342.000
INCLS: 514/369.000; 514/573.000
NCL NCLM: 514/342.000
NCLS: 514/369.000; 514/573.000
IC [7]
ICM: A61K031-4439
ICS: A61K031-426; A61K031-557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 365 USPATFULL on STN
AN 2004:159164 USPATFULL
TI Antiangiogenesis by inhibiting protein kinase CK2 activity
IN Ljubimov, Alexander, Studio City, CA, UNITED STATES
Castellon, Raquel, Norwalk, CA, UNITED STATES
Grant, Maria, Fairfield, FL, UNITED STATES
PI US 2004121968 A1 20040624
AI US 2002-328646 A1 20021223 (10)
DT Utility
FS APPLICATION
LN.CNT 1647
INCL INCLM: 514/043.000
INCLS: 514/680.000; 424/744.000
NCL NCLM: 514/043.000
NCLS: 514/680.000; 424/744.000
IC [7]
ICM: A61K031-7056
ICS: A61K031-12; A61K035-78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 365 USPATFULL on STN
AN 2004:158657 USPATFULL
TI Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances
IN Castellon, Raquel, Norwalk, CA, UNITED STATES
PI US 2004121457 A1 20040624
AI US 2002-328812 A1 20021223 (10)
DT Utility
FS APPLICATION
LN.CNT 2059
INCL INCLM: 435/325.000
NCL NCLM: 435/325.000
IC [7]
ICM: G01N033-574
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 365 USPATFULL on STN
AN 2004:126837 USPATFULL
TI Method of indentifying an eventual modification of at least one biological parameter implementing young and aged living cells
IN Perrier, Eric, Les Cotes d'Arey, FRANCE
Pivard, Francoise, Lyon, FRANCE
Branka, Jean-Eric, Chavanay, FRANCE
Andre, Valerie, Ampuis, FRANCE
PA COLETICA, Lyon, FRANCE (non-U.S. corporation)
PI US 2004096816 A1 20040520
AI US 2003-365894 A1 20030212 (10)
PRAI FR 2002-14492 20021119
DT Utility
FS APPLICATION
LN.CNT 1846
INCL INCLM: 435/004.000
INCLS: 435/006.000
NCL NCLM: 435/004.000

IC [7]
ICM: C12Q001-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 365 USPATFULL on STN
AN 2004:126836 USPATFULL
TI Method of identifying an eventual modification of at least one biological parameter making use of living cells which are subjected to a stress and living cells which are not subjected to this same stress
IN Perrier, Eric, Les Cotes d'Arey, FRANCE
Andre, Valerie, Ampuis, FRANCE
Grenier, Stephane, Luzinay, FRANCE
Reymermier, Corinne, Charly, FRANCE
PA COLETICA, Lyon, FRANCE (non-U.S. corporation)
PI US 2004096815 A1 20040520
AI US 2003-365853 A1 20030212 (10)
PRAI FR 2002-14491 20021119
DT Utility
FS APPLICATION
LN.CNT 1908
INCL INCLM: 435/004.000
NCL NCLM: 435/004.000
IC [7]
ICM: C12Q001-02
ICS: C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 365 USPATFULL on STN
AN 2004:114659 USPATFULL
TI Synthetic heparin-binding factor analogs
IN Pena, Louis A., Poquott, NY, UNITED STATES
Zamora, Paul O., Gaithersburg, MD, UNITED STATES
Lin, Xinhua, Plainview, NY, UNITED STATES
Glass, John D., Shoreham, NY, UNITED STATES
PI US 2004087505 A1 20040506
AI US 2003-644703 A1 20030819 (10)
RLI Continuation-in-part of Ser. No. US 2002-224268, filed on 20 Aug 2002, PENDING
DT Utility
FS APPLICATION
LN.CNT 2075
INCL INCLM: 514/012.000
INCLS: 530/397.000
NCL NCLM: 514/012.000
NCLS: 530/397.000
IC [7]
ICM: A61K038-18
ICS: C07K014-475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 365 USPATFULL on STN
AN 2004:108604 USPATFULL
TI Medical prosthetic devices having improved biocompatibility
IN Ellingsen, Jan Eirik, Bekkestua, NORWAY
Lyngstadaas, Staale Petter, Nesoddtangen, NORWAY
PA Astra Tech AB, Molndal, NORWAY (non-U.S. corporation)
PI US 2004083006 A1 20040429
AI US 2003-410660 A1 20030409 (10)
PRAI DK 2002-515 20020409
US 2002-375928P 20020425 (60)
DT Utility
FS APPLICATION
LN.CNT 1458
INCL INCLM: 623/023.570
INCLS: 205/322.000
NCL NCLM: 623/023.570
NCLS: 205/322.000
IC [7]
ICM: A61F002-00
ICS: A61F002-28; C25D011-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 365 USPATFULL on STN
AN 2004:102220 USPATFULL

IN Binette, Francois, Weymouth, MA, UNITED STATES
Hwang, Julia, Wayland, MA, UNITED STATES
Dhanaraj, Sridevi, Raritan, NJ, UNITED STATES
Gosiewska, Anna, Skilman, NJ, UNITED STATES
PI US 2004078090 A1 20040422
AI US 2003-374772 A1 20030225 (10)
PRAI US 2002-420093P 20021018 (60)
US 2002-419539P 20021018 (60)
DT Utility
FS APPLICATION
LN.CNT 2319
INCL INCLM: 623/023.760
INCLS: 435/395.000
NCL NCLM: 623/023.760
NCLS: 435/395.000
IC [7]
ICM: A61F002-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 365 USPATFULL on STN
AN 2004:102207 USPATFULL
TI Biocompatible scaffold for ligament or tendon repair
IN Binette, Francois, Weymouth, MA, UNITED STATES
Hwang, Julia, Watertown, MA, UNITED STATES
Zimmerman, Mark, East Brunswick, NJ, UNITED STATES
Melican, Mora Carolynne, Bridgewater, NJ, UNITED STATES
PI US 2004078077 A1 20040422
AI US 2003-374754 A1 20030225 (10)
PRAI US 2002-420093P 20021018 (60)
US 2002-419539P 20021018 (60)
DT Utility
FS APPLICATION
LN.CNT 1934
INCL INCLM: 623/013.170
NCL NCLM: 623/013.170
IC [7]
ICM: A61F002-08

L4 ANSWER 28 OF 365 USPATFULL on STN
AN 2004:101709 USPATFULL
TI Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA
IN Kadomatsu, Kenji, Aichi, JAPAN
Horiba, Mitsuru, Aichi, JAPAN
Muramatsu, Takashi, Aichi, JAPAN
Ikematsu, Shinya, Kanagawa, JAPAN
Sakuma, Sadatoshi, Kanagawa, JAPAN
PI US 2004077579 A1 20040422
AI US 2003-703783 A1 20031106 (10)
RLI Continuation of Ser. No. US 2001-763586, filed on 23 Apr 2001, ABANDONED A 371 of International Ser. No. WO 1999-JP4550, filed on 24 Aug 1999, UNKNOWN
PRAI JP 1998-251812 19980824
DT Utility
FS APPLICATION
LN.CNT 879
INCL INCLM: 514/044.000
INCLS: 424/145.100
NCL NCLM: 514/044.000
NCLS: 424/145.100
IC [7]
ICM: A61K048-00
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 365 USPATFULL on STN
AN 2004:101093 USPATFULL
TI Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Aziz, Natasha, Palo Alto, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA, UNITED STATES, 94080-7019 (U.S. corporation)
PI US 2004076955 A1 20040422
AI US 2002-188832 A1 20020702 (10)

US 2001-350666P 20011113 (60)
US 2001-343705P 20011108 (60)
US 2001-310099P 20010803 (60)
US 2001-302814P 20010703 (60)
DT Utility
FS APPLICATION
LN.CNT 27357
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 365 USPATFULL on STN
AN 2004:95921 USPATFULL
TI Methods and compositions for regulating bone and cartilage formation
IN Pittman, Debra D., Windham, NH, UNITED STATES
Clancy, Brian M., Ashland, MA, UNITED STATES
PI US 2004073377 A1 20040415
AI US 2002-329056 A1 20021223 (10)
RLI Continuation-in-part of Ser. No. US 2002-125691, filed on 18 Apr 2002, PENDING
PRAI US 2001-284786P 20010418 (60)
DT Utility
FS APPLICATION
LN.CNT 12882
INCL INCLM: 702/020.000
NCL NCLM: 702/020.000
IC [7]
ICM: G06F019-00
ICS: G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 365 USPATFULL on STN
AN 2004:94842 USPATFULL
TI ***Human*** RGR oncogene and truncated transcripts thereof detected in T cell malignancies, antibodies to the encoded polypeptides and methods of use
IN Pellicer, Angel, New York, NY, UNITED STATES
Leonardi, Peter, East Haven, CT, UNITED STATES
Inghirami, Giorgio, Mt. Vernon, NY, UNITED STATES
PA New York University, New York, NY, UNITED STATES, 10012 (U.S. corporation)
PI US 2004072295 A1 20040415
AI US 2003-625471 A1 20030723 (10)
PRAI US 2002-397873P 20020724 (60)
DT Utility
FS APPLICATION
LN.CNT 2231
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 424/143.100; 530/388.220
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 424/143.100; 530/388.220
IC [7]
ICM: C07K014-705
ICS: C07H021-04; A61K039-395; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 365 USPATFULL on STN
AN 2004:94708 USPATFULL
TI Molecular toxicology modeling
IN Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES
PI US 2004072160 A1 20040415
AI US 2002-152319 A1 20020522 (10)
PRAI US 2001-292335P 20010522 (60)

US 2001-298925P 20010619 (60)
US 2001-303810P 20010710 (60)
US 2001-303807P 20010710 (60)
US 2001-303808P 20010710 (60)
US 2001-315047P 20010828 (60)
US 2001-324928P 20010927 (60)
US 2001-330867P 20011101 (60)
US 2001-330462P 20011022 (60)
US 2001-331805P 20011121 (60)
US 2001-336144P 20011206 (60)
US 2001-340873P 20011219 (60)
US 2002-357843P 20020221 (60)
US 2002-357842P 20020221 (60)
US 2002-357844P 20020221 (60)
US 2002-364134P 20020315 (60)
US 2002-370206P 20020408 (60)
US 2002-370247P 20020408 (60)
US 2002-370144P 20020408 (60)
US 2002-371679P 20020412 (60)
US 2002-372794P 20020417 (60)
DT Utility
FS APPLICATION
LN.CNT 27909
INCL INCLM: 435/006.000
INCLS: 435/091.200; 436/084.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 436/084.000
IC [7]
ICM: C12Q001-68
ICS: C12P019-34; G01N033-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 365 USPATFULL on STN
AN 2004:88573 USPATFULL
TI Multi-disciplinary approach to validating or identifying targets using an in vivo system
IN Lu, Patrick Y., Gaithersburg, MD, UNITED STATES
Scaria, Puthupparampil, Montgomery Village, MD, UNITED STATES
Woodle, Martin C., Bethesda, MD, UNITED STATES
PI US 2004067543 A1 20040408
AI US 2003-610821 A1 20030702 (10)
RLI Continuation of Ser. No. US 2002-263470, filed on 3 Oct 2002, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1012
INCL INCLM: 435/007.230
INCLS: 435/006.000
NCL NCLM: 435/007.230
NCLS: 435/006.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 365 USPATFULL on STN
AN 2004:82307 USPATFULL
TI Methods for stable transduction of cells with viral vectors
IN Humeau, Laurent, Germantown, MD, UNITED STATES
Han, Wei, Montgomery Village, MD, UNITED STATES
Lu, Xiaobin, Germantown, MD, UNITED STATES
Slepushkin, Vladimir, Damascus, MD, UNITED STATES
Lesher, Mechelle, Columbia, MD, UNITED STATES
Davis, Brian, Gaithersburg, MD, UNITED STATES
Chang, Yung-Nien, Cockeysville, MD, UNITED STATES
Dropulic, Boro, Ellicott City, MD, UNITED STATES
PI US 2004062756 A1 20040401
AI US 2003-664331 A1 20030916 (10)
RLI Continuation of Ser. No. US 2000-653088, filed on 31 Aug 2000, GRANTED, Pat. No. US 6627442
DT Utility
FS APPLICATION
LN.CNT 1599
INCL INCLM: 424/093.210
INCLS: 435/456.000
NCL NCLM: 424/093.210

IC [7]
ICM: A61K048-00
ICS: C12N015-867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 365 USPATFULL on STN
AN 2004:70141 USPATFULL
TI Collagen-binding hybrid polypeptide
IN Ishikawa, Tetsuya, Kanagawa, JAPAN
Kitajima, Takashi, Kanagawa, JAPAN
PI US 2004053368 A1 20040318
AI US 2003-344634 A1 20030214 (10)
WO 2001-JP7036 20010815
PRAI JP 2000-246341 20000815
DT Utility
FS APPLICATION
LN.CNT 2016
INCL INCLM: 435/069.700
INCLS: 435/320.100; 435/325.000; 536/023.500; 530/356.000
NCL NCLM: 435/069.700
NCLS: 435/320.100; 435/325.000; 536/023.500; 530/356.000
IC [7]
ICM: C07H021-04
ICS: C12P021-04; C07K014-78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 365 USPATFULL on STN
AN 2004:70050 USPATFULL
TI Strong gene sets for glioma classification
IN Zhang, Wei, Houston, TX, UNITED STATES
Fuller, Greg, Houston, TX, UNITED STATES
Dougherty, Ed, College Station, TX, UNITED STATES
Hess, Kenneth, Houston, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
The Texas A&M University System (U.S. corporation)
PI US 2004053277 A1 20040318
AI US 2003-390343 A1 20030317 (10)
PRAI US 2002-364608P 20020315 (60)
DT Utility
FS APPLICATION
LN.CNT 3590
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 365 USPATFULL on STN
AN 2004:58175 USPATFULL
TI Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
IN Hunt, Joan S, Shawnee Mission, KS, UNITED STATES
Morales, Pedro J., Kansas City, MO, UNITED STATES
Pertroff, Margaret G., Merriam, KS, UNITED STATES
PI US 2004044182 A1 20040304
AI US 2003-380880 A1 20030728 (10)
WO 2001-US29228 20010917
DT Utility
FS APPLICATION
LN.CNT 1712
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C07K014-74
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 365 USPATFULL on STN
AN 2004:50862 USPATFULL
TI Wound healing biomarkers

Johnson, Claire Michelle, Sandwich, UNITED KINGDOM
Cooper, Lisa, London, UNITED KINGDOM
Martin, Paul, London, UNITED KINGDOM
PI US 2004038292 A1 20040226
AI US 2002-175184 A1 20020618 (10)
PRAI GB 2001-14869 20010618
US 2001-305346P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 67123
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: G01N033-53
ICS: C07H021-04; C12P021-02; C12N005-06; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 39 OF 365 USPATFULL on STN
AN 2004:40522 USPATFULL
TI Regulation of ***human*** skin healing
IN Herlyn, Meenhard, Wynnewood, PA, UNITED STATES
Berking, Carola, Munich, GERMANY, FEDERAL REPUBLIC OF
Satyamoorthy, Kapaettu, Santhekatte, INDIA
Velazquez, Omaida, Cherry Hill, NJ, UNITED STATES
PI US 2004031067 A1 20040212
AI US 2003-398980 A1 20030822 (10)
WO 2001-US31555 20011011
DT Utility
FS APPLICATION
LN.CNT 1708
INCL INCLM: 800/009.000
INCLS: 435/006.000; 435/455.000
NCL NCLM: 800/009.000
NCLS: 435/006.000; 435/455.000
IC [7]
ICM: C12N005-08
ICS: A01K067-00; C12N015-63; C12N015-87; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 365 USPATFULL on STN
AN 2004:13082 USPATFULL
TI DNA modifying molecules and methods of use thereof
IN Seidman, Michael M., Washington, DC, UNITED STATES
Puri, Nitin, Austin, TX, UNITED STATES
Majumdar, Alokes, Gaithersburg, MD, UNITED STATES
PA The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services (U.S. corporation)
PI US 2004009602 A1 20040115
AI US 2003-438076 A1 20030513 (10)
PRAI US 2002-378025P 20020513 (60)
DT Utility
FS APPLICATION
LN.CNT 3073
INCL INCLM: 435/446.000
INCLS: 435/325.000
NCL NCLM: 435/446.000
NCLS: 435/325.000
IC [7]
ICM: C12N015-63
ICS: C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 365 USPATFULL on STN
AN 2004:12961 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ***human*** prostate cancer
IN Schlegel, Robert, Auburndale, MA, UNITED STATES
Endege, Wilson O., Norwood, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2004009481 A1 20040115
AI US 2002-166883 A1 20020611 (10)
PRAI US 2001-297285P 20010611 (60)
DT Utility

LN.CNT 15572
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 365 USPATFULL on STN
AN 2004:7329 USPATFULL
TI Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2004005563 A1 20040108
AI US 2002-173999 A1 20020617 (10)
PRAI US 2002-372246P 20020412 (60)
US 2001-350666P 20011113 (60)
US 2001-315287P 20010827 (60)
US 2001-299234P 20010618 (60)
DT Utility
FS APPLICATION
LN.CNT 32540
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 365 USPATFULL on STN
AN 2004:7326 USPATFULL
TI Markers of neuronal differentiation and morphogenesis
IN Loring, Jeanne F., Foster City, CA, UNITED STATES
Kaser, Matthew R., Castro Valley, CA, UNITED STATES
PI US 2004005559 A1 20040108
AI US 2002-62674 A1 20020130 (10)
RLI Continuation-in-part of Ser. No. US 2000-625102, filed on 24 Jul 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 5725
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000
NCLS: 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 365 USPATFULL on STN
AN 2004:1827 USPATFULL
TI Prostate-specific membrane antigen and uses thereof
IN Israeli, Ron S., Staten Island, NY, UNITED STATES
Heston, Warren D.W., New York, NY, UNITED STATES
Fair, William R., New York, NY, UNITED STATES
Ouerfelli, Ouathek, New York, NY, UNITED STATES
Pinto, John, East Norwalk, CT, UNITED STATES
PA Sloan-Kettering Institute For Cancer Research (U.S. corporation)
PI US 2004001846 A1 20040101
AI US 2003-443694 A1 20030521 (10)
RLI Continuation of Ser. No. US 1996-705477, filed on 29 Aug 1996, GRANTED, Pat. No. US 6569432 Continuation-in-part of Ser. No. WO 1996-US2424, filed on 23 Feb 1996, PENDING Continuation-in-part of Ser. No. US 1995-394152, filed on 24 Feb 1995, GRANTED, Pat. No. US 5935818
DT Utility
FS APPLICATION

INCL INCLM: 424/185.100
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 424/185.100
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K039-00
ICS: C07H021-04; C07K014-47; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 45 OF 365 USPATFULL on STN
AN 2004:135666 USPATFULL
TI Nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, United States
Zhou, Ping, Cupertino, CA, United States
Goodrich, Ryle, San Jose, CA, United States
Liu, Chenghua, San Jose, CA, United States
Asundi, Vinod, Foster City, CA, United States
Ren, Feiyan, Cupertino, CA, United States
Zhang, Jie, Campbell, CA, United States
Zhao, Qing A., San Jose, CA, United States
Yang, Yonghong, San Jose, CA, United States
Xue, Aidong J., Sunnyvale, CA, United States
Wehrman, Tom, Stanford, CA, United States
Wang, Jian-Rui, Cupertino, CA, United States
Wang, Dunrui, Poway, CA, United States
Drmanac, Radoje T., Palo Alto, CA, United States
PA Nuvelo, Sunnyvale, CA, United States (U.S. corporation)
PI US 6743619 B1 20040601
AI US 2001-774528 20010130 (9)
DT Utility
FS GRANTED
LN.CNT 6327
INCL INCLM: 435/233.000
INCLS: 435/234.000; 536/023.200
NCL NCLM: 435/233.000
NCLS: 435/234.000; 536/023.200
IC [7]
ICM: C12N009-90
ICS: C12N009-92; C07H021-04
EXF 435/233; 435/234; 435/7.4; 536/23.2; 536/23.1; 053/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 46 OF 365 USPATFULL on STN
AN 2004:66006 USPATFULL
TI DNA array sequence selection
IN Lorenz, Matthias, Bethesda, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6706867 B1 20040316
AI US 2000-741238 20001219 (9)
DT Utility
FS GRANTED
LN.CNT 23532
INCL INCLM: 536/023.100
INCLS: 536/024.320; 536/024.310; 536/024.300; 435/006.000
NCL NCLM: 536/023.100
NCLS: 435/006.000; 536/024.300; 536/024.310; 536/024.320
IC [7]
ICM: C07H021-04
ICS: C12Q001-68
EXF 435/6; 536/24.32; 536/24.31; 536/24.33; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 47 OF 365 USPATFULL on STN
AN 2004:53300 USPATFULL
TI Tethered ligands and methods of use
IN Schall, Thomas J., Menlo Park, CA, United States
Premack, Brett, San Francisco, CA, United States
Miao, Zhenhua, San Jose, CA, United States
Wei, Zheng, Redwood City, CA, United States
PA ChemoCentryx, Inc., San Carlos, CA, United States (U.S. corporation)
PI US 6699677 B1 20040302
AI US 2000-721908 20001124 (9)
PRAI US 2000-186626P 20000303 (60)
US 1999-172979P 19991220 (60)

FS GRANTED
LN.CNT 2860
INCL INCLM: 435/007.240
INCLS: 435/069.700; 435/325.000; 436/501.000
NCL NCLM: 435/007.240
NCLS: 435/069.700; 435/325.000; 436/501.000
IC [7]
ICM: G01N033-567
ICS: G01N033-566; C12P021-04; C12N005-00
EXF 436/501; 435/7.24; 435/69.7; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 48 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:490250 SCISEARCH
GA The Genuine Article (R) Number: 822ET
TI Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity
AU Ohuchida T (Reprint); Okamoto K; Akahane K; Higure A; Todoroki H; Abe Y; Kikuchi M; Ikematsu S; Muramatsu T; Itoh H
CS Univ Occupat & Environm Hlth, Dept Surg 1, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan (Reprint); Univ Occupat & Environm Hlth, Dept Surg 1, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Dept Med Technol 2, Kitakyushu, Fukuoka 807, Japan; Meiji Dairies Corp, Odawara, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem, Nagoya, Aichi, Japan
CYA Japan
SO CANCER, (1 JUN 2004) Vol. 100, No. 11, pp. 2430-2436.
Publisher: JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA.
ISSN: 0008-543X.
DT Article; Journal
LA English
REC Reference Count: 38
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 49 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:678996 SCISEARCH
GA The Genuine Article (R) Number: 840UY
TI Identification of heparin affin regulatory peptide domains with potential role on angiogenesis
AU Polykratis A; Delbe J; Courty J; Papadimitriou E (Reprint); Katsoris P
CS Univ Patras, Dept Pharm, Mol Pharmacol Lab, GR-26504 Patras, Greece (Reprint); Univ Patras, Dept Biol, Cell Biol Lab, Patras, Greece; Univ Paris 12, CNRS, FRE 2412, Lab Rech Croissance Cellulaire, CRRET, Creteil, France
CYA Greece; France
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, (OCT 2004) Vol. 36, No. 10, pp. 1954-1966.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
ISSN: 1357-2725.
DT Article; Journal
LA English
REC Reference Count: 38
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 50 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
AN 2004:175120 CAPLUS
DN 140:369268
TI Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis
AU Heroult, Melanie; Bernard-Pierrot, Isabelle; Delbe, Jean; Hamma-Kourbali, Yamina; Katsoris, Panagiotis; Barritault, Denis; Papadimitriou, Evangelia; Plouet, Jean; Courty, Jose
CS FRE CNRS 2412, la Reparation et la Regeneration Tissulaires (CRRET), Laboratoire de Recherche sur la Croissance Cellulaire, Universit Paris XII-Val de Marne, Creteil, 233, Fr.
SO Oncogene (2004), 23(9), 1745-1753
CODEN: ONCNES; ISSN: 0950-9232
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 5
AN 2004:233726 CAPLUS
DN 140:373385
TI Gene expression fingerprints in ***human*** tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression
AU Henger, Anna; Kretzler, Matthias; Doran, Peter; Bonrouhi, Mahnaz; Schmid, Holger; Kiss, Eva; Cohen, Clemens D.; Madden, Stephen; Porubsky, Stefan; Groene, Elisabeth F.; Schloendorff, Detlef; Nelson, Peter J.; Groene, Hermann-Josef
CS Medical Policlinic, University of Munich, Munich, Germany
SO Kidney International (2004), 65(3), 904-917
CODEN: KDYIA5; ISSN: 0085-2538
PB Blackwell Publishing, Inc.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004160049 EMBASE
TI Delivery systems for bone growth factors - The new players in skeletal regeneration.
AU Rose F.R.A.J.; Hou Q.; Oreffo R.O.C.
CS F.R.A.J. Rose, School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom. F.Rose@nottingham.ac.uk
SO Journal of Pharmacy and Pharmacology, (2004) 56/4 (415-427).
Refs: 169
ISSN: 0022-3573 CODEN: JPPMAB
CY United Kingdom
DT Journal; General Review
FS 022 Human Genetics
030 Pharmacology
033 Orthopedic Surgery
037 Drug Literature Index
039 Pharmacy
LA English
SL English

L4 ANSWER 53 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
AN 2004:30322 CAPLUS
DN 140:229892
TI Heparin affin regulatory peptide in milk: its involvement in mammary gland homeostasis
AU Bernard-Pierrot, Isabelle; Delbe, Jean; Heroult, Melanie; Rosty, Christophe; Soulie, Patrick; Barritault, Denis; Milhiet, Pierre-Emmanuel; Courty, Jose
CS Laboratoire de Recherche sur la Croissance Cellulaire, la Reparation et la Regeneration Tissulaires FRE CNRS No. 2412, Universite Paris Val de Marne, Creteil, 94010, Fr.
SO Biochemical and Biophysical Research Communications (2004), 314(1), 277-282
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier Science
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 54 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004287936 EMBASE
TI ***Receptor*** protein tyrosine phosphatase .zeta. as a therapeutic target for glioblastoma therapy.
AU Muller S.; Lamszus K.; Nikolich K.; Westphal M.
CS S. Muller, AGY Therapeutics, 270 East Grant Avenue, South San Francisco, CA 94080, United States. bine343@yahoo.com
SO Expert Opinion on Therapeutic Targets, (2004) 8/3 (211-220).
Refs: 101
ISSN: 1472-8222 CODEN: EOTTAO
CY United Kingdom
DT Journal; General Review
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
016 Cancer

030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 55 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 7
AN 2004:157619 BIOSIS
DN PREV200400158066
TI Midkine and ***pleiotrophin*** in neural development and cancer.
AU Kadomatsu, Kenji [Reprint Author]; Muramatsu, Takashi
CS Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
kkadoma@med.nagoya-u.ac.jp
SO Cancer Letters, (February 20 2004) Vol. 204, No. 2, pp. 127-143. print.
ISSN: 0304-3835 (ISSN print).
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 17 Mar 2004
Last Updated on STN: 17 Mar 2004

L4 ANSWER 56 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004160994 EMBASE
TI The Role of ECM Molecules in Activity-Dependent Synaptic Development and Plasticity.
AU Pavlov I.; Lauri S.; Taira T.; Rauvala H.
CS Dr. T. Taira, Neuroscience Center, Department of Biosciences, University of Helsinki, Viikinkaari 1, FIN-00014, Helsinki, Finland.
Tomi.Taira@Helsinki.fi
SO Birth Defects Research Part C - Embryo Today: Reviews, (2004) 72/1 (12-24).
Refs: 196
ISSN: 1542-975X CODEN: BDRPDV
CY United States
DT Journal; General Review
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
LA English
SL English

L4 ANSWER 57 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:89530 CAPLUS
DN 141:154705
TI ***Pleiotrophin*** signaling through ptnr in glioblastoma multiforme
AU Powers, Ciaran James
CS Medical Center, Georgetown Univ., Washington, DC, USA
SO (2003) 107 pp. Avail.: UMI, Order No. DA3085389
From: Diss. Abstr. Int., B 2003, 64(3), 1192
DT Dissertation
LA English

L4 ANSWER 58 OF 365 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 2003:57834 DISSABS Order Number: AAI3085389
TI ***Pleiotrophin*** signaling through PTNR in glioblastoma multiforme
AU Powers, Ciaran James [Ph.D.]; Wellstein, Anton [advisor]
CS Georgetown University Medical Center (0544)
SO Dissertation Abstracts International, (2003) Vol. 64, No. 3B, p. 1192.
Order No.: AAI3085389. 107 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 20031201
Last Updated on STN: 20031201

L4 ANSWER 59 OF 365 NTIS COPYRIGHT 2004 NTIS on STN
AN 2004(13):00444 NTIS Order Number: ADA420767/XAB
TI Gene Regulation and Expression Pattern of the Growth Factor ***Pleiotrophin*** in Breast Cancer. Annual summary rept. 1 Sep 2002-31 Aug 2003.
AU Stoica, G. E.
CS Georgetown Univ., Washington, DC. Medical Center. (011489008 153650)
NR ADA420767/XAB

NC Contract(s): DAMD17-99-1-9204
DT Report
CY United States
LA English
AV Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA. NTIS Prices: PC A03/MF A01
OS GRA&I0413

L4 ANSWER 60 OF 365 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN DUPLICATE 8
AN 2003-16235 BIOTECHDS
TI Identifying mammalian cell capable of producing a proteinaceous molecule, by analyzing post-translational modification on a protein produced by mammalian cell, and determining whether protein comprises the modification;
recombinant protein production via cell culture transfection for use in disease therapy
AU OPSTELTEN D J E; KAPTEYN J C; PASSIER P C J J; BRUS R H P; BOUT A
PA CRUCELL HOLLAND BV
PI WO 2003038100 8 May 2003
AI WO 2002-NL686 29 Oct 2002
PRAI WO 2002-257 19 Apr 2002; WO 2001-792 29 Oct 2001
DT Patent
LA English
OS WPI: 2003-421522 [39]

L4 ANSWER 61 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 9
AN 2003:173752 CAPLUS
DN 138:215251
TI Screening assays for identifying differentiation-inducing agents, and production of differentiated cells for cell therapy
IN West, Michael D.; Page, Raymond; Scholer, Hans; Chapman, Karen
PA Advanced Cell Technology, Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018760	A2	20030306	WO 2002-US26945	20020826
	WO 2003018760	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003224345	A1	20031204	US 2002-227282	20020826
	EP 1444326	A2	20040811	EP 2002-759444	20020826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-314316P	P	20010824		
	WO 2002-US26945	W	20020826		

L4 ANSWER 62 OF 365 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 10
AN 10479916 IFIPAT;IFIUDB;IFICDB
TI SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY
IN Chapman Karen; Page Raymond; Scholer Hans; West Michael D
PA Advanced Cell Tech
PI US 2003224345 A1 20031204
AI US 2002-227282 20020826
PRAI US 2001-314316P 20010824 (Provisional)
FI US 2003224345 20031204
DT Utility; Patent Application - First Publication
FS CHEMICAL

CLMN 84
GI 24 Figure(s).
FIG. 1A is a photograph that shows primate Cyno-1FF ES-like cells conditioned to grow on tissue culture dishes without feeder fibroblasts (1 x).
FIG. 1B shows Cyno-1 FF cells at a higher magnification, showing the typical morphology of ES-like cells (40 x).
FIG. 2: Table 1 identifies the factors added to each of the wells of the duplicate 24-well plates of Example 2.
FIG. 3 is a photograph showing Cyno-1 FF cells that were exposed to Flt-3 ligand.
FIG. 4 shows mesoderm and cells with the morphology of nestin positive neuronal stem cells obtained by culturing Cyno-1 FF cells in the presence of TGF beta-1.
FIG. 5 shows cells having the appearance of endodermal precursor cells obtained by culturing Cyno-1 FF cells in the presence of the extracellular matrix protein tenascin.
FIG. 6 shows Cyno-1 FF cells exposed to a chimeric protein made from the ***receptor*** for Tie-1 and an immunoglobulin Fc region.
FIG. 7 shows fibroblast-like connective tissue cells produced by culturing Cyno-1 FF cells in the presence of BMP-2.
FIG. 8: Table 2 identifies the primers that were used to detect expression of cell type-associated genes by RT-PCR, and the expected sizes of the DNA fragments produced by the RT-PCR reactions.
FIG. 9 shows examples of the results of RT-PCR analysis of cells from four different wells, each containing a different inducing agent (see Example 2). The figure shows photographs of the lanes of electrophoretic gels in which the DNA molecules produced by RT-PCR were separated, stained with ethidium bromide, and illuminated with uv light.
FIG. 10 shows the detection of desmin by ICC in Cyno-1 FF cells exposed to a differentiation-inducing agent (see Example 3).
FIG. 11 shows the detection of nestin by ICC in Cyno-1 FF cells exposed to a differentiation-inducing agent (see Example 3).
FIGS. 12A and 12B are phase contrast photographs of the cells in well #16 of Example 5 that were exposed to IL-1-alpha.
FIG. 12A (on left): The arrowhead points to a beating myocardial cell.
FIG. 12B (on right): The arrowhead points to an endothelial cell adjacent to myocardial cells.
FIG. 13: Table 3 identifies the combinations of putative differentiation-inducing agents added to the wells of the 24 well plates in which murine ES cells were cultured as described in Example 6.
FIG. 14 shows the detection of desmin by ICC in murine ES cells cultured in TGF-beta-1 and FGF-4 for five days on type I collagen and ***human*** plasma fibronectin (see Example 6).
FIG. 15 shows the detection of X-gal staining of cells of the murine gene trap ES cell line K18E2 that were cultured for five days on type I collagen and ***human*** plasma fibronectin in the presence of TGF-beta-1 and FGF-4 (see Example 7). Detection of expression of the marker beta-galactosidase gene in the gene trap ES cells indicates that the cells were induced to differentiate.
FIG. 16 shows the detection of beta-galactosidase by ICC (using antibody to beta-galactosidase) in cells of murine gene trap ES cell line M7H7 that were cultured for five days on type I collagen and ***human*** plasma fibronectin in the presence of TGFbeta-1 and FGF-4. Nuclei are co-visualized by DAPI staining.
FIG. 17 shows the detection of beta-galactosidase by ICC in cells of murine gene trap ES cell line K18E2 that were cultured for five days on type I collagen and ***human*** plasma fibronectin in the presence of FGF-4.
FIG. 18 shows the presence of beta-galactosidase in K18E2 cells that were cultured with FGF-4 and TGF-beta 1 on inducer fibroblasts for 5 days, then sub-cultured for an additional 5 days with FGF-4 and TGF-beta 1 alone.
FIG. 19 shows the presence of beta-galactosidase in M7H7 cells that were cultured with FGF-4 and TGF-beta 1 on inducer fibroblasts for 5 days, then sub-cultured for an additional 5 days with FGF-4 and TGF-beta 1 alone.
FIG. 20: shows the presence of beta-galactosidase in K18E2 cells that were cultured with FGF-4 and TGF-beta 1 in the absence of inducer fibroblasts, and then sub-cultured for 5 more days in the same conditions.
FIG. 21 shows the presence of beta-galactosidase in M7H7 cells that were cultured with FGF-4 and TGF-beta 1 in the absence of inducer fibroblasts, and then sub-cultured for 5 more days in same conditions.

L4 ANSWER 63 OF 365 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 11

TI METHOD OF SCREENING PTP C ACTIVITIY PROMOTER OR INHIBITOR
IN Fujikawa Akihiro (JP); Noda Masaharu (JP)
PA Unassigned Or Assigned To Individual (68000)
PI US 2003186284 A1 20031002
AI US 2003-333786 20030124
    WO 2001-JP6343 20010723
                    20030124 PCT 371 date
                    20030124 PCT 102(e) date
PRAI JP 2000-223184 20000724
FI US 2003186284 20031002
DT Utility; Patent Application - First Publication
FS CHEMICAL
    APPLICATION
CLMN 21
GI 13 Figure(s).
FIG. 1 is a view showing the examination results of character phenotypes of PTP zeta-deficient mice in an open field test and circadian rhythm.
FIG. 2 is a view showing the changes of monoamine metabolism in the brains of PTP zeta-deficient mice.
FIG. 3 is a view showing the examination results of immunohistochemistry of dopamine pathway in PTP zeta-deficient mice.
FIG. 4 is a view showing the decrease of locomotor activity to methamphetamine and GBR 129909 in PTP zeta-deficient mice.
FIG. 5 is a view showing the abnormal DA neurotransmission in nucleus accumbens of PTP zeta-deficient mice.
FIG. 6 is a view showing the examination results of expression property of PTP zeta in dopamine pathway of adult mice brains.
FIG. 7 is a view showing the results of stress and fear behaviors in PTP zeta-deficient mice.
FIG. 8 is a view showing the results of exploration behavior of wild-type mice and PTP zeta-deficient mice to a novel object.
FIG. 9 is a view showing the examination results of PTP zeta expression in gastric epithelial cell layer of wild-type mice and PTP zeta-deficient mice.
FIG. 10 is a view showing the examination results of transcription (RT-PCR) and expression (Western blot) of PTP zeta in gastric epithelial cell layer of mice.
FIG. 11 is a view showing the results of gastric ulcer formation in wild-type mice and PTP zeta-deficient mice orally administered with VacA, a toxin of Helicobacter pylori.
FIG. 12 is a view showing the examination results of tyrosine phosphorylation of GIT1, a substrate molecule of PTP zeta, caused by stimulus with VacA.
FIG. 13 is a view showing the results of mucosal damage in gastric epithelium of mice caused by administration of ***pleiotrophin*** .

L4 ANSWER 64 OF 365 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 12
AN 10408140 IFIPAT;IFIUDB;IFICDB
TI VITRO MICRO-ORGANS, AND USES RELATED THERETO
IN Mitrani Eduardo N (IL)
PI US 2003152562 A1 20030814
AI US 2003-376506 20030303
RLI WO 2001-IL976 20011023 CONTINUATION
FI US 2003152562 20030814
DT Utility; Patent Application - First Publication
FS CHEMICAL
    APPLICATION
CLMN 73
GI 18 Figure(s).
FIG. 1 is a diagrammatic representation of a micro-organ depicting the dimensions that determine Aleph where x=thickness and a=width of tissue.
FIG. 2 is a histogram showing cell proliferation in a guinea pig micro-organ culture as determined by BrdU labeling after incubation for different time periods.
FIG. 3 is a histogram showing cell proliferation in a ***human*** back skin micro-organ culture as determined by BrdU labeling after incubation of cultures for 1-8 days.
FIGS. 4A-4D are micrographs showing immunofluorescence corresponding to replicating cells of mouse skin (mag. 50 x) (FIG. 4A), guinea pig skin (mag. 75 x) (FIG. 4B) ***human*** foreskin (mag. 50 x) (FIG. 4C) and ***human*** foreskin (mag. 75 x) (FIG. 4D).
FIGS. 5A-5C are transverse sections of ***human*** epidermal microorgan explants. (mag x 75) showing tissue architecture at zero (FIG. 5A), three (FIG. 5B) and six (FIG. 6D) days in culture.
FIG. 6 is a histogram demonstrating the effect on epidermal proliferation

BrdU incorporation where (a) has been kept constant at 4 mm.
FIGS. 7A-7B are micrographs showing immunofluorescence corresponding to proliferating cells in pancreas-derived microorgan cultures (mag 75 x).
FIG. 8 is a histogram showing amounts of insulin released by adult pig pancreas micro-organ cultures.
FIG. 9 is a histogram showing 3H-Thymidine incorporation in proliferating cells in micro-organ cultures of the colon, liver, kidney, duodenum and esophagus, at three days, four days and six days of culture.
FIGS. 10A-10C are micrographs showing active proliferation of hair follicles in micro-organ cultures as determined by immunofluorescence. Magnification 40 x (FIG. 10A), 40 x (FIG. 10B), and 75 x (FIG. 10C).
FIG. 11 is a histogram showing the size distribution of hair shafts at the beginning and end of the microculture.
FIG. 12 is a histogram showing the inhibition of mitogenesis in micro-organ cultures in the presence of 2.5 ng/ml TGF-beta in guinea-pig skin cultures.
FIG. 13 is a diagrammatic representation of a micro-organ explant for treatment of chronic skin ulcers showing incomplete sectioning of tissue slices so as to maintain a structure that can be readily manipulated in vivo.
FIG. 14 is a photograph of the surface of a mouse after replacement of a piece of normal skin with a micro-organ culture; healing, generation of new hair shafts in the implant, and incorporation of the implant into the normal mouse skin can be observed (mag 10 x).
FIG. 15 is a graphic representation of the expression of a luciferase reporter gene in a guinea pig skin micro-organ culture after transfection (of the culture with a plasmid encoding the luciferase reporter gene.
FIG. 16 is a graphic representation of the expression of a luciferase gene in rat lung and thymus micro-organ cultures after cationic lipid mediated transfection of the culture with plasmid encoding the luciferase reporter gene.
FIG. 17 is a graphic representation of the activation of telogen follicles upon treatment with FGF in micro-organ cultures of the present invention.
FIG. 18 is a graphic representation of the expression of a transgenic luciferase gene in micro-organ explants of the present invention.

L4 ANSWER 65 OF 365 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 13
AN 10374166 IFIPAT;IFIUDB;IFICDB
TI USE OF PROTEIN BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS; HAVING MOIETIES WHICH SPECIFICALLY BIND TO ***HUMAN*** VASOACTIVE INTESTINAL PEPTIDE ***RECEPTOR*** -2, WHEREIN THE BINDING ALTERS THE FUNCTION OF THE VASOACTIVE INTESTINAL PEPTIDE ***RECEPTOR*** -2
IN Chin Daniel; Melcher Thorsten; Muller Sabine
PA AGY Therapeutics
PI US 2003118585 A1 20030626
AI US 2001-983000 20011017
FI US 2003118585 20030626
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 17
GI 3 Figure(s).
FIG. 1: A diagram of the three known splicing variant isoforms of PTP zeta . The approximate position of the domains of the isoforms is indicated underneath the isoforms, as well as the approximate exon size (for size reference, exon 12 is 3.6 kilobases.) Isoform PTP zeta-alpha is the full length isoform, which contains the primary amino acid sequence aa 25-2314 of SEQ ID NO. 2 (aa 1-24 are a signal polypeptide). In Isoform PTP zeta-beta, aa 755-1614 are missing. Isoform PTP zeta-S (phosphacan), is a secreted isoform which comprise the extracellular domains of PTP zeta-alpha, in which the transmembrane and cytosol domains are missing.
FIG. 2: A diagram of the two newly discovered splicing variant isoforms of PTP zeta . The approximate position of the domains of the isoforms is indicated underneath the isoforms, as well as the approximate exon size (for size reference, exon 12 is 3. 6 kilobases.) SM 1 fails to splice correctly after the 9th exon, yielding an mRNA with tow extra codons followed by a stop codon after the normal terminus of exon 9. SM 2 contains a 116 nucleotide insertion from between exons 23 &24.
FIG. 3: A diagram comparing the three known PTP zeta isoforms with the two novel isoforms.

L4 ANSWER 66 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:282704 CAPLUS
DN 138:300153

assays
IN Rosenberg, Robert D.; Wu, Zhengliang
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029415	A2	20030410	WO 2002-US31080	20021001
	WO 2003029415	A3	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003138849	A1	20030724	US 2002-263338	20021001
PRAI	US 2001-326270P	P	20011001		

L4 ANSWER 67 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:532140 CAPLUS
DN 139:106450
TI Targeted multivalent macromolecules
IN Wartchow, Charles Aaron; Dechene, Neal Edward; Pease, John S.; Shen, Zhimin; Trulson, Julie; Bednarski, Mark David; Danthi, S. Narasimhan; Zhang, Michael; Choi, Hoyul Steven
PA Targesome, Inc., USA
SO U.S. Pat. Appl. Publ., 71 pp., Cont.-in-part of U.S. Ser. No. 976,254.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003129223	A1	20030710	US 2002-158777	20020530
	US 2002071843	A1	20020613	US 2001-976254	20011011
PRAI	US 2000-239684P	P	20001011		
	US 2001-294309P	P	20010530		
	US 2001-309104P	P	20010731		
	US 2001-312435P	P	20010815		
	US 2001-976254	A2	20011011		

L4 ANSWER 68 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:511844 CAPLUS
DN 139:90457
TI Combined compositions for tumor vasculature coaguligand treatment
IN Thorpe, Philip E.; King, Steven W.; Gottstein, Claudia
PA Board of Regents, The University of Texas System, USA
SO U.S. Pat. Appl. Publ., 98 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003124132	A1	20030703	US 2002-259223	20020927
	WO 2003028840	A2	20030410	WO 2002-EP10913	20020927
	WO 2003028840	A3	20030828		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

```
     US 2003139374         A1    20030724    US 2002-259236          20020927
     US 2003211075         A1    20031113    US 2002-259244          20020927
     EP 1432447            A2    20040630    EP 2002-800138          20020927
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRAI US 2001-325532P       P     20010927
     WO 2002-EP10913       W     20020927

L4   ANSWER 69 OF 365  USPATFULL on STN
AN     2003:330220  USPATFULL
TI     Cellular transplantation for heart regeneration
IN     Law, Peter K., Germantown, TN, UNITED STATES
PI     US 2003232431       A1   20031218
AI     US 2003-403520      A1   20030401 (10)
PRAI   US 2002-368563P      20020401 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1021
INCL   INCLM: 435/366.000
NCL    NCLM:  435/366.000
IC     [7]
       ICM: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 70 OF 365  USPATFULL on STN
AN     2003:325052  USPATFULL
TI     Multi-component biological transport systems
IN     Waugh, Jacob, Millbrae, CA, UNITED STATES
       Dake, Michael, Stanford, CA, UNITED STATES
PA     Essentia Biosystems, Inc., Palo Alto, CA, 94301 (U.S. corporation)
PI     US 2003229034       A1   20031211
AI     US 2001-910432      A1   20010720 (9)
PRAI   US 2000-220244P      20000721 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1531
INCL   INCLM: 514/044.000
       INCLS: 435/455.000; 424/239.100
NCL    NCLM:  514/044.000
       NCLS:  435/455.000; 424/239.100
IC     [7]
       ICM: A61K048-00
       ICS: A61K039-08; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 71 OF 365  USPATFULL on STN
AN     2003:312278  USPATFULL
TI     Albumin fusion proteins
IN     Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Haseltine, William A., Washington, DC, UNITED STATES
PI     US 2003219875       A1   20031127
AI     US 2001-833118      A1   20010412 (9)
PRAI   US 2000-256931P      20001221 (60)
       US 2000-199384P      20000425 (60)
       US 2000-229358P      20000412 (60)
DT     Utility
FS     APPLICATION
LN.CNT 15415
INCL   INCLM: 435/069.700
       INCLS: 435/325.000; 435/320.100; 530/362.000; 514/012.000; 536/023.500
NCL    NCLM:  435/069.700
       NCLS:  435/325.000; 435/320.100; 530/362.000; 514/012.000; 536/023.500
IC     [7]
       ICM: A61K038-38
       ICS: C07H021-04; C12P021-04; C07K014-76
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 72 OF 365  USPATFULL on STN
AN     2003:312170  USPATFULL
TI     Compositions, kits, and methods for identification, assessment,
       prevention, and therapy of breast cancer
IN     Ayers, Mark D., Ayer, MA, UNITED STATES
       Stec, Jim, Plymouth, MA, UNITED STATES
       Damokosh, Andrew, West Hartford, CT, UNITED STATES
       Clark, Edwin, Ashland, MA, UNITED STATES
```

Hortobagyi, Gabriel N., Bellaire, TX, UNITED STATES
Pusztai, Lajos, Pearland, TX, UNITED STATES
Symmans, W. Fraser, Houston, TX, UNITED STATES
PA MILLENNIUM PHARMACEUTICALS, INC., Cambridge, MA, 02139 (U.S. corporation)
M.D. Anderson Cancer Center, Houston, TX, 77030 (U.S. corporation)
PI US 2003219767 A1 20031127
AI US 2002-285393 A1 20021031 (10)
PRAI US 2001-334994P 20011031 (60)
US 2001-335981P 20011102 (60)
DT Utility
FS APPLICATION
LN.CNT 8308
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 73 OF 365 USPATFULL on STN
AN 2003:312148 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Goodrich, Ryle, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2003219745 A1 20031127
AI US 2002-120988 A1 20020411 (10)
RLI Continuation of Ser. No. US 2001-774528, filed on 30 Jan 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 7867
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200; 514/012.000; 424/146.100
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200; 514/012.000; 424/146.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47; A61K039-395; A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 365 USPATFULL on STN
AN 2003:306371 USPATFULL
TI Novel genes, compositions, kits, and methods for identification, assessment prevention, and therapy of breast cancer
IN Lillie, James, Natick, MA, UNITED STATES
Palermo, Adam, Stanford, MA, UNITED STATES
Wang, Youzhen, Newton, MA, UNITED STATES
Steinmann, Kathleen, Winchester, MA, UNITED STATES
Elias, Josh, Brookline, MA, UNITED STATES
Mertens, Maureen, Stow, MA, UNITED STATES
PA Millennium Pharmaceutical, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2003215805 A1 20031120
AI US 2002-125968 A1 20020419 (10)
PRAI US 2001-285163P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 16331
INCL INCLM: 435/006.000
INCLS: 435/007.230; 702/019.000
NCL NCLM: 435/006.000
NCLS: 435/007.230; 702/019.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 365 USPATFULL on STN
AN 2003:305980 USPATFULL
TI Induction of hair growth with vascular endothelial growth factor
IN Waugh, Jacob, Palo Alto, CA, UNITED STATES
Dake, Michael, Stanford, CA, UNITED STATES
PA Essentia Biosystems, Inc., Palo Alto, CA, 94301 (U.S. corporation)
PI US 2003215412 A1 20031120
AI US 2003-370830 A1 20030221 (10)
RLI Continuation-in-part of Ser. No. US 2001-910432, filed on 20 Jul 2001, PENDING
PRAI US 2002-359400P 20020221 (60)
US 2000-220244P 20000721 (60)
DT Utility
FS APPLICATION
LN.CNT 1588
INCL INCLM: 424/070.140
INCLS: 514/012.000
NCL NCLM: 424/070.140
NCLS: 514/012.000
IC [7]
ICM: A61K038-18
ICS: A61K007-06; A61K007-11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 76 OF 365 USPATFULL on STN
AN 2003:300388 USPATFULL
TI Establishment of cellular manipulations which enhance oligo-mediated gene targeting
IN Seidman, Michael M., Washington, DC, UNITED STATES
Majumdar, Alokes, Gaithersburg, MD, UNITED STATES
PI US 2003211612 A1 20031113
AI US 2003-239595 A1 20030318 (10)
WO 2001-US9218 20010322
DT Utility
FS APPLICATION
LN.CNT 2366
INCL INCLM: 435/455.000
NCL NCLM: 435/455.000
IC [7]
ICM: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 77 OF 365 USPATFULL on STN
AN 2003:299857 USPATFULL
TI Pseudo-antibody constructs
IN Heavner, George A., Malvern, PA, UNITED STATES
PI US 2003211078 A1 20031113
AI US 2002-309722 A1 20021204 (10)
PRAI US 2001-336707P 20011207 (60)
DT Utility
FS APPLICATION
LN.CNT 2660
INCL INCLM: 424/085.100
INCLS: 424/130.100; 514/012.000; 514/054.000; 530/351.000; 530/350.000; 530/387.100; 536/123.000; 525/054.100
NCL NCLM: 424/085.100
NCLS: 424/130.100; 514/012.000; 514/054.000; 530/351.000; 530/350.000; 530/387.100; 536/123.000; 525/054.100
IC [7]
ICM: A61K038-19
ICS: A61K038-17; A61K031-715; C07K016-46; C07K014-52; A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 78 OF 365 USPATFULL on STN
AN 2003:288202 USPATFULL
TI Therapeutic angiogenic factors and methods for their use
IN Colley, Kenneth J., San Mateo, CA, UNITED STATES
PI US 2003202960 A1 20031030
AI US 2003-457915 A1 20030609 (10)
RLI Continuation of Ser. No. US 1999-293287, filed on 16 Apr 1999, PENDING
PRAI US 1998-82155P 19980417 (60)
DT Utility
FS APPLICATION
LN.CNT 1201
INCL INCLM: 424/085.100

NCL NCLM: 424/085.100
NCLS: 514/012.000
IC [7]
ICM: A61K038-19
ICS: A61K038-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 79 OF 365 USPATFULL on STN
AN 2003:265885 USPATFULL
TI Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
IN Prezant, Toni Rita, West Hills, CA, UNITED STATES
Heaney, Anthony P., Los Angeles, CA, UNITED STATES
Melmed, Shlomo, Los Angeles, CA, UNITED STATES
PI US 2003186902 A1 20031002
AI US 2001-854326 A1 20010511 (9)
RLI Continuation-in-part of Ser. No. US 2001-777422, filed on 5 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-730469, filed on 4 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-687911, filed on 13 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-569956, filed on 12 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-894251, filed on 23 Jul 1999, GRANTED, Pat. No. US 6455305 A 371 of International Ser. No. WO 1997-US21463, filed on 21 Nov 1997, UNKNOWN
PRAI US 1996-31338P 19961121 (60)
DT Utility
FS APPLICATION
LN.CNT 5275
INCL INCLM: 514/044.000
INCLS: 514/012.000
NCL NCLM: 514/044.000
NCLS: 514/012.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 365 USPATFULL on STN
AN 2003:265302 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2003186317 A1 20031002
AI US 2001-971782 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3143
INCL INCLM: 435/007.100
INCLS: 435/007.900
NCL NCLM: 435/007.100
NCLS: 435/007.900
IC [7]
ICM: G01N033-53
ICS: G01N033-542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 365 USPATFULL on STN
AN 2003:264780 USPATFULL
TI Therapeutic angiogenic factors and methods for their use
IN Colley, Kenneth J., San Mateo, CA, UNITED STATES
PI US 2003185794 A1 20031002
AI US 2002-323533 A1 20021218 (10)
RLI Division of Ser. No. US 1999-293287, filed on 16 Apr 1999, PENDING
PRAI US 1998-82155P 19980417 (60)
DT Utility
FS APPLICATION
LN.CNT 1202
INCL INCLM: 424/085.100
INCLS: 514/012.000
NCL NCLM: 424/085.100
NCLS: 514/012.000
IC [7]
ICM: A61K038-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 365 USPATFULL on STN
AN 2003:237990 USPATFULL
TI Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
IN Lee, ChiChang, Norristown, PA, UNITED STATES
Savino, Edward, UNITED STATES
Moore, Gordon, Wayne, PA, UNITED STATES
Ly, Celia, Lancaster, PA, UNITED STATES
PI US 2003166147 A1 20030904
AI US 2002-316311 A1 20021211 (10)
PRAI US 2001-339429P 20011214 (60)
DT Utility
FS APPLICATION
LN.CNT 2532
INCL INCLM: 435/069.100
INCLS: 435/366.000; 435/326.000
NCL NCLM: 435/069.100
NCLS: 435/366.000; 435/326.000
IC [7]
ICM: C12N005-06
ICS: C12N005-08; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 365 USPATFULL on STN
AN 2003:237989 USPATFULL
TI Myeloma cell line useful for manufacturing recombinant proteins in chemically defined media
IN Lee, ChiChang, Norristown, PA, UNITED STATES
Savino, Edward, Malvern, PA, UNITED STATES
Moore, Gordon, Wayne, PA, UNITED STATES
Ly, Celia, Lancaster, PA, UNITED STATES
PI US 2003166146 A1 20030904
AI US 2002-316308 A1 20021211 (10)
PRAI US 2001-339428P 20011214 (60)
DT Utility
FS APPLICATION
LN.CNT 2558
INCL INCLM: 435/069.100
INCLS: 435/326.000; 435/366.000; 435/069.500; 435/069.520
NCL NCLM: 435/069.100
NCLS: 435/326.000; 435/366.000; 435/069.500; 435/069.520
IC [7]
ICM: C12P021-02
ICS: C12P021-04; C12N005-06; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 365 USPATFULL on STN
AN 2003:237674 USPATFULL
TI Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
IN Lee, John, Somerville, MA, UNITED STATES
Thompson, Pamela, Stow, MA, UNITED STATES
Lillie, James, Natick, MA, UNITED STATES
PI US 2003165831 A1 20030904
AI US 2001-814353 A1 20010321 (9)
PRAI US 2000-191031P 20000321 (60)
US 2000-207124P 20000525 (60)
US 2000-211940P 20000615 (60)
US 2000-216820P 20000707 (60)
US 2000-220661P 20000725 (60)
US 2000-257672P 20001221 (60)
DT Utility
FS APPLICATION
LN.CNT 4104
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/388.260; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/388.260; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 85 OF 365 USPATFULL on STN
AN 2003:225736 USPATFULL
TI Method for diagnosing schizophrenia using objective indices
IN Nawa, Hiroyuki, Niigata-shi, JAPAN
Takahashi, Hitoshi, Niigata-shi, JAPAN
Iritani, Shuji, Tokyo, JAPAN
PI US 2003157548 A1 20030821
AI US 2003-388410 A1 20030317 (10)
RLI Continuation of Ser. No. US 2000-723224, filed on 28 Nov 2000, PENDING
PRAI JP 2000-61775 20000307
DT Utility
FS APPLICATION
LN.CNT 1846
INCL INCLM: 435/006.000
INCLS: 435/007.100; 424/009.200
NCL NCLM: 435/006.000
NCLS: 435/007.100; 424/009.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; A61K049-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 86 OF 365 USPATFULL on STN
AN 2003:219268 USPATFULL
TI Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
IN Luft, Christopher, Chapel Hill, NC, UNITED STATES
Wilkison, William O., Bahama, NC, UNITED STATES
Cheatham, Bentley, Durham, NC, UNITED STATES
Gimble, Jeffrey M., Chapel Hill, NC, UNITED STATES
Halvorsen, Yuan-Di C., Branford, CT, UNITED STATES
PI US 2003152558 A1 20030814
AI US 2002-293394 A1 20021112 (10)
PRAI US 2001-344555P 20011109 (60)
DT Utility
FS APPLICATION
LN.CNT 1143
INCL INCLM: 424/093.210
INCLS: 435/366.000
NCL NCLM: 424/093.210
NCLS: 435/366.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08

L4 ANSWER 87 OF 365 USPATFULL on STN
AN 2003:213772 USPATFULL
TI Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
IN Berger, Allison, Watertown, MA, UNITED STATES
Guillemette, Tracy L., Plaistow, NH, UNITED STATES
Schlegel, Robert, Auburndale, MA, UNITED STATES
Monahan, John E., Walpole, MA, UNITED STATES
Kamatkar, Shubhangi, Newton, MA, UNITED STATES
Thibodeau, Stephen N., Rochester, MN, UNITED STATES
Burgart, Lawrence J., Rochester, MN, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003148410 A1 20030807
AI US 2002-301822 A1 20021121 (10)
PRAI US 2001-339971P 20011210 (60)
US 2002-361978P 20020305 (60)
US 2002-381988P 20020520 (60)
DT Utility
FS APPLICATION
LN.CNT 3911
INCL INCLM: 435/007.230
INCLS: 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/007.230
NCLS: 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: G01N033-574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 88 OF 365 USPATFULL on STN
AN 2003:213676 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
IN Berger, Allison, Watertown, MA, UNITED STATES
Guillemette, Tracy L., Waltham, MA, UNITED STATES
Bryant, Barbara Moore, Cambridge, MA, UNITED STATES
Morrissey, Michael P., Brighton, MA, UNITED STATES
Schlegel, Robert, Auburndale, MA, UNITED STATES
PA MILLENNIUM PHARMACEUTICALS, INC., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2003148314 A1 20030807
AI US 2002-210314 A1 20020801 (10)
PRAI US 2001-309415P 20010801 (60)
US 2001-330233P 20011017 (60)
US 2001-309458P 20010801 (60)
DT Utility
FS APPLICATION
LN.CNT 4728
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 89 OF 365 USPATFULL on STN
AN 2003:213657 USPATFULL
TI Expression profiles and methods of use
IN Wan, Jackson Shek-Lam, San Diego, CA, UNITED STATES
Wang, Yixin, San Diego, CA, UNITED STATES
PI US 2003148295 A1 20030807
AI US 2002-101510 A1 20020320 (10)
PRAI US 2001-276947P 20010320 (60)
DT Utility
FS APPLICATION
LN.CNT 7505
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 365 USPATFULL on STN
AN 2003:206852 USPATFULL
TI Targeted adenovirus vectors for delivery of heterologous genes
IN Vigne, Emmanuelle, L'Hay-Les-Roses, FRANCE
Dedieu, Jean-Francois, Paris, FRANCE
Latta, Martine, Charenton Le pont, FRANCE
Yeh, Patrice, Gif Sur Yvette, FRANCE
Perricaudet, Michel, Ecrosnes, FRANCE
PI US 2003143209 A1 20030731
AI US 2001-791524 A1 20010222 (9)
RLI Continuation of Ser. No. WO 1999-IB1524, filed on 27 Aug 1999, UNKNOWN
PRAI US 1998-98028P 19980827 (60)
DT Utility
FS APPLICATION
LN.CNT 3374
INCL INCLM: 424/093.210
INCLS: 435/235.100
NCL NCLM: 424/093.210
NCLS: 435/235.100
IC [7]
ICM: A61K048-00
ICS: C12N007-00; C12N007-01
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 365 USPATFULL on STN
AN 2003:200864 USPATFULL
TI Methods for determining oligosaccharide binding
IN Rosenberg, Robert D., Boston, MA, UNITED STATES
Wu, Zhengliang, Waltham, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2003138849 A1 20030724
AI US 2002-263338 A1 20021001 (10)
PRAI US 2001-326270P 20011001 (60)
DT Utility
FS APPLICATION
LN.CNT 3335
INCL INCLM: 435/007.100
INCLS: 435/007.500; 530/387.100
NCL NCLM: 435/007.100
NCLS: 435/007.500; 530/387.100
IC [7]
ICM: G01N033-53
ICS: C07K016-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 92 OF 365 USPATFULL on STN
AN 2003:200807 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
IN Schlegel, Robert, Auburndale, MA, UNITED STATES
Chen, Yan, Cambridge, MA, UNITED STATES
Deeds, James D., Somerville, MA, UNITED STATES
Zhao, Xumei, Burlington, MA, UNITED STATES
Bryant, Barbara Moore, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2003138792 A1 20030724
AI US 2002-161469 A1 20020531 (10)
PRAI US 2001-295144P 20010531 (60)
DT Utility
FS APPLICATION
LN.CNT 4744
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 93 OF 365 USPATFULL on STN
AN 2003:187456 USPATFULL
TI Compositions comprising nucleic acids incorporated in bilaminar mineral particles
IN Pitard, Bruno, Reze, FRANCE
PI US 2003129243 A1 20030710
AI US 2002-169392 A1 20021003 (10)
WO 2000-FR3702 20001227
PRAI FR 1999-16707 19991230
DT Utility
FS APPLICATION
LN.CNT 736
INCL INCLM: 424/489.000
INCLS: 514/044.000; 435/459.000
NCL NCLM: 424/489.000
NCLS: 514/044.000; 435/459.000
IC [7]
ICM: A61K048-00
ICS: C12N015-87; A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 94 OF 365 USPATFULL on STN
AN 2003:180370 USPATFULL
TI Compositions and methods for improving integrity of compromised body passageways and cavities
IN Signore, Pierre E., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA
PA University of British Columbia, Vancouver, CANADA (non-U.S. corporation)

AI US 2002-323401 A1 20021218 (10)
RLI Continuation of Ser. No. US 2000-511570, filed on 23 Feb 2000, ABANDONED
PRAI US 1999-121424P 19990223 (60)
DT Utility
FS APPLICATION
LN.CNT 1939
INCL INCLM: 424/499.000
INCLS: 424/501.000; 514/449.000; 514/283.000; 514/054.000; 514/055.000
NCL NCLM: 424/499.000
NCLS: 424/501.000; 514/449.000; 514/283.000; 514/054.000; 514/055.000
IC [7]
ICM: A61K031-728
ICS: A61K031-4745; A61K031-337; A61K009-14; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 95 OF 365 USPATFULL on STN
AN 2003:172712 USPATFULL
TI Targeted retrograde gene delivery to motor neurons
IN Kaspar, Brian K., San Diego, CA, UNITED STATES
Gage, Fred H., La Jolla, CA, UNITED STATES
PI US 2003118556 A1 20030626
AI US 2002-237567 A1 20020905 (10)
RLI Continuation-in-part of Ser. No. US 2001-32047, filed on 21 Dec 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 1371
INCL INCLM: 424/093.200
INCLS: 435/456.000
NCL NCLM: 424/093.200
NCLS: 435/456.000
IC [7]
ICM: A61K048-00
ICS: C12N015-861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 96 OF 365 USPATFULL on STN
AN 2003:153383 USPATFULL
TI Nucleic acid treatment of diseases or conditions related to levels of HER2
IN McSwiggen, James, Boulder, CO, UNITED STATES
PI US 2003105051 A1 20030605
AI US 2002-163552 A1 20020606 (10)
PRAI US 2001-296249P 20010606 (60)
DT Utility
FS APPLICATION
LN.CNT 12746
INCL INCLM: 514/044.000
INCLS: 536/023.200; 435/199.000
NCL NCLM: 514/044.000
NCLS: 536/023.200; 435/199.000
IC [7]
ICM: A61K048-00
ICS: C12N009-22; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 97 OF 365 USPATFULL on STN
AN 2003:153380 USPATFULL
TI Oligobenzimidazole derivatives and their use as DNA transfecting agents
IN Scherman, Daniel, Paris, FRANCE
Bessodes, Michel, Villejuif, FRANCE
Pitard, Bruno, Reze, FRANCE
Soto, Javier, Vigo, SPAIN
Byk, Gerardo, Qyriat Ono, ISRAEL
PI US 2003105048 A1 20030605
AI US 2002-139549 A1 20020506 (10)
RLI Continuation of Ser. No. WO 2000-FR3087, filed on 6 Nov 2000, UNKNOWN
PRAI FR 1999-13934 19991105
US 2000-174648P 20000105 (60)
DT Utility
FS APPLICATION
LN.CNT 1146
INCL INCLM: 514/044.000
INCLS: 435/455.000; 514/254.060; 514/394.000; 548/305.400; 544/370.000
NCL NCLM: 514/044.000

IC [7]
ICM: C12N015-87
ICS: A61K048-00; C07D043-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 98 OF 365 USPATFULL on STN
AN 2003:147077 USPATFULL
TI Architecture tool and methods of use
IN Warren, William L., Stillwater, OK, UNITED STATES
Parkhill, Robert L., Stillwater, OK, UNITED STATES
Stewart, Robert L., Stillwater, OK, UNITED STATES
Kachurin, Anatoly M., Stillwater, OK, UNITED STATES
Taylor, Robert M., Perkins, OK, UNITED STATES
Hargrave, Brian H., Stillwater, OK, UNITED STATES
Church, Kenneth H., Stillwater, OK, UNITED STATES
Nguyen, Michael N., Stillwater, OK, UNITED STATES
Kargel, Mark L., Stillwater, OK, UNITED STATES
Simpkins, Mark W., Stillwater, OK, UNITED STATES
PI US 2003100824 A1 20030529
AI US 2002-227146 A1 20020823 (10)
PRAI US 2001-314344P 20010823 (60)
US 2001-337378P 20011204 (60)
US 2001-337383P 20011204 (60)
US 2001-340706P 20011211 (60)
DT Utility
FS APPLICATION
LN.CNT 5171
INCL INCLM: 600/407.000
NCL NCLM: 600/407.000
IC [7]
ICM: A61B005-05

L4 ANSWER 99 OF 365 USPATFULL on STN
AN 2003:146229 USPATFULL
TI Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
IN Lillie, James, Natick, MA, UNITED STATES
Xu, Yongyao, Belmont, MA, UNITED STATES
Wang, Youzhen, Newton, MA, UNITED STATES
Steinmann, Kathleen, Winchester, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2003099974 A1 20030529
AI US 2002-198846 A1 20020718 (10)
PRAI US 2001-306220P 20010718 (60)
DT Utility
FS APPLICATION
LN.CNT 3910
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.800; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.800; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 100 OF 365 USPATFULL on STN
AN 2003:127058 USPATFULL
TI Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
IN Schlegel, Robert, Auburndale, MA, UNITED STATES
Chen, Yan, Cambridge, MA, UNITED STATES
Zhao, Xumei, Burlington, MA, UNITED STATES
Monahan, John E., Walpole, MA, UNITED STATES
Kamatkar, Shubhangi, Newton, MA, UNITED STATES
Gannavarapu, Manjula, Acton, MA, UNITED STATES
Glatt, Karen, Natick, MA, UNITED STATES
Hoersh, Sebastian, Arlington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2003087270 A1 20030508
AI US 2002-171311 A1 20020612 (10)
PRAI US 2001-298159P 20010613 (60)
US 2001-298155P 20010613 (60)

DT Utility
FS APPLICATION
LN.CNT 3827
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 365 USPATFULL on STN
AN 2003:127047 USPATFULL
TI Methods and compositions for regulating bone and cartilage formation
IN Clancy, Brian M., Ashland, MA, UNITED STATES
Pittman, Debra D., Windham, NH, UNITED STATES
PI US 2003087259 A1 20030508
AI US 2002-125691 A1 20020418 (10)
PRAI US 2001-284786P 20010418 (60)
DT Utility
FS APPLICATION
LN.CNT 12451
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 365 USPATFULL on STN
AN 2003:127043 USPATFULL
TI Peptides which stimulate the immune response and tissue regeneration
IN Barritault, Denis, Paris, FRANCE
Achour, Ammar, Creteil, FRANCE
Courty, Jose, Villecresnes, FRANCE
PI US 2003087255 A1 20030508
AI US 2002-116391 A1 20020404 (10)
RLI Continuation of Ser. No. WO 2000-FR2786, filed on 6 Oct 2000, UNKNOWN
PRAI FR 1999-12714 19991012
DT Utility
FS APPLICATION
LN.CNT 902
INCL INCLM: 435/006.000
INCLS: 514/012.000; 514/013.000; 514/015.000; 514/014.000; 435/005.000; 530/350.000; 530/324.000; 530/325.000; 530/327.000; 530/326.000; 435/007.100
NCL NCLM: 435/006.000
NCLS: 514/012.000; 514/013.000; 514/015.000; 514/014.000; 435/005.000; 530/350.000; 530/324.000; 530/325.000; 530/327.000; 530/326.000; 435/007.100
IC [7]
ICM: A61K038-16
ICS: C12Q001-70; A61K038-00; C07K007-00; C07K017-00; C07K001-00; C12Q001-68; C07K005-00; A61K038-04; G01N033-53; C07K016-00; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 103 OF 365 USPATFULL on STN
AN 2003:126723 USPATFULL
TI Basal cell markers in breast cancer and uses thereof
IN Botstein, David, Belmont, CA, UNITED STATES
Brown, Patrick O., Stanford, CA, UNITED STATES
Perou, Charles M., Carrboro, NC, UNITED STATES
Ring, Brian, Foster City, CA, UNITED STATES
Ross, Douglas, Burlingame, CA, UNITED STATES
Seitz, Rob, Hampton Cove, AL, UNITED STATES
van de Rijn, Jan Matthijs, LaHanda, CA, UNITED STATES
PI US 2003086934 A1 20030508
AI US 2001-916849 A1 20010726 (9)
PRAI US 2000-220967P 20000726 (60)

FS APPLICATION
LN.CNT 6518
INCL INCLM: 424/185.100
INCLS: 435/006.000; 435/007.230
NCL NCLM: 424/185.100
NCLS: 435/006.000; 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 104 OF 365 USPATFULL on STN
AN 2003:120319 USPATFULL
TI In vivo ssDNA expression vectors for altering gene expression
IN Conrad, Charles A., Houston, TX, UNITED STATES
Chen, Yin, Pearland, TX, UNITED STATES
PA CytoGenix, Inc., Houston, TX, UNITED STATES (U.S. corporation)
PI US 2003082800 A1 20030501
AI US 2002-136218 A1 20020501 (10)
RLI Continuation-in-part of Ser. No. US 1999-411568, filed on 4 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-397782, filed on 16 Sep 1999, PENDING Continuation-in-part of Ser. No. US 1998-169793, filed on 9 Oct 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 1803
INCL INCLM: 435/325.000
INCLS: 435/320.100
NCL NCLM: 435/325.000
NCLS: 435/320.100
IC [7]
ICM: C12N015-00
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 365 USPATFULL on STN
AN 2003:120307 USPATFULL
TI Recombinant infectious laryngotracheitis virus and uses thereof
IN Wild, Martha A., San Diego, CA, UNITED STATES
Cochran, Mark D., Carlsbad, CA, UNITED STATES
PI US 2003082788 A1 20030501
AI US 2001-994064 A1 20011106 (9)
RLI Division of Ser. No. US 1995-468190, filed on 6 Jun 1995, ABANDONED Continuation of Ser. No. US 1995-410121, filed on 23 Mar 1995, ABANDONED Continuation-in-part of Ser. No. US 1993-126597, filed on 24 Sep 1993, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 5987
INCL INCLM: 435/235.100
INCLS: 424/204.100; 435/005.000
NCL NCLM: 435/235.100
NCLS: 424/204.100; 435/005.000
IC [7]
ICM: C12Q001-70
ICS: A61K039-12; C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 106 OF 365 USPATFULL on STN
AN 2003:107058 USPATFULL
TI Implant delivery catheter system and methods for its use
IN Rosenman, Daniel C., South San Francisco, CA, UNITED STATES
Altman, Peter A., South San Francisco, CA, UNITED STATES
Lovich, Mark A., South San Francisco, CA, UNITED STATES
Schwartz, Michael A., South San Francisco, CA, UNITED STATES
Miller, Aaron J., South San Francisco, CA, UNITED STATES
PA BioCardia, Inc. (U.S. corporation)
PI US 2003073972 A1 20030417
AI US 2002-292667 A1 20021112 (10)
RLI Continuation of Ser. No. US 2000-543127, filed on 5 Apr 2000, GRANTED, Pat. No. US 6478776
DT Utility
FS APPLICATION
LN.CNT 1056
INCL INCLM: 604/502.000

NCL NCLM: 604/502.000
NCLS: 604/891.100
IC [7]
ICM: A61M031-00

L4 ANSWER 107 OF 365 USPATFULL on STN
AN 2003:93779 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Vernet, Corine A.M., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Quinn, Kerry E., Hamden, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Herrmann, John L., Guilford, CT, UNITED STATES
PI US 2003065140 A1 20030403
AI US 2001-825751 A1 20010403 (9)
PRAI US 2000-194314P 20000403 (60)
US 2000-225693P 20000816 (60)
DT Utility
FS APPLICATION
LN.CNT 6382
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-435; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 365 USPATFULL on STN
AN 2003:93672 USPATFULL
TI Lipid derivatives of polythiourea
IN Herscovici, Jean, Paris, FRANCE
Scherman, Daniel, Paris, FRANCE
Tranchant, Isabelle, Paris, FRANCE
Mignet, Nathalie, Paris, FRANCE
Girard, Christian, Paris, FRANCE
PI US 2003065033 A1 20030403
AI US 2002-143751 A1 20020514 (10)
PRAI FR 2001-6330 20010514
US 2001-297482P 20010613 (60)
DT Utility
FS APPLICATION
LN.CNT 2154
INCL INCLM: 514/586.000
INCLS: 554/037.000
NCL NCLM: 514/586.000
NCLS: 554/037.000
IC [7]
ICM: A61K031-17
ICS: C07C335-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 365 USPATFULL on STN
AN 2003:78446 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ***human*** colon cancer
IN Schlegel, Robert, Auburndale, MA, UNITED STATES
Berger, Allison, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
PI US 2003054366 A1 20030320
AI US 2002-56605 A1 20020123 (10)
PRAI US 2001-263620P 20010123 (60)
DT Utility
FS APPLICATION
LN.CNT 4268
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 365 USPATFULL on STN
AN 2003:64276 USPATFULL
TI Methods for treating diseases and increasing longevity
IN Elia, James P., Scottsdale, AZ, UNITED STATES
PI US 2003044396 A1 20030306
AI US 2002-268833 A1 20021010 (10)
RLI Continuation-in-part of Ser. No. US 2002-179589, filed on 25 Jun 2002, PENDING Continuation-in-part of Ser. No. US 1998-64000, filed on 21 Apr 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 2697
INCL INCLM: 424/093.210
INCLS: 435/366.000
NCL NCLM: 424/093.210
NCLS: 435/366.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 111 OF 365 USPATFULL on STN
AN 2003:45279 USPATFULL
TI Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
IN Ruoslahti, Erkki I., Rancho Santa Fe, CA, UNITED STATES
Longaker, Michael T., San Francisco, CA, UNITED STATES
Whitby, David J., Adel, UNITED KINGDOM
Harper, John R., Carlsbad, CA, UNITED STATES
Pierschbacher, Michael D., San Diego, CA, UNITED STATES
Border, Wayne A., Salt Lake City, UT, UNITED STATES
PA The Burnham Institute (U.S. corporation)
PI US 2003032591 A1 20030213
AI US 2001-935216 A1 20010821 (9)
RLI Continuation of Ser. No. US 1995-458834, filed on 2 Jun 1995, GRANTED, Pat. No. US 6277812 Continuation of Ser. No. US 1994-303238, filed on 8 Sep 1994, GRANTED, Pat. No. US 5654270 Continuation of Ser. No. US 1992-978931, filed on 17 Nov 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-882345, filed on 13 May 1992, ABANDONED Continuation of Ser. No. US 1991-792192, filed on 14 Nov 1991, ABANDONED Continuation-in-part of Ser. No. US 1990-467888, filed on 22 Jan 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-212702, filed on 28 Jun 1988, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1480
INCL INCLM: 514/012.000
INCLS: 514/054.000
NCL NCLM: 514/012.000
NCLS: 514/054.000
IC [7]
ICM: A61K038-17
ICS: A61K031-728
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 112 OF 365 USPATFULL on STN
AN 2003:38104 USPATFULL
TI VEGF fusion proteins
IN Kovesdi, Imre, Rockville, MD, UNITED STATES
Kessler, Paul D., Frederick, MD, UNITED STATES
PA GenVec, Inc., Gaithersburg, MD, UNITED STATES, 20878 (U.S. corporation)
PI US 2003027751 A1 20030206
AI US 2001-832355 A1 20010410 (9)
DT Utility
FS APPLICATION
LN.CNT 7034
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000
NCLS: 530/350.000
IC [7]
ICM: A61K038-18
ICS: C07K014-515

L4 ANSWER 113 OF 365 USPATFULL on STN
AN 2003:37685 USPATFULL
TI Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
IN Lanza, Robert, Clinton, MA, UNITED STATES
West, Michael, Boston, MA, UNITED STATES
PI US 2003027330 A1 20030206
AI US 2002-112939 A1 20020402 (10)
PRAI US 2001-280138P 20010402 (60)
DT Utility
FS APPLICATION
LN.CNT 1650
INCL INCLM: 435/366.000
INCLS: 435/455.000
NCL NCLM: 435/366.000
NCLS: 435/455.000
IC [7]
ICM: C12N005-08
ICS: C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 365 USPATFULL on STN
AN 2003:24158 USPATFULL
TI Methods of using pituitary tumor transforming gene (PTTG) carboxy-terminal peptides to inhibit neoplastic cellular proliferation and/or transformation of breast and ovarian cells
IN Heaney, Anthony P., Los Angeles, CA, UNITED STATES
Horwitz, Gregory A., Calabasas, CA, UNITED STATES
Zhang, Xun, Malden, MA, UNITED STATES
Melmed, Shlomo, Los Angeles, CA, UNITED STATES
PI US 2003018001 A1 20030123
AI US 2000-730469 A1 20001204 (9)
RLI Continuation-in-part of Ser. No. US 2000-687911, filed on 13 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-569956, filed on 12 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-894251, filed on 23 Jul 1999, PENDING A 371 of International Ser. No. WO 1997-US21463, filed on 21 Nov 1997, UNKNOWN
PRAI US 1996-31338P 19961121 (60)
DT Utility
FS APPLICATION
LN.CNT 3868
INCL INCLM: 514/044.000
INCLS: 514/012.000; 424/093.210
NCL NCLM: 514/044.000
NCLS: 514/012.000; 424/093.210
IC [7]
ICM: A61K048-00
ICS: A61K038-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 365 USPATFULL on STN
AN 2003:4083 USPATFULL
TI Nucleotide triphosphates and their incorporation into oligonucleotides
IN Beigelman, Leonid, Longmont, CO, UNITED STATES
Burgin, Alex, San Diego, CA, UNITED STATES
Beaudry, Amber, Denver, CO, UNITED STATES
Karpeisky, Alexander, Lafayette, CO, UNITED STATES
Matulic-Adamic, Jasenka, Boulder, CO, UNITED STATES
Sweedler, David, Louisville, CO, UNITED STATES
Zinnen, Shawn, Denver, CO, UNITED STATES
PI US 2003004122 A1 20030102
AI US 2001-825805 A1 20010404 (9)
RLI Continuation-in-part of Ser. No. US 2000-578223, filed on 23 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-476387, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-474432, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, GRANTED, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS APPLICATION
LN.CNT 5252
INCL INCLM: 514/044.000

NCL NCLM: 514/044.000
NCLS: 435/455.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 365 USPATFULL on STN
AN 2003:4052 USPATFULL
TI MEDICINAL COMBINATION USEFUL FOR IN VIVO EXOGENIC TRANSFECTION AND EXPRESSION
IN PERRICAUDET, MICHEL, ECROSNES, FRANCE
LEE, MARTIN, PARIS, FRANCE
CHATENOUD, LUCIENNE, PARIS, FRANCE
HADDADA, HEDI, BG LA REIVE, FRANCE
BACH, JEAN-FRANCOIS, PARIS, FRANCE
WEBB, MICHELLE, LONDON, FRANCE
PI US 2003004091 A1 20030102
AI US 1998-894246 A1 19980522 (8)
WO 1996-FR218 19960212
PRAI FR 1995-1662 19950214
DT Utility
FS APPLICATION
LN.CNT 1095
INCL INCLM: 514/001.000
INCLS: 424/130.100; 514/044.000; 435/320.100; 435/325.000; 435/455.000
NCL NCLM: 514/001.000
NCLS: 424/130.100; 514/044.000; 435/320.100; 435/325.000; 435/455.000
IC [7]
ICM: A61K048-00
ICS: A61K039-395; C12N015-861; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 365 USPATFULL on STN
AN 2003:3444 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
IN Kovats, Steven G., Wilmington, MA, UNITED STATES
Sen, Ami, Framingham, MA, UNITED STATES
Morrissey, Michael P., Brighton, MA, UNITED STATES
Lillie, James, Natick, MA, UNITED STATES
PA Millennium Pharmaceutical, Inc., Cambridge, MA (U.S. corporation)
PI US 2003003479 A1 20030102
AI US 2002-126227 A1 20020419 (10)
PRAI US 2001-285443P 20010419 (60)
DT Utility
FS APPLICATION
LN.CNT 5284
INCL INCLM: 435/006.000
INCLS: 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 365 USPATFULL on STN
AN 2003:260677 USPATFULL
TI Methods for stable transduction of cells with hiv-derived viral vectors
IN Humeau, Laurent, Gaithersburg, MD, United States
Han, Wei, Montgomery Village, MD, United States
Lu, Xiaobin, Gaithersburg, MD, United States
Slepushkin, Vladimir, Damascus, MD, United States
Lesher, Mechelle, Frederick, MD, United States
Davis, Brian, Gaithersburg, MD, United States
Chang, Yung-Nien, Cockeysville, MD, United States
Dropulic, Boro, Ellicott City, MD, United States
PA VIRxSYS Corporation, Gaithersburg, MD, United States (U.S. corporation)
PI US 6627442 B1 20030930
AI US 2000-653088 20000831 (9)
DT Utility
FS GRANTED
LN.CNT 1633
INCL INCLM: 435/455.000

NCL NCLM: 435/455.000
NCLS: 435/320.100; 435/325.000; 435/372.000
IC [7]
ICM: C12N015-85
ICS: C12N015-86; C12N015-87; C12N005-00; C12N005-08; C12N015-00
EXF 435/456; 435/459; 435/320.1; 435/455; 435/325; 435/366; 424/93.1; 424/93.2; 424/93.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 365 USPATFULL on STN
AN 2003:240449 USPATFULL
TI Oligoribonucleotides with enzymatic activity
IN Beigelman, Leonid, Broomfield, CO, United States
Burgin, Alex B., Chula Vista, CA, United States
Beaudry, Amber, Broomfield, CO, United States
Karpeisky, Alexander, Lafayette, CO, United States
Matulic-Adamic, Jasenka, Boulder, CO, United States
Sweedler, David, Louisville, CO, United States
Zinnen, Shawn, Denver, CO, United States
PA Sirna Therapeutics, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6617438 B1 20030909
AI US 1999-476387 19991230 (9)
RLI Continuation-in-part of Ser. No. US 1999-474432, filed on 29 Dec 1999, now patented, Pat. No. US 6528640 Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999, now patented, Pat. No. US 6482932 Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, now patented, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS GRANTED
LN.CNT 4484
INCL INCLM: 536/023.100
INCLS: 536/025.100; 536/025.300; 536/024.500; 514/044.000
NCL NCLM: 536/023.100
NCLS: 536/024.500; 536/025.100; 536/025.300
IC [7]
ICM: C07H021-02
EXF 536/23.1; 536/25.1; 536/25.3; 536/24.5; 514/44; 435/91.1; 435/194; 435/199; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 365 USPATFULL on STN
AN 2003:142835 USPATFULL
TI Prostate-specific membrane antigen and uses thereof
IN Israeli, Ron S., Staten Island, NY, United States
Heston, Warren D. W., New York, NY, United States
Fair, William R., New York, NY, United States
Ouerfelli, Ouathek, New York, NY, United States
Pinto, John, East Norwalk, CT, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6569432 B1 20030527
AI US 1996-705477 19960829 (8)
RLI Continuation-in-part of Ser. No. WO 1996-US2424, filed on 19 Jul 1996 Continuation-in-part of Ser. No. US 1995-394152, filed on 24 Feb 1995, now patented, Pat. No. US 5935818
DT Utility
FS GRANTED
LN.CNT 4510
INCL INCLM: 424/185.100
INCLS: 424/277.100; 530/350.000
NCL NCLM: 424/185.100
NCLS: 424/277.100; 530/350.000
IC [7]
ICM: A61K039-00
ICS: C07K014-705
EXF 530/350; 424/185.1; 424/277.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 121 OF 365 USPATFULL on STN
AN 2003:60295 USPATFULL
TI Synthetic ribonucleic acids with RNAse activity
IN Beigelman, Leonid, Broomfield, CO, United States
Burgin, Alex, Chula Vista, CA, United States

Karpeisky, Alexander, Lafayette, CO, United States
Matulic-Adamic, Jasenka, Boulder, CO, United States
Sweedler, David, Louisville, CO, United States
Zinnen, Shawn, Denver, CO, United States
PA Ribozyme Pharmaceuticals, incorporated, Boulder, CO, United States (U.S. corporation)
PI US 6528640 B1 20030304
AI US 1999-474432 19991229 (9)
RLI Continuation-in-part of Ser. No. US 1999-301511, filed on 28 Apr 1999
Continuation-in-part of Ser. No. US 1998-186675, filed on 4 Nov 1998, now patented, Pat. No. US 6127535
PRAI US 1998-83727P 19980429 (60)
US 1997-64866P 19971105 (60)
DT Utility
FS GRANTED
LN.CNT 3964
INCL INCLM: 536/025.100
INCLS: 536/624.300; 536/024.310; 536/024.347; 536/023.100
NCL NCLM: 536/025.100
NCLS: 536/023.100; 536/024.300; 536/024.310
IC [7]
ICM: C07H021-02
EXF 536/23.1; 536/25.1; 536/29.3; 536/24.31; 536/24.32
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 365 USPATFULL on STN
AN 2003:47528 USPATFULL
TI Transfecting compounds which are sensitive to reducing conditions, pharmaceutical compositions containing them and their applications
IN Byk, Gerardo, Qyriat Ono, ISRAEL
Dubertret, Catherine, Sevres, FRANCE
Pitard, Bruno, Brindas, FRANCE
Scherman, Daniel, Paris, FRANCE
PA Aventis Pharma S.A., Antony, FRANCE (non-U.S. corporation)
PI US 6521252 B1 20030218
AI US 2000-610727 20000706 (9)
RLI Continuation of Ser. No. WO 1999-FR162, filed on 28 Jan 1999
PRAI FR 1998-1065 19980130
US 1998-77026P 19980306 (60)
DT Utility
FS GRANTED
LN.CNT 1397
INCL INCLM: 424/450.000
INCLS: 435/458.000; 514/044.000; 536/023.100
NCL NCLM: 424/450.000
NCLS: 435/458.000; 514/044.000; 536/023.100
IC [7]
ICM: A61K009-127
EXF 424/450; 435/458; 514/44; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 14
AN 2003:702045 CAPLUS
DN 139:319004
TI Heterogeneity of the Chondroitin Sulfate Portion of Phosphacan/6B4 Proteoglycan Regulates Its Binding Affinity for ***Pleiotrophin*** /Heparin Binding Growth-associated Molecule
AU Maeda, Nobuaki; He, Jue; Yajima, Yuki; Mikami, Tadahisa; Sugahara, Kazuyuki; Yabe, Tomio
CS Department of Developmental Neuroscience, Tokyo Metropolitan Institute for Neuroscience, Fuchu, Tokyo, 183-8526, Japan
SO Journal of Biological Chemistry (2003), 278(37), 35805-35811
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 124 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:984935 SCISEARCH
GA The Genuine Article (R) Number: 738RF
TI An endoaenous retroviral long terminal repeat is the dominant promoter for ***human*** beta 1,3-galactosyltransferase 5 in the colon

CS British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada (Reprint); British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Lund Univ, Ctr Biomed, Dept Mol & Cell Biol, S-22184 Lund, Sweden; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z1, Canada
CYA Canada; Sweden
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (28 OCT 2003) Vol. 100, No. 22, pp. 12841-12846.
Publisher: NATL ACAD SCIENCES, 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA.
ISSN: 0027-8424.
DT Article; Journal
LA English
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 125 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:537843 SCISEARCH
GA The Genuine Article (R) Number: 691GX
TI Functional analysis of the endogenous retroviral promoter of the ***human*** endothelin B ***receptor*** gene
AU Landry J R; Mager D L (Reprint)
CS British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada (Reprint); British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1L3, Canada
CYA Canada
SO JOURNAL OF VIROLOGY, (JUL 2003) Vol. 77, No. 13, pp. 7459-7466.
Publisher: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA.
ISSN: 0022-538X.
DT Article; Journal
LA English
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 126 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 15
AN 2003:535859 BIOSIS
DN PREV200300523968
TI A role for ***receptor*** tyrosine phosphatasezeta in glioma cell migration.
AU Mueller, Sabine [Reprint Author]; Kunkel, Philip; Lamszus, Katrin; Ulbricht, Ulrike; Lorente, Gustavo Angel; Nelson, April Michelle; von Schack, David; Chin, Daniel J.; Lohr, Scott Curtis; Westphal, Manfred; Melcher, Thorsten
CS AGY Therapeutics, Inc., 290 Utah Avenue, South San Francisco, CA, 94080, USA
sabine@agyinc.com
SO Oncogene, (2 October 2003) Vol. 22, No. 43, pp. 6661-6668. print.
ISSN: 0950-9232 (ISSN print).
DT Article
LA English
ED Entered STN: 12 Nov 2003
Last Updated on STN: 12 Nov 2003

L4 ANSWER 127 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2003:37372206 BIOTECHNO
TI A role for ***receptor*** tyrosine phosphatase.zeta. in glioma cell migration
AU Muller S.; Kunkel P.; Lamszus K.; Ulbricht U.; Lorente G.A.; Nelson A.M.; Von Schack D.; Chin D.J.; Lohr S.C.; Westphal M.; Melcher T.
CS S. Muller, AGY Therapeutics, Inc., 290 Utah Avenue, South San Francisco, CA 94080, United States.
E-mail: sabine@agyinc.com
SO Oncogene, (29 SEP 2003), 22/42 REV. ISS. 4 (6661-6668), 30 reference(s)
CODEN: ONCNES ISSN: 0950-9232
DT Journal; Article
CY United Kingdom
LA English
SL English

L4 ANSWER 128 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN

DN 139:211763
TI Correlation of elevated level of blood midkine with poor prognostic factors of ***human*** neuroblastomas
AU Ikematsu, S.; Nakagawara, A.; Nakamura, Y.; Sakuma, S.; Wakai, K.; Muramatsu, T.; Kadomatsu, K.
CS Department of Biochemistry, Nagoya University Graduate School of Medicine, Showaku, 466-8550, Japan
SO British Journal of Cancer (2003), 88(10), 1522-1526
CODEN: BJCAAI; ISSN: 0007-0920
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 129 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 17
AN 2003:384336 BIOSIS
DN PREV200300384336
TI Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors.
AU Brockmann, Marc-Alexander; Ulbricht, Ulrike; Gruener, Katrin; Fillbrandt, Regina; Westphal, Manfred; Lamszus, Katrin [Reprint Author]
CS Department of Neurosurgery, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
lamszus@uke.uni-hamburg.de
SO Neurosurgery (Hagerstown), (June 2003) Vol. 52, No. 6, pp. 1391-1399. print.
ISSN: 0148-396X (ISSN print).
DT Article
LA English
ED Entered STN: 20 Aug 2003
Last Updated on STN: 18 Sep 2003

L4 ANSWER 130 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 18
AN 2004:119449 BIOSIS
DN PREV200400121862
TI Expression and function of the ***receptor*** protein tyrosine phosphatase zeta and its ligand ***pleiotrophin*** in ***human*** astrocytomas.
AU Ulbricht, Ulrike; Brockmann, Marc A.; Aigner, Achim; Eckerich, Carmen; Mueller, Sabine; Fillbrandt, Regina; Westphal, Manfred; Lamszus, Katrin [Reprint Author]
CS Department of Neurosurgery, Laboratory for Brain Tumor Biology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
lamszus@uke.uni-hamburg.de
SO Journal of Neuropathology & Experimental Neurology, (December 2003) Vol. 62, No. 12, pp. 1265-1275. print.
ISSN: 0022-3069 (ISSN print).
DT Article
LA English
ED Entered STN: 3 Mar 2004
Last Updated on STN: 3 Mar 2004

L4 ANSWER 131 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:476084 BIOSIS
DN PREV200300476084
TI Restriction of tyrosine and phenylalanine in DU145 and PC-3 alters the expression of several genes involved in invasion and metastasis.
AU Herman, Jeffery Guy [Reprint Author]; Zhang, Hui [Reprint Author]; Li, Yi-Qi [Reprint Author]; Fu, Ya-Min [Reprint Author]; Meadows, Gary G. [Reprint Author]
CS Washington State University, Pullman, WA, USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (July 2003) Vol. 44, pp. 1014. print.
Meeting Info.: 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA. July 11-14, 2003.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 15 Oct 2003
Last Updated on STN: 15 Oct 2003

L4 ANSWER 132 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 2003:36760396 BIOTECHNO
TI Expression of the ***human*** oestrogen ***receptor*** -.alpha. gene is regulated by promoter F in MG-63 osteoblastic cells
AU Lambertini E.; Penolazzi L.; Giordano S.; Del Senno L.; Piva R.
CS R. Piva, Dipto. di Biochim. e Biol. Molec., Univ. degli Studi di Ferrara, Via L. Borsari 46, 44100 Ferrara, Italy.
E-mail: piv@unife.it
SO Biochemical Journal, (15 JUN 2003), 372/3 (831-839), 40 reference(s)
CODEN: BIJOAK ISSN: 0264-6021
DT Journal; Article
CY United Kingdom
LA English
SL English

L4 ANSWER 133 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:281521 CAPLUS
DN 138:399783
TI Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in ***human*** skin grafted to SCID mice
AU Gruss, Claus J.; Satyamoorthy, Kapaettu; Berking, Carola; Lininger, John; Nesbit, Mark; Schaider, Helmut; Liu, Zhao-June; Oka, Masahiro; Hsu, Mei-Yu; Shirakawa, Takashi; Li, Gang; Bogenrieder, Thomas; Carmeliet, Peter; El-Deiry, Wafik S.; Eck, Stephen L.; Rao, Justi S.; Baker, Andrew H.; Bennet, Jean T.; Crombleholme, Timothy M.; Velazquez, Omaida; Karmacharya, Jagajan; Margolis, David J.; Wilson, James M.; Detmar, Michael; Skobe, Mihaela; Robbins, Paul D.; Buck, Clayton; Herlyn, Meenhard
CS The Wistar Institute, Philadelphia, PA, 19104, USA
SO Journal of Investigative Dermatology (2003), 120(4), 683-692
CODEN: JIDEAE; ISSN: 0022-202X
PB Blackwell Publishing, Inc.
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 134 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:228435 SCISEARCH
GA The Genuine Article (R) Number: 653LY
TI Expression of ***pleiotrophin*** , an embryonic growth and differentiation factor, in rheumatoid arthritis
AU Pufe T; Bartscher M; Petersen W; Tillmann B; Mentlein R (Reprint)
CS Univ Kiel, Dept Anat, Olshaussenstr 40, D-24098 Kiel, Germany (Reprint); Univ Kiel, Dept Anat, D-24098 Kiel, Germany
CYA Germany
SO ARTHRITIS AND RHEUMATISM, (MAR 2003) Vol. 48, No. 3, pp. 660-667.
Publisher: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA.
ISSN: 0004-3591.
DT Article; Journal
LA English
REC Reference Count: 29
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 135 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:474893 BIOSIS
DN PREV200300474893
TI ***Pleiotrophin*** - ***receptor*** expression promotes pancreatic cancer cell growth and may contribute to neuronal tumor invasion.
AU Flachmann, Sabine [Reprint Author]; Powers, Cirian [Reprint Author]; Wellstein, Anton [Reprint Author]; Juhl, Hartmut [Reprint Author]
CS Lombardi Cancer Center, Georgetown University, Washington, DC, USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (July 2003) Vol. 44, pp. 246. print.
Meeting Info.: 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA. July 11-14, 2003.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 15 Oct 2003

L4 ANSWER 136 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004047549 EMBASE
TI Progesterone ***Receptors*** in Mammary Gland Development and Tumorigenesis.
AU Conneely O.M.; Jericevic B.M.; Lydon J.P.
CS O.M. Conneely, Dept. of Molec. and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States
SO Journal of Mammary Gland Biology and Neoplasia, (2003) 8/2 (205-214). Refs: 68
ISSN: 1083-3021 CODEN: JMBNFU
CY United States
DT Journal; General Review
FS 016 Cancer
021 Developmental Biology and Teratology
022 Human Genetics
029 Clinical Biochemistry
037 Drug Literature Index
LA English
SL English

L4 ANSWER 137 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:168354 BIOSIS
DN PREV200400162166
TI ***Pleiotrophin*** signal disruption of cell-cell adhesion, translocation of beta-catenin to the nucleus, and association of beta-catenin with different transcription activators in ***pleiotrophin*** -stimulated cells.
AU Pinera, Pablo Perez [Reprint Author]; Deuel, Thomas F. [Reprint Author]; Vega-Alvarez, Jose A.
CS Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA, USA
SO Blood, (November 16 2003) Vol. 102, No. 11, pp. 201b. print.
Meeting Info.: 45th Annual Meeting of the American Society of Hematology. San Diego, CA, USA. December 06-09, 2003. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 Mar 2004
Last Updated on STN: 24 Mar 2004

L4 ANSWER 138 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:962371 CAPLUS
DN 140:125777
TI HB-GAM/ ***Pleiotrophin*** and Midkine are Differently Expressed and Distributed During Retinoic Acid-induced Neural Differentiation of P19 Cells
AU Brunet-De Carvalho, Nicole; Raulais, Daniel; Rauvala, Heikki; Souttou, Boussad; Vigny, Marc
CS INSERM U 440/UPM, Signalisation et Differenciation Cellulaires dans les Systemes Nerveux et Musculaire, Inst. du Fer a Moulin, Paris, F-75005, Fr.
SO Growth Factors (2003), 21(3-4), 139-149
CODEN: GRFAEC; ISSN: 0897-7194
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 139 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 20
AN 2003:95093 BIOSIS
DN PREV200300095093
TI ***Receptor*** protein tyrosine phosphatases as mediators of cellular adhesion.
AU Beltran, Pedro J.; Bixby, John L. [Reprint Author]
CS Department of Pharmacology and Neuroscience Program, University of Miami, Miami, FL, 33136, USA
jbixby@chroma.med.miami.edu
SO Frontiers in Bioscience, (January 1 2003) Vol. 8, No. Cited January 3, 2003, pp. d87-99. http://www.bioscience.org/. online.
ISSN: 1093-4715 (ISSN online).

General Review; (Literature Review)
LA English
ED Entered STN: 12 Feb 2003
Last Updated on STN: 12 Feb 2003

L4 ANSWER 140 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004000560 EMBASE
TI Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: The 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity.
AU Arendt T.
CS T. Arendt, Paul Flechsig Inst. of Brain Res., Department of Neuroanatomy, University of Leipzig, Jahnallee 59, D-04109 Leipzig, Germany. aret@medizin.uni-leipzig.de
SO Progress in Neurobiology, (2003) 71/2-3 (83-248).
Refs: 3143
ISSN: 0301-0082 CODEN: PGNBA5
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 141 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:202958 BIOSIS
DN PREV200400203501
TI Transcriptional identification of acutely isolated progenitor cells of the adult ***human*** subcortical white matter.
AU Sim, F. J. [Reprint Author]; Roy, N. S. [Reprint Author]; Nunes, M. C. [Reprint Author]; Kukreja, A. [Reprint Author]; Waldau, B. [Reprint Author]; Chandross, K. J.; Natesan, S.; Merrill, J. E.; Goldman, S. A. [Reprint Author]
CS Neurol., Cornell U. Med. Col, NY, NY, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 674.4. http://sfn.scholarone.com. e-file.
Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L4 ANSWER 142 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:411096 BIOSIS
DN PREV200300411096
TI ***Pleiotrophin*** stimulates the redistribution of serine phosphorylated adducin-2beta in ***pleiotrophin*** -stimulated HeLa and U87MG cells.
AU Pariser, Harold Phillip [Reprint Author]; Deuel, Thomas F.
CS Molecular Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, MEM 268, USA hpariser@scripps.edu; tfdeuel@scripps.edu
SO FASEB Journal, (March 2003) Vol. 17, No. 4-5, pp. Abstract No. 620.10. http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. San Diego, CA, USA. April 11-15, 2003. FASEB.
ISSN: 0892-6638 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 10 Sep 2003
Last Updated on STN: 10 Sep 2003

L4 ANSWER 143 OF 365 NTIS COPYRIGHT 2004 NTIS on STN
AN 2003(13):00050 NTIS Order Number: ADA410204/XAB
TI Gene Regulation and Expression Pattern of the Growth Factor ***Pleiotrophin*** in Breast Cancer. Annual summary 1 Sep 2001-31 Aug 2002.
AU Stoica, G. E.
CS Georgetown Univ., Washington, DC. Medical Center. (011489008 153650)

13p; Sep 2002
NC Contract(s): DAMD17-99-1-9204
DT Report
CY United States
LA English
AV Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.
NTIS Prices: PC A03/MF A01
OS GRA&I0313

L4 ANSWER 144 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 21
AN 2002:482988 CAPLUS
DN 137:62138
TI Recombinant infectious bovine rhinotracheitis virus with US2, gE and gG genes deleted for use as vaccine
IN Cochran, Mark D.
PA Syntro Corporation, USA
SO U.S., 133 pp., Cont.-in-part of U. S. 5,834,305.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 18

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6410033	B1	20020625	US 1996-379647	19960805
	EP 658623	A2	19950621	EP 1995-100565	19880727
	EP 658623	A3	19950927		
	R: BE, DE, FR, GB, IT, NL				
	US 5783195	A	19980721	US 1994-191866	19940204
	US 5593873	A	19970114	US 1994-247475	19940523
	US 5834305	A	19981110	US 1994-334428	19941104
	WO 9521261	A1	19950810	WO 1995-US1491	19950202
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5599544	A	19970204	US 1995-479650	19950607
	US 5804372	A	19980908	US 1996-674169	19960701
	US 6121043	A	20000919	US 1997-915520	19970815
	US 6210961	B1	20010403	US 1997-912803	19970818
PRAI	US 1987-78519	B1	19870727		
	US 1991-649380	B1	19910131		
	US 1993-37707	B1	19930325		
	US 1994-191866	A2	19940204		
	US 1994-334428	A2	19941104		
	WO 1995-US1491	W	19950202		
	US 1985-773430	A2	19850906		
	US 1986-823102	A2	19860127		
	US 1986-887140	B2	19860717		
	US 1986-902887	B2	19860902		
	US 1986-933107	B1	19861120		
	US 1988-192866	A2	19880519		
	EP 1988-907889	A3	19880727		
	US 1988-225032	A2	19880727		
	US 1991-696262	B2	19910419		
	US 1991-732584	B2	19910718		
	US 1994-247475	A1	19940523		

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 145 OF 365 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 22
AN 10091205 IFIPAT;IFIUDB;IFICDB
TI ***PLEIOTROPHIN*** GROWTH FACTOR ***RECEPTOR*** FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS; COMPLEX OF A ***PLEIOTROPHIN*** PROTEIN AND A ***PLEIOTROPHIN*** - ***RECEPTOR*** PROTEIN
IN Wellstein Anton
PA Unassigned Or Assigned To Individual (68000)
PI US 2002034768 A1 20020321
AI US 2001-880097 20010614

FI US 2002034768 20020321
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 68
GI 9 Figure(s).
FIG. 1 (a) Schematic of ALK gene showing factor binding sites. (b) Binding of the PTN to recombinant ECD of ALK. (c) SELDI analysis of PTN-ligand binding. (d) SELDI analysis of conditioned media, initial PTN binding to ECD, and completed PTN binding to ECD.
FIG. 2 (a) Competition of PTN binding to 32D/ALK-transfected cells, and (b) saturation binding of PTN to 32D/ALK and 32D/ control cells.
FIG. 3 (a) SW-13 or SW-13/ALK cells stimulated with PTN and immunoprecipitated with anti-PY, anti-ALK, or anti-IRS-1 antibodies. (b) SW-13/ALK cells stimulated with PTN, ECD or anti-PTN and immunoprecipitated with anti-PY or WB anti-PTN. (c) PTN stimulation of SW-13/ALK cells immunoprecipitated with anti-PY.
FIG. 4 Affect of ALK overexpression on PTN-stimulated growth.
FIG. 5 (a-d) ALK expression in ***human*** GBM tissue and cell lines. (e) Detection of ALK mRNA in various cell lines by RNase protection.
FIG. 6 (a-c) ***Pleiotrophin*** -induced AKT phosphorylation in U87MG cells.
FIG. 7 (a) Autoradiogram and (b) quantitation by phosphoimager analysis of ALK mRNA. (c) Dose response of ***pleiotrophin*** , and (d) PDGF BB on phosphoAkt/Akt. (e) Comparison of the effect of PTN as a function of ALK levels in different cell lines.
FIG. 8 Xenograft tumor growth showing (a) size and (b) relative ALK/GAPDH as a function of time after tumor cell inoculation. (c) Mice survival curves from panel (a).
FIG. 9 Analysis of mitosis and apoptosis in tumor xenografts using (a) a high power (400 X) H & E (left column) and TUNEL (right column) stained sections from size-matched pRC/CMV (upper row) and Rz1-2 (lower row) xenograft tumors. (b) Number of mitotic figures and TUNEL positive cells as a function of relative ALK levels.

L4 ANSWER 146 OF 365 USPATFULL on STN DUPLICATE 23
AN 2002:300795 USPATFULL
TI COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS FOR NEURONAL REGENERATION AND SURVIVAL
IN BAIRD, ANDREW, UNITED STATES
PI US 2002168338 A1 20021114
US 6551618 B2 20030422
AI US 1998-178286 A1 19981023 (9)
RLI Continuation-in-part of Ser. No. US 1998-88419, filed on 1 Jun 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3899
INCL INCLM: 424/093.200
INCLS: 514/044.000; 424/423.000; 424/424.000; 424/425.000; 424/468.000; 424/469.000; 424/486.000; 424/193.100; 536/024.500; 536/024.100; 435/320.100
NCL NCLM: 424/484.000
NCLS: 424/468.000; 424/469.000; 424/486.000; 435/091.400; 435/320.100; 435/455.000; 514/044.000
IC [7]
ICM: A61K048-00
ICS: C07H021-04; A61K039-385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 365 USPATFULL on STN DUPLICATE 24
AN 2002:198576 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002106676 A1 20020808
US 6653102 B2 20031125
AI US 2001-973963 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3181

INCLS: 435/368.000; 435/320.100; 435/069.100; 536/023.200; 435/226.000
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/252.300; 435/254.110; 435/254.200; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 148 OF 365 USPATFULL on STN DUPLICATE 25
AN 2002:191154 USPATFULL
TI Diagnostic/therapeutic agents
IN Klaveness, Jo, Oslo, NORWAY
Rongved, Pal, Oslo, NORWAY
Hogset, Anders, Oslo, NORWAY
Tolleshaug, Helge, Oslo, NORWAY
Cuthbertson, Alan, Oslo, NORWAY
Godal, Aslak, Oslo, NORWAY
Hoff, Lars, Oslo, NORWAY
Gogstad, Geir, Oslo, NORWAY
Bryn, Klaus, Oslo, NORWAY
Naevestad, Anne, Oslo, NORWAY
Lovhaug, Dagfinn, Oslo, NORWAY
Hellebust, Halldis, Oslo, NORWAY
Solbakken, Magne, Oslo, NORWAY
PA Nycomed Imaging AS (non-U.S. corporation)
PI US 2002102217 A1 20020801
US 6680047 B2 20040120
AI US 2001-925715 A1 20010810 (9)
RLI Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, PATENTED
PRAI GB 1996-22366 19961028
GB 1996-22369 19961028
GB 1997-2195 19970204
GB 1997-8265 19970424
GB 1997-11837 19970606
GB 1997-11839 19970606
US 1997-49263P 19970607 (60)
US 1997-49264P 19970606 (60)
US 1997-49266P 19970607 (60)
DT Utility
FS APPLICATION
LN.CNT 5190
INCL INCLM: 424/009.520
NCL NCLM: 424/009.520
NCLS: 424/001.210; 424/009.320; 424/009.400; 424/450.000; 424/489.000
IC [7]
ICM: A61B008-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 149 OF 365 USPATFULL on STN DUPLICATE 26
AN 2002:171622 USPATFULL
TI Transplant media
IN Murphy, Chistopher J., Madison, WI, UNITED STATES
McAnulty, Jonathan F., Oregon, WI, UNITED STATES
PI US 2002090369 A1 20020711
US 6696238 B2 20040224
AI US 2001-917340 A1 20010727 (9)
PRAI US 2000-221632P 20000728 (60)
US 2000-249602P 20001117 (60)
US 2001-290932P 20010515 (60)
DT Utility
FS APPLICATION
LN.CNT 2230
INCL INCLM: 424/094.630
INCLS: 514/060.000
NCL NCLM: 435/001.100
NCLS: 435/001.200; 435/001.300
IC [7]
ICM: A61K038-48
ICS: A61K031-718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 150 OF 365 USPATFULL on STN DUPLICATE 27
AN 2002:32511 USPATFULL
TI PREVENTIVE AND THERAPEUTIC COMPOSITIONS FOR DRUG INDUCED NEPHROPATHY AND

IN MURAMATSU, TAKASHI, AICHI, JAPAN
KADOMATSU, KENJI, AICHI, JAPAN
ODA, MUNEHIRO, KANAGAWA, JAPAN
IKEMATSU, SHINYA, KANAGAWA, JAPAN
SAKUMA, SADATOSHI, KANAGAWA, JAPAN
PI US 2002019333 A1 20020214
US 6572851 B2 20030603
AI US 1999-380882 A1 19991202 (9)
WO 1998-JP1050 19980312
PRAI JP 1997-74684 19970312
DT Utility
FS APPLICATION
LN.CNT 362
INCL INCLM: 514/002.000
INCLS: 514/012.000; 530/351.000
NCL NCLM: 424/085.100
NCLS: 424/198.100; 514/002.000; 514/012.000; 530/350.000; 530/399.000
IC [7]
ICM: A61K038-18
ICS: A61K038-17; A61K038-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 151 OF 365 USPATFULL on STN DUPLICATE 28
AN 2002:16917 USPATFULL
TI Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof
IN Wolf, David A., Houston, TX, UNITED STATES
Goodwin, Thomas J., Friendswood, TX, UNITED STATES
PA National Aeronautics & Space Administration (U.S. corporation)
PI US 2002009797 A1 20020124
US 6673597 B2 20040106
AI US 2001-798854 A1 20010228 (9)
RLI Division of Ser. No. US 2000-587028, filed on 2 Jun 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1200
INCL INCLM: 435/289.100
INCLS: 435/298.200; 435/173.800
NCL NCLM: 435/298.200
NCLS: 435/299.100
IC [7]
ICM: C12M003-00
ICS: C12N013-00

L4 ANSWER 152 OF 365 USPATFULL on STN DUPLICATE 29
AN 2002:12019 USPATFULL
TI DEFECTIVE ADENOVIRUSES INCLUDING A THERAPEUTIC GENE AND AN IMMUNOPROTECTIVE GENE
IN PERRICAUDET, MICHEL, ECROSNES, FRANCE
LEE, MARTIN, PARIS, FRANCE
PI US 2002006395 A1 20020117
US 6669942 B2 20031230
AI US 1997-817494 A1 19970415 (8)
WO 1995-FR1326 19951011
PRAI FR 1994-12346 19941017
DT Utility
FS APPLICATION
LN.CNT 1130
INCL INCLM: 424/093.210
INCLS: 435/235.100
NCL NCLM: 424/199.100
NCLS: 424/233.100; 435/069.100; 435/320.100; 536/023.720
IC [7]
ICM: A61K048-00
ICS: C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 153 OF 365 USPATFULL on STN DUPLICATE 30
AN 2002:246354 USPATFULL
TI Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
IN Mueller, Sabine, San Francisco, CA, United States
Melcher, Thorsten, San Francisco, CA, United States
Chin, Daniel J., Foster City, CA, United States
PA AGY Therapeutics, Inc., South San Francisco, CA, United States (U.S.

PI US 6455026 B1 20020924
US 2002146370 A1 20021010
AI US 2001-816703 20010323 (9)
DT Utility
FS GRANTED
LN.CNT 2286
INCL INCLM: 424/001.490
INCLS: 424/001.110; 424/001.650; 424/009.100; 435/021.000
NCL NCLM: 424/001.490
NCLS: 424/001.110; 424/001.650; 424/009.100; 435/021.000
IC [7]
ICM: A61K051-00
ICS: A61M036-14
EXF 424/1.11; 424/1.49; 424/1.65; 424/1.69; 424/9.1; 424/9.3; 424/9.4; 424/9.5; 424/9.6; 435/6; 435/2; 435/195; 435/69.1; 435/698; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 154 OF 365 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2002-14560 BIOTECHDS
TI Diagnosing or prognosing development of prostate cancer in a subject involves detecting abnormality in hormone refractory prostate cancer (HRPC)-related nucleic acid molecules, whose expression is altered in prostate cancer;
for use as DNA microarrays and in drug screening and prostate cancer prognosis, diagnosis and therapy
AU MOUSSES S; KALLIONIEMI O P; BUBENDORF L
PA US DEPT HEALTH and HUMAN SERVICES
PI WO 2002031209 18 Apr 2002
AI WO 2000-US31932 13 Oct 2000
PRAI US 2000-240585 13 Oct 2000
DT Patent
LA English
OS WPI: 2002-416869 [44]

L4 ANSWER 155 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:964539 CAPLUS
DN 138:34222
TI Differentially expressed ***human*** genes and their encoded proteins useful for identification, assessment, prevention, and therapy of cervical cancer
IN Schlegel, Robert; Chen, Yan; Zhao, Xumei; Monahan, John E.; Kamatkar, Shubhangi; Gannavarapu, Manjula; Glatt, Karen; Hoersch, Sebastian
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 386 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002101075	A2	20021219	WO 2002-US18638	20020612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003087270	A1	20030508	US 2002-171311	20020612
PRAI US 2001-298155P	P	20010613		
US 2001-298159P	P	20010613		
US 2001-335936P	P	20011114		

L4 ANSWER 156 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:832815 CAPLUS
DN 137:348175
TI Use of non-native tRNAs and amino acyl tRNA synthetases with relaxed substrate specificity in the in vivo incorporation of unnatural amino acids
IN Schultz, Peter; Wang, Lei; Anderson, John Christopher; Chin, Jason W. K.; Liu, David R.; Magliery, Thomas J.; Meggers, Eric L.; Mehl, Ryan Aaron; Pastrnak, Miro; Santoro, Steven William; Zhang, Zhiwen

SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085923	A2	20021031	WO 2002-US12465	20020419
	WO 2002085923	A3	20040527		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003082575	A1	20030501	US 2002-126927	20020419
	US 2003108885	A1	20030612	US 2002-126931	20020419
PRAI	US 2001-285030P	P	20010419		
	US 2002-355514P	P	20020206		

OS MARPAT 137:348175

L4 ANSWER 157 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:716017 CAPLUS
DN 137:237708
TI Stabilized therapeutic and imaging agents
IN Bednarski, Mark D.; Dechene, Neal Edward; Pease, John S.; Wartchow, Charles Aaron; Brunke, Karen J.
PA Targesome, Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072011	A2	20020919	WO 2002-US7037	20020308
	WO 2002072011	A3	20030213		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002197210	A1	20021226	US 2002-93845	20020308
	EP 1372739	A2	20040102	EP 2002-713800	20020308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004525916	T2	20040826	JP 2002-570971	20020308
PRAI	US 2001-274361P	P	20010308		
	WO 2002-US7037	W	20020308		

L4 ANSWER 158 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:107055 CAPLUS
DN 136:161392
TI Method of enhancing bone density or formation with nucleic acid encoding angiogenic protein
IN Crystal, Ronald G.; Hidaka, Chisa; Boachile-Adjei, Oheneba; Rawlins, Bernard A.; Kovesdi, Imre
PA Cornell Research Foundation, Inc., USA; Hospital for Special Surgery; Genvec, Inc.
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009644	A2	20020207	WO 2001-US23909	20010730
	WO 2002009644	A3	20030227		

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2001080898	A5	20020213	AU 2001-80898	20010730
EP	1307235	A2	20030507	EP 2001-959331	20010730

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI	US 2000-629074	A2	20000731		
	WO 2001-US23909	W	20010730		

L4 ANSWER 159 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:72748 CAPLUS
DN 136:146104
TI ***Human*** stress genes identified using DNA microarrays
IN Chenchik, Alex; Lukashev, Matvey E.
PA Clontech, USA
SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 441,920.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002009730	A1	20020124	US 2001-782909	20010213
PRAI US 1998-222256	B2	19981228		
US 1999-440305	B2	19991117		
US 1999-441920	A2	19991117		

L4 ANSWER 160 OF 365 USPATFULL on STN
AN 2002:336844 USPATFULL
TI Method for growing ***human*** organs and suborgans
IN Elia, James P., Scottsdale, AZ, UNITED STATES
PI US 2002192198 A1 20021219
AI US 2002-179589 A1 20020625 (10)
RLI Continuation-in-part of Ser. No. US 1998-64000, filed on 21 Apr 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 2436
INCL INCLM: 424/093.210
INCLS: 435/366.000; 514/044.000
NCL NCLM: 424/093.210
NCLS: 435/366.000; 514/044.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 161 OF 365 USPATFULL on STN
AN 2002:324393 USPATFULL
TI System and method for using neural nets for analyzing micro-arrays
IN O'Neill, Michael, Baltimore, MD, UNITED STATES
PI US 2002184569 A1 20021205
AI US 2002-127498 A1 20020423 (10)
PRAI US 2001-286067P 20010425 (60)
DT Utility
FS APPLICATION
LN.CNT 870
INCL INCLM: 714/039.000
NCL NCLM: 714/039.000
IC [7]
ICM: H04L001-22

L4 ANSWER 162 OF 365 USPATFULL on STN
AN 2002:322455 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
IN Lillie, James, Natick, MA, UNITED STATES
Mills, Gordon, Houston, TX, UNITED STATES
Lee, John, Somerville, MA, UNITED STATES

PI US 2002182619 A1 20021205
AI US 2001-35415 A1 20011108 (10)
PRAI US 2000-246839P 20001108 (60)
DT Utility
FS APPLICATION
LN.CNT 6649
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 163 OF 365 USPATFULL on STN
AN 2002:307859 USPATFULL
TI Diagnosis of pathologies of mononucleated blood cells
IN Barritault, Denis, Paris, FRANCE
Achour, Ammar, Creteil, FRANCE
Courty, Jose, Villecresnes, FRANCE
Baudoin, Francoise, Boulogne-Billancourt, FRANCE
PI US 2002172983 A1 20021121
AI US 2002-116076 A1 20020404 (10)
RLI Continuation of Ser. No. WO 2000-FR2788, filed on 6 Oct 2000, UNKNOWN
PRAI FR 1999-12715 19991012
DT Utility
FS APPLICATION
LN.CNT 471
INCL INCLM: 435/007.210
NCL NCLM: 435/007.210
IC [7]
ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 164 OF 365 USPATFULL on STN
AN 2002:301580 USPATFULL
TI Recombinant production of polyanionic polymers and uses thereof
IN Leung, David W., Mercer Island, WA, UNITED STATES
Bergman, Philip A., Mountlake Terrace, WA, UNITED STATES
Lofquist, Alan, Kirkland, WA, UNITED STATES
Pietz, Gregory E., Seattle, WA, UNITED STATES
Tompkins, Christopher K., Bothell, WA, UNITED STATES
Waggoner, David W., JR., Seattle, WA, UNITED STATES
PA CELL THERAPEUTICS, INC. (U.S. corporation)
PI US 2002169125 A1 20021114
AI US 2002-101487 A1 20020320 (10)
PRAI US 2001-277705P 20010321 (60)
DT Utility
FS APPLICATION
LN.CNT 1942
INCL INCLM: 514/012.000
INCLS: 424/085.100; 424/085.400; 424/085.200; 530/350.000; 530/351.000; 530/399.000; 435/069.500; 435/069.700
NCL NCLM: 514/012.000
NCLS: 424/085.100; 424/085.400; 424/085.200; 530/350.000; 530/351.000; 530/399.000; 435/069.500; 435/069.700
IC [7]
ICM: A61K038-17
ICS: A61K038-18; A61K038-19; A61K038-20; A61K038-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 165 OF 365 USPATFULL on STN
AN 2002:301095 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ***human*** prostate cancer
IN Schlegel, Robert, Auburndale, MA, UNITED STATES
Endege, Wilson, Norwood, MA, UNITED STATES
Monahan, John, Walpole, MA, UNITED STATES
PI US 2002168638 A1 20021114
AI US 2001-768827 A1 20010124 (9)
PRAI US 2000-178525P 20000124 (60)
US 2000-183245P 20000217 (60)
US 2000-190139P 20000316 (60)
US 2000-208126P 20000531 (60)

US 2000-255160P 20001213 (60)
DT Utility
FS APPLICATION
LN.CNT 57808
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 365 USPATFULL on STN
AN 2002:295195 USPATFULL
TI Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
IN Glasky, Alvin J., Tustin, CA, UNITED STATES
Rathbone, Michel P., Hamilton, CANADA
PI US 2002165242 A1 20021107
AI US 2002-67662 A1 20020204 (10)
RLI Continuation of Ser. No. US 1997-878656, filed on 19 Jun 1997, GRANTED, Pat. No. US 6350752 Continuation of Ser. No. US 1995-492929, filed on 20 Jul 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-488976, filed on 8 Jun 1995, GRANTED, Pat. No. US 5801184 Continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jul 1994, GRANTED, Pat. No. US 5447939
DT Utility
FS APPLICATION
LN.CNT 2138
INCL INCLM: 514/263.350
NCL NCLM: 514/263.350
IC [7]
ICM: A61K031-522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 365 USPATFULL on STN
AN 2002:294612 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002164655 A1 20021107
AI US 2001-973941 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3277
INCL INCLM: 435/007.200
INCLS: 435/183.000; 530/388.260
NCL NCLM: 435/007.200
NCLS: 435/183.000; 530/388.260
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12N009-00; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 365 USPATFULL on STN
AN 2002:288109 USPATFULL
TI Methods for inhibiting angiogenesis
IN Banerjee, Dipak K., Guaynabo, PR, UNITED STATES
Martinez, Juan A., Rio Piedras, PR, UNITED STATES
PI US 2002160979 A1 20021031
AI US 2001-779447 A1 20010209 (9)
PRAI US 2000-181312P 20000209 (60)
DT Utility
FS APPLICATION
LN.CNT 3016
INCL INCLM: 514/050.000
NCL NCLM: 514/050.000
IC [7]
ICM: A61K031-7068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:280006 USPATFULL
TI Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
IN Ljubimova, Julia Y., Studio City, CA, UNITED STATES
Ljubimov, Alexander V., Studio City, CA, UNITED STATES
Black, Keith L., Los Angeles, CA, UNITED STATES
PI US 2002155440 A1 20021024
AI US 2000-741550 A1 20001219 (9)
DT Utility
FS APPLICATION
LN.CNT 2437
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 365 USPATFULL on STN
AN 2002:273550 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002151681 A1 20021017
AI US 2001-925300 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5988, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LN.CNT 29771
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/325.000; 435/320.100; 435/069.300
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/325.000; 435/320.100; 435/069.300
IC [7]
ICM: C07K014-435
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 171 OF 365 USPATFULL on STN
AN 2002:266283 USPATFULL
TI Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (PTTG)
IN Heaney, Anthony P., Los Angeles, CA, UNITED STATES
Ishikawa, Hiroki, Nagasaki, JAPAN
Yu, Run, Los Angeles, CA, UNITED STATES
Horwitz, Gregory A., Los Angeles, CA, UNITED STATES
Zhang, Xun, Malden, MA, UNITED STATES
Melmed, Shlomo, Los Angeles, CA, UNITED STATES
PI US 2002147162 A1 20021010
AI US 2001-777422 A1 20010205 (9)
RLI Continuation-in-part of Ser. No. US 2000-730469, filed on 4 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-687911, filed on 13 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-569956, filed on 12 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-894251, filed on 23 Jul 1999, PENDING A 371 of International Ser. No. WO 1997-US21463, filed on 21 Nov 1997, UNKNOWN
PRAI US 1996-31338P 19961121 (60)
DT Utility
FS APPLICATION
LN.CNT 4221
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K031-70
ICS: A01N043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 172 OF 365 USPATFULL on STN
AN 2002:243796 USPATFULL
TI Bioengineered vehicles for targeted nucleic acid delivery
IN Huston, James S., Chestnut Hill, MA, UNITED STATES

Zhu, Quan, Needham, MA, UNITED STATES
Laurent, Oliver, Berkley, CA, UNITED STATES
Marasco, Wayne A., Oakland, CA, UNITED STATES
Scherman, Daniel, Paris, FRANCE
PI US 2002132990 A1 20020919
AI US 2001-888721 A1 20010625 (9)
PRAI US 2000-213653P 20000623 (60)
DT Utility
FS APPLICATION
LN.CNT 2019
INCL INCLM: 530/391.100
INCLS: 514/008.000
NCL NCLM: 530/391.100
NCLS: 514/008.000
IC [7]
ICM: A61K048-00
ICS: C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 173 OF 365 USPATFULL on STN
AN 2002:229107 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PI US 2002124273 A1 20020905
AI US 2001-973965 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3256
INCL INCLM: 800/003.000
INCLS: 435/007.930
NCL NCLM: 800/003.000
NCLS: 435/007.930
IC [7]
ICM: G01N033-00
ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 365 USPATFULL on STN
AN 2002:221785 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002119927 A1 20020829
AI US 2001-972757 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3204
INCL INCLM: 514/012.000
INCLS: 424/146.100
NCL NCLM: 514/012.000
NCLS: 424/146.100
IC [7]
ICM: A61K039-395
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 365 USPATFULL on STN
AN 2002:221020 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002119155 A1 20020829
AI US 2001-972038 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility

LN.CNT 3081
INCL INCLM: 424/146.100
INCLS: 530/388.260; 435/226.000; 435/007.200; 435/006.000
NCL NCLM: 424/146.100
NCLS: 530/388.260; 435/226.000; 435/007.200; 435/006.000
IC [7]
ICM: A61K039-395
ICS: C12Q001-68; G01N033-53; C12N009-64; G01N033-567; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 365 USPATFULL on STN
AN 2002:214220 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002115607 A1 20020822
AI US 2001-975072 A1 20011012 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3574
INCL INCLM: 514/012.000
INCLS: 424/146.100; 435/226.000; 530/350.000; 435/194.000
NCL NCLM: 514/012.000
NCLS: 424/146.100; 435/226.000; 530/350.000; 435/194.000
IC [7]
ICM: A61K038-17
ICS: A61K039-395; C12N009-64; C07K014-435; C12N009-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 365 USPATFULL on STN
AN 2002:214219 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002115606 A1 20020822
AI US 2001-973964 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3354
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 365 USPATFULL on STN
AN 2002:213743 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Mark, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc. (U.S. corporation)
PI US 2002115119 A1 20020822
AI US 2001-973063 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3133
INCL INCLM: 435/007.210
NCL NCLM: 435/007.210
IC [7]
ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 365 USPATFULL on STN
AN 2002:213426 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases

Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002114799 A1 20020822
AI US 2001-973077 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3207
INCL INCLM: 424/130.100
NCL NCLM: 424/130.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 365 USPATFULL on STN
AN 2002:213408 USPATFULL
TI Methods of increasing distribution of therapeutic agents
IN Bankiewicz, Krys, Piedmont, CA, UNITED STATES
Hamilton, John, Washington, DC, UNITED STATES
Oldfield, Edward, Philomont, VA, UNITED STATES
Phillips, Heidi, Palo Alto, CA, UNITED STATES
PI US 2002114780 A1 20020822
AI US 2001-999203 A1 20011130 (9)
PRAI US 2000-250286P 20001130 (60)
DT Utility
FS APPLICATION
LN.CNT 942
INCL INCLM: 424/085.100
INCLS: 514/056.000
NCL NCLM: 424/085.100
NCLS: 514/056.000
IC [7]
ICM: A61K038-19
ICS: A61K031-727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 365 USPATFULL on STN
AN 2002:206990 USPATFULL
TI Medical prosthetic devices and implants having improved biocompatibility
IN Ellingsen, Jan Eirik, Bekkestua, NORWAY
Lyngstadaas, Staale Petter, Nesoddtangen, NORWAY
PA BIOTI AS, Nesoddtangen, NORWAY, N-1450 (non-U.S. corporation)
PI US 2002111694 A1 20020815
AI US 2001-10140 A1 20011206 (10)
PRAI DK 2000-1829 20001206
US 2000-254987P 20001212 (60)
DT Utility
FS APPLICATION
LN.CNT 1134
INCL INCLM: 623/023.570
INCLS: 623/023.530
NCL NCLM: 623/023.570
NCLS: 623/023.530
IC [7]
ICM: A61F002-28

L4 ANSWER 182 OF 365 USPATFULL on STN
AN 2002:206770 USPATFULL
TI Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
IN Lo, Donald C., Chapel Hill, NC, UNITED STATES
Barney, Shawn, Apex, NC, UNITED STATES
Thomas, Mary Beth, Chapel Hill, NC, UNITED STATES
Portbury, Stuart D., Durham, NC, UNITED STATES
Puranam, Kasturi, Durham, NC, UNITED STATES
Katz, Lawrence C., Durham, NC, UNITED STATES
PA COGENT NEUROSCIENCE, INC., DURHAM, NC, UNITED STATES, 27704 (U.S. corporation)
PI US 2002111471 A1 20020815
AI US 2001-922261 A1 20010803 (9)
RLI Division of Ser. No. US 1999-461697, filed on 14 Dec 1999, PATENTED
DT Utility
FS APPLICATION

INCL INCLM: 536/023.200
INCLS: 514/044.000
NCL NCLM: 536/023.200
NCLS: 514/044.000
IC [7]
ICM: A61K048-00
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 183 OF 365 USPATFULL on STN
AN 2002:198673 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002106773 A1 20020808
AI US 2001-973064 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3066
INCL INCLM: 435/196.000
INCLS: 435/007.100; 435/006.000; 530/388.260
NCL NCLM: 435/196.000
NCLS: 435/007.100; 435/006.000; 530/388.260
IC [7]
ICM: C12N009-16
ICS: C12Q001-68; G01N033-53; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 365 USPATFULL on STN
AN 2002:198547 USPATFULL
TI Nucleic acid compositions and methods of introducing nucleic acids into cells
IN Segal, Andrew H., Cambridge, MA, UNITED STATES
Wilson, Jeffrey, Brighton, MA, UNITED STATES
PI US 2002106647 A1 20020808
AI US 2001-834109 A1 20010412 (9)
RLI Continuation-in-part of Ser. No. US 1998-120533, filed on 22 Jul 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-898094, filed on 22 Jul 1997, ABANDONED
PRAI WO 1998-US15130 19980722
US 1996-22324P 19960724 (60)
DT Utility
FS APPLICATION
LN.CNT 1429
INCL INCLM: 435/006.000
INCLS: 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 185 OF 365 USPATFULL on STN
AN 2002:191666 USPATFULL
TI Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
IN Hearing, Patrick, St. James, NY, UNITED STATES
Bahou, Wadie F., Setauket, NY, UNITED STATES
Sandalon, Ziv, Port Jefferson Station, NY, UNITED STATES
Gnatenko, Dmitri V., Port Jefferson, NY, UNITED STATES
PA The Research Foundation of State University of New York (U.S. corporation)
PI US 2002102731 A1 20020801
AI US 2001-782378 A1 20010212 (9)
PRAI US 2000-237747P 20001002 (60)
DT Utility
FS APPLICATION
LN.CNT 9338
INCL INCLM: 435/456.000
INCLS: 435/320.100

NCLS: 435/320.100
IC [7]
ICM: C12N015-861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 186 OF 365 USPATFULL on STN
AN 2002:185258 USPATFULL
TI GENETICALLY MODIFIED CELLS AND THEIR USE IN THE PROPHYLAXIS OR THERAPY OF DISORDERS
IN HAVEMANN, KLAUS, MARBURG, GERMANY, FEDERAL REPUBLIC OF
MUELLER, DR.ROLF, MARBURG, GERMANY, FEDERAL REPUBLIC OF
SEDLACEK, DR.HANS-HARALD, MARBURG, GERMANY, FEDERAL REPUBLIC OF
PI US 2002098166 A1 20020725
AI US 1998-119659 A1 19980721 (9)
PRAI DE 1997-19731154 19970721
DE 1997-19752299 19971126
DT Utility
FS APPLICATION
LN.CNT 1960
INCL INCLM: 424/093.100
INCLS: 435/325.000
NCL NCLM: 424/093.100
NCLS: 435/325.000
IC [7]
ICM: A61K048-00
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 187 OF 365 USPATFULL on STN
AN 2002:172482 USPATFULL
TI Acid-sensitive compounds, their preparation and uses
IN Bessodes, Michel, Villejuif, FRANCE
Masson, Christophe, Montgeron, FRANCE
Scherman, Daniel, Paris, FRANCE
Wetzer, Barbara, Paris, FRANCE
PI US 2002091242 A1 20020711
AI US 2001-972854 A1 20011010 (9)
PRAI US 2000-239116P 20001011 (60)
DT Utility
FS APPLICATION
LN.CNT 2467
INCL INCLM: 536/018.700
INCLS: 549/371.000
NCL NCLM: 536/018.700
NCLS: 549/371.000
IC [7]
ICM: C08B037-00
ICS: C07D319-06; C07H005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 365 USPATFULL on STN
AN 2002:164723 USPATFULL
TI Method of diagnosing breast cancer using nipple fluid
IN Nguyen, Mai H., Thousand Oaks, CA, UNITED STATES
PI US 2002086341 A1 20020704
AI US 2001-901339 A1 20010709 (9)
PRAI US 2000-217372P 20000711 (60)
DT Utility
FS APPLICATION
LN.CNT 408
INCL INCLM: 435/007.230
INCLS: 514/009.000
NCL NCLM: 435/007.230
NCLS: 514/009.000
IC [7]
ICM: G01N033-574
ICS: A61K038-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 365 USPATFULL on STN
AN 2002:105912 USPATFULL
TI Methods for detecting prostate cancer
IN Fett, James, Waltham, MA, UNITED STATES
Olson, Karen A., Brookline, MA, UNITED STATES
PI US 2002055117 A1 20020509

PRAI US 2000-234386P 20000920 (60)
DT Utility
FS APPLICATION
LN.CNT 822
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 365 USPATFULL on STN
AN 2002:48319 USPATFULL
TI ***Human*** cord blood as a source of neural tissue for repair of the brain and spinal cord
IN Sanberg, Paul, Spring Hill, FL, UNITED STATES
Sanchez-Remos, Juan, Tampa, FL, UNITED STATES
Willing, Alison, Tampa, FL, UNITED STATES
Richard, Daniel D., Sedona, AZ, UNITED STATES
PI US 2002028510 A1 20020307
AI US 2001-801221 A1 20010307 (9)
PRAI US 2000-188069P 20000309 (60)
US 2001-269238P 20010216 (60)
DT Utility
FS APPLICATION
LN.CNT 3155
INCL INCLM: 435/368.000
NCL NCLM: 435/368.000
IC [7]
ICM: C12N005-08

L4 ANSWER 191 OF 365 USPATFULL on STN
AN 2002:37339 USPATFULL
TI Composition and methods for immproving integrity of compromised body passageways and cavities
IN Signore, Pierre E, Vancouver British Columbia, CANADA
PI US 2002022055 A1 20020221
AI US 2000-511570 A1 20000223 (9)
PRAI US 1999-121424P 19990223 (60)
DT Utility
FS APPLICATION
LN.CNT 1938
INCL INCLM: 424/486.000
NCL NCLM: 424/486.000
IC [7]
ICM: A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 365 USPATFULL on STN
AN 2002:16844 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
IN Schlegel, Robert, Auburndale, MA, UNITED STATES
Deeds, James D., Somerville, MA, UNITED STATES
Berger, Allison, Cambridge, MA, UNITED STATES
Zhao, Xumei, Burlington, MA, UNITED STATES
PI US 2002009724 A1 20020124
AI US 2000-732560 A1 20001208 (9)
PRAI US 1999-169811P 19991208 (60)
US 1999-171330P 19991221 (60)
US 2000-189113P 20000314 (60)
US 2000-193943P 20000331 (60)
US 2000-203772P 20000512 (60)
US 2000-210820P 20000609 (60)
US 2000-220113P 20000721 (60)
DT Utility
FS APPLICATION
LN.CNT 4368
INCL INCLM: 435/006.000
INCLS: 435/007.230; 530/388.800; 435/070.210; 435/344.000
NCL NCLM: 435/006.000
NCLS: 435/007.230; 530/388.800; 435/070.210; 435/344.000
IC [7]

ICS: G01N033-574; C12P021-04; C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 365 USPATFULL on STN
AN 2002:340150 USPATFULL
TI Recombinant swinepox virus
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6497882 B1 20021224
AI US 1995-472679 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-375992, filed on 19 Jan 1995, now patented, Pat. No. US 6328975 Continuation-in-part of Ser. No. WO 1994-US8277, filed on 22 Jul 1994 Continuation-in-part of Ser. No. US 1993-97554, filed on 22 Jul 1993, now patented, Pat. No. US 5869312 Continuation-in-part of Ser. No. US 1992-820154, filed on 13 Jan 1992, now patented, Pat. No. US 5382425
DT Utility
FS GRANTED
LN.CNT 9669
INCL INCLM: 424/199.100
INCLS: 424/093.200; 435/235.100; 435/320.100
NCL NCLM: 424/199.100
NCLS: 424/093.200; 435/235.100; 435/320.100
IC [7]
ICM: A61K039-12
ICS: A61K039-275; C12N007-01; C12N015-863
EXF 435/235.1; 435/320.2; 435/172.3; 424/199.1; 424/232.1; 424/43.2; 935/65; 935/22; 935/32
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 365 USPATFULL on STN
AN 2002:317300 USPATFULL
TI Methods and compositions for producing viral particles
IN Torrent, Christophe, Paris, FRANCE
Yeh, Patrice, Gif sur Yvette, FRANCE
Perricaudet, Michel, Ecrosnes, FRANCE
Klatzmann, David, Paris, FRANCE
Salzmann, Jean-Loup, Paris, FRANCE
PA Aventis Pharma S.A., Antony, FRANCE (non-U.S. corporation)
Genopoietic, Paris, FRANCE (non-U.S. corporation)
PI US 6489142 B1 20021203
WO 9960144 19991125
AI US 2001-700422 20010125 (9)
WO 1999-FR1184 19990518
PRAI FR 1998-6258 19980518
DT Utility
FS GRANTED
LN.CNT 1361
INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/069.700; 530/387.300; 536/023.400; 536/023.720
NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/069.700; 530/387.300; 536/023.400; 536/023.720
IC [7]
ICM: C12P021-06
ICS: C12P021-04; C12P021-08; C12Q001-68; C07H021-04
EXF 435/6; 435/69.1; 435/69.7; 530/387.3; 536/23.4; 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 365 USPATFULL on STN
AN 2002:310806 USPATFULL
TI Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof
IN Wolf, David A., Houston, TX, United States
Goodwin, Thomas J., Friendswood, TX, United States
PA The United States of America as represented by the Administrator of the National Aeronautics and Space Administration, Washington, DC, United States (U.S. government)
PI US 6485963 B1 20021126
AI US 2000-587028 20000602 (9)
DT Utility
FS GRANTED
LN.CNT 1224
INCL INCLM: 435/298.200
INCLS: 435/299.100

NCLS: 435/299.100
IC [7]
ICM: C12M001-10
EXF 435/173.1; 435/173.8; 435/298.2; 435/299.1

L4 ANSWER 196 OF 365 USPATFULL on STN
AN 2002:297084 USPATFULL
TI Implant delivery catheter system and methods for its use
IN Rosenman, Daniel C., South San Francisco, CA, United States
Altman, Peter A., South San Francisco, CA, United States
Lovich, Mark A., South San Francisco, CA, United States
Schwartz, Micheal A., South San Francisco, CA, United States
Miller, Aaron J., South San Francisco, CA, United States
PA BioCardia, Inc., So. San Francisco, CA, United States (U.S. corporation)
PI US 6478776 B1 20021112
AI US 2000-543127 20000405 (9)
DT Utility
FS GRANTED
LN.CNT 1073
INCL INCLM: 604/164.010
INCLS: 607/127.000; 607/120.000
NCL NCLM: 604/164.010
NCLS: 607/120.000; 607/127.000
IC [7]
ICM: A61M005-178
EXF 604/523; 604/508; 604/507; 604/164.01; 604/502; 607/119-120; 607/122; 607/126; 607/127; 607/128

L4 ANSWER 197 OF 365 USPATFULL on STN
AN 2002:276070 USPATFULL
TI DNA vaccine for protecting an avian against infectious bursal disease virus
IN Aboud-Pirak, Esther, Kyriat Tiveon, ISRAEL
Pirak, Michael E., Kyriat Tiveon, ISRAEL
Shaoul, Esther, Nesher, ISRAEL
Monadeev, Limor, Givat-Ella, ISRAEL
PA Innovo Biotechnologies Ltd., Nararetth, ISRAEL (non-U.S. corporation)
PI US 6468984 B1 20021022
AI US 1999-450433 19991130 (9)
PRAI US 1999-138093P 19990608 (60)
DT Utility
FS GRANTED
LN.CNT 1012
INCL INCLM: 514/044.000
INCLS: 435/320.100; 424/093.200
NCL NCLM: 514/044.000
NCLS: 424/093.200; 435/320.100
IC [7]
ICM: C12N015-00
ICS: A61K031-70; A01N063-00
EXF 514/44; 435/320.1; 424/278.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 198 OF 365 USPATFULL on STN
AN 2002:129313 USPATFULL
TI Method and construct for producing graft tissue from an extracellular matrix
IN Bell, Eugene, Boston, MA, United States
PA TEI Biosciences, Inc., Boston, MA, United States (U.S. corporation)
PI US 6398819 B1 20020604
AI US 2000-511433 20000223 (9)
RLI Continuation of Ser. No. US 1998-143986, filed on 31 Aug 1998, now patented, Pat. No. US 6051750 Division of Ser. No. US 1995-471535, filed on 6 Jun 1995, now patented, Pat. No. US 5800537 Continuation-in-part of Ser. No. US 1994-302087, filed on 6 Sep 1994, now patented, Pat. No. US 5893888 Continuation of Ser. No. US 1992-926885, filed on 7 Aug 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 743
INCL INCLM: 623/066.000
INCLS: 623/901.000; 424/422.000
NCL NCLM: 435/001.300
NCLS: 424/422.000; 600/036.000; 623/901.000; 623/915.000
IC [7]

ICS: A61K009-14
EXF 623/11.11; 623/66; 424/422; 424/424; 424/425; 424/426; 424/484; 428/305.5; 428/323; 435/1.3; 435/401; 435/402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 199 OF 365 USPATFULL on STN
AN 2002:122491 USPATFULL
TI Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
IN Tuan, Dorothy, Martinez, GA, United States
Long, Qiaoming, Ottawa, CANADA
Bengra, Chikh, Charlottesville, VA, United States
PA Medical College of Georgia Research Institute, Inc., Augusta, GA, United States (U.S. corporation)
PI US 6395549 B1 20020528
AI US 1999-422576 19991021 (9)
PRAI US 1998-105256P 19981022 (60)
DT Utility
FS GRANTED
LN.CNT 1982
INCL INCLM: 435/455.000
INCLS: 435/320.100; 435/069.100; 435/325.000; 536/024.100
NCL NCLM: 435/455.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/024.100
IC [7]
ICM: C12N015-63
ICS: C12N015-09; C07H021-04; C12P021-06
EXF 424/93.21; 514/44; 435/320.1; 435/69.1; 435/455; 435/325; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 200 OF 365 USPATFULL on STN
AN 2002:39928 USPATFULL
TI Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
IN Glasky, Alvin J., 12231 Pevero, Tustin, CA, United States 92680
Rathbone, Michel P., 40 Spadina Avenue, Hamilton,Ontario, CANADA L8M 2X1
PI US 6350752 B1 20020226
AI US 1997-878656 19970619 (8)
RLI Continuation of Ser. No. US 1995-492929, filed on 20 Jul 1995, now abandoned Continuation-in-part of Ser. No. US 1995-488976, filed on 8 Jun 1995, now patented, Pat. No. US 5801184 Continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jul 1994, now patented, Pat. No. US 5447939
DT Utility
FS GRANTED
LN.CNT 2004
INCL INCLM: 514/262.000
INCLS: 514/310.000
NCL NCLM: 514/263.350
NCLS: 514/310.000
IC [7]
ICM: A61K031-52
ICS: A61K031-47
EXF 514/262; 514/310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 201 OF 365 USPATFULL on STN
AN 2002:9755 USPATFULL
TI Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
IN Glasky, Alvin J., Tustin, CA, United States
Rathbone, Michael P., Hamilton, CANADA
PA NeoTherapeutics, Inc., Irvine, CA, United States (U.S. corporation)
PI US 6338963 B1 20020115
AI US 1999-420543 19991019 (9)
RLI Continuation-in-part of Ser. No. US 1998-86878, filed on 29 May 1998, now patented, Pat. No. US 6027936 Division of Ser. No. US 1995-488976, filed on 8 Jun 1995, now patented, Pat. No. US 5801184 Continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jun 1994, now patented, Pat. No. US 5447936
DT Utility
FS GRANTED
LN.CNT 3564
INCL INCLM: 435/325.000

544/276.000
NCL NCLM: 435/325.000
NCLS: 435/007.210; 514/045.000; 514/263.300; 514/263.380; 514/310.000; 544/265.000; 544/276.000
IC [7]
ICM: C12N005-00
ICS: G01N033-567; A61K031-70; A01N043-42; C07D473-00
EXF 435/7.21; 435/325; 514/45; 514/310; 514/262; 544/265; 544/276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 202 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 31
AN 2002:862682 CAPLUS
DN 138:163972
TI Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues
AU Deepa, Sarama Sathyaseelan; Umehara, Yuko; Higashiyama, Shigeki; Itoh, Nobuyuki; Sugahara, Kazuyuki
CS Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe, 658-8558, Japan
SO Journal of Biological Chemistry (2002), 277(46), 43707-43716
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 203 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2002:35148519 BIOTECHNO
TI Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex
AU Willis D.M.; Loewy A.P.; Charlton-Kachigian N.; Shao J.-S.; Ornitz D.M.; Towler D.A.
CS D.A. Towler, Washington University Medical Center, Division of Mineral Diseases, Barnes-Jewish Hospital, 216 South Kingshighway Blvd., St. Louis, MO 63110, United States.
E-mail: dtowler@im.wustl.edu
SO Journal of Biological Chemistry, (04 OCT 2002), 277/40 (37280-37291), 82 reference(s)
CODEN: JBCHA3 ISSN: 0021-9258
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 204 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 33
AN 2002:571641 BIOSIS
DN PREV200200571641
TI Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
AU Stoica, Gerald E.; Kuo, Angera; Powers, Ciaran; Bowden, Emma T.; Sale, Elaine Buchert; Riegel, Anna T.; Wellstein, Anton [Reprint author]
CS Lombardi Cancer Center, Georgetown University, 3970 Reservoir Rd., N. W., Washington, DC, 20007, USA
wellstea@georgetown.edu
SO Journal of Biological Chemistry, (September 27, 2002) Vol. 277, No. 39, pp. 35990-35998. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 7 Nov 2002
Last Updated on STN: 7 Nov 2002

L4 ANSWER 205 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 34
AN 2002:571627 BIOSIS
DN PREV200200571627
TI Anti-apoptotic signaling of ***pleiotrophin*** through its ***receptor*** , anaplastic lymphoma kinase.
AU Bowden, Emma T.; Stoica, Gerald E.; Wellstein, Anton [Reprint author]
CS Dept. of Oncology, Lombardi Cancer Center, Medical School, Georgetown University, 3970 Reservoir Rd., NW, Research Bldg. E311, Washington, DC,

wellstea@georgetown.edu
SO Journal of Biological Chemistry, (September 27, 2002) Vol. 277, No. 39, pp. 35862-35868. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 7 Nov 2002
Last Updated on STN: 7 Nov 2002

L4 ANSWER 206 OF 365 CANCERLIT on STN DUPLICATE 35
AN 2002192907 CANCERLIT
DN 22191306 PubMed ID: 12070152
TI Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.
AU Bernard-Pierrot Isabelle; Delbe Jean; Rouet Vincent; Vigny Marc; Kerros Marie-Emmanuelle; Caruelle Daniele; Raulais Daniel; Barritault Denis; Courty Jose; Milhiet Pierre Emmanuel
CS Laboratoire de recherche sur la Croissance Cellulaire, la Reparation et la Regeneration Tissulaires (CRRET), CNRS UPRES-A 7053, Universite Paris XII, Avenue du General de Gaulle, 94010 Creteil Cedex, France.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 Aug 30) 277 (35) 32071-7.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2002452367
EM 200210
ED Entered STN: 20021115
Last Updated on STN: 20021115

L4 ANSWER 207 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 36
AN 2002:420194 BIOSIS
DN PREV200200420194
TI ***Pleiotrophin*** signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
AU Powers, Ciaran; Aigner, Achim; Stoica, Gerald E.; McDonnell, Kevin; Wellstein, Anton [Reprint author]
CS Dept. of Oncology, Georgetown University, 3970 Reservoir Rd., Washington, DC, 20007, USA
wellstea@georgetown.edu
SO Journal of Biological Chemistry, (April 19, 2002) Vol. 277, No. 16, pp. 14153-14158. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 7 Aug 2002
Last Updated on STN: 7 Aug 2002

L4 ANSWER 208 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:486273 SCISEARCH
GA The Genuine Article (R) Number: 559ZQ
TI ***Pleiotrophin*** /heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver
AU Asahina K; Sato H; Yamasaki C; Kataoka M; Shiokawa M; Katayama S; Tateno C; Yoshizato K (Reprint)
CS Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Dev Biol Lab, 1-3-1 Kagamiyama, Hiroshima 7398526, Japan (Reprint); Hiroshima Prefectural Inst Ind Sci & Technol, Japan Sci & Technol Corp, Hiroshima Prefecture Collaborat Reg Ent Advanceme, Hiroshima Tissue Regenerat Project, Hiroshima, Japan; Japan Med Supply Co Ltd, Hiroshima, Japan; Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Dev Biol Lab, Hiroshima, Japan; Hiroshima Univ, Sch Med, Dept Surg 2, Hiroshima, Japan
CYA Japan
SO AMERICAN JOURNAL OF PATHOLOGY, (JUN 2002) Vol. 160, No. 6, pp. 2191-2205.
Publisher: AMER SOC INVESTIGATIVE PATHOLOGY, INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA.
ISSN: 0002-9440.
DT Article; Journal
LA English
REC Reference Count: 53
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 209 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 37
AN 2003:408361 BIOSIS
DN PREV200300408361
TI ***Pleiotrophin*** /osteoblast-stimulating factor 1: Dissecting its diverse functions in bone formation.
AU Tare, Rahul S.; Oreffo, Richard O. C.; Clarke, Nicholas M. P.; Roach, Helmtrud I. [Reprint Author]
CS University Orthopaedics, Southampton General Hospital, CF86, MP 817, Southampton, SO16 6YD, UK
SO Journal of Bone and Mineral Research, (November 2002) Vol. 17, No. 11, pp. 2009-2020. print.
ISSN: 0884-0431 (ISSN print).
DT Article
LA English
ED Entered STN: 3 Sep 2003
Last Updated on STN: 3 Sep 2003

L4 ANSWER 210 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:532147 SCISEARCH
GA The Genuine Article (R) Number: 563XE
TI ***Pleiotrophin*** regulates bone morphogenetic protein (BMP)-induced ectopic osteogenesis
AU Sato Y; Takita H; Ohata N; Tamura M; Kuboki Y (Reprint)
CS Hokkaido Univ, Grad Sch Dent Med, Dept Oral Hlth Sci, Kita Ku, North 13, West 7, Sapporo, Hokkaido 0608586, Japan (Reprint); Hokkaido Univ, Grad Sch Dent Med, Dept Oral Hlth Sci, Kita Ku, Sapporo, Hokkaido 0608586, Japan; Hokkaido Univ, Grad Sch Dent Med, Dept Oral Funct Sci, Kita Ku, Sapporo, Hokkaido 0608586, Japan
CYA Japan
SO JOURNAL OF BIOCHEMISTRY, (JUN 2002) Vol. 131, No. 6, pp. 877-886.
Publisher: JAPANESE BIOCHEMICAL SOC, ISHIKAWA BLDG-3F, 25-16 HONGO-5-CHOME, BUNKYO-KU, TOKYO, 113, JAPAN.
ISSN: 0021-924X.
DT Article; Journal
LA English
REC Reference Count: 40
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 211 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:465423 CAPLUS
DN 137:228256
TI ***Human*** secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression
AU Barash, Steve; Wang, Wei; Shi, Yanggu
CS Department of Information Technology, Human Genome Sciences, Inc., Rockville, MD, 20850, USA
SO Biochemical and Biophysical Research Communications (2002), 294(4), 835-842
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier Science
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 212 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:930994 SCISEARCH
GA The Genuine Article (R) Number: 611YR
TI ***Pleiotrophin*** , an angiogenic and mitogenic growth factor, is expressed in ***human*** gliomas
AU Mentlein R (Reprint); Held-Feindt J
CS Univ Kiel, Inst Anat, Dept Anat, Olshausenstr 40, D-24098 Kiel, Germany (Reprint); Univ Kiel, Inst Anat, Dept Anat, D-24098 Kiel, Germany
CYA Germany
SO JOURNAL OF NEUROCHEMISTRY, (NOV 2002) Vol. 83, No. 4, pp. 747-753.
Publisher: BLACKWELL PUBLISHING LTD, P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND.
ISSN: 0022-3042.
DT Article; Journal
LA English
REC Reference Count: 36

L4 ANSWER 213 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:396011 BIOSIS
DN PREV200200396011
TI Abrogation of IL-3 dependence requires co-expression of the anaplastic lymphoma kinase ***receptor*** and its major substrate, IRS-1, in 32D cells.
AU Kuo, Angera H. [Reprint author]; Stoica, Gerald E. [Reprint author]; Riegel, Anna T. [Reprint author]; Wellstein, Anton [Reprint author]
CS Lombardi Cancer Center, Georgetown University, Washington, DC, USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2002) Vol. 43, pp. 725. print.
Meeting Info.: 93rd Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA. April 06-10, 2002.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 Jul 2002
Last Updated on STN: 24 Jul 2002

L4 ANSWER 214 OF 365 LIFESCI COPYRIGHT 2004 CSA on STN
AN 2002:80142 LIFESCI
TI Coordinating Early Kidney Development: Lessons from Gene Targeting
AU Vainio, S.; Lin, Yangfeng
SO Nature Reviews: Genetics [Nat. Rev. Genet.], (20020700) vol. 3, no. 7, pp. 533-543.
ISSN: 1471-0056.
DT Journal
TC General Review
FS G
LA English
SL English

L4 ANSWER 215 OF 365 CANCERLIT on STN DUPLICATE 38
AN 2002168776 CANCERLIT
DN 22041449 PubMed ID: 12046056
TI The prognostic molecular markers in hepatocellular carcinoma.
AU Qin Lun-Xiu; Tang Zhao-You
CS Liver Cancer Institute and Zhongshan Hospital, Fudan university, 136 Yi Xue Yuan Road, Shanghai 200032, China.
SO World J Gastroenterol, (2002 Jun) 8 (3) 385-92. Ref: 119
Journal code: 100883448. ISSN: 1007-9327.
CY China
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2002304350
EM 200208
ED Entered STN: 20021018
Last Updated on STN: 20021018

L4 ANSWER 216 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 39
AN 2003:8941 BIOSIS
DN PREV200300008941
TI Midkine and ***pleiotrophin*** : Two related proteins involved in development, survival, inflammation and tumorigenesis.
AU Muramatsu, Takashi [Reprint Author]
CS Department of Biochemistry, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
tmurama@med.nagoya-u.ac.jp
SO Journal of Biochemistry (Tokyo), (Sep 2002) Vol. 132, No. 3, pp. 359-371. print.
CODEN: JOBIAO. ISSN: 0021-924X.
DT Article
LA English
ED Entered STN: 18 Dec 2002
Last Updated on STN: 18 Dec 2002

L4 ANSWER 217 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

DN PREV200300016376
TI Effects of targeted overexpression of ***pleiotrophin*** on postnatal bone development.
AU Tare, Rahul S.; Oreffo, Richard O. C.; Sato, Kenzo; Rauvala, Heikki; Clarke, Nicholas M. P.; Roach, Helmtrud I. [Reprint Author]
CS University Orthopaedics, Bone and Joint Research Group, University of Southampton, Southampton, UK
hr@soton.ac.uk
SO Biochemical and Biophysical Research Communications, (November 1 2002) Vol. 298, No. 3, pp. 324-332. print.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 25 Dec 2002
Last Updated on STN: 25 Dec 2002

L4 ANSWER 218 OF 365 MEDLINE on STN
AN 2002434299 MEDLINE
DN PubMed ID: 12190985
TI The molecular control of renal branching morphogenesis: current knowledge and emerging insights.
AU Piscione Tino D; Rosenblum Norman D
CS Program in Development Biology, Division of Nephrology, The Hospital for Sick Children, University of Toronto, 555 University Ave., Ontario, M5G1X8, Canada.
SO Differentiation; research in biological diversity, (2002 Aug) 70 (6) 227-46. Ref: 163
Journal code: 0401650. ISSN: 0301-4681.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 200302
ED Entered STN: 20020823
Last Updated on STN: 20030207
Entered Medline: 20030206

L4 ANSWER 219 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 40
AN 2002:190702 BIOSIS
DN PREV200200190702
TI ***Pleiotrophin*** : A cytokine with diverse functions and a novel signaling pathway.
AU Deuel, Thomas F. [Reprint author]; Zhang, Nan; Yeh, Hsui-Jen; Silos-Santiago, Inmaculada; Wang, Zhao-Yi
CS Division of Growth Regulation, Beth Israel Deaconess Medical Center, Harvard Medical School, 21-27 Burlington Avenue, Room 553, Boston, MA, 02215, USA
tdeuel@caregroup.harvard.edu
SO Archives of Biochemistry and Biophysics, (January 15, 2002) Vol. 397, No. 2, pp. 162-171. print.
CODEN: ABBIA4. ISSN: 0003-9861.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 13 Mar 2002
Last Updated on STN: 13 Mar 2002

L4 ANSWER 220 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:332497 BIOSIS
DN PREV200200332497
TI Ribozyme-targeting elucidates the role of the growth factor ***pleiotrophin*** (PTN) and of the newly identified PTN-***receptor*** PTN-R/ALK in tumor growth.
AU Czubayko, Frank [Reprint author]; Malerczyk, Claudius [Reprint author]; Aigner, Achim [Reprint author]
CS Dept. of Pharmacology and Toxicology, Philipps-University, 35033, Marburg, Germany
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (March, 2002) Vol. 365, No. Supplement 1, pp. R9. print.
Meeting Info.: 43rd Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology. Mainz, Germany. March 12-14,

CODEN: NSAPCC. ISSN: 0028-1298.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 12 Jun 2002
Last Updated on STN: 12 Jun 2002

L4 ANSWER 221 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:379984 BIOSIS
DN PREV200300379984
TI HB - GAM IN NEURONAL PROLIFERATION AND MIGRATION: REVEALING THE ROLES OF THREE POSSIBLE ***RECEPTORS***
AU Hienola, A. E. [Reprint Author]; Kinnunen, T.; Rauvala, H. [Reprint Author]
CS Univ Helsinki, Helsinki, Finland
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 818.1. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 20 Aug 2003
Last Updated on STN: 20 Aug 2003

L4 ANSWER 222 OF 365 NTIS COPYRIGHT 2004 NTIS on STN
AN 2002(10):00293 NTIS Order Number: ADA398142/XAB
TI Novel Angiogenic Domains: Use in Identifying Unique Transforming and Tumor Promoting Pathways in ***Human*** Breast Cancer. Annual rept. 15 Sep 2000-14 Sep 2001.
AU Deuel, T. F.
CS Beth Israel Medical Center, New York. (028784000 432535)
NR ADA398142/XAB
12p; Sep 2001
NC Contract(s): DAMD17-00-1-0151
DT Report
CY United States
LA English
NTE Original contains color plates: All DTIC reproductions will be in black and white.
AV Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.
NTIS Prices: PC A03/MF A01
OS GRA&I0210

L4 ANSWER 223 OF 365 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
DUPLICATE 41
AN 2002-09978 BIOTECHDS
TI New ***pleiotrophin*** growth factor ***receptor*** proteins and polynucleotides, useful for treating or preventing proliferative (e.g., cancer), vascular and neurological disorders;
recombinant protein gene, vector expression in host cell, antibody, hybridoma cell culture, sense and antisense molecule useful in disease gene therapy and drug screening
AU WELLSTEIN A
PA UNIV GEORGETOWN MEDICAL CENT
PI WO 2001096394 20 Dec 2001
AI WO 2000-US18938 14 Jun 2000
PRAI US 2000-211491 14 Jun 2000
DT Patent
LA English
OS WPI: 2002-179508 [23]

L4 ANSWER 224 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 42
AN 2001:747847 CAPLUS
DN 135:299535
TI Novel ***human*** proteins and their encoding nucleic acids encoding
IN Vernet, Corine A. M.; Burgess, Catherine E.; Fernandes, Elma; Taupier, Raymond J., Jr.; Quinn, Kerry E.; Spytek, Kimberly Ann; Rastelli, Luca; Herrmann, John L.
PA Curagen Corporation, USA

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074897	A2	20011011	WO 2001-US10892	20010403
	WO 2001074897	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001049828	A5	20011015	AU 2001-49828	20010403
	EP 1268540	A2	20030102	EP 2001-923104	20010403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003065140	A1	20030403	US 2001-825751	20010403
	JP 2003529358	T2	20031007	JP 2001-572586	20010403
	US 2004010118	A1	20040115	US 2001-930512	20010815
PRAI	US 2000-193314P	P	20000403		
	US 2000-194314P	P	20000403		
	US 2000-225693P	P	20000816		
	US 2000-225692P	P	20000816		
	US 2000-225837P	P	20000816		
	US 2000-226236P	P	20000818		
	US 2000-226353P	P	20000818		
	US 2000-227085P	P	20000822		
	US 2000-227395P	P	20000823		
	US 2000-227492P	P	20000824		
	US 2000-227600P	P	20000824		
	US 2001-275952P	P	20010314		
	WO 2001-US10892	W	20010403		

L4 ANSWER 225 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:781078 CAPLUS
DN 135:348850
TI Albumin fusion proteins with therapeutic proteins for improved shelf-life
IN Rosen, Craig A.; Haseltine, William A.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 374 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079443	A2	20011025	WO 2001-US11924	20010412
	WO 2001079443	A3	20020221		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001059063	A5	20011030	AU 2001-59063	20010412
	EP 1274719	A2	20030115	EP 2001-932546	20010412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003125247	A1	20030703	US 2001-833041	20010412
	US 2003171267	A1	20030911	US 2001-833117	20010412
	JP 2003530846	T2	20031021	JP 2001-577427	20010412
	US 2003199043	A1	20031023	US 2001-832501	20010412
	US 2003219875	A1	20031127	US 2001-833118	20010412
	US 2004010134	A1	20040115	US 2001-833245	20010412
PRAI	US 2000-229358P	P	20000412		
	US 2000-199384P	P	20000425		
	US 2000-256931P	P	20001221		

L4 ANSWER 226 OF 365 USPATFULL on STN
AN 2001:182340 USPATFULL
TI Process for preparing functionalized polyalkyleneimines, compositions containing them and uses thereof
IN Leclercq, Francoise, Bures Sur Yvette, France
Herscovici, Jean, Paris, France
Scherman, Daniel, Paris, France
PI US 2001031498 A1 20011018
AI US 2001-783981 A1 20010216 (9)
PRAI FR 2000-2059 20000218
US 2000-203907P 20000512 (60)
DT Utility
FS APPLICATION
LN.CNT 634
INCL INCLM: 435/455.000
INCLS: 536/055.300; 525/054.200
NCL NCLM: 435/455.000
NCLS: 536/055.300; 525/054.200
IC [7]
ICM: C12N015-87
ICS: C08F008-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 227 OF 365 USPATFULL on STN
AN 2001:231041 USPATFULL
TI Targeted diagnostic/therapeutic agents having more than one different vectors
IN Klaveness, Jo, Olso, Norway
Rongved, P.ang.l, Olso, Norway
H.o slashed.gset, Anders, Olso, Norway
Tolleshaug, Helge, Olso, Norway
Cuthbertson, Alan, Olso, Norway
Hoff, Lars, Olso, Norway
Bryn, Klaus, Olso, Norway
Hellebust, Halldis, Olso, Norway
Solbakken, Magne, Olso, Norway
PA Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)
PI US 6331289 B1 20011218
AI US 1997-959206 19971028 (8)
PRAI GB 1996-22366 19961028
GB 1996-22369 19961028
GB 1997-2195 19970204
GB 1997-8265 19970424
GB 1997-11837 19970606
GB 1997-11839 19970606
US 1997-49263P 19970606 (60)
US 1997-49266P 19970607 (60)
DT Utility
FS GRANTED
LN.CNT 4091
INCL INCLM: 424/009.520
INCLS: 424/001.210; 424/009.400; 424/009.600; 424/450.000
NCL NCLM: 424/009.520
NCLS: 424/001.210; 424/009.400; 424/009.600; 424/450.000
IC [7]
ICM: A61B008-00
ICS: A61K051-00; A61K009-127
EXF 424/9.52; 424/9.51; 424/9.5; 424/450; 424/489; 424/498; 424/499; 424/502; 424/1.21; 424/9.4; 424/9.6; 424/9.1; 530/300; 530/324; 530/326; 530/327; 514/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 365 USPATFULL on STN
AN 2001:226255 USPATFULL
TI Recombinant swinepox virus
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6328975 B1 20011211
AI US 1995-375992 19950119 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US8277, filed on 22 Jul 1994
Continuation-in-part of Ser. No. US 1993-97554, filed on 22 Jul 1993, now patented, Pat. No. US 5869312 Continuation-in-part of Ser. No. US 1992-820154, filed on 13 Jan 1992, now patented, Pat. No. US 5382425

FS GRANTED
LN.CNT 4592
INCL INCLM: 424/199.100
NCL NCLM: 424/199.100
IC [7]
ICM: A61K039-02
EXF 424/199.1; 424/204.1; 424/232.1; 435/69.1; 435/69.3; 435/172.3; 435/235.1; 435/320.1; 435/9; 435/57; 435/32; 435/70; 530/300; 530/350; 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 365 USPATFULL on STN
AN 2001:202605 USPATFULL
TI Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof
IN Lehn, Jean-Marie, Strasbourg, France
Lehn, Pierre, Paris, France
Vigneron, Jean-Pierre, Boissy-sur-Saint-Yon, France
PA Centre National de la Recherche Scientifique, Paris, France (non-U.S. corporation)
PI US 6316422 B1 20011113
AI US 2000-706619 20001106 (9)
RLI Continuation of Ser. No. US 125825, now patented, Pat. No. US 6143729
PRAI FR 1996-2604 19960301
FR 1996-9557 19960730
DT Utility
FS GRANTED
LN.CNT 959
INCL INCLM: 514/044.000
INCLS: 424/450.000; 264/004.100; 264/004.300; 554/001.000; 560/001.000; 435/006.000; 435/325.000
NCL NCLM: 514/044.000
NCLS: 264/004.100; 264/004.300; 424/450.000; 435/006.000; 435/325.000; 554/001.000; 560/001.000
IC [7]
ICM: A01N043-04
ICS: A61K031-70; A61K009-127; C07C069-74; C12N005-00
EXF 536/23.1; 435/6; 435/325; 424/450; 424/417; 424/1.21; 424/1.45; 424/9.321; 514/44; 554/1; 560/1; 264/4.1; 264/4.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 365 USPATFULL on STN
AN 2001:173575 USPATFULL
TI Compounds, preparation and use for transferring nucleic acids into cells
IN Scherman, Daniel, Paris, France
Dubertret, Catherine, Sevres, France
Byk, Gerardo, Oyriat Ono, Israel
PA Aventis Pharma S.A., Antony, France (non-U.S. corporation)
PI US 6300321 B1 20011009
WO 9854130 19981203
AI US 1999-424380 19991215 (9)
WO 1998-FR1041 19980525
19991215 PCT 371 date
19991215 PCT 102(e) date
PRAI FR 1997-6549 19970528
DT Utility
FS GRANTED
LN.CNT 1479
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/325.000; 435/455.000; 435/458.000; 424/450.000
NCL NCLM: 514/044.000
NCLS: 424/450.000; 435/006.000; 435/325.000; 435/455.000; 435/458.000
IC [7]
ICM: A61K031-70
ICS: A01N043-04; C12Q001-68; C12N015-85; C12N015-86
EXF 536/23.1; 514/44; 435/6; 435/455; 435/325; 435/458; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 365 USPATFULL on STN
AN 2001:163000 USPATFULL
TI Protein fragment complementation assays for the detection of biological or drug interactions
IN Michnick, Stephen William Watson, Westmount, Canada
Remy, Ingrid, Montreal, Canada
PA Odyssey Pharmaceuticals Inc., San Ramon, CA, United States (U.S.

PI US 6294330 B1 20010925
AI US 1998-124850 19980730 (9)
RLI Continuation-in-part of Ser. No. US 1998-17412, filed on 2 Feb 1998
PRAI CA 1997-2196496 19970131
DT Utility
FS GRANTED
LN.CNT 3238
INCL INCLM: 435/006.000
INCLS: 435/069.700; 435/325.000; 435/252.300; 435/254.110; 435/440.000; 435/455.000; 435/468.000; 435/320.100; 536/023.400; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.700; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 435/440.000; 435/455.000; 435/468.000; 536/023.400; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C12N005-10; C12N001-21; C12N015-11; C12N015-63
EXF 435/6; 435/69.7; 435/320.1; 435/325; 435/252.3; 435/254.11; 435/440; 435/455; 435/468; 536/23.4; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 365 USPATFULL on STN
AN 2001:162850 USPATFULL
TI Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Schering-Plough Veterinary Corp., Reno, NV, United States (U.S. corporation)
PI US 6294176 B1 20010925
AI US 1998-113750 19980710 (9)
DT Utility
FS GRANTED
LN.CNT 2882
INCL INCLM: 424/199.100
INCLS: 424/232.100; 424/202.100; 424/221.100; 435/320.100; 435/235.100; 536/023.720
NCL NCLM: 424/199.100
NCLS: 424/202.100; 424/221.100; 424/232.100; 435/235.100; 435/320.100; 536/023.720
IC [7]
ICM: A61K039-12
ICS: A61K039-275; C12N015-00
EXF 424/199.1; 424/232.1; 424/201.1; 424/202.1; 424/221.1; 435/320.1; 435/235.1; 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 365 USPATFULL on STN
AN 2001:136775 USPATFULL
TI Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
IN Lo, Donald C., Chapel Hill, NC, United States
Barney, Shawn, Apex, NC, United States
Thomas, Mary Beth, Chapel Hill, NC, United States
Portbury, Stuart D., Durham, NC, United States
Puranam, Kasturi, Durham, NC, United States
Katz, Lawrence C., Durham, NC, United States
PA Cogent Neuroscience, Inc., Durham, NC, United States (U.S. corporation)
PI US 6277974 B1 20010821
AI US 1999-461697 19991214 (9)
DT Utility
FS GRANTED
LN.CNT 4670
INCL INCLM: 536/023.100
INCLS: 536/023.100; 536/023.500; 424/093.200; 424/093.100; 424/093.210; 435/069.100; 435/325.000; 435/352.000; 435/320.100; 530/300.000; 530/350.000
NCL NCLM: 536/023.100
NCLS: 424/093.100; 424/093.200; 424/093.210; 435/069.100; 435/320.100; 435/325.000; 435/352.000; 530/300.000; 530/350.000; 536/023.500
IC [7]
ICM: C07H021-02
EXF 536/23.1; 536/23.4; 435/320.1; 435/325; 435/69.1; 530/300; 530/350; 424/93.2; 424/93.21; 424/93.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:136616 USPATFULL
TI Methods for inhibiting TGF-.beta. activity
IN Ruoslahti, Erkki I., Rancho Santa Fe, CA, United States
Yamaguchi, Yu, San Diego, CA, United States
PA The Burnham Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6277812 B1 20010821
AI US 1995-458834 19950602 (8)
RLI Continuation of Ser. No. US 1994-303238, filed on 8 Sep 1994, now patented, Pat. No. US 5654270 Continuation of Ser. No. US 1992-978931, filed on 17 Nov 1992, now abandoned Continuation-in-part of Ser. No. US 1992-882345, filed on 13 May 1992, now abandoned Continuation of Ser. No. US 1991-792192, filed on 14 Nov 1991, now abandoned Continuation-in-part of Ser. No. US 1990-467888, filed on 22 Jan 1990, now abandoned Continuation-in-part of Ser. No. US 1988-212702, filed on 28 Jun 1988, now abandoned
DT Utility
FS GRANTED
LN.CNT 1532
INCL INCLM: 514/002.000
INCLS: 435/069.100; 514/002.000; 514/008.000; 530/395.000
NCL NCLM: 514/002.000
NCLS: 435/069.100; 514/008.000; 530/395.000
IC [7]
ICM: A01N061-00
EXF 435/69.1; 514/2; 514/8; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 235 OF 365 USPATFULL on STN
AN 2001:107635 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 6258550 B1 20010710
AI US 1999-413492 19991006 (9)
RLI Division of Ser. No. US 1997-934224, filed on 19 Sep 1997 Division of Ser. No. US 532818, now patented, Pat. No. US 5965698 Continuation-in-part of Ser. No. US 1993-51741, filed on 23 Apr 1993, now abandoned Continuation-in-part of Ser. No. US 1993-143364, filed on 29 Oct 1993, now abandoned
DT Utility
FS GRANTED
LN.CNT 1520
INCL INCLM: 435/007.100
INCLS: 435/183.000; 530/300.000
NCL NCLM: 435/007.100
NCLS: 435/183.000; 530/300.000
IC [7]
ICM: G01N033-53
EXF 435/7.1; 435/183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 236 OF 365 USPATFULL on STN
AN 2001:97428 USPATFULL
TI Recombinant swinepox virus
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, Lenexa, KS, United States (U.S. corporation)
PI US 6251403 B1 20010626
AI US 1995-488237 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-375992, filed on 19 Jan 1995 Continuation-in-part of Ser. No. WO 1994-US8277, filed on 22 Jul 1994 Continuation-in-part of Ser. No. US 1993-97554, filed on 22 Jul 1993, now patented, Pat. No. US 5869312 Continuation-in-part of Ser. No. US 1992-820154, filed on 13 Jan 1992, now patented, Pat. No. US 5382425
DT Utility
FS GRANTED
LN.CNT 6042
INCL INCLM: 424/199.100
INCLS: 424/204.100; 424/232.100; 435/320.100; 435/235.100; 530/350.000; 536/023.720; 935/057.000; 935/070.000
NCL NCLM: 424/199.100
NCLS: 424/204.100; 424/232.100; 435/235.100; 435/320.100; 530/350.000;

IC [7]
ICM: A61K039-12
ICS: A61K039-275; C12N015-00; C12N007-00
EXF 424/199.1; 424/204.1; 424/232.1; 435/320.1; 435/240.2; 435/235.1; 530/350; 536/23.72; 935/57; 935/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 237 OF 365 USPATFULL on STN
AN 2001:59385 USPATFULL
TI Recombinant swinepox virus
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, Lenexa, KS, United States (U.S. corporation)
PI US 6221361 B1 20010424
AI US 1996-686968 19960725 (8)
RLI Continuation-in-part of Ser. No. WO 1996-US1485, filed on 19 Jan 1996
Continuation-in-part of Ser. No. US 1995-472679, filed on 7 Jun 1995
Continuation-in-part of Ser. No. US 1995-488237, filed on 7 Jun 1995
Continuation-in-part of Ser. No. US 1995-480640, filed on 7 Jun 1995, now patented, Pat. No. US 6033904 Continuation-in-part of Ser. No. US 1995-375992, filed on 19 Jan 1995 , said Ser. No. US 472679
Continuation-in-part of Ser. No. US 1995-375992, filed on 19 Jan 1995 , said Ser. No. US 488237 Continuation-in-part of Ser. No. US 1995-375992, filed on 19 Jan 1995 , said Ser. No. US 480640 Continuation-in-part of Ser. No. US 375992
DT Utility
FS Granted
LN.CNT 7695
INCL INCLM: 424/199.100
INCLS: 435/320.100; 435/235.100; 424/232.100
NCL NCLM: 424/199.100
NCLS: 424/232.100; 435/235.100; 435/320.100
IC [7]
ICM: A61K039-275
ICS: C12N007-01; C12N015-86
EXF 435/235.1; 435/320.1; 424/199.1; 424/232.1; 935/68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 238 OF 365 USPATFULL on STN
AN 2001:36803 USPATFULL
TI Nucleic acid-containing composition, preparation and use thereof
IN Scherman, Daniel, Paris, France
Byk, Gerardo, Creteil, France
Schwartz, Bertrand, Maisons Alford, France
PA Aventis Pharma S.A., France (non-U.S. corporation)
PI US 6200956 B1 20010313
AI US 1999-306044 19990506 (9)
RLI Continuation of Ser. No. US 894339, now patented, Pat. No. US 5945400
PRAI FR 1995-1865 19950217
DT Utility
FS Granted
LN.CNT 1287
INCL INCLM: 514/013.000
INCLS: 514/012.000; 514/014.000; 514/015.000; 530/300.000; 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 514/013.000
NCLS: 514/012.000; 514/014.000; 514/015.000; 530/300.000; 530/326.000; 530/327.000; 530/328.000
IC [7]
ICM: A61K038-00
ICS: A61K038-04; C07K014-00; C07K016-00
EXF 424/450; 514/44; 514/12; 514/13; 514/14; 435/458; 536/23.1; 536/24.5; 530/300; 530/326; 530/327; 530/328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 365 USPATFULL on STN
AN 2001:18001 USPATFULL
TI Recombinant chimeric virus and uses thereof
IN Cochran, Mark D., Carlsbad, CA, United States
Wild, Martha A., San Diego, CA, United States
Winslow, Barbara J., Delmar, CA, United States
PA Schering-Plough Veterinary Corp., Reno, NV, United States (U.S. corporation)
PI US 6183753 B1 20010206
AI US 1997-804372 19970221 (8)

now patented, Pat. No. US 5853733 Continuation-in-part of Ser. No. WO 1995-US10245, filed on 9 Aug 1995 Continuation-in-part of Ser. No. US 1994-288065, filed on 9 Aug 1994, now patented, Pat. No. US 5961982
DT Utility
FS Granted
LN.CNT 3184
INCL INCLM: 424/199.100
INCLS: 424/229.100; 424/204.100; 424/222.100; 424/202.100; 435/320.100; 435/069.100; 435/069.300; 435/235.100; 536/023.720; 536/023.520
NCL NCLM: 424/199.100
NCLS: 424/202.100; 424/204.100; 424/222.100; 424/229.100; 435/069.100; 435/069.300; 435/235.100; 435/320.100; 536/023.520; 536/023.720
IC [7]
ICM: A61K039-12
ICS: A61K039-295; C12N015-00; C12P021-06
EXF 424/199.1; 424/202.1; 424/204.1; 424/222.1; 424/816; 424/229.1; 435/320.1; 435/69.1; 435/235.1; 435/177.3; 530/300; 530/350; 536/23.72; 536/23.52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 43
AN 2001:390198 BIOSIS
DN PREV200100390198
TI Identification of anaplastic lymphoma kinase as a ***receptor*** for the growth factor ***pleiotrophin*** .
AU Stoica, Gerald E.; Kuo, Angera; Aigner, Achim; Sunitha, Iruvanti; Souttou, Boussad; Malerczyk, Claudius; Caughey, Dana J.; Wen, Duanzhi; Karavanov, Alex; Riegel, Anna T.; Wellstein, Anton [Reprint author]
CS Lombardi Cancer Center, Georgetown University, 3970 Reservoir Rd. NW, Research Bldg. E311, Washington, DC, 20007, USA
wellstea@georgetown.edu
SO Journal of Biological Chemistry, (May 18, 2001) Vol. 276, No. 20, pp. 16772-16779. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
OS Genbank-AF149800; Genbank-AF236106; Genbank-M57399; Genbank-U66559
ED Entered STN: 15 Aug 2001
Last Updated on STN: 23 Feb 2002

L4 ANSWER 241 OF 365 CANCERLIT on STN DUPLICATE 44
AN 2001192279 CANCERLIT
DN 21192279 PubMed ID: 11150308
TI The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities.
AU Bernard-Pierrot I; Delbe J; Caruelle D; Barritault D; Courty J; Milhiet P E
CS Laboratoire de Recherche sur la Croissance Cellulaire, la Reparation et la Regeneration Tissulaires, CNRS UPRES-A 7053, Universite Paris XII, Avenue du General de Gaulle, 94010 Creteil Cedex, France.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2001 Apr 13) 276 (15) 12228-34.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2001287580
EM 200105
ED Entered STN: 20010614
Last Updated on STN: 20010614

L4 ANSWER 242 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:988880 SCISEARCH
GA The Genuine Article (R) Number: 499WX
TI Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells
AU Takei Y; Kadomatsu K; Matsuo S; Itoh H; Nakazawa K; Kubota S; Muramatsu T (Reprint)
CS Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan (Reprint); Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Koken Biosci Inst, Tokyo 1690072, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Tokyo 1130033,

CYA Japan
SO CANCER RESEARCH, (1 DEC 2001) Vol. 61, No. 23, pp. 8486-8491.
Publisher: AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL 35202 USA.
ISSN: 0008-5472.
DT Article; Journal
LA English
REC Reference Count: 54
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 243 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 2001:32538261 BIOTECHNO
TI Identification of GIT1/Cat-1 as a substrate molecule of protein tyrosine phosphatase .zeta./.beta. by the yeast substrate-trapping system
AU Kawachi H.; Fujikawa A.; Maeda N.; Noda M.
CS M. Noda, Division of Molecular Neurobiology, National Institute for Basic Biology, 38 Nishigonaka, Myodaiji-cho, Okazaki 444-8585, Japan.
E-mail: madon@nibb.ac.jp
SO Proceedings of the National Academy of Sciences of the United States of America, (05 JUN 2001), 98/12 (6593-6598), 40 reference(s)
CODEN: PNASA6 ISSN: 0027-8424
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 244 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:525041 CAPLUS
DN 135:255297
TI Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction
AU Evans, Chheng-Orn; Young, Andrew N.; Brown, Milton R.; Brat, Daniel J.; Parks, John. S.; Neish, Andrew S.; Oyesiku, Nelson M.
CS Department of Neurosurgery and Laboratory of Molecular Neurosurgery and Biotechnology, Emory University School of Medicine, Atlanta, GA, 30322, USA
SO Journal of Clinical Endocrinology and Metabolism (2001), 86(7), 3097-3107
CODEN: JCEMAZ; ISSN: 0021-972X
PB Endocrine Society
DT Journal
LA English
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 245 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:4159 CAPLUS
DN 136:383829
TI Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia
AU Stamey, Thomas A.; Warrington, Janet A.; Caldwell, Mitchell C.; Chen, Zuxiong; Fan, Zhenbin; Mahadevappa, Mamatha; McNeal, John E.; Nolley, Rosalie; Zhang, Zhaomei
CS Department of Urology, Stanford University, Stanford, CA, USA
SO Journal of Urology (Hagerstown, MD, United States) (2001), 166(6), 2171-2177
CODEN: JOURAA; ISSN: 0022-5347
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 246 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:103247 SCISEARCH
GA The Genuine Article (R) Number: 394MN
TI Long terminal repeats are used as alternative promoters for the endothelin B ***receptor*** and apolipoprotein C-I genes in ***humans***
AU Medstrand P; Landry J R; Mager D L (Reprint)
CS British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada (Reprint); British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1L3, Canada

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (19 JAN 2001) Vol. 276, No. 3, pp. 1896-1903.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.
ISSN: 0021-9258.
DT Article; Journal
LA English
REC Reference Count: 41
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 247 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:683120 SCISEARCH
GA The Genuine Article (R) Number: 466TC
TI Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo
AU Thybusch-Bernhardt A; Aigner A; Beckmann S; Czubayko F; Juhl H (Reprint)
CS Univ Hosp Kiel, Dept Surg, D-24105 Kiel, Germany (Reprint); Univ Marburg, Dept Pharmacol, D-35033 Marburg, Germany; Georgetown Univ, Ctr Med, Lombardi Canc Ctr, Washington, DC 20007 USA
CYA Germany; USA
SO EUROPEAN JOURNAL OF CANCER, (SEP 2001) Vol. 37, No. 13, pp. 1688-1694.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
ISSN: 0959-8049.
DT Article; Journal
LA English
REC Reference Count: 26
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 248 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:69301 BIOSIS
DN PREV200200069301
TI Characterization of ***pleiotrophin*** signal transduction through a ***receptor*** tyrosine kinase.
AU Kuo, Angera H. [Reprint author]; Stoica, Gerald E. [Reprint author]; Powers, Ciaran [Reprint author]; Bowden, Emma [Reprint author]; Riegel, Anna T. [Reprint author]; Wellstein, Anton [Reprint author]
CS Lombardi Cancer Center, Georgetown University, Washington, DC, USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2001) Vol. 42, pp. 955. print.
Meeting Info.: 92nd Annual Meeting of the American Association for Cancer Research. New Orleans, LA, USA. March 24-28, 2001.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Jan 2002
Last Updated on STN: 25 Feb 2002

L4 ANSWER 249 OF 365 CANCERLIT on STN DUPLICATE 46
AN 2001136931 CANCERLIT
DN 21136931 PubMed ID: 11241127
TI Construction and biological characterization of an HB-GAM/FGF-1 chimera for vascular tissue engineering.
AU Xue L; Tassiopoulos A K; Woloson S K; Stanton D L Jr; Ms C S; Hampton B; Burgess W H; Greisler H P
CS Department of Surgery, Loyola University Medical Center, Maywood, IL 60153, USA.
NC RO1-41272
SO JOURNAL OF VASCULAR SURGERY, (2001 Mar) 33 (3) 554-60.
Journal code: 8407742. ISSN: 0741-5214.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2001198251
EM 200104
ED Entered STN: 20010515
Last Updated on STN: 20010515

L4 ANSWER 250 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:452994 BIOSIS
DN PREV200100452994

kinase.
AU Stoica, Gerald E. [Reprint author]; Aigner, Achim [Reprint author]; Powers, Ciaran [Reprint author]; List, Heinz-Joachim [Reprint author]; Kuo, Angera [Reprint author]; Bowden, Emma T. [Reprint author]; Riegel, Anna T. [Reprint author]; Wellstein, Anton [Reprint author]
CS Lombardi Cancer Center, Georgetown University, Washington, DC, USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2001) Vol. 42, pp. 434. print.
Meeting Info.: 92nd Annual Meeting of the American Association for Cancer Research. New Orleans, LA, USA. March 24-28, 2001. American Association for Cancer Research.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Sep 2001
Last Updated on STN: 22 Feb 2002

L4 ANSWER 251 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:491155 CAPLUS
DN 136:130389
TI Cloning and characterization of ***human*** syndecan-3
AU Berndt, Christine; Casaroli-Marano, Ricardo P.; Vilaro, Senen; Reina, Manuel
CS Department of Cell Biology, University of Barcelona, Barcelona, 08028, Spain
SO Journal of Cellular Biochemistry (2001), 82(2), 246-259
CODEN: JCEBD5; ISSN: 0730-2312
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 252 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:373199 SCISEARCH
GA The Genuine Article (R) Number: 428BE
TI Molecular cloning, expression and purification of truncated midkine and its growth stimulatory activity on Wilms' tumor (G401) cells
AU Paul S; Mitsumoto T; Yamamoto I; Shinozawa T (Reprint)
CS Gunma Univ, Fac Engn, Dept Biol & Chem Engn, Gunma 3768515, Japan (Reprint)
CYA Japan
SO CANCER LETTERS, (26 FEB 2001) Vol. 163, No. 2, pp. 239-244.
Publisher: ELSEVIER SCI IRELAND LTD, CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND.
ISSN: 0304-3835.
DT Article; Journal
LA English
REC Reference Count: 35
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 253 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:618953 CAPLUS
DN 136:260354
TI Expression of Neural Markers in ***Human*** Umbilical Cord Blood
AU Sanchez-Ramos, Juan R.; Song, Shijie; Kamath, Siddharth G.; Zigova, Tanja; Willing, Alison; Cardozo-Pelaez, Fernando; Stedeford, Todd; Chopp, Michael; Sanberg, Paul R.
CS Center for Aging and Brain Repair, Department of Neurology and neurosurgery, University of South Florida College of Medicine, Tampa, FL, USA
SO Experimental Neurology (2001), 171(1), 109-115
CODEN: EXNEAC; ISSN: 0014-4886
PB Academic Press
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 254 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002443671 EMBASE
TI Molecular interactions of syndecans during development.

CS A.C. Rapraeger, Department of Pathology, Laboratory Medicine, University of Wisconsin-Madison, 1300 University Avenue, Madison, WI 53706, United States. acraprae@facstaff.wisc.edu
SO Seminars in Cell and Developmental Biology, (2001) 12/2 (107-116). Refs: 64
ISSN: 1084-9521 CODEN: SCDBFX
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 255 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002443670 EMBASE
TI Heparan sulfate proteoglycans in the nervous system: Their diverse roles in neurogenesis, axon guidance, and synaptogenesis.
AU Yamaguchi Y.
CS Y. Yamaguchi, Neurobiology Program, Burnham Institute, 10901 North Torrey Pines Road, San Diego, CA 92037, United States. yyamaguchi@burnham.org
SO Seminars in Cell and Developmental Biology, (2001) 12/2 (99-106). Refs: 65
ISSN: 1084-9521 CODEN: SCDBFX
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 256 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:775265 CAPLUS
DN 136:132090
TI Investigation of differentially expressed genes during the development of mouse cerebellum
AU Kagami, Yoshihiro; Furuichi, Teiichi
CS Laboratory for Molecular Neurogenesis, Brain Science Institute, RIKEN, Wako, 351-0198, Japan
SO Gene Expression Patterns (2001), 1(1), 39-59
CODEN: GEPEAD; ISSN: 1567-133X
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 257 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:775264 CAPLUS
DN 136:67342
TI A database for regional gene expression in the ***human*** brain
AU Siu, I-Mei; Lal, Anita; Riggins, Gregory J.
CS Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA
SO Gene Expression Patterns (2001), 1(1), 33-38
CODEN: GEPEAD; ISSN: 1567-133X
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 258 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:880921 CAPLUS
DN 134:41093
TI DNA vaccine for protecting an avian against infectious bursal disease virus
IN Aboud-Pirak, Esther; Pirak, Michael E.; Shaoul, Esther; Monadeev, Limor
PA Innovo Biotechnologies Ltd., Israel
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000074630	A2	20001214	WO 2000-IL325	20000606
	WO 2000074630	A3	20020606		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6468984	B1	20021022	US 1999-450433	19991130
PRAI	US 1999-138093P	P	19990608		
	US 1999-450433	A	19991130		

L4 ANSWER 259 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:335533 CAPLUS
DN 133:1477
TI Induction of cell differentiation in vitro using genes for growth or differentiation factors and use of the cells in the treatment of disease
IN Sedlacek, Hans-harald; Havemann, Klaus; Muller, Rolf
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000028010	A2	20000518	WO 1999-EP7902	19991019
	WO 2000028010	A3	20000727		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19850986	A1	20000525	DE 1998-19850986	19981105
	EP 1127109	A2	20010829	EP 1999-953880	19991019
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002529080	T2	20020910	JP 2000-581177	19991019
PRAI	DE 1998-19850986	A	19981105		
	WO 1999-EP7902	W	19991019		

L4 ANSWER 260 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:53434 CAPLUS
DN 132:106961
TI Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
IN Thorpe, Philip E.; Ran, Sophia
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000002587	A1	20000120	WO 1999-US15668	19990712
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9950958	A1	20000201	AU 1999-50958	19990712

	BR 9912053	A	20010403	BR 1999-12053	19990712
	EP 1098665	A1	20010516	EP 1999-935491	19990712
	EP 1098665	B1	20030108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6312694	B1	20011106	US 1999-351457	19990712
	JP 2002520297	T2	20020709	JP 2000-558846	19990712
	AT 230614	E	20030115	AT 1999-935491	19990712
	ES 2188202	T3	20030616	ES 1999-935491	19990712
	NZ 508873	A	20031031	NZ 1999-508873	19990712
	US 6783760	B1	20040831	US 2001-819386	20010328
	HK 1038498	A1	20040116	HK 2001-108089	20011116
PRAI	US 1998-92589P	P	19980713		
	US 1998-110600P	P	19981202		
	US 1999-351457	A3	19990712		
	WO 1999-US15668	W	19990712		

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 261 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:53432 CAPLUS
DN 132:106960
TI Cancer treatment methods using antibodies to aminophospholipids
IN Thorpe, Philip E.; Ran, Sophia
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 226 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000002584	A2	20000120	WO 1999-US15600	19990712
	WO 2000002584	A3	20000330		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333147	AA	20000120	CA 1999-2333147	19990712
	AU 9954585	A1	20000201	AU 1999-54585	19990712
	AU 771224	B2	20040318		
	EP 1096955	A2	20010509	EP 1999-940802	19990712
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6406693	B1	20020618	US 1999-351543	19990712
	JP 2002520295	T2	20020709	JP 2000-558843	19990712
	NZ 508950	A	20031031	NZ 1999-508950	19990712
	US 2003082187	A1	20030501	US 2001-998833	20011130
PRAI	US 1998-92672P	P	19980713		
	US 1998-110608P	P	19981202		
	US 1999-351543	A1	19990712		
	WO 1999-US15600	W	19990712		

L4 ANSWER 262 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:506081 CAPLUS
DN 133:125277
TI Drug targeting with bispecific antibodies for the specific coagulation of tumor vasculature
IN Thorpe, Philip E.; Edgington, Thomas S.
PA Board of Regents, the University of Texas System, USA; The Scripps Research Institute
SO U.S., 83 pp., Cont.-in-part of U. S. Ser. No. 273,567, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6093399	A	20000725	US 1995-482369	19950607
	EP 1306095	A2	20030502	EP 2002-24529	19930305

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

	US 5855866	A	19990105	US 1994-205330	19940302
	JP 2003055398	A2	20030226	JP 2002-164988	19950607
	US 6749853	B1	20040615	US 2000-483679	20000114
	US 2003219441	A1	20031127	US 2003-375716	20030227
PRAI	US 1992-846349	B2	19920305		
	US 1994-205330	A2	19940302		
	US 1994-273567	B2	19940711		
	EP 1993-906289	A3	19930305		
	JP 1996-504299	A3	19950607		
	US 1995-482369	A1	19950607		
	US 2000-483679	A1	20000114		

RE.CNT 230 THERE ARE 230 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 263 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:905499 CAPLUS
DN 134:26784
TI ***Human*** midkine ***receptor*** and its uses in drug screening and therapy
IN Kadomatsu, Kenji; Muramatsu, Takashi; Ikematsu, Shinya; Oda, Munehiro; Sakuma, Sadatoshi
PA Meiji Milk Products, Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000354487	A2	20001226	JP 1999-168549	19990615
PRAI	JP 1999-168549		19990615		

L4 ANSWER 264 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:275313 CAPLUS
DN 132:313670
TI Coated substrates for blood, plasma, or tissue washing and columns equipped with these substrates
IN Dunzendorfer, Udo; Will, Gottfried
PA Germany
SO Ger. Offen., 30 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19845286	A1	20000427	DE 1998-19845286	19981001
	EP 1004598	A2	20000531	EP 1999-118541	19990918
	EP 1004598	A3	20000607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	DE 1998-19845286		19981001		

L4 ANSWER 265 OF 365 USPATFULL on STN
AN 2000:160994 USPATFULL
TI Pharmaceutical composition useful for nucleic acid transfection, and use thereof
IN Blanche, Francis, Paris, France
Cameron, Beatrice, Paris, France
Crouzet, Joel, Sceaux, France
Thuillier, Vincent, Paris, France
PA Aventis Pharma S.A., Antony, France (non-U.S. corporation)
PI US 6153597 20001128
WO 9712051 19970403
AI US 1998-43856 19980327 (9)
WO 1996-FR1516 19960927
19980327 PCT 371 date
19980327 PCT 102(e) date
PRAI FR 1995-11411 19950928
DT Utility
FS Granted
LN.CNT 789
INCL INCLM: 514/044.000
INCLS: 435/320.100; 435/455.000; 435/458.000; 435/325.000; 435/366.000;

536/023.500; 536/024.500
NCL NCLM: 514/044.000
NCLS: 435/320.100; 435/325.000; 435/366.000; 435/455.000; 435/458.000; 530/350.000; 530/358.000; 530/387.100; 530/387.300; 536/023.100; 536/023.500; 536/024.500
IC [7]
ICM: A61K031-711
ICS: A61K031-7105
EXF 435/320.1; 435/455; 435/458; 435/325; 435/366; 530/350; 530/358; 530/387.1; 530/387.3; 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 266 OF 365 USPATFULL on STN
AN 2000:153821 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 6147189 20001114
AI US 1997-934223 19970919 (8)
RLI Division of Ser. No. US 532818
DT Utility
FS Granted
LN.CNT 2489
INCL INCLM: 530/333.000
INCLS: 548/533.000; 530/328.000
NCL NCLM: 530/333.000
NCLS: 530/328.000; 548/533.000
IC [7]
ICM: C07K007-06
ICS: C07K003-08; A61K037-02; A61K038-04
EXF 530/333; 435/81.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 267 OF 365 USPATFULL on STN
AN 2000:150149 USPATFULL
TI Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof
IN Lehn, Jean-Marie, Strasbourg, France
Lehn, Pierre, Paris, France
Vigneron, Jean-Pierre, Boissy-sur-Saint-Yon, France
PA Aventis Pharma S.A., Antony, France (non-U.S. corporation)
PI US 6143729 20001107
WO 9731935 19970904
AI US 1998-125825 19980911 (9)
WO 1997-FR364 19970228
19980911 PCT 371 date
19980911 PCT 102(e) date
PRAI FR 1996-2604 19960301
FR 1996-9557 19960730
DT Utility
FS Granted
LN.CNT 1044
INCL INCLM: 514/044.000
INCLS: 424/001.210; 424/001.450; 424/009.321; 424/093.200; 424/417.000; 424/450.000; 435/325.000; 264/004.100; 264/004.300; 935/052.000; 935/054.000
NCL NCLM: 514/044.000
NCLS: 264/004.100; 264/004.300; 424/001.210; 424/001.450; 424/009.321; 424/093.200; 424/417.000; 424/450.000; 435/325.000
IC [7]
ICM: A61K048-00
ICS: A61K031-70; A61K051-00; C12N005-00; B01J013-02; B01J013-04
EXF 514/44; 514/2; 424/450; 424/172.3; 554/1; 554/227; 560/1; 536/24.5; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 268 OF 365 USPATFULL on STN
AN 2000:141886 USPATFULL
TI Recombinant fowlpox viruses and uses thereof
IN Cochran, Mark D., 4506 Horizon Dr., Carlsbad, CA, United States 92008
Junker, David E., 6901 Galewood St., San Diego, CA, United States 92120
PI US 6136318 20001024

RLI Continuation-in-part of Ser. No. WO 1994-US2252, filed on 28 Feb 1994 which is a continuation of Ser. No. US 1993-24156, filed on 26 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3480
INCL INCLM: 424/199.100
INCLS: 424/232.100; 435/235.100; 435/320.100; 435/069.100; 435/069.300; 935/065.000
NCL NCLM: 424/199.100
NCLS: 424/232.100; 435/069.100; 435/069.300; 435/235.100; 435/320.100
IC [7]
ICM: A61K039-12
ICS: A61K039-275; C12N015-00; C12N007-01
EXF 435/235.1; 435/320.1; 435/69.1; 435/69.3; 435/172.3; 424/199.1; 424/93.2; 424/232.1; 935/65
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 269 OF 365 USPATFULL on STN
AN 2000:114095 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 6111069 20000829
AI US 1997-933843 19970919 (8)
RLI Division of Ser. No. US 532818
DT Utility
FS Granted
LN.CNT 2740
INCL INCLM: 530/333.000
INCLS: 548/533.000; 530/328.000
NCL NCLM: 530/333.000
NCLS: 530/328.000; 548/533.000
IC [7]
ICM: C07K007-06
ICS: C07K003-08; A61K037-02; A61K038-04
EXF 530/333; 548/533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 270 OF 365 USPATFULL on STN
AN 2000:102077 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Redmond, VA, United States (U.S. corporation)
PI US 6100044 20000808
AI US 1997-934224 19970919 (8)
RLI Division of Ser. No. US 1996-532818, filed on 3 May 1996, now patented, Pat. No. US 5965698 which is a continuation of Ser. No. WO 1994-US4294, filed on 21 Apr 1994 which is a continuation-in-part of Ser. No. US 1993-51741, filed on 23 Apr 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-143364, filed on 29 Oct 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2301
INCL INCLM: 435/007.100
INCLS: 436/501.000; 514/002.000; 514/012.000; 514/013.000; 548/533.000
NCL NCLM: 435/007.100
NCLS: 436/501.000; 514/002.000; 514/012.000; 514/013.000; 548/533.000
IC [7]
ICM: G01N033-53
ICS: G01N033-566; A61K038-00
EXF 514/13; 435/7.1; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 271 OF 365 USPATFULL on STN
AN 2000:84402 USPATFULL
TI Polypetides that include conformation-constraining groups which flank a protein-protein interaction site

Kini, R. Manjunatha, Singapore, India
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 6084066 20000704
AI US 1999-231797 19990115 (9)
RLI Continuation of Ser. No. US 532818
DT Utility
FS Granted
LN.CNT 2321
INCL INCLM: 530/333.000
INCLS: 548/533.000; 530/329.000
NCL NCLM: 530/333.000
NCLS: 530/329.000; 548/533.000
IC [7]
ICM: C07K007-06
ICS: C07K003-08; A61K037-02; A61K038-04
EXF 530/333; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 272 OF 365 USPATFULL on STN
AN 2000:84248 USPATFULL
TI Treatment of peptic ulcers using midkine (MK) proteins
IN Uchida, Masayuki, Kanagawa, Japan
Ikematsu, Shinya, Kanagawa, Japan
Yokoyama, Minehiko, Kanagawa, Japan
Yamashita, Akio, Kanagawa, Japan
Kumai, Hideshi, Kanagawa, Japan
Oda, Munehiro, Kanagawa, Japan
Kato, Naoki, Kanagawa, Japan
Sakuma, Sadatoshi, Kanagawa, Japan
Muramatsu, Takashi, Kanagawa, Japan
PA Meiji Milk Products Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 6083907 20000704
AI US 1998-12084 19980122 (9)
DT Utility
FS Granted
LN.CNT 560
INCL INCLM: 514/002.000
INCLS: 424/085.100
NCL NCLM: 514/002.000
NCLS: 424/085.100
IC [7]
ICM: A61K038-18
EXF 514/2; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 273 OF 365 USPATFULL on STN
AN 2000:61574 USPATFULL
TI Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
IN Lappi, Douglas A., Del Mar, CA, United States
Wiley, Ronald G., Brentwood, TN, United States
PA Advanced Targeting Systems, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6063758 20000516
AI US 1997-890157 19970709 (8)
DT Utility
FS Granted
LN.CNT 1109
INCL INCLM: 514/002.000
INCLS: 514/013.000; 530/320.000; 530/350.000
NCL NCLM: 514/002.000
NCLS: 514/013.000; 530/320.000; 530/350.000
IC [7]
ICM: A61K038-00
ICS: A61K038-16
EXF 514/2; 514/13; 530/350; 530/326; 530/370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 274 OF 365 USPATFULL on STN
AN 2000:47407 USPATFULL
TI Method and construct for producing graft tissue from an extracellular matrix
IN Bell, Eugene, Boston, MA, United States
PA Tissue Engineering, Inc., Boston, MA, United States (U.S. corporation)
PI US 6051750 20000418

RLI Division of Ser. No. US 1995-471535, filed on 6 Jun 1995, now patented, Pat. No. US 5800537 which is a continuation-in-part of Ser. No. US 1994-302087, filed on 6 Sep 1994, now patented, Pat. No. US 5893888 which is a continuation of Ser. No. US 1992-926885, filed on 7 Aug 1992, now abandoned
DT Utility
FS Granted
LN.CNT 717
INCL INCLM: 623/011.000
NCL NCLM: 623/011.110
IC [7]
ICM: A61F002-02
EXF 623/1; 623/2; 623/11; 623/12; 623/66; 424/195.1; 424/424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 275 OF 365 USPATFULL on STN
AN 2000:27800 USPATFULL
TI Recombinant swinepox virus
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, Lenexa, KS, United States (U.S. corporation)
PI US 6033904 20000307
AI US 1995-480640 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-375922, filed on 19 Jan 1995 which is a continuation-in-part of Ser. No. WO 1994-US8277, filed on 22 Jul 1994 which is a continuation-in-part of Ser. No. US 1993-97554, filed on 22 Jul 1993, now patented, Pat. No. US 5869312 And a continuation-in-part of Ser. No. US 1992-820154, filed on 13 Jan 1992, now patented, Pat. No. US 5382425, issued on 17 Jan 1995
DT Utility
FS Granted
LN.CNT 8999
INCL INCLM: 435/320.100
INCLS: 435/235.100; 435/069.100; 424/204.100; 424/232.100; 530/350.000; 935/057.000; 935/070.000
NCL NCLM: 435/320.100
NCLS: 424/204.100; 424/232.100; 435/069.100; 435/235.100; 530/350.000
IC [7]
ICM: C12N007-01
ICS: C12N015-86; A61K039-12
EXF 424/199.1; 424/204.1; 424/232.1; 435/320.1; 435/69.1; 435/240.2; 435/235.1; 530/350; 536/23.72; 935/70; 935/57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 276 OF 365 USPATFULL on STN
AN 2000:21430 USPATFULL
TI Carbon monoxide dependent guanyly cyclase modifiers and methods of use
IN Glasky, Alvin J., 12231 Pevero, Tustin, CA, United States 92680
PI US 6027936 20000222
AI US 1998-86878 19980529 (9)
RLI Division of Ser. No. US 1995-488976, filed on 8 Jun 1995, now patented, Pat. No. US 5801184 which is a continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jul 1994, now patented, Pat. No. US 5447936
DT Utility
FS Granted
LN.CNT 1966
INCL INCLM: 435/325.000
INCLS: 514/045.000; 514/310.000; 514/262.000; 544/265.000; 544/276.000; 435/007.210
NCL NCLM: 435/325.000
NCLS: 435/007.210; 514/045.000; 514/263.380; 514/310.000; 544/265.000; 544/276.000
IC [7]
ICM: C12N005-00
ICS: A01N043-04; A01N043-42; A01N043-90; C07D473-00
EXF 514/310; 514/262; 514/45; 544/265; 544/276; 435/7.21; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 277 OF 365 USPATFULL on STN
AN 2000:18280 USPATFULL
TI Nucleic acid sequence of senescence asssociated gene
IN Funk, Walter, Hayward, CA, United States
PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6025194 20000215
AI US 1997-974180 19971119 (8)

FS Granted
LN.CNT 4667
INCL INCLM: 435/320.100
INCLS: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000
NCL NCLM: 435/320.100
NCLS: 435/325.000; 536/023.100; 536/023.500; 536/024.100
IC [7]
ICM: C07H021-04
ICS: C12N015-63; C12N015-85; C12N015-11
EXF 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 278 OF 365 USPATFULL on STN
AN 2000:4404 USPATFULL
TI Nucleic acid containing composition, preparation and uses of same
IN Behr, Jean-Paul, Strasbourg, France
Demeneix, Barbara, Paris, France
Lezoualch, Franck, Paris, France
Mergny, Mojgan, Ivry Sur Seine, France
Scherman, Daniel, Paris, France
Boussif, Otmane, Strasbourg, France
PA Rhone-Poulenc Rorer SA, Anthony Cedex, France (non-U.S. corporation)
PI US 6013240 20000111
WO 9602655 19960201
AI US 1997-765679 19970228 (8)
WO 1995-FR914 19950707
19970228 PCT 371 date
19970228 PCT 102(e) date
PRAI FR 1994-8735 19940713
DT Utility
FS Granted
LN.CNT 796
INCL INCLM: 424/001.210
INCLS: 435/006.000; 514/044.000
NCL NCLM: 424/001.210
NCLS: 435/006.000; 514/044.000
IC [6]
ICM: A61K009-127
EXF 435/6; 514/44; 264/4.1; 424/1.21; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 279 OF 365 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2000-350295 [30] WPIDS
DNC C2000-106478
TI Compositions comprising a biologically active agent encapsulated by a carboxylic acid, useful for the oral delivery of pharmaceutical agents.
DC B05 C02 C03 D16
IN RUSSELL-JONES, G J
PA (BIOT-N) BIOTECH AUSTRALIA PTY LTD
CYC 89
PI WO 2000022909 A2 20000427 (200030)* EN 31 A61K047-12
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU 2000010712 A 20000508 (200037) A61K047-12
ADT WO 2000022909 A2 WO 1999-IB1872 19991018; AU 2000010712 A AU 2000-10712 19991018
FDT AU 2000010712 A Based on WO 2000022909
PRAI US 1998-104827P 19981019
IC ICM A61K047-12

L4 ANSWER 280 OF 365 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2000-317974 [27] WPIDS
CR 2000-317973 [27]; 2001-266304 [27]; 2003-576612 [54]
DNC C2000-096325
TI Genetic element for producing and delivering single-stranded DNA, comprises a gene encoding reverse transcriptase and a sequence of interest flanked by an inverted tandem repeat and primer binding site.
DC B04 D16
IN CONRAD, C A
PA (INGE-N) INGENE INC
CYC 91

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 9962988 A 20000501 (200036)
EP 1119615 A1 20010801 (200144) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
BR 9914773 A 20020205 (200213)
JP 2004503203 W 20040205 (200412) 201 C12N015-09
MX 2001003643 A1 20030701 (200420) A61K031-711

ADT WO 2000022114 A1 WO 1999-US23936 19991012; AU 9962988 A AU 1999-62988 19991012; EP 1119615 A1 EP 1999-950296 19991012, WO 1999-US23936 19991012; BR 9914773 A BR 1999-14773 19991012, WO 1999-US23936 19991012; JP 2004503203 W WO 1999-US23936 19991012, JP 2000-576005 19991012; MX 2001003643 A1 WO 1999-US23936 19991012, MX 2001-3643 20010409

FDT AU 9962988 A Based on WO 2000022114; EP 1119615 A1 Based on WO 2000022114; BR 9914773 A Based on WO 2000022114; JP 2004503203 W Based on WO 2000022114; MX 2001003643 A1 Based on WO 2000022114

PRAI US 1999-411568 19991004; US 1998-169793 19981009; US 1999-397782 19990916

IC ICM A61K031-711; C12N015-09; C12N015-10
ICS A61K035-76; A61K048-00; C12N001-15; C12N001-19; C12N001-21; C12N005-10; C12N015-11; C12N015-85; C12P019-34; G01N033-15; G01N033-50

L4 ANSWER 281 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 47
AN 2000:494613 CAPLUS
DN 133:160235
TI A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican
AU Zou, Kun; Muramatsu, Hisako; Ikematsu, Shinya; Sakuma, Sadatoshi; Salama, Ragaa H. M.; Shinomura, Tamayuki; Kimata, Koji; Muramatsu, Takashi
CS Department of Biochemistry, Nagoya University School of Medicine, Nagoya, 466-8550, Japan
SO European Journal of Biochemistry (2000), 267(13), 4046-4053
CODEN: EJBCAI; ISSN: 0014-2956
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 282 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 48
AN 2000:178701 BIOSIS
DN PREV200000178701
TI ***Pleiotrophin*** signals increased tyrosine phosphorylation of beta-catenin through inactivation of the intrinsic catalytic activity of the ***receptor*** -type protein tyrosine phosphatase beta/zeta.
AU Meng, Kung; Rodriguez-Pena, A.; Dimitrov, Todor; Chen, Wen; Yamin, Moshe; Noda, Masaharu; Deuel, Thomas F. [Reprint author]
CS Division of Growth Regulation, Department of Medicine, Beth Israel Deacones Medical Center, Harvard Medical School, Boston, MA, 02215, USA
SO Proceedings of the National Academy of Sciences of the United States of America, (March 14, 2000) Vol. 97, No. 6, pp. 2603-2608. print.
CODEN: PNASA6. ISSN: 0027-8424.
DT Article
LA English
ED Entered STN: 11 May 2000
Last Updated on STN: 4 Jan 2002

L4 ANSWER 283 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:360822 SCISEARCH
GA The Genuine Article (R) Number: 311PL
TI ErbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation
AU Hsieh S S; Malerczyk C; Aigner A; Czubayko F (Reprint)
CS MED FORSCHUNGSEINRICHTUNGEN, KARL FRISCH STR 1, D-35033 MARBURG, GERMANY (Reprint); UNIV MARBURG, DEPT PHARMACOL & TOXICOL, MARBURG, GERMANY
CYA GERMANY
SO INTERNATIONAL JOURNAL OF CANCER, (1 JUN 2000) Vol. 86, No. 5, pp. 644-651.

NY 10158-0012.
ISSN: 0020-7136.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 21
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 284 OF 365 CANCERLIT on STN DUPLICATE 49
AN 2000119358 CANCERLIT
DN 20119358 PubMed ID: 10652254
TI Regulation of cell migration by amphoterin.
AU Fages C; Nolo R; Huttunen H J; Eskelinen E; Rauvala H
CS Laboratory of Molecular Neurobiology, Institute of Biotechnology, Division of Biochemistry, Department of Biosciences, Viikinkaari 5, FIN-00014 University of Helsinki, Finland.
SO JOURNAL OF CELL SCIENCE, (2000 Feb) 113 (Pt 4) 611-20.
Journal code: 0052457. ISSN: 0021-9533.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2000119358
EM 200004
ED Entered STN: 20000515
Last Updated on STN: 20000515

L4 ANSWER 285 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2000:30687452 BIOTECHNO
TI Heparin-binding proteins HB-GAM (***pleiotrophin***) and amphoterin in the regulation of cell motility
AU Rauvala H.; Huttunen H.J.; Fages C.; Kaksonen M.; Kinnunen T.; Imai S.; Raulo E.; Kilpelainen I.
CS H. Rauvala, Programme of Molecular Neurobiology, Institute of Biotechnology, University of Helsinki, Viikinkaari 5, FIN-00014 Helsinki, Finland.
E-mail: heikki.rauvala@helsinki.fi
SO Matrix Biology, (2000), 19/5 (377-387), 50 reference(s)
CODEN: MTBOEC ISSN: 0945-053X
PUI S0945053X00000846
DT Journal; General Review
CY Netherlands
LA English
SL English

L4 ANSWER 286 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:349691 SCISEARCH
GA The Genuine Article (R) Number: 310FX
TI Reversal of HER-2 over-expression renders ***human*** ovarian cancer cells highly resistant to taxol
AU Aigner A; Hsieh S S; Malerczyk C; Czubayko F (Reprint)
CS UNIV MARBURG, DEPT PHARMACOL & TOXICOL, FORSCHUNGSEINRICHTUNGEN, KARL FRISCH STR 1, D-35033 MARBURG, GERMANY (Reprint); UNIV MARBURG, DEPT PHARMACOL & TOXICOL, FORSCHUNGSEINRICHTUNGEN, D-35033 MARBURG, GERMANY; CARDIOVASC RES ELI LILLY & CO, LILLY CORP CTR, INDIANAPOLIS, IN 46285
CYA GERMANY; USA
SO TOXICOLOGY, (3 APR 2000) Vol. 144, No. 1-3, pp. 221-228.
Publisher: ELSEVIER SCI IRELAND LTD, CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND.
ISSN: 0300-483X.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 26
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 287 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:82557 BIOSIS
DN PREV200100082557
TI KGF-induced gene expression in MCF-7 cells using cDNA expression arrays.
AU Zang, X. [Reprint author]; Learner, M. L.; Brackett, D. J.; Pento, J. T. [Reprint author]

USA
SO Breast Cancer Research and Treatment, (November, 2000) Vol. 64, No. 1, pp. 110. print.
Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium. San antonio, Texas, USA. December 06-09, 2000. Cancer Therapy and Research Center Research Foundation.
CODEN: BCTRD6. ISSN: 0167-6806.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L4 ANSWER 288 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2001074571 EMBASE
TI Molecular mechanisms of tumor angiogenesis and tumor progression.
AU Cavallaro U.; Christofori G.
CS G. Christofori, Res. Inst. of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria. christofori@nt.imp.univie.ac.at
SO Journal of Neuro-Oncology, (2000) 50/1-2 (63-70).
Refs: 80
ISSN: 0167-594X CODEN: JNODD2
CY United States
DT Journal; General Review
FS 016 Cancer
030 Pharmacology
022 Human Genetics
037 Drug Literature Index
LA English
SL English

L4 ANSWER 289 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:825599 CAPLUS
DN 135:14997
TI Differential gene expression of rat neonatal heart analyzed by suppression subtractive hybridization and expressed sequence tag sequencing
AU Chim, Stephen S.; Cheung, Simon S. F.; Tsui, Stephen K. W.
CS Department of Biochemistry, The Chinese University of Hong Kong, Hong Kong, Peop. Rep. China
SO Journal of Cellular Biochemistry (2000), 80(1), 24-36
CODEN: JCEBD5; ISSN: 0730-2312
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 290 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2000119321 EMBASE
TI The endometrium and hormone replacement: Safety and bleeding.
AU Rees M.
CS Dr. M. Rees, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
SO Journal of the British Menopause Society, (2000) 6/SUPPL. 1 (6-9).
Refs: 42
ISSN: 1362-1807 CODEN: JBMSFN
CY United Kingdom
DT Journal; Conference Article
FS 030 Pharmacology
037 Drug Literature Index
010 Obstetrics and Gynecology
016 Cancer
029 Clinical Biochemistry
003 Endocrinology
LA English

L4 ANSWER 291 OF 365 CANCERLIT on STN DUPLICATE 51
AN 2000278617 CANCERLIT
DN 20278617 PubMed ID: 10818676
TI New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
AU Cherrington J M; Strawn L M; Shawver L K
CS SUGEN, Inc., South San Francisco, CA 94080, USA.

Journal code: 0370416. ISSN: 0065-230X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2000390031
EM 200008
ED Entered STN: 20000920
Last Updated on STN: 20000920

L4 ANSWER 292 OF 365 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:862471 PROMT
TITLE: A question of blood supply.(therapeutic angiogenesis)
AUTHOR(S): West, David C.
SOURCE: Chemistry and Industry, (15 Mar 1999) No. 6, pp. 214(5).
ISSN: ISSN: 0009-3068.
PUBLISHER: Society of Chemical Industry
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 4407
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 293 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:795994 CAPLUS
DN 132:31744
TI Gene probes used for genetic profiling in healthcare screening and planning
IN Roberts, Gareth Wyn
PA Genostic Pharma Ltd., UK
SO PCT Int. Appl., 745 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964627	A2	19991216	WO 1999-GB1780	19990604
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 1998-12099	A	19980606		
	GB 1998-13291	A	19980620		
	GB 1998-13611	A	19980624		
	GB 1998-13835	A	19980627		
	GB 1998-14110	A	19980701		
	GB 1998-14580	A	19980707		
	GB 1998-15438	A	19980716		
	GB 1998-15574	A	19980718		
	GB 1998-15576	A	19980718		
	GB 1998-16085	A	19980724		
	GB 1998-16086	A	19980724		
	GB 1998-16921	A	19980805		
	GB 1998-17097	A	19980807		
	GB 1998-17200	A	19980808		
	GB 1998-17632	A	19980814		
	GB 1998-17943	A	19980819		

L4 ANSWER 294 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:795993 CAPLUS
DN 132:31743
TI Gene probes used for genetic profiling in healthcare screening and planning
IN Roberts, Gareth Wyn
PA Genostic Pharma Limited, UK
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964626	A2	19991216	WO 1999-GB1779	19990604
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2330929	AA	19991216	CA 1999-2330929	19990604
	AU 9941586	A1	19991230	AU 1999-41586	19990604
	AU 766544	B2	20031016		
	AU 9941587	A1	19991230	AU 1999-41587	19990604
	GB 2339200	A1	20000119	GB 1999-12914	19990604
	GB 2339200	B2	20010912		
	EP 1084273	A1	20010321	EP 1999-925207	19990604
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2003528564	T2	20030930	JP 2000-553616	19990604
	US 2003198970	A1	20031023	US 2002-206568	20020729
PRAI	GB 1998-12098	A	19980606		
	GB 1998-28289	A	19981223		
	GB 1998-16086	A	19980724		
	GB 1998-16921	A	19980805		
	GB 1998-17097	A	19980807		
	GB 1998-17200	A	19980808		
	GB 1998-17632	A	19980814		
	GB 1998-17943	A	19980819		
	US 1999-325123	B1	19990603		
	WO 1999-GB1779	W	19990604		

L4 ANSWER 295 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:808543 CAPLUS
DN 132:69305
TI Bispecific antibodies for the targeted coagulation of tumor vasculature
IN Thorpe, Philip E.; Edgington, Thomas S.
PA Board of Regents, the University of Texas System, USA; The Scripps Research Institute
SO U.S., 83 pp., Cont.-in-part of U.S. Ser. No. 273,567, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004555	A	19991221	US 1995-487427	19950607
	EP 1306095	A2	20030502	EP 2002-24529	19930305
	EP 1306095	A3	20030625		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	US 5855866	A	19990105	US 1994-205330	19940302
	JP 2003055398	A2	20030226	JP 2002-164988	19950607
PRAI	US 1992-846349	B2	19920305		
	US 1994-205330	A2	19940302		
	US 1994-273567	B2	19940711		
	EP 1993-906289	A3	19930305		
	JP 1996-504299	A3	19950607		

RE.CNT 215 THERE ARE 215 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 296 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:166214 CAPLUS
DN 130:213618
TI Tissue factor compositions and ligands for the specific coagulation of vasculature
IN Thorpe, Philip E.; Edgington, Thomas S.
PA The Scripps Research Institute, USA; Board of Regents, the University of Texas System
SO U.S., 83 pp., Cont.-in-part of U.S. Ser. No. 273,567.
CODEN: USXXAM
DT Patent

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5877289	A	19990302	US 1995-479733	19950607
	EP 1306095	A2	20030502	EP 2002-24529	19930305
	EP 1306095	A3	20030625		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	US 5855866	A	19990105	US 1994-205330	19940302
	JP 2003055398	A2	20030226	JP 2002-164988	19950607
PRAI	US 1992-846349	A2	19920305		
	US 1994-205330	A2	19940302		
	US 1994-273567	A2	19940711		
	EP 1993-906289	A3	19930305		
	JP 1996-504299	A3	19950607		

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 297 OF 365 USPATFULL on STN
AN 1999:163226 USPATFULL
TI Recombinant fowlpox viruses and uses thereof
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, Lenexa, KS, United States (U.S. corporation)
PI US 6001369 19991214
AI US 1995-477459 19950607 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US2252, filed on 28 Feb 1994 which is a continuation of Ser. No. US 1993-24156, filed on 26 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3668
INCL INCLM: 424/199.100
INCLS: 424/214.100; 424/229.100; 424/093.200; 424/232.100; 435/235.100; 435/320.100
NCL NCLM: 424/199.100
NCLS: 424/093.200; 424/214.100; 424/229.100; 424/232.100; 435/235.100; 435/320.100
IC [6]
ICM: A61K039-295
ICS: A61K039-275; C12N007-01
EXF 435/235.1; 435/320.1; 424/199.1; 424/85.1; 424/85.4; 424/214.1; 424/229.1; 424/232.1; 424/93.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 298 OF 365 USPATFULL on STN
AN 1999:125034 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 5965698 19991012
AI US 1996-532818 19960503 (8)
RLI Continuation-in-part of Ser. No. US 143364
DT Utility
FS Granted
LN.CNT 2272
INCL INCLM: 530/326.000
INCLS: 530/324.000; 530/300.000; 530/333.000; 530/380.000; 548/533.000
NCL NCLM: 530/326.000
NCLS: 530/300.000; 530/324.000; 530/333.000; 530/380.000; 548/533.000
IC [6]
ICM: A61K038-04
ICS: A61K038-10; A61K038-16; A61K038-36
EXF 530/326; 514/13; 548/533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 299 OF 365 USPATFULL on STN
AN 1999:124475 USPATFULL
TI Recombinant chimeric virus and uses thereof
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
Wild, Martha A., San Diego, CA, United States
Singer, Phillip A., San Diego, CA, United States

PI US 5965138 19991012
AI US 1994-362240 19941222 (8)
RLI Continuation of Ser. No. US 1994-288065, filed on 9 Aug 1994 And a continuation-in-part of Ser. No. WO 1993-US5681, filed on 14 Jun 1993 Ser. No. Ser. No. US 1992-898087, filed on 12 Jun 1992, now abandoned Ser. No. Ser. No. US 1988-225032, filed on 21 Jul 1988, now patented, Pat. No. US 5223424, issued on 29 Jun 1993 Ser. No. Ser. No. US 1991-649380, filed on 31 Jan 1991, now abandoned And Ser. No. US 1992-914057, filed on 13 Jul 1992, now abandoned which is a continuation of Ser. No. US 1991-696262, filed on 30 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-933107, filed on 20 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-773430, filed on 6 Sep 1985, now patented, Pat. No. US 4877737, issued on 31 Oct 1989 And Ser. No. US 1986-823102, filed on 27 Jan 1986, now patented, Pat. No. US 5068192 , said Ser. No. US 288065 which is a continuation of Ser. No. US 1993-23610, filed on 26 Feb 1993 , said Ser. No. US 225032 which is a continuation-in-part of Ser. No. US 1987-78519, filed on 27 Jul 1987, now abandoned Ser. No. Ser. No. US 1986-933107, filed on 20 Nov 1986, now abandoned Ser. No. Ser. No. US 1986-902887, filed on 2 Sep 1986, now abandoned Ser. No. Ser. No. US 1986-823102, filed on 27 Jan 1986, now patented, Pat. No. US 5068192, issued on 26 Nov 1991 And Ser. No. US 1985-773430, filed on 6 Sep 1985, now patented, Pat. No. US 4877737, issued on 31 Oct 1989 , said Ser. No. US 649380 which is a continuation of Ser. No. US 78519 which is a continuation-in-part of Ser. No. US 993107 Ser. No. Ser. No. US 902877 Ser. No. Ser. No. US 1986-887140, filed on 17 Jul 1986, now abandoned Ser. No. Ser. No. US 823102 And Ser. No. US 773430
DT Utility
FS Granted
LN.CNT 6177
INCL INCLM: 424/199.100
INCLS: 424/186.100; 424/201.100; 424/202.100; 424/204.100; 424/214.100; 424/229.100; 424/222.100; 435/320.100; 435/069.100; 435/235.100; 435/240.100; 435/240.200; 536/023.720; 536/024.200; 536/023.510; 536/023.520; 536/023.200
NCL NCLM: 424/199.100
NCLS: 424/186.100; 424/201.100; 424/202.100; 424/204.100; 424/214.100; 424/222.100; 424/229.100; 435/069.100; 435/235.100; 435/320.100; 536/023.200; 536/023.510; 536/023.520; 536/023.720; 536/024.200
IC [6]
ICM: A61K039-12
ICS: A61K039-295; C12N015-00; C12P021-06
EXF 424/186.1; 424/199.1; 424/201.1; 424/202.1; 424/204.1; 424/214.1; 424/229.1; 424/222.1; 435/69.3; 435/69.1; 435/235.1; 435/240.1; 435/240.2; 435/320.1; 536/23.72; 536/24.2; 536/23.51; 536/23.52; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 300 OF 365 USPATFULL on STN
AN 1999:110454 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 5952465 19990914
AI US 1998-207621 19981209 (9)
RLI Continuation of Ser. No. US 532818
DT Utility
FS Granted
LN.CNT 2281
INCL INCLM: 530/333.000
INCLS: 530/326.000; 530/327.000; 530/328.000; 548/533.000; 424/185.100; 424/278.100
NCL NCLM: 530/333.000
NCLS: 424/185.100; 424/278.100; 530/326.000; 530/327.000; 530/328.000; 548/533.000
IC [6]
ICM: C07K007-06
ICS: C07K003-08; A61K037-02; A61K038-04
EXF 530/333; 530/326-328; 548/533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 301 OF 365 USPATFULL on STN

TI Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 5948887 19990907
AI US 1997-933402 19970919 (8)
RLI Division of Ser. No. US 532818
DT Utility
FS Granted
LN.CNT 2303
INCL INCLM: 530/333.000
INCLS: 548/533.000
NCL NCLM: 530/333.000
NCLS: 548/533.000
IC [6]
ICM: C07K007-06
ICS: C07K003-08; A61K037-02; A61K038-04
EXF 530/333; 548/533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 302 OF 365 USPATFULL on STN
AN 1999:102789 USPATFULL
TI Nucleic acid-containing composition, preparation and use thereof
IN Scherman, Daniel, Paris, France
Byk, Gerardo, Creteil, France
Schwartz, Bertrand, Maisons Alfort, France
PA Rhone-Poulenc Rorer SA, Anthony Cedex, France (non-U.S. corporation)
PI US 5945400 19990831
WO 9625508 19960822
AI US 1997-894339 19970815 (8)
WO 1996-FR248 19960215
19970815 PCT 371 date
19970815 PCT 102(e) date
PRAI FR 1995-1865 19950217
DT Utility
FS Granted
LN.CNT 1321
INCL INCLM: 514/013.000
INCLS: 514/012.000; 514/014.000; 514/015.000; 530/300.000; 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 514/013.000
NCLS: 514/012.000; 514/014.000; 514/015.000; 530/300.000; 530/326.000; 530/327.000; 530/328.000
IC [6]
ICM: A61K038-10
ICS: A61K038-08; C07K009-00; C07K007-00
EXF 514/13; 514/14; 514/15; 514/12; 530/300; 530/326; 530/327; 530/328; 935/52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 303 OF 365 USPATFULL on STN
AN 1999:92535 USPATFULL
TI Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
IN Israeli, Ron S., Staten Island, NY, United States
Heston, Warren D. W., New York, NY, United States
Fair, William R., New York, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 5935818 19990810
AI US 1995-394152 19950224 (8)
DT Utility
FS Granted
LN.CNT 4384
INCL INCLM: 435/069.300
INCLS: 435/325.000; 435/362.000; 435/365.000; 435/252.300; 435/320.100; 435/069.300; 435/348.000; 536/023.500; 536/024.100
NCL NCLM: 435/069.300
NCLS: 435/252.300; 435/320.100; 435/325.000; 435/348.000; 435/362.000; 435/365.000; 536/023.500; 536/024.100
IC [6]
ICM: C12P021-06
EXF 435/69.3; 435/320.1; 435/252.3; 435/325; 435/362; 435/365; 435/348;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 304 OF 365 USPATFULL on STN
AN 1999:85247 USPATFULL
TI Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site
IN Evans, Herbert J., Richmond, VA, United States
Kini, R. Manjunatha, Singapore, Singapore
PA Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)
PI US 5928896 19990727
AI US 1997-934222 19970919 (8)
RLI Division of Ser. No. US 532818
DT Utility
FS Granted
LN.CNT 2316
INCL INCLM: 435/069.100
INCLS: 435/091.200; 530/300.000; 530/324.000
NCL NCLM: 435/069.100
NCLS: 435/091.200; 530/300.000; 530/324.000
IC [6]
ICM: C12P021-06
ICS: C12P019-34; A61K038-04
EXF 530/333; 435/91.2; 435/69.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 305 OF 365 USPATFULL on STN
AN 1999:81550 USPATFULL
TI Recombinant fowlpox viruses and uses thereof
IN Cochran, Mark D., Carlsbad, CA, United States
Junker, David E., San Diego, CA, United States
PA Syntro Corporation, Lenexa, KS, United States (U.S. corporation)
PI US 5925358 19990720
AI US 1995-484575 19950607 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US2252, filed on 28 Feb 1994 which is a continuation of Ser. No. US 1993-24156, filed on 26 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3589
INCL INCLM: 424/199.100
INCLS: 424/232.100; 435/235.100; 435/320.100
NCL NCLM: 424/199.100
NCLS: 424/232.100; 435/235.100; 435/320.100
IC [6]
ICM: A61K039-275
ICS: C12N007-01
EXF 435/235.1; 435/320.1; 435/69.1; 435/69.3; 435/172.3; 424/199.1; 424/93.2; 935/65
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 306 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 52
AN 1999:248407 BIOSIS
DN PREV199900248407
TI Domain structure of ***pleiotrophin*** required for transformation.
AU Zhang, Nan; Zhong, Rong; Deuel, Thomas F. [Reprint author]
CS Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA, 02215, USA
SO Journal of Biological Chemistry, (May 7, 1999) Vol. 274, No. 19, pp. 12959-12962. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 2 Jul 1999
Last Updated on STN: 2 Jul 1999

L4 ANSWER 307 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 1999:29215480 BIOTECHNO
TI A ***receptor*** -like protein-tyrosine phosphatase PTP.zeta./RPTP.beta. binds a heparin-binding growth factor midkine: Involvement of arginine 78 of midkine in the high affinity binding to PTP.zeta.
AU Maeda N.; Ichihara-Tanaka K.; Kimura T.; Kadomatsu K.; Muramatsu T.; Noda

CS M. Noda, Division of Molecular Neurobiology, National Institute for Basic Biology, 38 Nishigonaka, Myodaiji-cho, Okazaki 444-8585, Japan. E-mail: madon@nibb.ac.jp
SO Journal of Biological Chemistry, (30 APR 1999), 274/18 (12474-12479), 30 reference(s)
CODEN: JBCHA3 ISSN: 0021-9258
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 308 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 1999:29512725 BIOTECHNO
TI Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin ***receptor*** and sensitivity to diphtheria toxin in ***human*** neutrophils
AU Vinante F.; Marchi M.; Rigo A.; Scapini P.; Pizzolo G.; Cassatella M.A.
CS Dr. F. Vinante, Cattedra di Ematologia, Policlinico GB Rossi, 37134 Verona, Italy.
E-mail: VINANTE@borgoroma.univnit
SO Blood, (01 NOV 1999), 94/9 (3169-3177), 65 reference(s)
CODEN: BLOOAW ISSN: 0006-4971
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 309 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:6679 CAPLUS
DN 132:178466
TI Gene expression profiles of ***human*** fetal nasopharyngeal tissue
AU He, Zhi-Wei; Xu, Liang-Guo; Xie, Lu; Zhang, Ling; Lan, Ke; Ren, Cai-Ping; Yao, Kai-Tai
CS Cancer Research Institute, Hunan Medical University, Changsha, 410078, Peop. Rep. China
SO Shengwu Huaxue Yu Shengwu Wuli Xuebao (1999), 31(6), 711-714
CODEN: SHWPAU; ISSN: 0582-9879
PB Shanghai Kexue Jishu Chubanshe
DT Journal
LA Chinese

L4 ANSWER 310 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:738584 CAPLUS
DN 132:33745
TI Expression of proteoglycan core proteins in ***human*** bone marrow stroma
AU Schofield, Karen P.; Gallagher, John T.; David, Guido
CS Department of Medical Oncology, Paterson Institute for Cancer Research, Manchester, M20 4BX, UK
SO Biochemical Journal (1999), 343(3), 663-668
CODEN: BIJOAK; ISSN: 0264-6021
PB Portland Press Ltd.
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 311 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:53102 CAPLUS
DN 132:306779
TI Expression pattern alterations of syndecans and glypican-1 in normal and pathological trophoblast
AU Crescimanno, Caterina; Marzioni, Daniela; Paradinas, Fernando J.; Schrurs, Brigitte; Muhlhauser, Judith; Todros, Tullia; Newlands, Edward; David, Guido; Castellucci, Mario
CS Institute of Anatomy and Histology, University of Verona, Italy
SO Journal of Pathology (1999), 189(4), 600-608
CODEN: JPTLAS; ISSN: 0022-3417
PB John Wiley & Sons Ltd.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 312 OF 365 CANCERLIT on STN DUPLICATE 55
AN 1999377411 CANCERLIT
DN 99377411 PubMed ID: 10448302
TI Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor.
AU Godden J L; Edward M; MacKie R M
CS Department of Dermatology, University of Glasgow, U.K.
SO EUROPEAN JOURNAL OF CANCER, (1999 Mar) 35 (3) 473-80.
Journal code: 9005373. ISSN: 0959-8049.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 1999377411
EM 199908
ED Entered STN: 19990913
Last Updated on STN: 19990913

L4 ANSWER 313 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:37753 SCISEARCH
GA The Genuine Article (R) Number: 271FG
TI Glycosaminoglycans promote HARP/PTN dimerization
AU BernardPierrot I; Heroult M (Reprint); Lemaitre G; Barritault D; Courty J; Milhiet P E
CS UNIV PARIS 12, LAB RECH CROISSANCE CELLULAIRE REPARAT & REGENERA, CNRS UPRESA 7053, F-94010 CRETEIL, FRANCE (Reprint); UNIV PARIS 12, LAB RECH CROISSANCE CELLULAIRE REPARAT & REGENERA, CNRS UPRESA 7053, F-94010 CRETEIL, FRANCE
CYA FRANCE
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (20 DEC 1999) Vol. 266, No. 2, pp. 437-442.
Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495.
ISSN: 0006-291X.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 314 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 56
AN 1999:151739 BIOSIS
DN PREV199900151739
TI Levels of expression of ***pleiotrophin*** and protein tyrosine phosphatase alpha are decreased in ***human*** colorectal cancers.
AU Yamakawa, Taishi; Kurosawa, Nobuyuki; Kadomatsu, Kenji; Matsui, Takanori; Itoh, Katsuki; Maeda, Nobuaki; Noda, Masaharu; Muramatsu, Takashi [Reprint author]
CS Dep. Biochemistry, Nagoya Univ. Sch. Med., 67 Tsurumai-cho, Showa-ku, Nagoya 466, Japan
SO Cancer Letters, (Jan. 8, 1999) Vol. 135, No. 1, pp. 91-96. print.
CODEN: CALEDQ. ISSN: 0304-3835.
DT Article
LA English
ED Entered STN: 13 Apr 1999
Last Updated on STN: 13 Apr 1999

L4 ANSWER 315 OF 365 NTIS COPYRIGHT 2004 NTIS on STN
AN 2000(16):00850 NTIS Order Number: ADA372245/XAB
TI ***Pleiotrophin*** as a Growth Factor and Therapeutic Target in Breast Cancer. Final rept. 15 Sep 94-14 Sep 98.
AU Wellstein, A.
CS Georgetown Univ., Washington, DC. (011489000 153600)
NR ADA372245/XAB
25p; Oct 1998
NC Contract(s): DAMD17-94-J-4445
DT Report
CY United States
LA English
AV Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

OS GRA&I0009

L4 ANSWER 316 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:388630 CAPLUS
DN 129:37207
TI Transfecting composition usable in gene therapy containing viral vector and transfecting agent such as cationic polymers or lipofectants
IN Aubailly, Nathalie; Benoit, Patrick; Branellec, Didier; Le Roux, Aude; Mahfoudi, Abderrahim; Ratet, Nathalie
PA Rhone-Poulenc Rorer S.A., Fr.; Aubailly, Nathalie; Benoit, Patrick; Branellec, Didier; Le Roux, Aude; Mahfoudi, Abderrahim; Ratet, Nathalie
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9823765	A1	19980604	WO 1997-FR2157	19971128
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2756491	A1	19980605	FR 1996-14693	19961129
	FR 2756491	B1	19990108		
	ZA 9701070	A	19970825	ZA 1997-1070	19970210
	AU 9874010	A1	19980622	AU 1998-74010	19971128
	AU 737846	B2	20010830		
	EP 948636	A1	19991013	EP 1997-948959	19971128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	BR 9713434	A	20000201	BR 1997-13434	19971128
	JP 2001514485	T2	20010911	JP 1998-524378	19971128
	NO 9902577	A	19990728	NO 1999-2577	19990528
	KR 2000057307	A	20000915	KR 1999-704738	19990528
PRAI	FR 1996-14693	A	19961129		
	ZA 1996-1109	A	19960212		
	WO 1997-FR2157	W	19971128		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 317 OF 365 USPATFULL on STN
AN 1998:104754 USPATFULL
TI Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
IN Glasky, Alvin J., 12231 Pevero, Tustin, CA, United States 92680
Rathbone, Michel P., 40 Spadine Avenue, Hamilton, Ontario, Canada L8M 2X1
PI US 5801184 19980901
AI US 1995-488976 19950608 (8)
RLI Continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jul 1994, now patented, Pat. No. US 5447939
DT Utility
FS Granted
LN.CNT 1987
INCL INCLM: 514/310.000
INCLS: 514/262.000; 544/265.000; 544/276.000
NCL NCLM: 514/310.000
NCLS: 514/263.380; 544/265.000; 544/276.000
IC [6]
ICM: A01N043-42
ICS: A01N043-90; C07D473-00
EXF 514/310; 514/262; 544/265; 544/276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 318 OF 365 USPATFULL on STN
AN 1998:104116 USPATFULL
TI Method and construct for producing graft tissue from an extracellular matrix
IN Bell, Eugene, Boston, MA, United States
PA Tissue Engineering, Inc., Boston, MA, United States (U.S. corporation)
PI US 5800537 19980901
AI US 1995-471535 19950606 (8)

which is a continuation of Ser. No. US 1992-926885, filed on 7 Aug 1992, now abandoned
DT Utility
FS Granted
LN.CNT 708
INCL INCLM: 623/011.000
INCLS: 623/066.000; 424/195.100
NCL NCLM: 424/093.100
IC [6]
ICM: A61F002-02
EXF 623/1; 623/2; 623/11; 623/12; 623/15; 623/16; 623/66; 424/195.1; 424/424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 319 OF 365 USPATFULL on STN
AN 1998:33576 USPATFULL
TI Hematopoietic cells: compositions and methods
IN Taichman, Russell S., Ann Arbor, MI, United States
Emerson, Stephen G., Wayne, PA, United States
PA The Regent of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
PI US 5733541 19980331
AI US 1995-426792 19950421 (8)
DT Utility
FS Granted
LN.CNT 3768
INCL INCLM: 424/093.100
INCLS: 424/093.700; 435/325.000; 435/347.000; 435/377.000; 435/373.000; 435/375.000
NCL NCLM: 424/093.100
NCLS: 424/093.700; 435/325.000; 435/347.000; 435/373.000; 435/375.000; 435/377.000
IC [6]
ICM: A01N063-02
ICS: C12N005-00; C12N005-06
EXF 435/325; 435/347; 435/355; 435/373; 435/375; 435/384; 435/385; 435/386; 435/240.1; 424/93.1; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 320 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 57
AN 1998:132448 BIOSIS
DN PREV199800132448
TI Midkine induces tumor cell proliferation and binds to a high affinity signaling ***receptor*** associated with JAK tyrosine kinases.
AU Ratovitski, Edward A. [Reprint author]; Kotzbauer, Paul T.; Milbrandt, Jeffrey; Lowenstein, Charles J.; Burrow, Christopher R.
CS Dep. Pathol., Johns Hopkins Univ. Sch. Med., 950 Ross Build., 720 Rutland Ave., Baltimore, MD 21205, USA
SO Journal of Biological Chemistry, (Feb. 6, 1998) Vol. 273, No. 6, pp. 3654-3660. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 20 Mar 1998
Last Updated on STN: 4 May 1998

L4 ANSWER 321 OF 365 CANCERLIT on STN DUPLICATE 58
AN 1999130708 CANCERLIT
DN 99130708 PubMed ID: 9931916
TI [Ribozyme targeting as gene therapy method for treatment of malignant tumors].
Ribozym-targeting als gentherapeutisches Verfahren zur Behandlung maligner Tumore.
AU Juhl H; Czubayko F; Henne-Bruns D
CS Klinik fur Allgemeine Chirurgie und Thoraxchirurgie der Christian-Albrechts-Universitat, Kiel.
SO LANGENBECKS ARCHIV FUR CHIRURGIE. SUPPLEMENT. KONGRESSBAND, (1998) 115 1474-7.
Journal code: 9200456. ISSN: 0942-2854.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS MEDLINE; Priority Journals
OS MEDLINE 1999130708
EM 199904

Last Updated on STN: 19990519

L4 ANSWER 322 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1998408136 EMBASE
TI Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM).
AU Imai S.; Kaksonen M.; Raulo E.; Kinnunen T.; Fages C.; Meng X.; Lakso M.; Rauvala H.
CS Dr. S. Imai, Department of Anatomy, Shiga University of Medical Science, Setatsukinowa-cho, Otsu-shi, Shiga-ken 520-2192, Japan. simai@belle.shiga-med.ac.jp
SO Journal of Cell Biology, (16 Nov 1998) 143/4 (1113-1128).
Refs: 51
ISSN: 0021-9525 CODEN: JCLBA3
CY United States
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 323 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999016085 EMBASE
TI Regulation of protein-DNA interactions at the interferon-.gamma. gene promoter by corticosteroids. Implications for inflammatory bowel diseases.
AU Barbulescu K.; Becker C.; Zum Buschenfelde K.-H.M.; Neurath M.F.
CS Dr. M.F. Neurath, Laboratory of Immunology, I, Medical Clinic, University of Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
SO Annals of the New York Academy of Sciences, (1998) 859/- (194-197).
Refs: 6
ISSN: 0077-8923 CODEN: ANYAA
CY United States
DT Journal; Conference Article
FS 022 Human Genetics
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
048 Gastroenterology
LA English
SL English

L4 ANSWER 324 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999053735 EMBASE
TI Topography of amphiregulin expression in cultured ***human*** keratinocytes: Colocalization with the epidermal growth factor ***receptor*** and CD44.
AU Nylander N.; Smith L.T.; Underwood R.A.; Piepkorn M.
CS M. Piepkorn, Univ. of Washington Sch. of Medicine, Division of Dermatology, Box 356524, Seattle, WA 98195-6524, United States
SO In Vitro Cellular and Developmental Biology - Animal, (1998) 34/2 (182-188).
Refs: 31
ISSN: 1071-2690 CODEN: ICDBEO
CY United States
DT Journal; Article
FS 001 Anatomy, Anthropology, Embryology and Histology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 325 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 59
AN 1999053081 EMBASE
TI Levels of expression of ***pleiotrophin*** and protein tyrosine phosphatase.zeta. are decreased in ***human*** colorectal cancers.
AU Yamakawa T.; Kurosawa N.; Kadomatsu K.; Matsui T.; Itoh K.; Maeda N.; Noda M.; Muramatsu T.
CS T. Muramatsu, Department of Biochemistry, Nagoya University Sch. Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466, Japan
SO Cancer Letters, (1998) 135/1 (91-96).
Refs: 28
ISSN: 0304-3835 CODEN: CALEDQ
PUI S 0304-3835(98)00275-4

DT Journal; Article
FS 016 Cancer
029 Clinical Biochemistry
048 Gastroenterology
LA English
SL English

L4 ANSWER 326 OF 365 NTIS COPYRIGHT 2004 NTIS on STN
AN 1998(21):04730 NTIS Order Number: AD-A346 541/6/XAB
TI ***Pleiotrophin*** as a Growth Factor and Therapeutic Target in Breast Cancer. Annual rept. 15 Sep 96-14 Sep 97.
AU Wellstein, A.
CS Georgetown Univ., Washington, DC. (011489000 153600)
NR AD-A346 541/6/XAB
75p; Oct 1997
NC Contract(s): DAMD17-94-J-4445
DT Report
CY United States
LA English
AV Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)605-6900; and email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.
NTIS Prices: PC A05/MF A01
OS GRA&I9819

L4 ANSWER 327 OF 365 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:596672 PROMT
TITLE: Cancer Gene Therapy "Adenovirus-Mediated Transduction of Ribozymes Abrogates HER-2/neu and ***Pleiotrophin*** Expression and Inhibits Tumor Cell Proliferation."
SOURCE: Cancer Weekly Plus, (10 Nov 1997) pp. N/A.
LANGUAGE: English
WORD COUNT: 187
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 328 OF 365 USPATFULL on STN
AN 97:68440 USPATFULL
TI Use of fibromodulin to prevent or reduce dermal scarring
IN Ruoslahti, Erkki I., Rancho Santa Fe, CA, United States
Longaker, Michael T., San Francisco, CA, United States
Whitby, David J., Adel, United Kingdom
PA La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S. corporation)
PI US 5654270 19970805
AI US 1994-303238 19940908 (8)
RLI Continuation of Ser. No. US 1992-978931, filed on 17 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-882345, filed on 13 May 1992, now abandoned which is a continuation of Ser. No. US 1991-792192, filed on 14 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-467888, filed on 22 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-212702, filed on 28 Jun 1988, now abandoned
DT Utility
FS Granted
LN.CNT 1648
INCL INCLM: 514/008.000
INCLS: 514/002.000; 435/069.100
NCL NCLM: 514/008.000
NCLS: 435/069.100; 514/002.000
IC [6]
ICM: C07K014-435
ICS: A61K038-17
EXF 514/2; 514/8; 435/69.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 329 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 97:874829 SCISEARCH
GA The Genuine Article (R) Number: YG647
TI HER-2/neu is rate-limiting for ovarian cancer growth - Conditional depletion of HER-2/neu by ribozyme targeting
AU Juhl H; Downing S G; Wellstein A; Czubayko F (Reprint)
CS GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, DEPT PHARMACOL,

CTR, VINCENT T LOMBARDI CANC RES CTR, DEPT PHARMACOL, WASHINGTON, DC 20007; CHRISTIAN ALBRECHTS UNIV KIEL KLINIKUM, DEPT SURG, D-24105 KIEL, GERMANY
CYA USA; GERMANY
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (21 NOV 1997) Vol. 272, No. 47, pp. 29482-29486.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0021-9258.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 22
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 330 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:106072 BIOSIS
DN PREV199800106072
TI Growth factors as targets in tumor gene therapy.
AU Czubayko, F.; Juhl, H.; Aigner, A.; Downing, S. G.; Hsieh, S. S.; Wellstein, A.
CS Georgetown Univ., Lombardi Cancer Cent., Res. Build. E312, 3970 Reservoir Rd. NW, Washington, DC 20007, USA
SO Anticancer Research, (Nov.-Dec., 1997) Vol. 17, No. 6A, pp. 3987. print.
Meeting Info.: International Conference on Gene Therapy in Cancer. Athens, Greece. September 27-30, 1997.
CODEN: ANTRD4. ISSN: 0250-7005.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Mar 1998
Last Updated on STN: 3 Mar 1998

L4 ANSWER 331 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 60
AN 1997:159325 BIOSIS
DN PREV199799458528
TI Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and ***pleiotrophin*** in ***human*** primary breast cancer and its relation to angiogenesis.
AU Relf, Michele; Lejeune, Susan; Scott, Prudence A. E.; Fox, Stephen; Smith, Kenneth; Leek, Russell; Moghaddam, Amir; Whitehouse, Ruth; Bicknell, Roy; Harris, Adrian L. [Reprint author]
CS Mol. angiogenesis Group, Molecular Oncol. Lab., Imperial Cancer Res. Fund, Inst. Mol. Med., John Radcliffe Hosp., Oxford OX3 9DU, UK
SO Cancer Research, (1997) Vol. 57, No. 5, pp. 963-969.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
LA English
ED Entered STN: 15 Apr 1997
Last Updated on STN: 15 Apr 1997

L4 ANSWER 332 OF 365 BIOENG COPYRIGHT on STN 2004 CSADUPLICATE 61
AN 2004347573 BIOENG
DN 4230010
TI Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and ***pleiotrophin*** expression and inhibits tumor cell proliferation
AU Czubayko, F; Downing, SG; Hsieh, SS; Goldstein, DJ; Lu, PY; Trapnell, BC; Wellstein, A
CS Lombardi Cancer Center, Georgetown University, Research Building, E312, 3970 Reservoir Road, NW, Washington DC 20007, USA
SO Gene Therapy [GENE THER.]. Vol. 4, no. 9, pp. 943-949. Sep 1997.
ISSN: 0969-7128
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts; Genetics Abstracts

L4 ANSWER 333 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:709047 CAPLUS
DN 128:20913
TI Proteoglycan synthesis in hematopoietic cells: isolation and

bone-marrow stromal cell line MS-5
AU Drzeniek, Zofia; Siebertz, Barbara; Stocker, Georg; Just, Ursula; Ostertag, Wolfram; Greiling, Helmut; Haubeck, Hans-Dieter
CS Med. Fac., Inst. Clin. Chem. Pathobiochem., Univ. Technol., Aachen, D-52057, Germany
SO Biochemical Journal (1997), 327(2), 473-480
CODEN: BIJOAK; ISSN: 0264-6021
PB Portland Press
DT Journal
LA English
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 334 OF 365 CANCERLIT on STN DUPLICATE 62
AN 1998101055 CANCERLIT
DN 98101055 PubMed ID: 9438174
TI Expression of nine developmental stage-specific genes in ***human*** kidney and cultured renal cells.
AU Haltia A; Solin M L; Muramatsu T; Jalanko H; Holmberg C; Miettinen A; Holthofer H
CS Haartman Institute, Department of Bacteriology and Immunology, University of Helsinki, Finland.. anni.haltia@helsinki.fi
SO EXPERIMENTAL NEPHROLOGY, (1997 Nov-Dec) 5 (6) 457-64.
Journal code: 9302239. ISSN: 1018-7782.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 1998101055
EM 199802
ED Entered STN: 19980417
Last Updated on STN: 19980417

L4 ANSWER 335 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 63
AN 1997:313899 BIOSIS
DN PREV199799604387
TI Midkine stimulates Wilms' tumor cell proliferation via its signaling ***receptor*** .
AU Ratovitski, Edward A. [Reprint author]; Burrow, Christopher R.
CS Dep. Pathol., Johns Hopkins Univ., 950 Ross, 720 Rutland Ave., Baltimore, MD 21287-6417, USA
SO Cellular and Molecular Biology (Noisy-Le-Grand), (1997) Vol. 43, No. 3, pp. 425-431.
DT Article
LA English
ED Entered STN: 26 Jul 1997
Last Updated on STN: 26 Jul 1997

L4 ANSWER 336 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:144150 CAPLUS
DN 126:181784
TI Monoclonal antibodies directed against the EGF ***receptor*** show differential bindings of amphiregulin and EGF to the EGF ***receptor***
AU Modjtahedi, Helmout; Cohen, Bruce D.; Dean, Christopher
CS McElwain Laboratories, The Institute of Cancer Research, Belmont, UK
SO International Journal of Oncology (1997), 10(2), 339-347
CODEN: IJONES; ISSN: 1019-6439
PB International Journal of Oncology
DT Journal
LA English

L4 ANSWER 337 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 97172610 EMBASE
DN 1997172610
TI HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts.
AU Rauvala H.; Peng H.B.
CS H. Rauvala, Laboratory of Molecular Neurobiology, Inst. of Biotechnol./Biosci. Dept., University of Helsinki Biocentre, Helsinki, Finland
SO Progress in Neurobiology, (1997) 52/2 (127-144).
Refs: 136
ISSN: 0301-0082 CODEN: PGNBA5

CY United Kingdom
DT Journal; General Review
FS 002 Physiology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 338 OF 365 CANCERLIT on STN DUPLICATE 64
AN 97202303 CANCERLIT
DN 97202303 PubMed ID: 9049830
TI Expression of TrkA, TrkB and TrkC in ***human*** neuroblastomas.
AU Brodeur G M; Nakagawara A; Yamashiro D J; Ikegaki N; Liu X G; Azar C G; Lee C P; Evans A E
CS Division of Oncology, Children's Hospital of Philadelphia, PA, USA.
NC CA-05587 (NCI)
CA-49712 (NCI)
SO JOURNAL OF NEURO-ONCOLOGY, (1997 Jan) 31 (1-2) 49-55.
Journal code: 8309335. ISSN: 0167-594X.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 97202303
EM 199705
ED Entered STN: 19970618
Last Updated on STN: 19970618

L4 ANSWER 339 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:254276 CAPLUS
DN 124:340904
TI Methods and bifunctional ligands for specific tumor inhibition by blood coagulation in tumor vasculature
IN Thorpe, Philip E.; Edgington, Thomas S.
PA Univ. of Texas System, USA; Scripps Res. Inst.
SO PCT Int. Appl., 325 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9601653	A1	19960125	WO 1995-US7439	19950607
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2194369	AA	19960125	CA 1995-2194369	19950607
	AU 9528249	A1	19960209	AU 1995-28249	19950607
	AU 702250	B2	19990218		
	EP 771216	A1	19970507	EP 1995-923817	19950607
	EP 771216	B1	20010117		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1162267	A	19971015	CN 1995-194801	19950607
	BR 9508402	A	19971021	BR 1995-8402	19950607
	HU 76970	A2	19980128	HU 1997-84	19950607
	HU 220347	B	20011228		
	JP 10505327	T2	19980526	JP 1995-504299	19950607
	AT 198712	E	20010215	AT 1995-923817	19950607
	ES 2153483	T3	20010301	ES 1995-923817	19950607
	PT 771216	T	20010731	PT 1995-923817	19950607
	JP 2003055398	A2	20030226	JP 2002-164988	19950607
	HK 1014496	A1	20010727	HK 1998-115809	19981228
	GR 3035617	T3	20010629	GR 2001-400463	20010321
PRAI	US 1994-273567	A	19940711		
	JP 1996-504299	A3	19950607		
	WO 1995-US7439	W	19950607		

L4 ANSWER 340 OF 365 CANCERLIT on STN DUPLICATE 65
AN 96355517 CANCERLIT
DN 96355517 PubMed ID: 8702927
TI 6B4 proteoglycan/phosphacan, an extracellular variant of ***receptor*** -like protein-tyrosine phosphatase zeta/RPTPbeta, binds

AU Maeda N; Nishiwaki T; Shintani T; Hamanaka H; Noda M
CS Division of Molecular Neurobiology, National Institute for Basic Biology, and the Department of Molecular Biomechanics, The Graduate University for Advanced Studies, Okazaki 444, Japan.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 Aug 30) 271 (35) 21446-52. Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96355517
EM 199610
ED Entered STN: 19961106
Last Updated on STN: 19970509

L4 ANSWER 341 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 96:51249 SCISEARCH
GA The Genuine Article (R) Number: TM754
TI PIG UTERINE LUMINAL FLUID CONTAINS THE DEVELOPMENTALLY-REGULATED NEUROTROPHIC FACTOR, ***PLEIOTROPHIN***
AU BRIGSTOCK D R (Reprint); KIM G Y; STEFFEN C L
CS CHILDRENS HOSP, DEPT SURG, 700 CHILDRENS DR, COLUMBUS, OH, 43205 (Reprint); CHILDRENS HOSP, DEPT BIOCHEM MED, COLUMBUS, OH, 43205; OHIO STATE UNIV, COLL MED, COLUMBUS, OH, 43205
CYA USA
SO JOURNAL OF ENDOCRINOLOGY, (JAN 1996) Vol. 148, No. 1, pp. 103-111. ISSN: 0022-0795.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 39
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 342 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 96:649796 SCISEARCH
GA The Genuine Article (R) Number: VE622
TI ROLE OF HB-GAM (HEPARIN-BINDING GROWTH-ASSOCIATED MOLECULE) IN PROLIFERATION ARREST IN CELLS OF THE DEVELOPING RAT LIMB AND ITS EXPRESSION IN THE DIFFERENTIATING NEUROMUSCULAR SYSTEM
AU SZABAT E (Reprint); RAUVALA H
CS UNIV HELSINKI, INST BIOTECHNOL, MOL NEUROBIOL LAB, FIN-00014 HELSINKI, FINLAND (Reprint); UNIV HELSINKI, DIV BIOCHEM, DEPT BIOSCI, FIN-00014 HELSINKI, FINLAND
CYA FINLAND
SO DEVELOPMENTAL BIOLOGY, (25 AUG 1996) Vol. 178, No. 1, pp. 77-89. ISSN: 0012-1606.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 68
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 343 OF 365 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004151296 EMBASE
TI Clinical Pharmacology and Oncology: Preface.
AU Kuhlmann J.; Klotz U.
CS Germany
SO Klinische Pharmakologie, (1996) -/14 (VII-VIII). ISSN: 0937-0978 CODEN: KLPHEH
CY Germany
DT Journal; Conference Article
FS 016 Cancer
030 Pharmacology
037 Drug Literature Index
LA English

L4 ANSWER 344 OF 365 CANCERLIT on STN
AN 96606414 CANCERLIT
DN 96606414
TI The role of angiogenesis in the progression of ***human*** breast cancer (Meeting abstract).
AU Lippman M E

Washington, DC.
SO Non-serial, (1995) Hormones and Growth Factors in Development and Neoplasia, Fogarty International Conference, June 26-28, 1995, NIH, Bethesda, MD, p.26, 1995. .
DT (MEETING ABSTRACTS)
LA English
FS Institute for Cell and Developmental Biology
EM 199605
ED Entered STN: 19970509
Last Updated on STN: 19970509

L4 ANSWER 345 OF 365 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 95:41517 PROMT
TITLE: Melanoma Tx May Be a Few Years Away
Melanoma treatment progress made with advances in microbiology & immunology
SOURCE: Dermatology Times, (Jan 1995) pp. 1.
ISSN: 0196-6197.
LANGUAGE: English
WORD COUNT: 696
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 346 OF 365 USPATFULL on STN
AN 95:80308 USPATFULL
TI Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
IN Glasky, Alvin J., 12231 Pevero, Tustin, CA, United States 92680
Rathbone, Michael P., 40 Spadina Avenue, Hamilton, Ontario, Canada L8M 2X1
PI US 5447939 19950905
AI US 1994-280719 19940725 (8)
DT Utility
FS Granted
LN.CNT 1990
INCL INCLM: 514/310.000
INCLS: 514/262.000; 544/265.000; 544/276.000
NCL NCLM: 514/310.000
NCLS: 514/263.370; 514/263.380; 544/265.000; 544/276.000
IC [6]
ICM: A61K031-52
EXF 514/310; 514/262; 544/265; 544/276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 347 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 95:294824 SCISEARCH
GA The Genuine Article (R) Number: QT913
TI THE ROLE OF HEPARIN-BINDING GROWTH-ASSOCIATED MOLECULE (HB-GAM) IN THE POSTSYNAPTIC INDUCTION IN CULTURED MUSCLE-CELLS
AU PENG H B (Reprint); ALI A A; DAI Z S; DAGGETT D F; RAULO E; RAUVALA H
CS UNIV N CAROLINA, DEPT CELL BIOL & ANAT, CB 7090, 108 TAYLOR HALL, CHAPEL HILL, NC, 27599 (Reprint); UNIV N CAROLINA, CURRICULUM NEUROBIOL, CHAPEL HILL, NC, 27599; UNIV HELSINKI, INST BIOTECHNOL, HELSINKI, FINLAND
CYA USA; FINLAND
SO JOURNAL OF NEUROSCIENCE, (APR 1995) Vol. 15, No. 4, pp. 3027-3038.
ISSN: 0270-6474.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 77
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 348 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 66
AN 1995:254965 BIOSIS
DN PREV199598269265
TI Differential expression of ***pleiotrophin*** and midkine in advanced neuroblastomas.
AU Nakagawara, Akira [Reprint author]; Milbrandt, Jeffrey; Muramatsu, Takashi; Deuel, Thomas F.; Zho, Huaqing; Cnaan, Avital; Brodeur, Garrett M.
CS Div. Oncology, Children's Hosp. Phila., 324 South 34th St., Philadelphia, PA 19104, USA
SO Cancer Research, (1995) Vol. 55, No. 8, pp. 1792-1797.
CODEN: CNREA8. ISSN: 0008-5472.

LA English
ED Entered STN: 13 Jun 1995
Last Updated on STN: 13 Jun 1995

L4 ANSWER 349 OF 365 CANCERLIT on STN DUPLICATE 67
AN 95408268 CANCERLIT
DN 95408268 PubMed ID: 7677748
TI Developmental and differential regulations in gene expression of Xenopus pleiotrophic factors-alpha and -beta.
AU Tsujimura A; Yasojima K; Kuboki Y; Suzuki A; Ueno N; Shiokawa K; Hashimoto-Gotoh T
CS Department of Biochemistry and Molecular Genetics, Kyoto Prefectural University of Medicine, Japan.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1995 Sep 14) 214 (2) 432-9.
Journal code: 0372516. ISSN: 0006-291X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 95408268; GENBANK-D42057; GENBANK-D42058; GENBANK-D42059; GENBANK-D42060
EM 199510
ED Entered STN: 19951108
Last Updated on STN: 19970509

L4 ANSWER 350 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 68
AN 1995:156813 BIOSIS
DN PREV199598171113
TI The isolation and long-term culture of normal ***human*** endometrial epithelium and stroma: Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges.
AU Zhang, Lyna; Rees, Margaret C. P.; Bicknell, Roy [Reprint author]
CS Molecular Angiogenesis Group, Imperial Cancer Res. Fund, Inst. Molecular Med., Univ. Oxford, Oxford OX3 9DU, UK
SO Journal of Cell Science, (1995) Vol. 108, No. 1, pp. 323-331.
CODEN: JNCSAI. ISSN: 0021-9533.
DT Article
LA English
ED Entered STN: 11 Apr 1995
Last Updated on STN: 12 Apr 1995

L4 ANSWER 351 OF 365 CANCERLIT on STN DUPLICATE 69
AN 96352511 CANCERLIT
DN 96352511 PubMed ID: 8714367
TI Biochemical and mitogenic properties of the heparin-binding growth factor HARP.
AU Laaroubi K; Vacherot F; Delbe J; Caruelle D; Barritault D; Courty J
CS Laboratoire de Recherche sur la Croissance Cellulaire, Universite Paris Val de Marne, Creteil, France.
SO PROGRESS IN GROWTH FACTOR RESEARCH, (1995) 6 (1) 25-34. Ref: 49
Journal code: 8912757. ISSN: 0955-2235.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96352511
EM 199610
ED Entered STN: 19961216
Last Updated on STN: 19961216

L4 ANSWER 352 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:410557 CAPLUS
DN 123:136567
TI Polypeptides that interact with other proteins and that include conformation-constraining groups flanking a protein-protein interaction site
IN Evans, Herbert J.; Kini, R. Manjunatha
PA USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9425482	A1	19941110	WO 1994-US4294	19940421
	W: AU, BR, CA, JP, KR, NZ, US, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2161108	AA	19941110	CA 1994-2161108	19940421
	AU 9467707	A1	19941121	AU 1994-67707	19940421
	US 5965698	A	19991012	US 1996-532818	19960503
	US 6100044	A	20000808	US 1997-934224	19970919
	US 6258550	B1	20010710	US 1999-413492	19991006
PRAI	US 1993-51741	A	19930423		
	US 1993-143364	A	19931029		
	WO 1994-US4294	W	19940421		
	US 1996-532818	A3	19960503		
	US 1997-934224	A3	19970919		

L4 ANSWER 353 OF 365 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 70
AN 1994:451712 BIOSIS
DN PREV199497464712
TI Midkine and ***pleiotrophin*** expression in normal and malignant breast tissue.
AU Garver, Robert I., Jr.; Radford, Diane M.; Donis-Keller, Helen; Wick, Mark R.; Milner, Peter G. [Reprint author]
CS CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304, USA
SO Cancer (Philadelphia), (1994) Vol. 74, No. 5, pp. 1584-1590.
CODEN: CANCAR. ISSN: 0008-543X.
DT Article
LA English
ED Entered STN: 24 Oct 1994
Last Updated on STN: 16 Dec 1994

L4 ANSWER 354 OF 365 CANCERLIT on STN DUPLICATE 71
AN 94334295 CANCERLIT
DN 94334295 PubMed ID: 8056766
TI The midkine (MK) family of growth/differentiation factors: structure of an MK-related sequence in a pseudogene and evolutionary relationships among members of the MK family.
AU Obama H; Matsubara S; Guenet J L; Muramatsu T
CS Department of Biochemistry, Faculty of Medicine, Kagoshima University.
SO JOURNAL OF BIOCHEMISTRY, (1994 Mar) 115 (3) 516-22.
Journal code: 0376600. ISSN: 0021-924X.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 94334295; GENBANK-D14498
EM 199409
ED Entered STN: 19990618
Last Updated on STN: 19990618

L4 ANSWER 355 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 1994:24319901 BIOTECHNO
TI Cytokine networks in solid ***human*** tumors: Regulation of angiogenesis
AU Leek R.D.; Harris A.L.; Lewis C.E.
CS Nuffield Dept. Pathol. Bacteriology, University of Oxford, John Radcliffe Hospital,Oxford OX3 9DU, United Kingdom.
SO Journal of Leukocyte Biology, (1994), 56/4 (423-435)
CODEN: JLBIE7 ISSN: 0741-5400
DT Journal; General Review
CY United States
LA English
SL English

L4 ANSWER 356 OF 365 CANCERLIT on STN DUPLICATE 73
AN 95186809 CANCERLIT
DN 95186809 PubMed ID: 7533562
TI The potential role of the heparin-binding growth factor ***pleiotrophin*** in breast cancer.
AU Riegel A T; Wellstein A
CS Vincent T. Lombardi Cancer Center, Georgetown University, Washington, DC 20007.

Journal code: 8111104. ISSN: 0167-6806.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 95186809
EM 199504
ED Entered STN: 19950509
Last Updated on STN: 19970509

L4 ANSWER 357 OF 365 CANCERLIT on STN DUPLICATE 74
AN 94220851 CANCERLIT
DN 94220851 PubMed ID: 8167469
TI Refolding and characterization of ***human*** recombinant heparin-binding neurite-promoting factor.
AU Seddon A P; Hulmes J D; Decker M M; Kovesdi I; Fairhurst J L; Backer J; Dougher-Vermazen M; Bohlen P
CS Department of Protein Chemistry, American Cyanamid Company, Lederle Laboratories, Pearl River, New York 10965.
SO PROTEIN EXPRESSION AND PURIFICATION, (1994 Feb) 5 (1) 14-21.
Journal code: 9101496. ISSN: 1046-5928.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 94220851
EM 199405
ED Entered STN: 19990618
Last Updated on STN: 19990618

L4 ANSWER 358 OF 365 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:401755 CAPLUS
DN 119:1755
TI Cell growth-inhibiting activities of heparin-binding neurite-outgrowth promoting factor
IN Backer, Joseph Mark; Bohlen, Peter
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 535337	A2	19930407	EP 1992-113632	19920810
	EP 535337	A3	19930519		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9226043	A1	19930401	AU 1992-26043	19920929
	AU 648437	B2	19940421		
	ZA 9207469	A	19930413	ZA 1992-7469	19920929
	JP 05213771	A2	19930824	JP 1992-282262	19920929
PRAI	US 1991-769063		19910930		

L4 ANSWER 359 OF 365 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 1993:23097103 BIOTECHNO
TI A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other ***human*** carcinomas
AU Tsutsui J.-I.; Kadomatsu K.; Matsubara S.; Nakagawara A.; Hamanoue M.; Takao S.; Shimazu H.; Ohi Y.; Muramatsu T.
CS Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka,Kagoshima 890, Japan.
SO Cancer Research, (1993), 53/6 (1281-1285)
CODEN: CNREA8 ISSN: 0008-5472
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 360 OF 365 CANCERLIT on STN DUPLICATE 76
AN 95010164 CANCERLIT
DN 95010164 PubMed ID: 7925491
TI ***Receptor*** binding of osteoblast-specific factor 1 (OSF-1/HB-GAM)

AU Gieffers C; Engelhardt W; Brenzel G; Matsuishi T; Frey J
CS Fakultat fur Chemie, Biochemie II, Universitat Bielefeld, Germany.
SO EUROPEAN JOURNAL OF CELL BIOLOGY, (1993 Dec) 62 (2) 352-61.
Journal code: 7906240. ISSN: 0171-9335.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 95010164
EM 199411
ED Entered STN: 19960517
Last Updated on STN: 19970509

L4 ANSWER 361 OF 365 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 92:525187 SCISEARCH
GA The Genuine Article (R) Number: JL480
TI THE NEW GROWTH-FACTOR ***PLEIOTROPHIN*** (HB-GAM) MESSENGER-RNA IS SELECTIVELY PRESENT IN THE MENINGOTHELIAL CELLS OF ***HUMAN*** MENINGIOMAS
AU MAILLEUX P (Reprint); VANDERWINDEN J M; VANDERHAEGHEN J J
CS UNIV LIBRE BRUXELLES, ERASME ACAD HOSP, FAC MED, NEUROPHYSIOL LAB, B-1070 BRUSSELS, BELGIUM; UNIV LIBRE BRUXELLES, ERASME ACAD HOSP, FAC MED, DEPT SURG, B-1070 BRUSSELS, BELGIUM
CYA BELGIUM
SO NEUROSCIENCE LETTERS, (03 AUG 1992) Vol. 142, No. 1, pp. 31-35. ISSN: 0304-3940.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 14
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 362 OF 365 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:159833 FEDRIP
NR CRISP 1R01CA10181-01
TI Inhibition of the ALK ***Receptor*** Kinase
SF Principal Investigator: WELLSTEIN, ANTON; WELLSTEA@GEORGETOWN.EDU, LOMBARDI CANCER CTR, 3970 RESERVOIR RD NW
CSP GEORGETOWN UNIVERSITY, WASHINGTON, DIST OF COL
CSS Supported By: NATIONAL CANCER INSTITUTE
DB 2008 (/01/03)
FYR 2003
DE 2007 (/31/07)
FU New Award (Type 1)
FS National Institutes of Health

L4 ANSWER 363 OF 365 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:152375 FEDRIP
NR CRISP 5P01CA25874-24
TI ***HUMAN*** MELANOMA--ETIOLOGY, PROGRESSION AND THERAPY
SF Principal Investigator: HERLYN, MEENHARD; HERLYNM@WISTAR.UPENN.EDU, THE WISTAR INSTITUTE, 3601 SPRUCE STREET
CSP WISTAR INSTITUTE, PHILADELPHIA, PENNSYLVANIA
CSS Supported By: NATIONAL CANCER INSTITUTE
DB 2004 (/06/90)
FYR 2003
DE 2004 (/30/04)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L4 ANSWER 364 OF 365 PHAR COPYRIGHT 2004 PJB on STN
AN 31478 PHAR
DN 037160
CN anti-PTN MAb, Protein Design
CN anti- ***pleiotrophin*** MAb, PDL
STA Active

CO

Type	Company Name (Country)	Development Status
Originator	Protein Design Labs (United States)	Preclinical

SO Pharmaprojects. PJB Publications Ltd., Richmond, Surrey, UK

targeting ***pleiotrophin*** (PTN), a heparin-binding growth factor, for the treatment of cancer.PreclinicalIn vitro, anti-PTN MAbs inhibited the angiogenic and oncogenic effects of PTN. In a ***human*** pancreatic cancer xenograft model, 1 MAb suppressed tumour growth by increasing the rate of apoptosis and decreasing the vessel density in tumours (AACR-NCI-EORTC Molec Targ Cancer Ther (Boston), 2003, Abs B237). Entered by SM on 28/11/2003.

DSTA World: Preclinical
United States: Preclinical

CC T3A9 Monoclonal antibody, other
K3 Anticancer, immunological

CT Indication: Cancer, general

ORGM BI-P-A (Biological, protein, antibody)

RTE UN (Unknown)

RDAT 20031128 RNTE ##Act##New Product

NRAT 1:Novelty Rating - All Preclinical

MRAT 3:Market Rating - US$ 2001-5000 million

SRAT 1:Speed Rating - Development not started

TRAT 0:Total Rating - Total Rating unavailable

PHCD GF-HB-8-AN; Heparin binding growth factor 8 antagonist; ***Receptor*** , Biochemical, Heparin binding growth factor 8 antagonist; ***Pleiotrophin*** antagonist; R-B-GF-HB-8-AN.

PHCD APOP-AG; Apoptosis agonist; Physiological, Biochemical, Apoptosis agonist; General apoptosis agonist; Apoptosis stimulant; P-B-APOP-AG.

PHCD ANGG-AN; Angiogenesis inhibitor; Physiological, Hormonal, Angiogenesis inhibitor; P-H-ANGG-AN.

PHCD R; R-AN; R-B; R-B-AN; R-B-GF; R-B-GF-AN; R-B-GF-HB; R-B-GF-HB-AN; R-B-GF-HB-8; R-B-GF-HB-8-AN; B; B-AN; B-GF; B-GF-AN; B-GF-HB; B-GF-HB-AN; B-GF-HB-8; B-GF-HB-8-AN; GF; GF-AN; GF-HB; GF-HB-AN; GF-HB-8; GF-HB-8-AN; HB; HB-AN; HB-8; HB-8-AN; 8; 8-AN; P; P-AG; P-B; P-B-AG; P-B-APOP; P-B-APOP-AG; B; B-AG; B-APOP; B-APOP-AG; APOP; APOP-AG; P; P-AN; P-H; P-H-AN; P-H-ANGG; P-H-ANGG-AN; H; H-AN; H-ANGG; H-ANGG-AN; ANGG; ANGG-AN.

LN

Therapy (CC)	Pharmacology (PHCD)	Status (DSTC)
T3A9	GF-HB-8-AN APOP-AG ANGG-AN	P
K3	GF-HB-8-AN APOP-AG ANGG-AN	P

LCDAT 20031128: SM : New product entry

STRUCTURE DIAGRAM IS NOT AVAILABLE

L4 ANSWER 365 OF 365 PHAR COPYRIGHT 2004 PJB on STN
AN 15565 PHAR
DN 026732
CN Pharmaprojects No.5624
STA Ceased

CO

Type	Company Name (Country)	Development Status
Originator	Novartis (Switzerland)	No Development Reported

SO Pharmaprojects. PJB Publications Ltd., Richmond, Surrey, UK

TX Genetic Therapy (Novartis) was developing adenovirus vectors expressing ribozymes, which inhibit expression of the tyrosine kinase ***receptor*** HER-2/neu or growth factor ***pleiotrophin*** (PTN) for use in cancer gene therapy.

Preclinical

In ***human*** SW-13 adrenal carcinoma, U87 glioblastoma and 1205 melanoma cells, protein expression of HER-2/neu and PTN was significantly inhibited by the treatment. There were high expression levels of ribozymes in SW-13 and V87 cells but lower levels in 1205 melanoma cells. In SK-OV-3 cells, HER-2/neu mRNA levels were reduced by 75% 1 day after infection (Gene Ther, 1997, 4, 943; Direct communication, Novartis, 8 Mar 1999). Updated by CM on 24/3/1999.

DSTA World: No Development Reported
United States: Preclinical

K6Z Anticancer, other
CT Indication: Cancer, general (No Development Reported)
ORGM BI-N-VV (Biological, nucleic acid, viral vector)
RTE UN (Unknown)
RDAT 20000912 RNTE ##Actual; No Development Reported
19971107 ##Estimated; New Product
PHCD ONCOG-AN; Oncogene inhibitor; Physiological, Biochemical, Oncogene inhibitor; P-B-ONCOG-AN.
PHCD P; P-AN; P-B; P-B-AN; P-B-ONCOG; P-B-ONCOG-AN; B; B-AN; B-ONCOG; B-ONCOG-AN; ONCOG; ONCOG-AN.

LN

Therapy (CC)	Pharmacology (PHCD)	Status (DSTC)
T4A	ONCOG-AN	N
K6Z	ONCOG-AN	N

LCDAT 20000912: IL : No development reported

STRUCTURE DIAGRAM IS NOT AVAILABLE
STN INTERNATIONAL LOGOFF AT 09:36:31 ON 13 SEP 2004